8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 1 ...... 11 ...... 12 ...... 41 ...... 8...... 12...... 42 ...... 46 ...... 14 ...... 4...... 13...... 17 ...... 12 ...... 51 ...... 18 ...... 5...... 52 ...... 63 ...... 73 ...... 83 ...... 2...... 38 AUSPICES OF: AUSPICES OF: AUSPICES OF: AUSPICES OF: AUSPICES OF: , University of Rome “La Sapienza” , University of Rome “La Sapienza” , University of Rome “La Sapienza” , University of Rome “La Sapienza” , University of Rome “La Sapienza” The City of Rome The City of Rome The City of Rome The City of Rome The City of Rome The Italian Society of Neurology The Italian Society of Neurology The Italian Society of Neurology The Italian Society of Neurology The Italian Society of Neurology The President of the Italian Republic The President of the Italian Republic The President of the Italian Republic The President of the Italian Republic The President of the Italian Republic The National Research Council (CNR) The National Research Council (CNR) The National Research Council (CNR) The National Institute of Health (ISS) The National Institute of Health (ISS) The National Research Council (CNR) The National Research Council (CNR) The National Institute of Health (ISS) The National Institute of Health (ISS) The National Institute of Health (ISS) The Prime Minister of the Italian government The Prime Minister of the Italian government The Prime Minister of the Italian government The Prime Minister of the Italian government The Prime Minister of the Italian government THE CONGRESS IS UNDER THE THE CONGRESS IS UNDER THE THE CONGRESS IS UNDER THE THE CONGRESS IS UNDER THE THE CONGRESS IS UNDER THE The School of Medicine and Surgery The School of Medicine and Surgery The School of Medicine and Surgery The School of Medicine and Surgery The School of Medicine and Surgery Continuing Medical Education ...... Evaluations...... Press Room...... Social Events...... Invitation ...... Acknowledgements...... Organization...... Forces Task MDS Committees and ...... Registration and VenueInternational Congress ...... InformationInternational Congress ...... Program at a Glance ...... Scientific Sessions ...... Faculty ...... Force MeetingsCommittee and Task ...... Exhibitor Information and Directory...... Floor Plan and Meeting Space ...... Map of Rome ...... Poster Session 1...... Poster Session 2...... Poster Session 3...... Poster Session 4...... TABLE OF CONTENTS OF TABLE CONTENTS OF TABLE TABLE OF CONTENTS OF TABLE TABLE OF CONTENTS OF TABLE CONTENTS OF TABLE 2 Rome, Italy THE President C. Warren Olanow Sincerely, welcome tothe8 On behalfoftheOfficersandInternationalExecutiveCommitteeThe Dear Colleagues, the successof8 In closing,IwouldliketothankalloftheInternationalCongressattendeesfortheirparticipationin Brancaccio, offeringamixofRomanPatricianarchitecture,aswellenchantinggardens. the exquisitetastesandtalentsofItaly. TheCongressGalaEventtakesplaceatthePalazzo Palazzo deiCongressi.Thiseventoffersattendeestheopportunitytogreeteachotherwhiletakingin program willincludeaSundayOpeningCeremonywhichbeheldontherooftopterraceof allowed ustoofferInternationalCongressattendeesthebestthatRomehasoffer. Thesocial Committee foralloftheirhardworkoverthepasttwoyears.Theirdedicationinplanninghas I wouldliketothanktheInternationalCongressOversightCommitteeandOrganizing further serveourparticipants,timehasalsobeenallottedfor16posterplatformpresentations. plenary sessions,parallelseminarsandvideodinners.Postersessionsareunopposedand,to through unrestrictededucationalgrantsfromindustry. Theweekcontinueswithawidearrayof The InternationalCongressweekbeginswithavarietyofKickoffSeminars,whicharesupported this exemplaryscientificprogramandfortheircontributiontotheInternationalCongress. I wouldliketothankthefacultyandmembersofCongressScientificProgramCommitteefor MOVEMENT th InternationalCongressofParkinson’s DiseaseandMovementDisorders. th DISORDERSOCIETY InternationalCongress. Movement Movement Disorder Society, INVIT INVIT INVIT INVIT INVIT A A A A A TION TION TION TION TION 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 3 Disorder Society, welcome to Disorder Society, Movement International Congress of Parkinson’s Disease and Move- of Parkinson’s International Congress th TION TION TION TION TION A A A A A Professor Alfredo Berardelli Congress Organizing Committee Chair, Rome. Dear Colleagues, to welcome you to the 8 It is my pleasure for the Interna- cities, Rome is an ideal venue most beautiful As one of the world’s ment Disorders. the city has to offer. I hope that you will enjoy all that tional Congress and of the Rivers of the Nile, part of the Fountain the front page shows the Statue The photograph on Fountain is by Pope Innocenzo X. The Gian Lorenzo Bernini and commissioned created in 1651 by and is one of the finest symbols of Baroque art. Its importance located in the middle of Piazza Navona figures, statues, landscapes, and water into one of his most lies in the way the sculptor has fused and grottoes forming the fountain is surmounted by a tall imposing creations. The mass of rocks repre- are colossal figures of the rivers Danube, Ganges, Nile and Plate, At the four corners obelisk. senting the four quarters of the globe. from all over the world. The aim of the Interna- this symbolism in mind, I welcome participants With knowledge in the field of Movement Disorders by sharing global tional Congress is to increase our with MDS tradition, the scientific program is informative, compre- research and perspectives. In line plenary session lectures, parallel sessions, platform presentations, hensive and innovative, including and video dinners. abstract poster presentations, seminars Committee and The On behalf of the Congress Organizing INVIT INVIT INVIT INVIT INVIT 4 Rome, Italy their support: The THE Movement MOVEMENT DisorderSocietywishestoacknowledgeandthankthefollowingcompaniesfor DISORDERSOCIETY DOUBLE PLA DOUBLE PLA DOUBLE PLA DOUBLE PLA DOUBLE PLA PLA PLA PLA PLA PLA PLA PLA PLA PLA PLA TINUM PLUSLEVEL TINUM PLUSLEVEL TINUM PLUSLEVEL TINUM PLUSLEVEL TINUM PLUSLEVEL BRONZE LEVEL BRONZE LEVEL BRONZE LEVEL BRONZE LEVEL BRONZE LEVEL GOLD LEVEL GOLD LEVEL GOLD LEVEL GOLD LEVEL GOLD LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL TINUM LEVEL ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 5 AND GOALS AND GOALS AND GOALS AND GOALS AND GOALS and the general public designed to advance scientific and and the general public clinical knowledge about Movement Disorders Disorders lay groups standards and peer materials committed to high scientific review support for research research Movement Disorders and related disorders therapeutic interven- approval process of safe and effective tions new research and therapeutic advances affect support of research and patient care PURPOSE, MISSION MISSION PURPOSE, MISSION PURPOSE, PURPOSE, MISSION MISSION PURPOSE, Purpose: advance the Society shall be to and mission of the The object to to Movement Disorders; sciences pertaining neurological educational scholarly and for scientific, operate exclusively as research; to provide forums, such purposes; to encourage symposia and International medical journals, scientific ideas and for advancing the related Congresses, for sharing disciplines; to encourage interest and clinical and scientific activities of the Society among healthcare participation in the with and scientists; and to collaborate and allied professionals and lay organizations. other related professional Mission and Goals: about Movement Disorders by: disseminate knowledge To • programs for clinicians, scientists Providing educational • Sponsoring congresses and symposia on Movement • with other international organizations and Collaborating • Publishing journals, videotapes and other collateral prevention and treatment of promote research into causes, To Movement Disorders by: •influence and resources to enhance Using the Society’s • Facilitating the dissemination of information about • Encouraging the training of basic and clinical scientists in will favorably formulate and promote public policy that To Disorders by: affect the care of patients with Movement • agencies to assist them in the with regulatory Working • Informing the public (media) and patient support groups of • of policies that Playing a proactive role in the development • the specialty Developing standards of training in PURPOSE, MISSION MISSION PURPOSE, MISSION PURPOSE, TION TION TION TION TION Disorder Society (MDS) is an international, (MDS) is an Disorder Society Disorder Society (MDS) was founded in 1985 Disorder Society (MDS) was founded Movement Movement Ataxia Blepharospasm Dysphonia Dystonic disorders Gait disorders disease Huntington’s Myoclonus disease Parkinson’s Spasticity dyskinesia Tardive syndrome and Tourette Tics Tremor ORGANIZA ORGANIZA on the initiative of Professors Stanley Fahn and C. David on the initiative of Professors Stanley guided the expansion Marsden, whose leadership and vision field. The organiza- of clinical expertise and research in this Medical Society tion merged in 1988 with the International for Motor Disturbances. The other scientists, and society of clinicians, professional Parkinson’s are interested in professionals, who healthcare and neurodevelopmental neurodegenerative disease, related abnormali- Disorders, and hyperkinetic Movement disorders, and motor control. The spectrum of clinical ties in muscle tone by the Society includes but is not disorders represented limited to: The ORGANIZA ORGANIZA ORGANIZA 6 Rome, Italy MDS OFFICERS MDS OFFICERS MDS OFFICERS John C.Rothwell,UnitedKingdom Peter Riederer, Germany Olivier Rascol,France José A. Obeso,Spain Yoshikuni Mizuno,Japan Joseph Jankovic,USA Etienne C.Hirsch,France Hardy,John A. USA Bruno Dubois,France Cynthia L.Comella,USA Alfredo Berardelli,Italy Alim L.Benabid,France Co-Chair 2005: Anthony E. Lang,Canada Co-Chair 2004: Anthony H.V. Schapira,UnitedKingdom Chair: C.Warren Olanow, USA Congress ScientificProgramCommittee Eduardo Tolosa, Spain Werner Poewe, Austria C. Warren Olanow, USA Wolfgang H.Oertel,Germany Chair: MarkHallett,USA International CongressOversightCommittee Marie Vidailhet, France Caroline M.Tanner, USA Kapil D.Sethi,USA Yoshikuni Mizuno,Japan Ann M.Graybiel,USA Nir Giladi,Israel Santiago Giménez-Roldán,Spain Cynthia L.Comella,USA Francisco Cardoso,Brazil Paul J.Bédard,Canada International ExecutiveCommittee Werner Poewe, Austria Past President Daniel Tarsy, USA Treasurer-Elect Wolfgang H.Oertel,Germany Treasurer Philip D.Thompson, Australia Secretary-Elect Andres M.Lozano,Canada Secretary Andrew J.Lees,UnitedKingdom President-Elect C. Warren Olanow, USA President THE MDS OFFICERS MDS OFFICERS MOVEMENT DISORDERSOCIETY Web site:www.movementdisorders.org E-mail: [email protected] Fax: +1414-276-3349 Tel: +1414-276-2145 USA Milwaukee, WI53202-3823 555 EastWells Street,11th Floor Past Presidents Disturbances StanleyFahn,USA International MedicalSocietyforMotor C.DavidMarsden,UnitedKingdom JosephJankovic,USA 1988-1991 EduardoTolosa, Spain 1991-1994 MarkHallett,USA 1995-1996 Werner Poewe, Austria 1997-1998 1999-2000 2001-2002 Past Presidents Mario Zappia,Italy Fabrizio Stocchi,Italy Stefano RuggieriItaly Mario Manfredi,Italy Giovanni Fabbrini,Italy Carlo Colosimo,Italy Ubaldo Bonuccelli,Italy Paolo Barone,Italy Italy Alberto Albanese, Italy Giovanni Abbruzzese, Chair: Alfredo Berardelli, Italy Congress OrganizingCommittee E-mail: [email protected] Fax: +390684543700 Tel: +3906845431 Via Tolmino, 5-00198Rome,Italy ARISTEA -LocalOrganizingSecretariat The C.DavidMarsden,UnitedKingdom MDS InternationalSecretariat MarioManfredi,Italy MarkHallett,USA 1985-1986 BastianConrad,Germany 1987-1988 C.Warren Olanow, USA 1989-1990 1991-1992 1993-1994 Movement DisorderSociety ORGANIZA ORGANIZA ORGANIZA ORGANIZA ORGANIZA TION TION TION TION TION 8 Rome, Italy Staff Liaison: Caley Kleczka Rivka Inzelberg Mark Hallett Francisco Cardoso Chair: JosephJankovic Journal OversightCommittee Staff Liaison:CaleyKleczka Ray L.Watts Eduardo Tolosa Werner Poewe Yoshikuni Mizuno Anthony E.Lang Chair: OlivierRascol Industrial RelationsCommittee Staff Liaison:CaleyKleczka Daniel Tarsy Werner Poewe Chair: Wolfgang H.Oertel Committee Financial Affairs Staff Liaison:JodyMcCarthy Kapil D.Sethi Yoshikuni Mizuno Kelly Lyons Robert Iansek Joaquim Ferreira Factor Stewart A. Co-Chair: FabrizioStocchi Chair: CynthiaL.Comella Education Committee Staff Liaisons:JennyOliva,JodyMcCarthy David Riley Michele Tagliati Dee E.Silver Robert L.Rodnitzky Ryan J.Uitti Irene Litvan Chair: RonaldF. Pfeiffer CME Committee Staff Liaison:CaleyKleczka Anette Schrag David Riley Elan D.Louis Alexis Elbaz Kailash P. Bhatia Chair: DemetriusM.Maraganore Bylaws Committee Staff Liaison:JennyOliva Etienne C.Hirsch Günther Deuschl Kailash P. Bhatia Paolo Barone Chair: OscarS.Gershanik Awards Committee Staff Liaison:JennyOliva Chair: Werner Poewe Archives Committee THE MOVEMENT DISORDERSOCIETY MDS COMMITTEES MDS COMMITTEES MDS COMMITTEES MDS COMMITTEES MDS COMMITTEES Staff Liaison:JodyMcCarthy Fabrizio Stocchi Obeso José A. Karl D.Kieburtz Joseph Jankovic Etienne C.Hirsch Thomas Gasser H.V.Chair: Anthony Schapira Scientific IssuesCommittee Staff Liaison:LisaSeidl Young H.Sohn Yasushi Osaki Elan D.Louis Irene Litvan Andrew J.Hughes Carlo Colosimo Francisco Cardoso Chair: GregorK.Wenning Membership Committee Staff Liaisons:LisaSeidl,Terri Walosz Bhim S.Singhal Ivan Rektor Eldad Melamed Regina Katzenschlager Beom S.Jeon Jonathan Carr Susan Bressman Chair: MatthewB.Stern Liaison/Public RelationsCommittee Staff Liaison: Jenny Oliva Web Ross Gustavo Roman Zvezdan Pirtosek Elan D.Louis Mathilde Leonardi Amos Korczyn Dusan Flisar Piu Chan James Bower Nadir Bharucha Yoav Ben-Shlomo Chair: CarolineTanner Task ForceonEpidemiology Staff Liaisons:CaleyKleczka,LisaSeidl Glenn Stebbins Cristina Sampaio Olivier Rascol Werner Poewe Chair: ChristopherGoetz for Parkinson’s Disease Task ForcefortheDevelopmentofRatingScales Staff Liaison:CaleyKleczka Werner Poewe C. Warren Olanow Andrew J.Lees Chair: MarkHallett Strategy andPlanningCommittee AND T AND T AND T AND T AND T ASK FORCES ASK FORCES ASK FORCES ASK FORCES ASK FORCES 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 9 Chair: Cristina Sampaio Jaime Kulisevsky Subcommittee Members: Richard Dodel, Statistical Testing Chair: Barbara C. Tilley Jean Teresi Subcommittee Members: Sue Leurgans, Staff Liaisons: Caley Kleczka, Lisa Seidl UPDRS Revision Task Force Revision Task UPDRS Goetz Chair: Christopher Part I UPDRS Poewe Chair: Werner Anette Schrag Bruno Dubois, Subcommittee Members: UPDRS Part II Chair: Matthew Stern Peter LeWitt Anthony Lang, Subcommittee Members: UPDRS Part III Chair: Stanley Fahn Olanow Joseph Jankovic, C. Warren Subcommittee Members: UPDRS Part IV Chair: Pablo Martinez-Martin Olivier Rascol, Bob Andrew Lees, Subcommittee Members: Hilten Van Scale Development Standards Chair: Glenn Stebbins David Nyenhuis Subcommittee Members: Robert Holloway, Appendices ASK FORCES ASK FORCES ASK ASK FORCES ASK ASK FORCES ASK FORCES ASK AND T AND T AND AND T AND AND T AND T AND Task Force on PD Dementia Task Co-Chair: Bruno Dubois Co-Chair: Murat Emre Co-Chair: Ian McKeith Dag Aarsland G. A. Broe (Tony) Richard Brown David John Burn Jeffrey L. Cummings Dennis Dickson Charles Duyckaerts Serge G. Gauthier Christopher G. Goetz Amos D. Korczyn Andrew J. Lees Richard Levy Irene Litvan Mizuno Yoshikuni Olanow C. Warren Poewe Werner Quinn Niall P. Cristina Sampaio Eduardo Tolosa Staff Liaison: Caley Kleczka Task Force on Evidence-Based Medicine in Medicine Force on Evidence-Based Task Disorders Movement Sampaio Chair: Cristina Goetz Christopher Koller William Poewe Werner Olivier Rascol McCarthy Staff Liaison: Jody MDS COMMITTEES COMMITTEES MDS COMMITTEES MDS MDS COMMITTEES COMMITTEES MDS MDS COMMITTEES COMMITTEES MDS COMMITTEES MDS

8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 11 th AND VENUE AND VENUE AND AND VENUE AND AND VENUE AND VENUE AND TION TION TION TION TION TION TION TION VENUE VENUE VENUE over the back of the atrium The cover suspended century. theatre thus functions as a hanging garden and outdoor inspiration from creating fascinating space that draws metaphysical aesthetics. Palazzo dei Congressi Palazzo dei Kennedy F. Piazzale J. Italy 00144 Rome, from a low Rome in June ranges temperature in The average of 77ºF/25ºC. of 61ºF/16ºC to a high Congressi and the EUR The Palazzo dei the place in the fascinating setting of The Congress will take located in the EUR district. This Palazzo dei Congressi, considered one of the most noteworthy modern quarter is Italian urban and architectural areas of contemporary EUR (Esposizione Universale culture. The monumental conceived in the late 1930s to host the Roma) complex, was which was to be held in 1942, but never Universal Exhibition of buildings in the urban district took place. The monumental set out in an architectural setting with EUR are spaciously lake. wide tree-lined avenues, parks and a outstanding works of The Palazzo dei Congressi is one of the the two wars. It Italian architecture from the period between project in line with the admirably synthesizes the ambitious time. The building was most modern architectural ideas of the Adalberto Libera in 1937 and was built in two designed by when building of the phases: the first between 1939 and 1943, 1952 and 1954, EUR district began, and the second between quarter and one of when EUR became a modern residential The main features of architec- most directional areas. Rome’s the Salone della tural interest are the immense cubic hall, in reinforced concrete, Cultura, covered by an imposing vault The Sala dei and the portico supported by granite columns. of the building, is Congressi, situated behind the main body Severini, a famous decorated with frescos painted by Gino beginning of the XX Italian futurist artist who lived at the VENUE VENUE 8:00 pm to 11:00 pm 8:00 pm to 11:00 Palazzo Brancaccio is the newest Roman patrician palace. Built by Princess one Elizabeth and Salvatore Brancaccio in 1880, this palace is still considered of the most beautiful places in Rome. dinner will itinerary begins with cocktails and hors d’oeuvres; The evening’s be served, and local entertainment will highlight the evening. to the Brancaccio Palace is provided from the Palazzo dei Transportation Congressi and Sheraton Roma beginning at 7:30 pm. Shuttles will depart the metro station, close to the A Brancaccio Palace at the end of the event. Brancaccio Palace, is also available for those staying in the city center. registration purchased in advance are enclosed in each delegate’s Tickets Additional tickets may be purchased, based on availability at the materials. Registration Desk in the Palazzo dei Congressi. Fee: $100 USD per person Monday, June 14 Monday, International Congress Banquet at the Brancaccio Palace CONGRESS REGISTRA CONGRESS REGISTRA CONGRESS CONGRESS REGISTRA CONGRESS CONGRESS REGISTRA CONGRESS REGISTRA CONGRESS TIONAL TIONAL TIONAL TIONAL TIONAL TION DESK TION DESK TION DESK TION DESK TION DESK ACCESSIBILITY NEEDS ACCESSIBILITY NEEDS ACCESSIBILITY NEEDS ACCESSIBILITY NEEDS ACCESSIBILITY NEEDS

SOCIAL EVENTS SOCIAL EVENTS Welcome Reception Welcome Location: Rooftop Terrace pm 9:30 pm to 11:00 All International Congress attendees and registered guests are invited to meet friends and colleagues during the tradi- tional Opening Cermony and Reception. Following Welcome a the Opening Ceremony, Reception moonlight Welcome will be held on the Rooftop Terrace. Opening Ceremony Location: Salone Della Cultura, Ground Floor 8:30 pm to 9:30 pm SOCIAL EVENTS June 13 Sunday, SOCIAL EVENTS SOCIAL EVENTS Saturday, June 12Saturday, June 13Sunday, June 14Monday, June 15Tuesday, June 16Wednesday, June 17 3:00 pm to 8:30 pm Thursday, 7:00 am to 7:30 pm 7:00 am to 7:30 pm 7:00 am to 7:30 pm 7:00 am to 7:30 pm 7:00 am to 5:00 pm Red = Delegate = Exhibitor Yellow Delegate Orange = Exhibitor Green = Guest Purple = Press Blue = Staff INTERNA INTERNA SPECIAL SPECIAL REGISTRA REGISTRA LANGUAGE LANGUAGE BADGES BADGES Delegates requiring special arrangements in order to fully Delegates requiring special arrangements should speak to an participate in the International Congress Desk located on the MDS staff member at the Registration Ground Floor of the Palazzo dei Congressi. SPECIAL Location: Ground Floor tickets and Interna- Name badges, seminar and special event at the International tional Congress bags can be collected the entrance lobby of Congress Registration Desk located in following hours: the Palazzo dei Congressi during the The official language of the International Congress is English. The official language REGISTRA LANGUAGE BADGES a name will receive Congress attendees All International should be materials. Badges their registration badge with access into all be used to control times as they will worn at all Individuals and activities. Congress sessions International follows: will be identified as INTERNA SPECIAL SPECIAL REGISTRA REGISTRA LANGUAGE LANGUAGE BADGES BADGES INTERNA INTERNA 12 Rome, Italy CONTINUING MEDICAL CONTINUING MEDICAL ABSTRACTS-ON-DISK ABSTRACTS-ON-DISK received anadditionalcopywiththeirMayjournalissue. their registrationmaterials.MDSmembershavealready CONTINUING MEDICAL ABSTRACTS-ON-DISK meeting room attendants alongwithcompleted evaluation gress. Completed CMERequestFormsshould behandedto following thelastsessionattended participants mustcomplete and submitaCMERequestForm pation inthiseducationalactivity, International Congress In ordertoreceiveaCMECertificate authenticatingpartici- Requesting CMECredit Certificates participation inapprovedliveeducationalactivities. Continuing MedicalEducation)creditsearnedthrough Category 1andEACCME(European Accreditation Councilfor agree totheexchangeandreciprocalrecognitionof AMA PRA Under thetermsofthisjointagreement,UEMSand AMA Medical Association (AMA)hasbeenextendeduntil2006. Union ofMedicalSpecialists(UEMS)andthe American A pilotCMEcreditreciprocitysystembetweentheEuropean Credit Systems Reciprocity betweentheEuropeanand AMA PRA Award. The American Medical Association (AMA)Physician’s Recognition reviewed andapprovedforCategory1credittowardthe Movement DisordersandParkinson’s Diseasehasbeen The scientificprogramofthe8thInternationalCongress Availability ofCMECredit approaches forthetreatmentofMovementDisorders. school studentswithaninterestinthecurrentresearchand clinicians, researchers,post-doctoralfellowsandmedical Parkinson’s DiseaseandMovementDisordersincludes The targetaudienceofthe8thInternationalCongress Target Audience Discussthepharmacological andnon-pharmacological · Discussthe diagnosticapproachesandtoolsavailablefor · Describethepathophysiology andneurobiologyof · should bebetterableto: As aresultofparticipatinginthisactivity, theattendee Objectives Movement published inanabstractsupplementtotheMDSJournal, All abstractsacceptedforposterpresentationhavebeen Abstract Volume located inyourregistrationbag. visit theMedtronicBooth#129andexchangevoucher grant fromMedtronicNeurological.To obtainacopy, please MDS andsupportedthroughanunrestrictededucational will alsobeavailableby Abstracts-On Disk™sponsoredby All abstractspublishedinthesupplementtoMDSJournal THE claimed foreachhourofparticipation. actually spentintheeducationalactivity. Onecreditmaybe Each physicianshouldclaimonlythosecreditsthathe/she educational activityforamaximumof39Category1credits. CONTINUING MEDICAL CONTINUING MEDICAL ABSTRACTS-ON-DISK ABSTRACTS-ON-DISK other MovementDisorders treatment optionsavailableforParkinson’s disease and Parkinson’s diseaseandotherMovementDisorders Parkinson’s diseaseandotherMovementDisorders MOVEMENT Disorders. Eachdelegatewillreceiveonecopywith Movement DisorderSocietyhasapprovedthis DISORDERSOCIETY TM EDUCA EDUCA EDUCA EDUCA EDUCA EACH DA EACH DA EACH DA EACH DA EACH DA Y Y Y oftheCon- Y Y INTERNA INTERNA INTERNA INTERNA INTERNA TION TION TION TION TION TIONAL TIONAL TIONAL TIONAL TIONAL disclosure ofcommercialrelationships. registration bagforcompleteinformationregardingfaculty Please seetheyellowinsertinyourInternationalCongress presented. possible biasineithertheexpositionorconclusions outsideinterest mayreflecta mine whetherthespeaker’s disclosure ofthefacts.Itremainsforaudiencetodeter- their ownjudgmentsaboutthepresentationwithfull should beidentifiedopenlysothatthelistenersmayform presentation. Itismerelyintendedthatanypotentialconflict speaker withapotentialconflictofinterestfrommaking presentation topic.Theintentofthispolicyisnottopreventa products orservicesarerelatedtothesubjectmatterof biomedical devicemanufacturers,orothercorporationswhose pertains torelationshipswithpharmaceuticalcompanies, of thecontinuingmedicaleducation(CME)activity. This interest thatmayhaveadirectbearingonthesubjectmatter to theactivityaudienceanyrealorapparentconflict(s) ing inanyMDSsponsoredactivitiesarerequiredtodisclose in allsponsorededucationalactivities. All facultyparticipat- ensure balance,independence,objectivity, andscientificrigor the RegistrationDesk. from allmeetingroomattendantsortheCMEDesknear ground floor. Additional CMERequestFormscanbeobtained are collecteduponregisteringattheRegistrationDeskon registration bags.InternationalCongressbags International Congressintheir Participants canfindCMERequestFormsforeachdayofthe Desk onthegroundfloorofCongressi. returned totheCMEDesksituatednearRegistration forms. Alternatively, completedCMERequestFormscanbe It isthepolicyofThe Faculty FinancialDisclosureInformation meeting room attendants ortotheMDSRegistration Desk. When completed, evaluationsmaybereturned toyour essential inplanningfuture educationalprogramsforMDS. for eachsessionyouattend. Your inputandcommentsare Please taketimetocomplete theevaluationformsprovided Evaluations at [email protected]. Society ofNeurology, attelephone+3950879740orbye-mail Technical SecretariatforCME Accreditation, theItalian Italian Physicians,pleasecontactMaddalenaRediniatthe For informationregardingContinuingMedicalEducation for Physicians Continuing MedicalEducationforItalian disclosure ofunlabeledproductusediscussion. registration bagforcompleteinformationregardingfaculty Please seetheyellowinsertinyourInternationalCongress Congress audienceoftheirintent. cial productsand/ordevicesmustadvisetheInternational Speakers whoplantodiscussnon-approvedusesforcommer- investigative natureoftheirproposedusestotheaudience. must clearlyacknowledgetheunlabeledindicationsor related tonon-approvedusesfordrugproductsand/ordevices Presentations whichprovideinformationinwholeorpart Discussion Faculty DisclosureofUnlabeledProductUse CONGRESSINFORMA CONGRESSINFORMA CONGRESSINFORMA CONGRESSINFORMA CONGRESSINFORMA Movement DisorderSociety(MDS)to TION TION TION TION TION 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 13 International Congress in the Press Room. Press International Congress in the Press Room. th TION TION TION TION TION Sunday, June 13 June Sunday, June 14Monday, June 15Tuesday, June 16Wednesday, 17 June Thursday, 8:00 am to 5:00 pm to 5:00 pm 8:00 am pm 8:00 am to 5:00 8:00 am to 5:00 pm 8:00 am to 5:00 pm SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM NO CAMERAS NO CAMERAS TOURS OPTIONAL TOURS OPTIONAL PRESS ROOM PRESS ROOM SCIENTIFIC PROGRAM NO CAMERAS TOURS OPTIONAL PRESS ROOM Kickoff Seminars treatment Kickoff Seminars emphasize pharmacological as well as diagnostic approaches for Movement Disorders, industry supported strategy overviews and updates. These Congress registrants. seminars are open to all International Plenary and Parallel Sessions to offer a variety of Plenary and Parallel Sessions continue discussion from popular topics in lecture format and panel renowned neurologists and Movement Disorder specialists from around the world. Each presenter offers his/her perspec- tive and information on the latest studies and research on disease and other Movement Disorders. These Parkinson’s main sessions are open to all International Congress regis- trants. Seminars Sessions offering Italian cuisine are featured throughout the and International Congress week, similar to the popular Wine Cheese Seminars from the 7th International Congress in view on Miami in 2002. Each session offers an expert’s Movement Disorders through a variety of topics. Seminars have limited registration to encourage discussion and interac- tion with presenters. Fee: $55 USD/ $40 USD for junior participants and allied health professionals. Cameras are not permitted in any 8th International Congress any 8th International are not permitted in Cameras poster areas. session or in the educational arranged by: have been Tours ARISTEA 5 Tolmino, Via 00198 Roma - Italy +39 06 845431 Tel. Fax +39 06 84543700 Area on the Desk in the Registration Please visit the Tours Additional tour your tour tickets. Ground Floor to collect at this desk, based on availability. tickets may be purchased Location: Press Room, Ground Floor without charge Members of the working media may register for the 8 must register, provide credentials and wear their badge for provide credentials and wear must register, admittance into MDS sessions. Press Room hours are as follows: SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM NO CAMERAS NO CAMERAS TOURS OPTIONAL TOURS OPTIONAL PRESS ROOM PRESS ROOM AND AND AND AND AND TION ST TION ST TION ST TION ST TION ST CONGRESS INFORMA CONGRESS INFORMA CONGRESS CONGRESS INFORMA CONGRESS CONGRESS INFORMA CONGRESS INFORMA CONGRESS AND INFORMA AND INFORMA AND INFORMA AND INFORMA AND INFORMA TIONAL TIONAL TIONAL TIONAL TIONAL Disorder Society (MDS) is an international Movement Saturday, June 12Saturday, June 13Sunday, June 14Monday, June 15Tuesday, June 16Wednesday, June 17 pm 3:00 pm to 8:30 Thursday, to 5:30 pm 8:00 am 8:00 am to 5:30 pm pm 8:00 am to 5:30 8:00 am to 5:30 pm 8:00 am to 5:00 pm Monday, June 14Monday, June 15Tuesday, June 16Wednesday, June 17Thursday, 8:00 am to 5:00 pm 8:00 am to 5:00 pm 8:00 am to 5:00 pm 8:00 am to 5:00 pm INTERNA INTERNA MDS EXHIBIT MDS EXHIBIT LUNCH OPTIONS LUNCH OPTIONS INTERNET CAFÉ INTERNET CAFÉ EXHIBITION EXHIBITION society of healthcare professionals committed to research and disease and other patient care in the fields of Parkinson’s disorders of movement and motor control. MDS supports and promotes a wide range of educational programming and other initiatives to advance scientific under- standing and standards of care as they pertain to Movement Disorders. For this, MDS provides forums such as a high ranking journal, scientific symposia and international congresses. Attendees are invited to take advantage of MDS member Learn more about MDS benefits by applying to the Society. initiatives and speak with a representative at the MDS Exhibit and Information Stand located in the Registration Area during the following hours: Location: Registration Area, Ground Floor Location: Registration The MDS EXHIBIT Location: Ground Floor and snacks may be Lunch bags containing sandwiches, fruit required for lunch and may be pur- are purchased. Tickets chased at the Registration Desk. Quick Lunch Rooftop Terrace Restaurant Rooftop Terrace Location: Rooftop Terrace Restau- Terrace Served lunch will be available at the Rooftop for lunch and may be purchased at are required rant. Tickets the Registration Desk. LUNCH OPTIONS INTERNET CAFÉ Location: First Floor attendees on the Internet access will be available to meeting The Internet Café is First Floor of the Palazzo dei Congressi. grant from supported through an unrestricted educational use to 15 minutes so Cephalon, Inc. Please limit your internet service. that other attendees can also access this EXHIBITION Ground Floor Location: to visit the in your daily schedule adequate time Please allow the Palazzo the Ground Level of throughout exhibits located your exhibition is an integral component of dei Congressi. The experience, offering you the opportu- International Congress representatives of companies that provide nity to speak with products directly related to Movement services and market will be available to discuss these Disorders. Representatives during the following hours: services and products INTERNA MDS EXHIBIT MDS EXHIBIT LUNCH OPTIONS LUNCH OPTIONS INTERNET CAFÉ INTERNET CAFÉ EXHIBITION EXHIBITION INTERNA INTERNA 14 Rome, Italy SOCIAL EVENTS SOCIAL EVENTS SOCIAL EVENTS 8:30 pmto9:30 pm Location: SaloneDellaCultura, GroundFloor Opening Ceremony Sunday, June13 Abstracts 1018-1338 Authors PresentEvenNumbers:1:00pmto2:00 Authors PresentOddNumbers:12:00pmto1:00 Poster Viewing: 8:30amto4:30pm Thursday, June17 Location: FirstFloor Poster Session4 Abstracts 695-1017 Authors PresentEvenNumbers:4:00pmto5:00 Authors PresentOddNumbers:11:30 amto12:30pm Poster Viewing: 8:30amto5:00pm Wednesday, June16 Location: FirstFloor Poster Session3 Abstracts 345-694 Authors PresentEvenNumbers:4:00pmto5:00 Authors PresentOddNumbers:11:30 amto12:30pm Poster Viewing: 8:30amto5:00pm Tuesday, June15 Location: FirstFloor Poster Session2 Abstracts 1-344 Authors PresentEvenNumbers:4:00pmto5:00 Authors PresentOddNumbers:12:00pmto1:00 Poster Viewing: 8:30amto5:00pm Monday, June14 Location: FirstFloor Poster Session1 are featuredeachdayutilizingthefollowingschedule: indicated agreatinterestinPosterSessions.Sessions Delegate feedbackfrompastInternationalCongresseshas Abstract PosterSessions Congress delegates. are heldasmainsessions,andopentoallInternational disease andMovementDisorders.ThePlatformPresentations newsworthy andcutting-edgeinformationaboutParkinson’s at theInternationalCongress.Theabstractsselectedfeature 16 abstractshavebeenselectedfororalplatformpresentation Platform Presentations health professionals. Fee: $80USD/$55USDforjuniorparticipantsandallied during thesessions. video sessionsparticipationislimited.Dinnerserved generate clinicaldiscussions.To ensuregreaterinteraction, tions ofatypicalMovementDisordersengagedelegatesand Congress, Video Dinnersareagainoffered.Video presenta- Due tooutstandingreviewsfromtheMiamiInternational Video Dinners THE SOCIAL EVENTS SOCIAL EVENTS MOVEMENT DISORDERSOCIETY INTERNA INTERNA INTERNA INTERNA INTERNA TIONAL TIONAL TIONAL TIONAL TIONAL TRANSPORT TRANSPORT SPEAKER READYROOM SPEAKER READYROOM Fee: $100USDperperson dei Congressi. based onavailabilityattheRegistrationDeskinPalazzo registration materials. Additional ticketsmaybepurchased, Tickets purchasedinadvanceareenclosedeachdelegate’s also availableforthosestayinginthecitycenter. the event. A metrostation,closetotheBrancaccioPalace,is pm. ShuttleswilldeparttheBrancaccioPalaceatendof Palazzo deiCongressiandSheratonRomabeginningat7:30 Transportation totheBrancaccioPalaceisprovidedfrom highlight theevening. d’oeuvres; dinnerwillbeserved,andlocalentertainment The evening’s itinerarybeginswithcocktailsand hors in Rome. this palaceisstillconsideredoneofthemostbeautifulplaces Built byPrincessElizabethandSalvatoreBrancaccioin1880, Palazzo BrancaccioisthenewestRomanpatricianpalace. 8:00 pmto11:00 pm Palace International CongressBanquetattheBrancaccio Monday, June14 be heldontheRooftopTerrace. the OpeningCeremony, amoonlightWelcome Receptionwill tional OpeningCermonyandWelcome Reception. Following are invitedtomeetfriendsandcolleaguesduringthetradi- All InternationalCongressattendeesandregisteredguests 9:30 pmto11:00 pm Location: RooftopTerrace Welcome Reception Palazzo deiCongressiisavailable. metro maponpage51. A shuttlefromFermiStationtothe subway taketheBLinetoFermi Station.Pleaserefertothe To reachthe PalazzodeiCongressifromtheCityCenterby materials. city centerreceivemetropassesintheiron-siteregistration and thePalazzodeiCongressi.Delegatescommutingfrom the Shuttle serviceisofferedbetweentheSheratonRomaHotel The SpeakerReadyRoomhoursareasfollows: for assistance. their presentations. Audio visualpersonnelwillbeavailable presentation. Equipmentisavailableforfacultytoreview presentation materialsonthedaypriortotheirscheduled All speakersmustcheckinattheSpeakerReadyRoomwith Location: SlideReviewRoom,GroundFloor TRANSPORT SPEAKER READYROOM TRANSPORT TRANSPORT SPEAKER READYROOM SPEAKER READYROOM hrdy ue1 7:00amto4:30pm 7:00amto8:00pm 7:00amto8:00pm 7:00amto6:00pm 7:00amto8:00pm Thursday, 5:00pmto8:00 June17 Wednesday, June16 Tuesday, June15 Monday, June14 Sunday, June13 Saturday, June12 CONGRESSINFORMA CONGRESSINFORMA CONGRESSINFORMA CONGRESSINFORMA CONGRESSINFORMA A A A A A TION TION TION TION TION TION TION TION TION TION tp_Medtronic_p15_16 6/1/04 9:34 AM Page 1

ACTIVA® THERAPY INCREASES PARKINSON’SPATIENT “ON” TIME BY AN AVERAGE OF 6 HOURS.*

ACTIVA IMPLANT SECOND HONEYMOON September 19, 2003 December 1, 2003

It’s Easier Than Ever to Add Activa Therapy to Your Neurology Practice

www.brainstimulation.net

When drugs no longer provide adequate relief, there’s Activa Therapy. • Effective for 87% of qualifying Parkinson’s disease patients.** • Effective for bradykinesia/akinesia, tremor, and/or rigidity.* • More than 25,000 people implanted worldwide.

Visit Medtronic at booth 129 to learn more.

* Results were for a subset of patients whose data were verified against medical records. Data on file at Medtronic, Inc. ** PD symptom improvement with medication off. Results were for a subset of patients whose data were verified against medical records. Data on file at Medtronic, Inc. tp_Medtronic_p15_16 6/1/04 9:34 AM Page 2

Activa® Parkinson’s Control Therapy and Tremor Control Therapy: Product technical manual must be reviewed prior to use for detailed disclosure.

Indications: Parkinson’s Control Therapy: Bilateral stimulation of the internal globus pallidus (GPi) or the subthalamic nucleus (STN) using Medtronic Activa® Parkinson’s Control Therapy is indicated for adjunctive therapy in reducing some of the symptoms of advanced, levodopa-responsive Parkinson’s disease that are not adequately controlled with medication. Tremor Control Therapy: Unilateral thalamic stimulation by the Medtronic Activa® Tremor Control System is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with Essential Tremor or Parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability. The safety or effectiveness of this therapy has not been established for bilateral stimulation.

Contraindications: Contraindications include patients who will be exposed to MRI using a full body radio-frequency (RF) coil or a head transmit coil that extends over the chest area, patients for whom test stimulation is unsuccessful, or patients who are unable to properly operate the neurostimulator. Also, diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy) is contraindicated because diathermy’s energy can be transferred through the implanted system (or any of the separate implanted components), which can cause tissue damage and can result in severe injury or death. Diathermy can damage parts of the neurostimulation system.

Warnings/Precautions/Adverse Events: There is a potential risk of tissue damage using stimulation parameter settings of high amplitudes and wide pulse widths. Extreme care should be used with lead implantation in patients with a heightened risk of intracranial hemorrhage. Do not place the lead-extension connector in the soft tissues of the neck. Placement in this location has been associated with an increased incidence of lead fracture. Theft detec- tors and security screening devices may cause stimulation to switch ON or OFF, and may cause some patients to experience a momentary increase in perceived stimulation. Although some MRI procedures can be performed safely with an implanted Activa System, clinicians should carefully weigh the decision to use MRI in patients with an implanted Activa System. MRI can cause induced voltages in the neurostimulator and/or lead possibly causing uncomfortable, jolting, or shocking levels of stimulation. MRI image quality may be reduced for patients who require the neurostimulator to control tremor, because the tremor may return when the neurostimulator is turned off.

Severe burns could result if the neurostimulator case is ruptured or pierced. The Activa System may be affected by or adversely affect medical equipment such as cardiac pacemakers or therapies, cardioverter/ defibrillators, external defibrillators, ultrasonic equipment, electrocautery, or radiation therapy. Safety and effectiveness has not been established for patients with neurological disease other than Parkinson’s disease or Essential Tremor, previous surgical ablation procedures, dementia, coagulopathies, or moderate to severe depression; or for patients who are pregnant, under 18 years, over 75 years of age (Parkinson’s Control Therapy) or over 80 years of age (Tremor Control Therapy). Adverse events related to the therapy, device, or procedure can include: stimulation not effective, cognitive disorders, pain, dyskinesia, dystonia, speech disorders including dysarthria, infection, paresthesia, intracranial hemorrhage, electromagnetic interference, cardiovascular events, visual disturbances, sensory disturbances, device migration, paresis/asthenia, abnormal gait, incoordination, headaches, lead repositioning, thinking abnormal, device explant, hemiplegia, lead fracture, seizures, respiratory events, and shocking or jolting stimulation.

Rx only 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 17 5:00 PM 6:00 PM 7:00 PM 8:00 PM 9:00 PM 7:00 AM 8:00 AM 9:00 AM 1:00 PM 2:00 PM 3:00 PM 4:00 PM 11:00 AM 11:00 10:00 AM 12:00 PM 10:00 PM , June 17 , June 17 , June 17 , June 17 , June 17 Thursday Thursday 7 & 8 Thursday Parallel Sessions Parallel Sessions Thursday Thursday , June 16 , June 16 , June 16 , June 16 , June 16 ednesday ednesday ednesday ednesday ednesday W W W W W , June 15 , June 15 , June 15 , June 15 , June 15 uesday uesday uesday uesday uesday T T Video DinnersVideo Dinners Video T Presentations Meeting Lunch Break Lunch Break T T , June 14 , June 14 , June 14 , June 14 , June 14 Monday Monday Congress Banquet Even Numbers Even Numbers Even Numbers Marsden LectureOdd Numbers Fahn Lecture and Lunch Monday Workgroups Workgroups Workgroups Workgroups Committees andCommittees and Committees Committees and Committees and Monday Monday GLANCE GLANCE GLANCE GLANCE GLANCE Kickoff Seminar Kickoff Seminar 9 Seminar Series Seminar Series Seminar Series KickoffSeminarAwards Junior 4 Poster Session 2 Poster Session 1 Poster Session 3 Seminar Odd Numbers6 Odd Numbers 3 & 4 Poster Session 4 A A A A A , June 13 , June 13 , June 13 , June 13 , June 13 T T T T T A A A A A Sunday Sunday Welcome Reception Welcome Opening Ceremony KickoffSeminar Kickoff Seminar 10 11 KickoffSeminar 7 8 Poster Session 1 2 Poster Session Poster Session 3 KickoffSeminar 5 Lunch Break Kickoff Plenary Session 2 Parallel Sessions Plenary Session 4 KickoffSeminar Kickoff Seminar3 2 MDS Business 5 & 6 Sunday KickoffSeminar Kickoff Seminar1A Session 1 Plenary Parallel Sessions 1B Plenary Session 3 Series Seminar 1 & 2 Platform Sunday Sunday 6:00 PM 8:00 PM 10:00 PM 9:00 PM 7:00 PM 5:00 PM 4:00 PM 3:00 PM 2:00 PM 1:00 PM 12:00 PM 11:00 AM 11:00 10:00 AM 7:00 AM 9:00 AM 8:00 AM PROGRAM PROGRAM PROGRAM PROGRAM PROGRAM PROGRAM PROGRAM PROGRAM 18 Rome, Italy KICKOFF SEMINARS KICKOFF SEMINARS SUNDA SUNDA KICKOFF SEMINARS SUNDA hi:MarkHallett Society. Chair: Disorder Movement The by Sponsored Location: Assembly Hall,GroundFloor insights intocauseandtreatment Kickoff Seminar1B:Essentialtremor:new 8:30 amto9:30 and instructpatientsinitsappropriatehandling. Parkinson’s disease;4.Useanapomorphineinjectablepen disease; 3.Explainwhen“rescuetherapy”isneededin apomorphine anditsuseasa“rescueagent”inParkinson’s advanced Parkinson’s disease;2.Discussthehistoryof to: 1.Describethemotorcomplicationsassociatedwith At theconclusionofthissession,participantsshouldbeable William Koller Society. Chairs: Disorder Movement The by Sponsored Location: SaloneDellaCultura,GroundFloor disease: turningofftoon Kickoff Seminar1A:ManagingParkinson’s 8:30 amto9:30 THE KICKOFF SEMINARS KICKOFF SEMINARS SUNDA SUNDA Supported through an unrestricted educational grant educational unrestricted an through Supported grant educational unrestricted an through Supported from Ortho-McNeil Pharmaceutical. Ortho-McNeil from Inc. Pharmaceuticals, Bertek from MOVEMENT specific objectives will be shared with participants at the beginning of the session. the of beginning the at participants with shared be will objectives specific Y Y Y Y Y Panel discussion Kiel, Germany Günther Deuschl Pathophysiology ofessentialtremor Houston, TX,USA Joseph Jankovic tremor Medical andsurgicaltreatmentofessential Bethesda, MD,USA Panel discussion Durham, NC,USA Mark Stacy disease Apomorphine asarescueagentinParkinson’s London, UnitedKingdom Andrew Lees The historyofapomorphine Rome, Italy Fabrizio Stocchi New York,NY, USA , JUNE13,2004 , JUNE13,2004 , JUNE13,2004 , JUNE13,2004 , JUNE13,2004 DISORDERSOCIETY In sessions not listing learning objectives, learning listing not sessions In for depressioninPD. PD; 3.Describewhataretheeffectivetherapeuticapproaches scales shouldbeusedtoevaluatetheseverityofdepressionin patients withParkinson’s disease;2.Describewhichrating to: 1.Describehowtoidentifyanddiagnosedepressionin At theconclusionofsession,participantsshouldbeable HeinzReichmann Society. Chairs: Disorder Movement The by Sponsored Location: Assembly Hall,GroundFloor disease: roleofdopamineagonists Kickoff Seminar2:DepressioninParkinson’s 10:00 amto11:00 am his ClaudiaTrenkwalder Society. Chairs: Disorder Movement The by Sponsored Location: SaloneDellaCultura,GroundFloor advances indiagnosisandtreatment Kickoff Seminar3:Restlesslegssyndrome: 10:00 amto12:00pm Supported through an unrestricted educational grant educational unrestricted an through Supported grant educational unrestricted an through Supported from Pfizer, Inc. Pfizer, from GmbH. International Ingelheim Boehringer from Panel discussion Napoli, Italy Paolo Barone depression inParkinson’s disease Role ofdopamineagonistsinthetreatment Chicago, IL,USA Christopher G.Goetz features andsignificance Depression inParkinson’s disease:clinical Tokyo, Japan Yoshikuni Mizuno Dresden, Germany Panel discussion Bremerhave, Germany Per Odin Dopaminergic treatment Edison, NJ,USA Arthur S.Walters Non-dopaminergic treatment Madrid, Spain Diego GarciaBorreguero Diagnosis anddifferentialdiagnosis London, UnitedKingdom Ray Chaudhuri Update onetiologyandpathogenesis Montreal, Canada Jacques Montplaisir Kassel, Germany SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 19 Disorder Society. Disorder Society.

Cheryl Waters USA NY, New York, Panel discussion Thomas Roth Detroit, MI, USA Restless legs syndrome—treatment Richard Allen Bethesda, MD, USA Panel discussion London, United Kingdom Weiner William Baltimore, MD, USA disease CDS, delivery methods in Parkinson’s Peter LeWitt Southfield, MI, USA Novel transdermal delivery approaches for disease Parkinson’s Ramat Aviv, Israel Ramat Aviv, Joaquim Ferreira Portugal Vedras, Torres perspectives in Dopamine agonists—historical disease Parkinson’s Kapil Sethi Augusta, GA, USA Restless legs syndrome—pathophysiology Paulus Walter Gottingen, Germany and Restless legs syndrome—diagnosis significance to patients from Schwarz Pharma. from GlaxoSmithKline. Supported through an unrestricted educational grant Supported through an unrestricted educational grant At the conclusion of this session, participants should be able to: At the conclusion of this session, participants to diagnose and treat 1. Discuss the syndrome, understand how pathogenisis. it and explain the theories on it; 2. Describe 1:30 pm to 2:30 pm delivery of Kickoff Seminar 6: Transdermal dopaminergic drugs Assembly Hall, Ground Floor Location: Sponsored by The Movement Chairs:Quinn Niall 1:00 pm to 3:00 pm 1:00 pm Agonists—New Seminar 5: Dopamine Kickoff of Parkinson’s in the treatment perspectives syndrome and restless legs disease Ground Floor Salone Della Cultura, Location: Sponsored by The Movement Chairs: Amos Korczyn Disorder Society.

David J. Brooks London, United Kingdom other Movement Disorders Neuroimaging in A. Jon Stoessl Canada Vancouver, Panel discussion London, United Kingdom Oertel Wolfgang Marburg, Germany diagnosis and assessment Use of imaging for disease of therapy in Parkinson’s from from Amersham Health. Supported through an unrestricted educational grant SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC At the conclusion of this session, participants should be able At the conclusion of this session, participants of PET and SPECT to: 1. Understand the basic principles disease; 2. Explain the role of SPECT imaging in Parkinson’s of Parkinson’s and PET imaging in diagnosis and therapy PET imaging in disease; 3. Define the role of SPECT and 4. Highlight the diagnosis of other Movement Disorders; imaging in the routine clinical value of dopamine transporter assess 5. To work-up of patients with Movement Disorders; for disease progres- the role of imaging as a surrogate marker sion in parkinsonian syndromes. Sponsored by The Movement Chairs: Lees Andrew 11:30 am to 12:30 pm am to 12:30 11:30 Seminar 4: Neuroimaging Kickoff Floor Assembly Hall, Ground Location: 20 Rome, Italy propargylamines. identify therationaleforMAO-B inhibitorsand trials ofdiseasemodifyingagents inParkinson’s diseaseand Parkinson’s disease;3.Discussissuesinthe designofclinical inhibitors andpropargylamines acrossthevariousstagesof Parkinson’s disease; 2.DefineefficacyandsafetyofMAO-B propargylamines inthetreatmentofdenovopatientswith to: 1.DescribetheroleofMAO-Binhibitorsand At theconclusionofsession,participantsshouldbeable AnthonyE.Lang Chairs: Movement The by Sponsored Location: SaloneDellaCultura,GroundFloor inhibitors andpropargylamines treatment ofParkinson’s diseaseusingMAO-B Kickoff Seminar8:Newdirectionsinthe 3:30 pmto5:30 BrunoDubois Chairs: Movement The by Sponsored Location: Assembly Hall,GroundFloor neuropsychiatric issuesinParkinson’s disease Kickoff Seminar7: Addressing dementiaand 3:00 pmto4:00 THE Supported through an unrestricted educational grant educational unrestricted an through Supported grant educational unrestricted an through Supported from Teva Pharmaceutical Industries Ltd., Teva Ltd., Industries Pharmaceutical Teva from Pharma. Novartis from Neuroscience, Lundbeck and Eisai. and Lundbeck Neuroscience, MOVEMENT Panel discussion Rochester, NY, USA Ira Shoulson progression Rationale andpotentialformodifyingdisease Toulouse, France Olivier Rascol Role inthetreatmentofadvanceddisease Philadelphia, PA, USA Matthew B.Stern Role inthetreatmentofearlydisease Innsbruck, Austria Werner Poewe Toronto, Canada Panel discussion Capa Istanbul,Turkey Murat Emre dementia andwithLewybodies Treatment optionsinParkinson’s disease USA Birmingham, AL, Ray Watts disease neuropsychiatric symptomsinParkinson’s The challengesofdementiaand Newcastle UponTyne, UnitedKingdom Ian McKeith Paris, France DISORDERSOCIETY

Disorder Society. Disorder Society. Disorder the developmentofimmunogenicityagainstbotulinumtoxin. botulinum toxinforcervicaldystonia;3.Listriskfactors adverse events;2.Discusslongtermbenefitsandsafetyof to: 1.ListfactorsassociatedwiththeoccurrenceofBTX-A At theconclusionofthissession,participantsshouldbeable AlfredoBerardelli Chairs: Movement The by Sponsored Location: Assembly Hall,GroundFloor Kickoff Seminar9:Isbotulinumtoxintoxic? 4:30 pmto5:30 Supported through an unrestricted educational grant educational unrestricted an through Supported from Allergan, Inc. Allergan, from Panel discussion Houston, TX,USA Joseph Jankovic toxin administration Immunogenicity andlong-termbotulinum Wuerzburg, Germany Markus Naumann Are therelong-termtoxicityissues? Chicago, IL,USA Cynthia L.Comella Rome, Italy SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM

Disorder Society. Disorder 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 21 Disorder Society.

Fabrizio Stocchi Rome, Italy of COMT inhibitors in the treatment disease Parkinson’s Robert Hauser FL, USA Tampa, Panel discussion Paris, France Olanow C. Warren USA NY, New York, motor complications Levodopa-related Eldad Melamed Israel Petah Tiqva, in CDS approaches to animal models disease Parkinson’s Peter Jenner London, United Kingdom CDS approaches to treating Parkinson’s disease patients from Novartis Pharma/Orion Pharma. Supported through an unrestricted educational grant 6:00 pm to 8:00 pm 6:00 pm the in Levodopa-CDS Seminar 11: Kickoff the role of disease: of Parkinson’s treatment COMT-inhibition Hall, Ground Floor Assembly Location: Sponsored by The Movement Chairs: Agid Yves Disorder Society.

Ken Marek USA New Haven, CT, Panel discussion Dopamine agonists in the prevention and Dopamine agonists in the prevention treatment of motor and non-motor complications José Obeso Pamplona, Spain Dopamine agonists as putative neuroprotective agents Etiology of Parkinson’s disease Etiology of Parkinson’s Etienne Hirsch Paris, France of Motor and non-motor complications disease levodopa-treated Parkinson’s Eduardo Tolosa Barcelona, Spain Buenos Aires, Argentina Schapira Anthony H.V. London, United Kingdom from Pfizer, Inc. Supported through an unrestricted educational grant SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC At the conclusion of this session, participants should be able At the conclusion of this session, participants that presently try to to: 1. Describe some of the hypothesis disease; of Parkinson’s explain the etiology and pathogenesis the putative 2. Discuss the controversies related to and the tools neuroprotective effects of dopamine agonists the motor and non- used in their evaluation; 3. Recognize under long-term motor complications that affect PD patients levodopa treatment. Chairs: Gershanik Oscar Location: Salone Della Cultura, Ground Floor Salone Della Cultura, Location: Sponsored by The Movement 6:00 pm to 8:00 pm 6:00 pm as agonists Seminar 10: Dopamine Kickoff Parkinson’s therapy in disease modifying potential disease SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC 22 Rome, Italy MONDA MONDA MONDA Authors presentoddnumbers Abstract Numbers1-344 Location: Poster Area, FirstFloor Abstract PosterSession1 12:00 pmto1:00 Location: SaloneDellaCultura,GroundFloor Junior Awards 11:30 amto12:00pm in theetiopathogenesisofParkinson’s disease. Parkinson’s disease;3.Explaintheroleofproteinprocessing involved inthemechanismofneuronaldegeneration Parkinson’s disease;2.Describethemechanismspotentially to: 1.Listthemajorfactorsinvolvedinetiopathogenesisof At theconclusionofthissession,participantsshouldbeable EtienneHirsch Co-chair: C.Warren Olanow Chair: Location: SaloneDellaCultura,GroundFloor in Parkinson’s disease Plenary Session1:Etiopathogenesisofcelldeath 8:30 amto11:00 am THE MONDA MONDA Location: SaloneDellaCultura,GroundFloor neurodegenerative diseases models forexperimentaltherapeuticsof The valueoftransgenicandgenetargeted C. DavidMarsdenLecture 11:00 amto11:30 am Baltimore, MD,USA Donald Price MOVEMENT New York,NY, USA Kevin McNaught The UPSandmodelsofParkinson’s disease New York,NY, USA Serge Przedborski neurodegeneration stress, inflammationandexcitotoxicityin Pathogenesis: Roleofmitochondria,oxidative Bethesda, MD,USA John Hardy Genetic causesofParkinson’s disease Sunnyvale, CA,USA J.W. Langston environmental factorsofcelldeath Etiology: Updateongeneticand Paris, France New York,NY, USA Y Y Y Y Y , JUNE14,2004 , JUNE14,2004 , JUNE14,2004 , JUNE14,2004 , JUNE14,2004 DISORDERSOCIETY ocar NobuoYanagisawa Co-chair: JoséObeso Chair: Location: SaloneDellaCultura,GroundFloor limitations pathophysiological model:contributionsand Plenary Session2:Thebasalganglia 1:30 pmto4:00 Location: RooftopTerraceVarious and Locations Lunch 1:00 pmto1:30 Authors presentevennumbers Abstract Numbers1-344 Location: Poster Area, FirstFloor Abstract PosterSession1 4:00 pmto5:00 ganglia activity Dopamine depletionandmodificationofbasal Jerusalem, Israel Hagai Bergman ganglia: misconceptions Anatomical chemicalorganizationofthebasal Kawasaki-City, Japan Nobuo Yanagisawa Introduction: themodel Kawasaki-City, Japan Pamplona, Spain Pamplona, Spain José Obeso Conclusion: lessonsfromthemodel London, UnitedKingdom John Rothwell man Consequence oflesionthebasalgangliain London, UnitedKingdom Peter Brown firing, rhythmsandpatterns Neuronal activityandMovementDisorders: St. Louis,MO,USA Joel Perlmutter Functional imagingofthebasalganglia Bordeaux, France Erwan Bezard SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 23 Peter Pramstaller Bolzano, Italy Lawrence Golbe New Brunswick, NJ, USA Christopher Goetz Christopher USA Chicago, IL, Cheryl Waters USA NY, New York, and management) Giovanni Fabbrini Rome, Italy François Tison Pessac, France S106Location: Meeting Room 2, First Floor - PSP/CBGD: clinical update Parkinsonism At the conclusion of this session, participants should be able to: 1. Recognize the clinical features of progressive supra- nuclear palsy and corticobasal degeneration and be able to apply formal clinical diagnostic criteria to distinguish PSP and CBD from each other and from competing diagnostic considerations; 2. Explain the clinical deficits of PSP and CBD to patients and caregivers in order to help them avoid complications of the illness, including those caused by unnecessary diagnostic testing and useless treatments; 3. Describe current understanding of the etiology and pathogen- esis of the brain degeneration in PSP and CBD, including what is known of the genetic and toxic factors so that they can provide informed answers to patients’ and families’ questions regarding familial and occupational risks. S104 Floor Meeting Room 3, First Location: disease Parkinson’s Case management: able this session, participants should be At the conclusion of disease based options for Parkinson’s to: 1. Define treatment from clinical trials; 2. Discuss treatment on current evidence evidence from disease, combining options for Parkinson’s practice experience; 3. Recognize manage- clinical trials with of problem-specific for the treatment ment options that are of disease progression. disease at different phases Parkinson’s S105Room 7, Ground Floor Location: Meeting disease in the elderly (diagnosis Parkinson’s should be able At the conclusion of this session, participants differential diagnosis to: 1. Discuss the general principals of 2. Describe the clinical in the elderly parkinsonian patients; aged parkinsonian phenotype and the clinical problems of pattern of patients, with regard to the biological the general neurodegeneration observed in the elderly, and psychiatric comorbidities, the incidence of dementia available treatment in disturbances; 3. Discuss the currently to the paucity of elderly parkinsonian patients, with regard pharmokinetic and controlled studies, the differences in the drugs in this popula- pharmacodynamic of antiparkinsonian tion. neurodegenerative disease Horacio Kaufmann USA NY, New York, Ronald Pfeiffer Memphis, TN, USA S.H. Subramony Jackson, MS, USA Stefan Pulst USA Angeles, CA, Los Philip Thompson Adelaide, Australia North Terrace, Hans Meinck Heidelberg, Germany SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC S103Location: Meeting Room 6, First Floor nervous system function in Autonomic At the conculsion of this session, participants should be able to: 1. Recognize autonomic dysfunction is a frequent and sometimes dominant feature of the “synucleinpathic” neurodegenerative Movement Disorders such such as and dementia disease multiple system atrophy, Parkinson’s with Lewy bodies; 2. Identify the specific cardiovascular, sexual, urinary and gastrointestinal features of autonomic dysfunction in neurodegenerative Movement Disorders; 3. Discuss appropriate diagnostic and treatment approaches for sexual, urinary and gastrointestinal the cardiovascular, manifestations of autonomic dysfunction in neurodegenerative Movement Disorders. S102Location: Meeting Room 1, First Floor Ataxias should be able At the conclusion of this session, participants of inherited to: 1. Recognize the clinical manifestations diagnosis; 2. Describe ataxias and discuss their differential with their interpreta- the use of genetic tests and be familiar and dominant tion; 3. Discuss the pathogenesis of recessive ataxias. Location: Meeting Room 5, First Floor Location: Meeting S101 syndrome Advances in stiff person should be able At the conclusion of this session, participants of the stiff man to: 1. Identify the clinical manifestations the appropriate syndrome and its variants; 2. Describe status and to rule out diagnostic tests to confirm the diagnosis therapeutic options. other relevant diseases; 3. Discuss the 5:00 pm to 6:30 pm 5:00 pm Series Seminar on Monday. are featured Italian cuisine Sessions featuring Disorders view on Movement offers an expert’s Each session discussion and encourage variety of topics. To through a and a series have limited registration interaction, the seminar admission. ticket is required for USD for junior participants and allied Fee: $55 USD/ $40 health professionals. 24 Rome, Italy medication, opirids,gabapentinandothers. ate treatmentstrategiesforRLSincludingdopaminergic pathophysiological conceptsofRLS;3.Indicatetheappropri- thy, sleepapneawithPLM,PLMDandtoexplainpossible that areimportanttodifferentiateRLSfromi.e.polyneuropa- role ofsleepdisturbance;2.Discussthedifferentialdiagnosis syndrome includingtheessentialdefinitioncriteriaand to: 1.Describeanddefinethekeyfeaturesofrestlesslegs At theconclusionofthissession,participantsshouldbeable Restlesslegssyndrome Location: MeetingRoom8,GroundFloor S108 the mostcommonpediatricMovementDisorders. Movement Disorders;3.Explainthedifferentialdiagnosisof Disorders; 2.Listthemostcommontreatmentsofchildhood to: 1.RecognizethemostcommonpediatricMovement At theconclusionofthissession,participantsshouldbeable PediatricMovementDisorders Location: MeetingRoom4,FirstFloor S107 THE MOVEMENT Kassel, Germany Claudia Trenkwalder Arnold, MD,USA Richard Allen Stanford, CA,USA Terence Sanger London, UnitedKingdom Robert Surtees DISORDERSOCIETY SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM

8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 27 in zona incerta , JUNE 15, 2004 , JUNE 15, 2004 , JUNE , JUNE 15, 2004 , JUNE , JUNE 15, 2004 , JUNE 15, 2004 , JUNE Y Y Y Y Y Roy Bakay Abstract Number: P947 Elan Louis Abstract Number: P954 AMPA and Combined use of NMDA antagonists further reduces levodopa-induced dyskinesias in MPTP-lesioned primates Francesco Bibbiani Abstract Number: P606 Predicting incident non-motor complications with of dopaminergic therapy in patients secondary A disease: early Parkinson’s analysis of the CALM-PD trial Kevin Biglan Abstract Number: P576 Is levodopa-induced dyskinesias risk decreased in parkinsonian patients initially longitudinal A treated with dopamine agonist? study among 425 patients Franck Durif Abstract Number: P608 Neuronal activity of Marcelo Merello Abstract Number: P894 Predicting success after deep brain stimulation placement in the subthalamic disease patients nucleus in Parkinson’s Chicago, IL, USA Marburg, Germany a novel PARK6, Identification of causing Parkinson’s mitochondrial protein disease Enza Maria Valente P1042 Abstract Number: in Endocannabinoid levels are altered parkinsonism and L-DOPA-induced macaque dyskinesia in the MPTP-lesioned Susan Fox Abstract Number: P1163 in the Parkinsonian signs in older people A community and risk of incident dementia: prospective longitudinal population-based study Parkinson’s disease patients Parkinson’s SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC TUESDA TUESDA TUESDA 8:30 am to 10:30 am 8:30 am Presentations: Session 1: Platform Parallel disease Parkinson’s Cultura, Ground Floor Location: Salone Della Chair: Cynthia Comella Co-chair: Oertel Wolfgang SCIENTIFIC PROGRAM SCIENTIFIC TUESDA TUESDA SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC 28 Rome, Italy Authors present oddnumbers Abstract Numbers345-694 Location: Poster Area, FirstFloor Abstract PosterSession 2 11:30 amto12:30pm SaloneDellaCultura,GroundFloor Location: MDS BusinessMeeting 10:30 amto11:30 am MuratEmre Co-chair: PeterRiederer Chair: Location: Assembly Hall,GroundFloor Movement Disorders Parallel Session2:PlatformPresentations:Other THE MOVEMENT Abstract Number:P977 Annie Lannuzel Guadeloupean parkinsonism Experimental evidenceforatoxicetiologyof Abstract Number:P982 Hansjoerg Baezner (Leukoaraiosis And DISability)project Cross-sectional resultsoftheLADIS with age-relatedwhitematterchanges- Gait andmotordisturbancesarecorrelated Abstract Number:P900 Philippe Damier multicentric studySTARDYS dyskinesia: PreliminaryreportoftheFrench Pallidal stimulationtotreattardive Abstract Number:P955 David Williams syndrome andPSP-Parkinsonism progressive supranuclearpalsy:Richardson’s phenotypes observedinpathologicallyproven Characteristics oftwodistinctclinical Abstract Number:P985 Maureen Leehey ataxia syndrome(FXTAS) Misdiagnosis offragileXassociatedtremor/ Abstract Number:P1263 Madhavi Thomas Disorders Long termprognosisofpsychogenicMovement Abstract Number:P124 Simone Rossi paradigm Evidence fromagatingstudyinSEP sensorimotor integrationdysfunction? Is ObsessiveCompulsiveDisorder(OCD)a Abstract Number:P156 Michael Orth Gilles delaTourette syndrome afferent sensoryinhibitioninpatientswith Nicotine correctsimpairedmotor-motor and Capa Istanbul,Turkey Wuerzburg, Germany DISORDERSOCIETY ocar I.G.McKeith Co-chair: Bruno Dubois Chair: Location: SaloneDellaCultura,GroundFloor dysfunction inMovementDisorders Parallel Session3:Cognitiveandbehavioral 1:30 pmto4:00 Location: RooftopTerraceVarious and Locations Lunch 12:30 pmto1:30 lobe-related processes. the basalgangliainexecutivefunctionsandotherfrontal lesions ofthebasalganglia;3.Recognizeinvolvement motivation andthemechanismofapathyinpatientswith Recognize theroleofbasalgangliainregulation associated withParkinson’s diseaseandrelateddisorders;2. to: 1.Describethepatternofcognitivechangesanddementia At theconclusionofthissession,participantsshouldbeable Pittsburg, PA, USA Peter Strick Movement Disorders cognitive andbehavioralchangesin Anatomical andphysiologicalbasisof Istanbul, Turkey Murat Emre Parkinson’s disease Cognitive changesanddementiain Newcastle UponTyne, UnitedKingdom Paris, France London, Canada Mandar Jog Reward andthebasalganglia Cambridge, UnitedKingdom Adrian Owen Executive functionandbasalganglia Paris, France Richard Levy Motivation, apathyandthebasalganglia SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 29 Daniel Perl USA NY, New York, David John Burn United Kingdom Newcastle Upon Tyne, Antonio Currà Rome, Italy Robert Chen Canada Toronto, Wilson’s, acanthocytosis, etc.) acanthocytosis, Wilson’s, Peter LeWitt MI, USA Southfield, Kailash Bhatia London, United Kingdom Kaji Ryuji Japan City, Tokushima Josep Valls-Solé Barcelona, Spain S204Location: Meeting Room 6, First Floor with Lewy bodies Dementia S205Location: Meeting Room 7, Ground Floor Magnetic stimulation in Movement Disorders At the conclusion of this session, participants should be able safety and limitations to: 1. Describe basic principles, utility, of transcranial magnetic stimulation (TMS); 2. Discuss the main TMS findings in common Movement Disorders such a myoclonus and disease, dystonia, chorea, tremor, Parkinson’s tics; 3. Identify the current and possible future clinical and research applications of TMS in Movement Disorders. S202 Floor Meeting Room 3, First Location: (PKAN, Disorders Rare genetic Movement able this session, participants should be At the conclusion of clinical features of several rare genetic to: 1. Recognize typical disease, including Wilson’s Movement Disorders, PKAN, neuroferritinopathy and others; neuroacanthocytosis, options for differentiating these 2. Discuss the diagnostic and define these various available Movement Disorders, the available management strategies genetic tests; 3. Indicate of these Movement Disorders. and the natural history S203Location: Meeting Room 5, First Floor dyskinesias Facial should be able At the conclusion of this session, participants presenting with to: 1. Describe the most relevant syndromes relevant clinical and facial dyskinesias; 2. Recognize the most each of the electrophysiological features that characterize 3. Discuss the syndromes presenting with facial dyskinesias; for differential key electrophysiological features useful with facial diagnosis between disorders presenting dyskinesias. Paolo Barone Napoli, Italy David Rye Atlanta, GA, USA Update on essential tremor Elan Louis USA NY, New York, Elena Cattaneo Milano, Italy ataxia Update on Friedreich’s Schapira Anthony H. V. London, United Kingdom Disorders Update on psychogenic Movement Mark Hallett Bethesda, MD, USA Update on dystonia Enza Maria Valente Rome, Italy disease Update on Huntington’s Rochester, NY, USA NY, Rochester, Boston, MA, USA SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC S201Location: Meeting Room 1, First Floor disease Sleep problems in Parkinson’s Seminar Series Sessions featuring Italian cuisine are featured on Tuesday. view on Movement Disorders Each session offers an expert’s encourage discussion and through a variety of topics. To interaction, Seminar Series have limited registration and a ticket is required for admission. Fee: $55 USD/ $40 USD for junior participants and allied health professionals. 5:00 pm to 6:30 pm Abstract Poster Session 2 Area, First Floor Location: Poster Abstract Numbers 345-694 Authors present even numbers 4:00 pm to 5:00 pm At the conclusion of this session, participants should be able At the conclusion of this session, participants 2. disease; to: 1 Describe the latest research in Huntington’s tremor; 3. Describe the Describe the latest update in essential the latest update in latest research in dystonia; 4. Describe the latest psychogenic Movement Disorders; 5. Describe update in essential tremor. Parallel Session 4: Update on other Movement Session 4: Update Parallel Disorders Floor Assembly Hall, Ground Location: Chair: Ira Shoulson Co-chair: Anne Young SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC 30 Rome, Italy 28PrinciplesofanimalmodelsinMovement Location: MeetingRoom4,FirstFloor S208 UPDRS sothattheoldandnewversionscanbecompared. 3. Recognizetheplansforclinimetrictestingofnew the UPDRS;2.Identifynewchangesandtheirrationales; to: 1.Definethehallmarksoforiginalandnewversions At theconclusionofthissession,participantsshouldbeable TheNewUPDRS Location: MeetingRoom2,FirstFloor S207 disease. increase ordecreasesusceptibilitytodevelopingParkinson’s nants ofparkinsonism;3.Understandthefactorsproposedto tion ofParkinson’s disease;2.Describethegeneticdetermi- to: 1.Describethedemographicsandinternationaldistribu- At theconclusionofthissession,participantsshouldbeable EpidemiologyandgeneticsofParkinson’s Location: MeetingRoom8,GroundFloor S206 THE MOVEMENT Boston, MA,USA Jie Shen Baltimore, MD,USA Ted M.Dawson Disorders Chicago, IL,USA Christopher G.Goetz New York,NY, USA Stanley Fahn Sunnyvale, CA,USA Caroline Tanner Rome, Italy Vincenzo Bonifati disease DISORDERSOCIETY 12Dystonia V102 different causesofatypicalparkinsonism. parkinsonism; 3.Discussthedifferentialdiagnosisbetween parkinsonism; 2.Identifyindividualspecificcausesofatypical to: 1.Recognizeclinicalfeaturessuggestiveofatypical At theconclusionofthissession,participantsshouldbeable Atypicalparkinsonism Location: MeetingRoom1,FirstFloor V101 health professionals. Fee: $80USD/$55USDforjuniorparticipantsandallied title indicates,dinnerisservedduringthesessions. of participants,andaticketisrequiredforadmission. As the interaction, Video Dinnersarelimitedtoamaximumnumber delegates andgenerateclinicaldiscussions.To ensuregreater Video presentationsofatypicalMovementDisordersengage Video Dinners 7:00 pmto9:00 these disorders. and startle;3. Describethevarioustreatment optionsfor syndromes; 2.Listthepossible etiologiesofformmyoclonus to: 1.Recognizethemajorforms ofmyoclonusandstartle At theconclusionofthissession, participantsshouldbeable Myoclonus/startleandotherjerks Location: MeetingRoom4,FirstFloor V104 disorders submittedbyanyoneattendingtheseminar. and peripheralnervoussystem;3.Discussunusualgait uncommon gaitdisorderscausedbypathologyofthecentral and lower-level gaitdisorders;2.Recognize thecommonand to: 1.Describetheclinicaldifferencesbetweenhighest-level At theconclusionofthissession,participantsshouldbe able Gait disorders Location: MeetingRoom2,FirstFloor V103 cological, chemodeneration,andsurgicalapproaches. Discuss therapeuticstrategiesindystonia,includingpharma- etiologic, includinggenetic,classificationofdystonia;3. and focaldystonia,asillustratedbyvideos;2.Discussthe to: 1.Recognizethephenomenologyofgeneralized,segmental At theconclusionofthissession,participantsshouldbeable Location: MeetingRoom3,FirstFloor London, UnitedKingdom Niall Quinn Barcelona, Spain Eduardo Tolosa Bethesda, MD,USA Hiroshi Shibasaki New York,NY, USA Steven Frucht Springfield, IL,USA Roger Elble Portland, OR,USA John Nutt Houston, TX,USA Joseph Jankovic Englewood, NJ,USA Susan Bressman SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 31 Parkinsonism and dementia David Burn United Kingdom Newcastle Upon Tyne, Toronto, Canada Toronto, Houston, TX, USA disease: in Parkinson’s Neuroprotective trials prospects design issues and Karl Kieburtz USA NY, Rochester, in symptomatic treatment New approaches Olivier Rascol France Toulouse, Atypical parkinsonism Andrew Lees London, United Kingdom New developments in neuroimaging A. Jon Stoessl Canada Vancouver, At the conclusion of this session, participants should be able At the conclusion of this session, participants in to: Identify the possible targets for neuroprotection and understand the research design disease Parkinson’s putative issues that must be considered in evaluating strategies; 2. Describe neuroprotective and disease-modifying of disorders the clinical and neuropathological aspects dementia associated presenting as atypical parkinsonism and available to with parkinsonism and discuss the approaches 3. Discuss new diagnosis and management of these disorders; parkinsonian disorders developments in the neuroimaging of treatment of and new approaches to the symptomatic disease. Parkinson’s 4:00 pm to 5:00 pm Abstract Poster Session 3 Area, First Floor Location: Poster Abstract Numbers 695-1017 Authors present even numbers 5:00 pm to 6:30 pm Seminar Series Sessions featuring Italian cuisine are featured on Wednesday. view on Movement Disorders Each session offers an expert’s encourage discussion and through a variety of topics. To interaction, Seminar Series have limited registration and a ticket is required for admission. Fee: $55 USD/ $40 USD for junior participants and allied health professionals. 1:30 pm to 4:00 pm 1:30 pm the concepts in Session 4: Modern Plenary of parkinsonism and treatment diagnosis Ground Floor Salone Della, Cultura, Location: Chair: Anthony E. Lang Co-chair: Joseph Jankovic , JUNE 16, 2004 , JUNE 16, 2004 , JUNE , JUNE 16, 2004 , JUNE , JUNE 16, 2004 , JUNE 16, 2004 , JUNE Y Y Y Y Y Trophic factors Trophic Clive Svendsen Madison, WI, USA Clinical point of view Olle Lindvall Lund, Sweden John Nutt Portland, OR, USA Stem cells Ole Isacson Belmont, MA, USA strategies Transplantation Patrik Brundin Lund, Sweden Lund, Sweden Portland, OR, USA Gene therapy Jeffrey Kordower Chicago, IL, USA Huda Zoghbi Houston, TX, USA Location: Salone Della Cultura, Ground Floor Stanley Fahn Lecture Molecular pathogenesis of dominately inherited ataxias 11:00 am to 11:30 am am to 11:30 11:00 SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC WEDNESDA WEDNESDA 12:30 pm to 1:30 pm Lunch Locations and Various Location: Rooftop Terrace Location: Poster Area, First Floor Location: Poster Abstract Numbers 695-1017 Authors present odd numbers 11:30 am to 12:30 pm 11:30 Abstract Poster Session 3 At the conclusion of this session, participants should be able At the conclusion of this session, participants of neurorestorative to: 1. Describe the three basic mechanisms neural grafting and adminis- therapies, namely gene therapy, the advantages and tration of neurotrophic factors; 2. Discuss fetal cells for neural disadvantages of stem cells relative to genes and neurotropic grafting; 3. List techniques to deliver factors to the central nervous system. Co-chair: John Nutt Location: Salone Della Cultura, Ground Floor Location: Salone Della Chair: Olle Lindvall WEDNESDA am to 11:00 8:30 am interventional Session 3: Experimental Plenary Disorders for Movement therapeutics SCIENTIFIC PROGRAM SCIENTIFIC WEDNESDA WEDNESDA SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC 32 Rome, Italy management. Describe appropriateinvestigations;3.therapeutic to: 1.DescribetypicalandatypicalpresentationsofMSA; 2. At theconclusionofthissessionparticipantsshouldbeable Parkinsonism-MSA:clinicalupdate Location: MeetingRoom6,FirstFloor S304 Disorders. the preventionandmanagementofdrug-inducedMovement antipsychotic drug-inducedMovementDisorders;3.Discuss medications; 2.Discussthepathophysiologicbasisfor chotic drugs,antidepressants,stimulants,lithiumandother to: 1.RecognizetheMovementDisorderscausedbyantipsy- At theconclusionofthissession,participantsshouldbeable DruginducedMovement Disorders Location: MeetingRoom3,FirstFloor S303 tious diseases. management ofMovementDisordersassociatedwithinfec- agents thatcancauseMovementDisorders;3.Discussthe associated withinfectiousdiseases;2.Listthe to: 1.DescribethephenomenologyofMovementDisorders At theconclusionofthissession,participantsshouldbeable Systemicandinfectiousdiseasesthatcause Location: MeetingRoom1,FirstFloor S302 factors thatleadtodystonia. dystonia; 3.Identifythegeneticandenvironmentalrisk dystonia; 2.Describetheepidemiologyandprevalenceof to: 1.Recognizeanddiagnosethevariousclinicalformsof At theconclusionofthissession,participantsshouldbeable Clinical/epidemiologyofdystonia Location: MeetingRoom5,FirstFloor S301 THE MOVEMENT Louisville, KY, USA Irene Litvan Innsbruck, Austria Gregor Wenning Boston, MA,USA Daniel Tarsy Baltimore, MD,USA William Weiner Belo HorizonteMG,Brazil Francisco Cardoso Atlanta, GA,USA Jorge LuisJuncos Movement Disorders Bari, Italy Gianni Defazio London, UnitedKingdom Thomas Warner DISORDERSOCIETY involved. pathophysiology ofParkinson’s diseasebasedonthegenes young onsetParkinson’s disease);3.Discuss themolecular genetics inParkinson’s disease(withparticularreferenceto tics ofyoungonsetParkinson’s disease; 2.Describetheroleof to: 1.Describetoclinicalandneuropathologicalcharacteris- At theconclusionofthissession,participantsshouldbeable Young onsetparkinsonism Location: MeetingRoom4,FirstFloor S306 Parkinson’s diseaseanddiscusstheirclinicalsignificance. pathological abnormalitiesinthecircuitsidiopathic control, discusstheirfunctionalconnectivity, identifyall basal gangliaandthalamicregionsinvolvedinmovement discuss theirclinicalsignificance;3.Identifythecortical, Parkinson’s diseaseidentifythebrainregionsinvolved,and new neuropathologicalstagingschemeforidiopathic and determineanyrelationshipbetweenthem;2.Describethe pathic Parkinson’s disease,discusstheirintracellularorigins to: 1.Identifythemaincellularpathologiesfoundinidio- At theconclusionofthissession,participantsshouldbeable Newdevelopmentsinthepathologyof Location: MeetingRoom7,GroundFloor S305 38Botulinumtoxinmechanismsandapplications Location: MeetingRoom8,GroundFloor S308 molecular pathophysiologyofParkinson’s disease. misfolded proteins;3.DiscusstherelevanceofUPSin the molecular chaperonesinmitigatingthedamagecaused by proteasome system(UPS);2.Explainthepotentialroles of to: 1.Describethemolecularcomponentsofubiquitin- At theconclusionofthissession,participantsshouldbeable Ubiquitinproteasome systeminParkinson’s Location: MeetingRoom2,FirstFloor S307 Munich, Germany Christoph Lücking London, UnitedKingdom Anette Schrag Randwick, Australia Glenda Halliday Frankfurt, Germany Heiko Braak Parkinson’s disease Rostock, Germany Dirk Dressler Rostock, Germany Reiner Benecke Watertown, MA,USA Michael Sherman Bethesda, MD,USA Mark Cookson disease SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 33 Rajesh Pahwa KS, USA Kansas City, Oscar Gershanik Argentina Buenos Aires, V204Location: 4, First Floor Meeting Room Movement Disorders Unusual able this session, participants should be At the conclusion of be are the necessary steps that have to to: 1. Indicate what of a analysis of the phenomenology made for the systematic the Movement Disorder; 2. Identify patient with an unusual can involuntary movements that different types of abnormal as cases shown during the video session be observed in the step towards the recognition of an unusual the first necessary will ask the audience to The presenters Movement Disorder. peculiar features that distinguish one carefully observe the a from the other and subsequently reach Movement Disorder of categorical descrip- reasoned identification with the help that can present tions. 3. Recognize a wide variety of diseases frequently constitute with unusual Movement Disorders and neurologist. a diagnostic challenge for the general Andrew Lees London, United Kingdom Nir Giladi Israel Aviv, Tel Anthony E. Lang Canada Toronto, John Morris Australia Sydney, Kailash Bhatia London, United Kingdom Kapil Sethi Augusta, GA, USA At the conclusion of this session, participants should be able At the conclusion of this session, participants to: 1. Recognize some unusual and rare causes of Parkinson’s syndrome; 2. Recognize some rare presentations of disease; 3. Receive factual information relating to Parkinson’s the nature and diagnosis of the rare cases to be presented by video. V203Location:Meeting Room 3, First Floor Rare examples of Parkinsonism At the conclusion of this session, participants should be able At the conclusion of this session, participants of psychogenic Move- to: 1. Identify the key clinical features between psy- ment Disorders; 2. Recognize the difference Disorders chogenic Movement Disorders and Movement nervous system; 3. associated with organic disease of the of psychogenic Define some of the underlying mechanisms Movement Disorders. Location: Meeting Room 2, First Floor V202 Movement Disorders Psychogenic Location: Meeting Room 1, First Floor Location: Meeting V201 Movement Disorders Paroxysmal 7:00 pm to 9:00 pm 7:00 pm Dinners Video engage Movement Disorders of atypical presentations Video greater ensure discussions. To and generate clinical delegates a maximum number are limited to Dinners Video interaction, As the a ticket is required for admission. of participants, and is served during the sessions. title indicates, dinner USD for junior participants and allied Fee: $80 USD/ $55 health professionals. SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC 34 Rome, Italy SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM THURSDA THURSDA SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM THURSDA dystonia, basedonclassificationandclinicalfeatures. to identifyandchoosethemostappropriatetreatmentfor At theconclusionofthissession,participantsshouldbe able Clinicalmanagementofdystonia Location: MeetingRoom1,FirstFloor S403 proaches tothetreatmentofchoreicdisease. history; 3.Discusstheappropriatepharmacologicalap- depending oncharacteristicsofdiseasepresentationand Describe theappropriatediagnosticwork-upforchorea to: 1.Recognizecommonandrarechoreicsyndromes;2. At theconclusionofthissession,participantsshouldbeable Differentialdiagnosisandmanagement of Location: MeetingRoom3,FirstFloor S402 inherited MovementDisorder. take tobeginmoleculargeneticanalysisofafamilywithan genetics studies;3.Recognizethefirststepsaclinicianshould Identify familiesandpopulationsofinterestformolecular aimed atidentifyinggenesthatcauseMovementDisorders;2. to: 1.Describethemajortypesofmoleculargeneticstudies At theconclusionofthissession,participantsshouldbeable BasicgeneticsinMovementDisorders Location: MeetingRoom5,FirstFloor S401 health professionals. Fee: $55USD/$40USDforjuniorparticipantsandallied registration andaticketisrequiredforadmission. discussion andinteraction,SeminarSerieshavelimited Movement Disordersthroughavarietyoftopics.To encourage featured onThursday. Eachsessionoffersanexpert’s viewon Sessions featuringanItaliancontinentalbreakfastare Seminar Series 8:30 amto10:00 THE THURSDA THURSDA MOVEMENT Paris, France Marie Vidailhet Milano, Italy Alberto Albanese Belo HorizonteMG,Brazil Francisco Cardoso Chicago, IL,USA Kathleen Shannon choreas Bethesda, MD,USA Andrew Singleton Bethesda, MD,USA John Hardy Y Y Y Y Y , JUNE17,2004 , JUNE17,2004 , JUNE17,2004 , JUNE17,2004 , JUNE17,2004 DISORDERSOCIETY PD-psychosis. psychosis; 3.Understandthepharmacotherapeuticchoicesin Understand thephamacotherapeuticstrategiesinPD- to: 1.UnderstandthepathophysiologyofPD-psychosis;2. At theconclusionofthissession,participantsshouldbeable Managementofpsychiatricdisturbancesin Location: MeetingRoom6,FirstFloor S405 treatment; 3.Identifytheoptimalstrategyinagivenpatient. available oralmedications,druginfusion,andsurgical the firstplaceandtotreatmotorcomplications,including List allavailablestrategiestopreventmotorcomplicationsin tions anddyskinesiasexplaintheirpathophysiology;2. to: 1.Describetheclinicalcharacteristicsofmotorfluctua- At theconclusionofthissession,participantsshouldbeable Managementofmotorcomplicationsin Location: MeetingRoom2,FirstFloor S404 stimulation throughDBSleads. tion-induced adverseeffects during intra-operativetest GPI andSTNinParkinson’s disease;3.Recognizestimula- STN; 2.Recognizeelectrophysiologiccharacteristicsofthe to: 1.DescribeMRI-basedtargetlocalizationforGPIand At theconclusionofthissession,participantsshouldbe able Targeting thebasal gangliaforfunctional Location: MeetingRoom4,FirstFloor S407 clinical trialsofcoenzymeQ10inneurodegererativediseases. neuroprotection inanimalstudies;3.Describetheresultsof coenzyme Q10;2.DescribetheresultsofQ10for to: 1.Explainthevariousneuroprotectivepropertiesof At theconclusionofthissession,participantsshouldbeable MitochondrialfunctionsinMovement Location: MeetingRoom7,GroundFloor S406 Atlanta, GA,USA Jorge LuisJuncos Amsterdam, Netherlands E. Ch.Wolters Parkinson’s disease USA Birmingham, AL, Ray Watts Grenoble, France Paul Krack Parkinson’s disease Pamplona, Spain Maria Rodriguez-Oroz San Francisco,CA,USA Philip Starr surgery New York,NY, USA M. FlintBeal San Diego,CA,USA Cliff Shults Disorders: therapeuticimplication 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 35 SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC Günther Deuschl Kiel, Germany of The use and physiological mechanisms with alternative cues to treat patients Movement Disorders Robert Iansek Cheltenham, Australia Conclusion John Rothwell London, United Kingdom Rome, Italy London, United Kingdom does the experimental Introduction: how Disorders fit with data in model for Movement individual diseases? Alfredo Berardelli Rome, Italy of basal ganglia plasticity Basic mechanisms Paolo Calabresi Rome, Italy pathology of The role of sensory deficits in the dystonia Giovanni Abbruzzese Genova, Italy Are we nearer to understanding the mechanisms of tremor? At the conclusion of this session, participants should be able At the conclusion of this session, participants ganglia and cortical to: 1. Describe the contribution of basal symptoms of patients plasticity to the presentation of clinical describe the possible mecha- with Movement Disorders; 2. To CNS regions in nisms of tremor and the roles of different and why it may be different types of tremor; 3. Discuss how necessary to treat some of Movement Disorder symptoms with alternative cues for movement. 12:00 pm to 2:00 pm Abstract Poster Sessions and Lunch Poster Location:Area, First Floor Poster Lunch Location: Locations and Various Rooftop Terrace Abstract Numbers 1018-1338 Authors present odd numbers from 12:00 pm to 1:00 pm Authors present even numbers from 1:00 pm to 2:00 pm Parallel Session 6: Pathophysiology of Movement of Session 6: Pathophysiology Parallel Disorders Floor Hall, Ground Location:Assembly Chair: Alfredo Berardelli Co-chair: John Rothwell Conclusion Stanley Fahn USA NY, New York, Graft-related dyskinesias Olanow C. Warren USA NY, New York, Pathophysiology of graft-related dyskinesias José Obeso Pamplona, Spain Angela Cenci Lund, Sweden Pathophysiologic basis of dyskinesia Jonathan Brotchie Canada Toronto, Molecular mechanisms Thomas Chase Bethesda, MD, USA Introduction and primate model Peter Jenner London, United Kingdom Rodent model of dyskinesia New York, NY, USA NY, New York, London, United Kingdom David Lichter USA NY, Clarence, Michael Trimble London, United Kingdom At the conclusion of this session, participants should be able to: 1. Have an understanding of the pathophysiology of levodopa-induced dyskinesias; 2. Recognize and understand the cause of graft-induced dyskinesias; 3. Better identify and treat dopa-induced dyskinesias. Parallel Session 5: Dyskinesias in Parkinson’s Parallel Session 5: Dyskinesias disease Floor Location: Salone Della Cultura, Ground Chair: Stanley Fahn Co-chair: Peter Jenner 10:00 am to 12:00 pm S408 Floor Meeting Room 8, Ground Location: syndrome update Tourette able this session, participants should be At the conclusion of syndrome criteria for Tourette to: 1. Discuss the diagnostic for assessment of tics and comorbid (TS) and tools available in TS, especially obsessive neuropsychiatric conditions (OCD) and attention deficit hyperactivity compulsive disorder Describe current concepts of pathophysi- disorder (ADHD); 2. of TS, as derived from post-mortem, ology and neurobiology and neurophysiologic, genetic neurochemical, neuroimaging, patients, as well as studies in experimen- clinical stdies in TS the pharmacological and non- tal animals; 3. Discuss of tics, OCD, pharmalogical options available for treatment in TS patients. ADHD and other comorbid disorders 36 Rome, Italy SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM treatment ofParkinson’s disease. Lewy bodiessignifyinParkinson’s disease;3.Discussinitial to: 1.DiscussPETisParkinson’s disease;2.Explainwhat At theconclusionofthissession,participantsshouldbe able DonaldCalne Co-chair: Yves Agid Chair: Location: SaloneDellaCultura,GroundFloor Parallel Session7:Controversies 2:00 pmto4:30 THE MOVEMENT New Haven,CT, USA Kenneth Marek normal F-dopa/PETorDAT/SPECT?: NO Can youhaveParkinson’s diseasewitha Petah Tiqva, Israel Eldad Melamed normal F-dopa/PETorDAT/SPECT?: YES Can youhaveParkinson’s diseasewitha Tokyo, Japan Yoshikuni Mizuno Parkinson’s disease?NO Do youneedLewybodiestodiagnose Jacksonville, FL,USA Dennis Dickson Parkinson’s disease? YES Do youneedLewybodiestodiagnose Baltimore, MD,USA Harvey Singer and Tourette’s: NO Immunology inMovementDisorders:PANDAS London, UnitedKingdom Gavin Giovannoni and Tourette’s: YES Immunology inMovementDisorders:PANDAS Rochester, MN,USA J. Eric Ahlskog progression: NO Imaging endpointsreflectParkinson’s disease London, UnitedKingdom David Brooks progression: YES Imaging endpointsreflectParkinson’s disease Baltimore, MD,USA William Weiner be withadopamineagonist:NO Initial therapyinParkinson’s diseaseshould Innsbruck, Austria Werner Poewe be withadopamineagonist: YES Initial therapyinParkinson’s diseaseshould Vancouver, Canada Paris, France DISORDERSOCIETY ocar William Koller Co-chair: AlimBenabid Chair: AssemblyHall,GroundFloor Location: Parallel Session8:Surgery in Parkinson’s disease. regarding themechanismofactionDBSsubthalamus Parkinson’s disease;3.Understandthecurrentknowledge clinical responsethatcanbeexpectedwithDBStreatmentof surgical treatmentofMovementDisorders;2. Appreciate the to: 1.Recognizetheindicationsandpatientselectionsof At theconclusionofthissession,participantsshouldbeable stimulation surgeryinMovementDisorders The futureofablativeanddeepbrain Buenos Aires, Argentina Marcelo Merello Surgery fordystoniaandtremor Grenoble, France Pierre Pollak neurologist’s pointofview Issues insurgeryforParkinson’s disease:a Kiel, Germany Jens Volkmann disease Deep brainstimulationforParkinson’s Atlanta, GA,USA Jerrold Vitek Ablative surgeryforParkinson’s disease New York,NY, USA Grenoble, France Toronto, Canada Andres Lozano

38 Rome, Italy PS03 Lund, Sweden Patrik Brundin PS02 London, UnitedKingdom Peter Brown PRS05 Toronto, Canada Jonathan M.Brotchie KS04, PRS07 London, UnitedKingdom David J.Brooks V102 Englewood, NJ,USA Susan B.Bressman S305 Frankfurt, Germany Heiko Braak S206 Roma, Italy Vincenzo Bonifati S202, V201 London, UnitedKingdom Kailash P. Bhatia PS02 Bordeaux, France Erwan Bezard PS02 Jerusalem, Isreal Hagai Bergman KS09, PRS06 Roma, Italy Alfredo Berardelli S308 Rostock, Germany Reiner Benecke PRS08 Grenoble, France Alim L.Benabid S406 New York,NY, USA M. FlintBeal KS02, S201 Napoli, Italy Paolo Barone KS05, S108 Arnold, MD,USA Richard P. Allen S403 Milano, Italy Alberto Albanese PRS07 Rochester, MN,USA J. Eric Ahlskog KS11, PRS07 Paris, France Yves Agid PRS06 Genova, Italy Giovanni Abbruzzese THE MOVEMENT DISORDERSOCIETY PS04, S204 Kingdom Newcastle UponTyne, United David JohnBurn S301 Bari, Italy Gianni Defazio S208 Baltimore, MD,USA Ted M.Dawson S205 Venafro, Italy Antonio Currà S307 Bethesda, MD,USA Mark Cookson KS09, PRS01 Chicago, IL,USA Cynthia L.Comella S205 Toronto, Canada Robert Chen KS03 London, UnitedKingdom Ray Chaudhuri PRS05 Bethesda, MD,USA Thomas N.Chase PRS05 Lund, Sweden Angela M.Cenci PRS04 Milano, Italy Elena Cattaneo S302, S402 Belo HorizonteMG,Brazil Francisco Cardoso PRS07 Vancouver, Canada Donald B.Calne PRS06 Rome, Italy Paolo Calabresi V103 Springfield, IL,USA Roger J.Elble KS07, PRS03 Paris, France Bruno Dubois S308 Rostock, Germany Dirk W. Dressler PRS07 Jacksonville, FL,USA Dennis Dickson KS1B, PRS06 Kiel, Germany Günther Deuschl Key: KS=KickoffSeminar, PS=PlenarySession,PRSParallelSSeminar, V=Video Dinner Nir Giladi KS10, V204 Buenos Aires,Argentina Oscar S.Gershanik KS03 Madrid, Spain Diego GarciaBorreguero V104 New York,NY, USA Steven Frucht KS05 Torres Vedras, Portugal Joaquim Ferreira PRS05, S207 New York,NY, USA Stanley Fahn S105 Rome, Italy Giovanni Fabbrini KS07, PRS02,PRS03 Capa Istanbul,Turkey Murat Emre KS10, PRS05 London, United Kingdom Peter Jenner KS1B, KS09, PS04,V102 Houston, TX,USA Joseph Jankovic PS03 Belmont, MA,USA Ole Isacson PRS06 Cheltenham, Australia Robert Iansek KS10, PS01 Paris, France Etienne C.Hirsch KS11 Tampa, FL,USA Robert Hauser PS01, S401 Bethesda, MD,USA Hardy John A. S305 Randwick, Australia Glenda M.Halliday KS1B, PRS04 Bethesda, MD,USA Mark Hallett S106 New Brunswick,NJ,USA Lawrence I.Golbe KS02, S104,S207 Chicago, IL,USA Christopher G.Goetz PRS07 London, UnitedKingdom Gavin Giovannoni V203 Tel Aviv,Israel Jeffrey H.Kordower KS05 Ramat-Aviv, Isreal Amos Korczyn KS1A, PRS08 New York,NY, USA William C.Koller PS04 Rochester, NY, USA Karl D.Kieburtz S103 New York,NY, USA Horacio Kaufman S203 Tokushima City, Japan Ryuji Kaji S302, S405 Atlanta, GA,USA Jorge LuisJuncos PRS03 London, Canada Mandar Jog S306 Munich, Germany Christoph Lücking PRS08 Toronto, Canada Andres M.Lozano PRS04 New York,NY, USA Elan D.Louis S304 Louisville, KY, USA Irene Litvan PS03 Lund, Sweden Olle Lindvall S408 Clarence, NY, USA David G.Lichter KS06, S202 Southfield, MI,USA LeWitt Peter A. PRS03 Paris, France Richard Levy KS1A, KS04,PS04,V203 London, UnitedKingdom Andrew J.Lees PS01 Sunnyvale, CA,USA J. William Langston KS08, PS04,V202 Toronto, Canada Anthony E.Lang S404 Grenoble, France Paul Krack PS03 Chicago, IL,USA FACUL FACUL FACUL FACUL FACUL TY TY TY TY TY 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 39 Anne B. Young Anne B. Boston, MA, USA PRS04 Huda Zoghbi Houston, TX, USA Stanley Fahn Lecturer Atlanta, GA, USA PRS08 Jens Volkmann Kiel, Germany PRS08 Arthur S. Walters Edison, NJ, USA KS03 Warner Thomas T. London, United Kingdom S301 Cheryl H. Waters USA NY, New York, KS06, S104 Ray L. Watts Birmingham, AL, USA KS07, S404 J. Weiner William Baltimore, MD, USA KS06, PRS07, S303 Gregor K. Wenning Innsbruck, Austria S304 E. Ch. Wolters Amsterdam, Netherlands S405 Nobuo Yanagisawa Japan Kawasaki-city, PS02 Francois Tison Pessac, France S105 Eduardo Tolosa Spain Barcelona, KS10, V101 Claudia M. Trenkwalder Kassel, Germany KS03, S108 Michael R. Trimble London, United Kingdom S408 Enza Maria Valente Rome, Italy PRS04 Josep Valls-Sole Barcelona, Spain S203 Marie Vidailhet Paris, France S403 Jerrold Lee Vitek Caroline M. Tanner Sunnyvale, CA, USA S206 Daniel Tarsy Boston, MA, USA S303 Philip D. Thompson Adelaide, North Terrace, Australia S101 Bethesda, MD, USA S401 Mark Stacy Durham, NC, USA KS1A Philip Starr San Francisco, CA, USA S407 Matthew Stern USA Philladelphia, PA, KS08 Fabrizio Stocchi Rome, Italy KS1A, KS11 A. Jon Stoessl Canada Vancouver, KS04, PS04 Peter L. Strick USA Pittsburg, PA, PRS03 S.H. Subramony Jackson, MS, USA S102 A. H. Surtees Robert London, United Kingdom S107 Clive N. Svendsen Madison, WI, USA PS03 Kathleen M. Shannon Kathleen M. USA Chicago, IL, S402 Jie Shen USA Boston, MA, S208 Sherman Michael Y. MA, USA Watertown, S307 Hiroshi Shibasaki Bethesda, MD, USA V104 Ira Shoulson USA NY, Rochester, KS08, PRS04 Cliff Shults San Diego, CA, USA S406 Harvey S. Singer Baltimore, MD, USA PRS07 Andrew Singleton Kapil D. Sethi Augusta, GA, USA KS05, V201 London, United Kingdom PRS06, PS02 David Rye Atlanta, GA, USA S201 Sanger Terence Stanford, CA, USA S107 Schapira Anthony H.V. London, United Kingdom KS10, PRS04 Anette Schrag London, United Kingdom S306 Heinz Reichmann Dresden, Germany KS02 Peter Riederer Germany Wuerzburg, PRS02 Maria Rodriguez-Oroz Pamplona, Spain S407 Thomas Roth Detroit, MI, USA KS05 John C. Rothwell Baltimore, MD, USA C. David Marsden Lecturer Serge Przedborski USA NY, New York, PS01 Stefan Pulst USA Angeles, CA, Los S102 Quinn Niall P. London, United Kingdom KS06, V101 Olivier Rascol France Toulouse, KS08, PS04 Ronald Pfeiffer TN, USA Memphis, S103 Poewe Werner Innsbruck, Austria KS08, PRS07 Pierre Pollak Grenoble, France PRS08 Peter Paul Pramstaller Bolzano, Italy S106 Donald L. Price Joel S. Perlmutter MO, USA St. Louis, PS02 TY TY TY TY TY Daniel P. Perl Daniel P. USA NY, New York, S204 Walter Paulus Walter Gottingen, Germany KS05 Rajesh Pahwa KS, USA Kansas City, V204 Adrian M. Owen Cambridge, United Kingdom PRS03 Marburg, Germany KS04, PRS01 Olanow C. Warren USA NY, New York, PRS05, PS01 KS11, Bremerhave, Germany KS03 H. Oertel Wolfgang José A. Obeso Pamplona, Spain KS10, PRS05, PS02 Per Odin John G. Nutt Portland, OR, USA PS03, V103 Markus Naumann Germany Wuerzburg, KS09 John G.L. Morris Australia Sydney, V202 Jacques Montplaisir Montreal, Canada KS03 Buenos Aires, Argentina PRS08 Mizuno Yoshikuni Japan Tokyo, KS02, PRS07 Petah Tiqva, Israel Petah Tiqva, PRS07 KS11, Marcelo Merello Heidelberg, Germany S101 Eldad Melamed Kevin McNaught USA NY, New York, PS01 Hans Michael Meinck Newcastle Upon Tyne, United Upon Tyne, Newcastle Kingdom KS07, PRS03 Kenneth Marek USA CT, New Haven, KS10, PRS07 I.G. McKeith Key: KS = Kickoff Seminar, PS = Plenary Session, PRS = Parallel Session, S = Seminar, V = Video Dinner V = Video S = Seminar, Session, PRS = Parallel Session, = Plenary PS Seminar, = Kickoff Key: KS FACUL FACUL FACUL FACUL FACUL

8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 41 , JUNE 16 , JUNE 16 , JUNE , JUNE 16 , JUNE , JUNE 16 , JUNE 16 , JUNE Y Y Y Y Y WEDNESDA WEDNESDA WEDNESDA Members Young Location: Meeting Room 1, First Floor 7:00 am to 8:30 am 7:00 am Committee Bylaws Floor Meeting Room 6, First Location: Force Task Neurosurgery Section Room 2, First Floor Location: Meeting Committee / Force Steering Task UPDRS Revision of Rating Scales Force for the Development Task for PD Room 5, First Floor Location: Meeting am 7:30 am to 8:30 Committee Scientific Issues Room 4, First Floor Location: Meeting 12:00 pm to 1:30 pm Force EBMR Task Location: Meeting Room 6, First Floor Force on Epidemiology Task Location: Meeting Room 5, First Floor WEDNESDA WEDNESDA 1:30 am 1:30 am 1:30 am 1:30 am 1:30 am , June 15 , June 15 , June 15 , June 15 , June 15 ANNUAL ANNUAL ANNUAL ANNUAL ANNUAL Ground Floor Ground Floor Ground Floor Ground Floor Ground Floor uesday uesday uesday uesday uesday T T T T T MDS MDS MDS MDS MDS , JUNE 15, 2004 , JUNE 15, 2004 , JUNE 15, 2004 , JUNE 15, 2004 , JUNE 15, 2004 10:30 am to 1 10:30 am to 1 10:30 am to 1 10:30 am to 1 10:30 am to 1 , JUNE 14 , JUNE 14 , JUNE , JUNE 14 , JUNE Salone Della Cultura, Salone Della Cultura, , JUNE 14 , JUNE 14 , JUNE Salone Della Cultura, Salone Della Cultura, Salone Della Cultura, Y Y Y Y Y Y Y Y Y Y BUSINESS MEETING BUSINESS MEETING BUSINESS MEETING BUSINESS MEETING BUSINESS MEETING COMMITTEE & TASK FORCE MEETINGS FORCE & TASK COMMITTEE MEETINGS FORCE & TASK COMMITTEE TUESDA TUESDA MONDA MONDA Liaison/Public Relations Committee Location: Meeting Room 6, First Floor Location: Meeting Room 3, First Floor Industrial Relations Committee Location: Meeting Room 4, First Floor TUESDA 7:00 am to 8:30 am (CME) Committee Continuing Medical Education 6:00 pm to 7:30 pm Membership Committee Location: Lounge 1, Ground Floor Task Force on PD Dementia Force on PD Task Ground Floor Location: Officers/IEC Workroom, International Congress Oversight Committee International Congress Ground Floor Workroom, Location: Officers/IEC 4:30 pm to 7:30 pm Journal Oversight Committee Journal Oversight Room 4, First Floor Location: Meeting pm 12:30 pm to 1:30 Financial Affairs Financial Affairs Committee Room 6, First Floor Location: Meeting Location: Meeting Room 5, First Floor Meeting Room 5, First Location: Education Committee Room 3, First Floor Location: Meeting MONDA to 8:30 am 7:00 am Committee Awards COMMITTEE & TASK FORCE MEETINGS FORCE & TASK COMMITTEE TUESDA TUESDA MONDA MONDA COMMITTEE & TASK FORCE MEETINGS FORCE & TASK COMMITTEE MEETINGS FORCE & TASK COMMITTEE 42 Rome, Italy EXHIBITION EXHIBITION EXHIBITION services. imply anendorsementbytheMDSoftheseproductsand and organizations.Thesearrangementsdonotconstitute nor arrangements betweentheMDSandparticipatingcompanies advertised intheprogramoccurbycontractualbusiness Products andservicesdisplayedintheExhibitHallor Endorsement Disclaimer fied asfollows: entrances forproperidentification.Exhibitorswillbeidenti- worn atalltimesassecurityguardswillmonitorExhibitHall installation, show, ordismantlementhours.Badgesshouldbe name badgeinordertogainaccesstheExhibitHallduring Exhibit boothpersonnelmustshowanofficialMDSexhibitor Exhibitor BadgePolicy hours: located inthePalazzodeiCongressiduringfollowing Exhibitors mayregisterattheExhibitorRegistrationDesk, Exhibitor Registration hours: Delegates mayentertheExhibitHallduringfollowing market productsdirectlyrelatedtoMovementDisorders. with representativesofcompaniesthatprovideservicesor Congress experience,offeringyoutheopportunitytospeak exhibition isanintegralcomponentofyourInternational Exhibit Hall,locatedinthePalazzodeiCongressi.The Please allowadequatetimeinyourdailyscheduletovisitthe General informationandExhibitHallHours THE EXHIBITION EXHIBITION Exhibitor DelegateBadge(Orange)- Exhibitor DelegateBadge(Orange)- Exhibitor Badge(Y Exhibitor Badge(Y additional cost). Wine andCheeseSeminarsVideo Dinnersatan scientific sessionsincludingposterpresentations(accessto to entertheexhibithallasanexhibitorandattend Exhibitor DelegateBadge(Orange) exhibit hallareaonly. Exhibitor Badge(Y 6:30amto6:00pm 6:30amto6:00pm 6:30amto6:00pm 6:30amto6:00pm 6:30amto6:00pm Thursday, 3:00pmto8:30 June17 Wednesday, June16 Tuesday, June15 Monday, June14 Sunday, June13 Saturday, June12 8:00amto5:00pm 8:00amto5:00pm 8:00amto5:00pm 8:00amto5:00pm Thursday, June17 Wednesday, June16 Tuesday, June15 Monday, June14 Exhibitor DelegateBadge(Orange)- Exhibitor DelegateBadge(Orange)- Exhibitor Badge(Y Exhibitor Badge(Y MOVEMENT ellow) - ellow) - ellow) - ellow) Allows admittancetothe ellow) - ellow) - DISORDERSOCIETY - Allowsthedelegate EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR INFORMA DIRECTOR DIRECTOR EXHIBITOR INFORMA EXHIBITOR INFORMA 44 countriesandatotalofabout 32,000employees. Ingelheim, Germany, itoperatesglobally with156affiliatesin variety ofuses. number ofBOTOX®clinicaltrialsunderwayforawide patients withCNSdisorders. by ourboothtoseehowwearemakingadifferencefor cal diseases,includingParkinson’s diseaseandEpilepsy. Stop pursuing newproductsforthetreatmentofseveralneurologi- Web site: Fax: +441494798700 Phone: +441494798668 United Kingdom Amersham, BucksHP79LL White LionRoad The GroveCenter(LH) Amersham worldwide. providing eyecareandspecialtypharmaceuticalproducts California, isatechnology-driven,globalhealthcarecompany Type-A, PurifiedNeurotoxinComplex. Allergan isthemanufacturerofBOTOX®,BotulinumToxin Booth Number: Web site: Fax: +441494473593 Phone: +441494427033 United Kingdom High Wycombe, BuckinghamshireHP123SH Coronation Road Allergan leading pharmaceuticalcompanies. The BoehringerIngelheimCorporation isoneoftheworld’s 20 Booth Number: Web site:www.boehringer-ingelheim.com Fax: +496132723625 Phone: +496132773625 Germany Ingelheim, 55216 Binger Str173 Boehringer-Ingelheim InternationalGmbH products divisionofMylanLaboratoriesInc. Bertek PharmaceuticalsInc.wasfoundedastheproprietary Booth Number: RTP, NC PO Box14149 Marketing Bertek Pharmaceuticals,Inc. Booth Number: DIRECTOR EXHIBITOR INFORMA veterinary medicine. novel products ofhightherapeuticvaluefor humanand committed toresearching,manufacturing andmarketing was foundedin1885,thefamily-owned companyhasbeen Web site: Fax: +1(919)993-5907 Phone: +1(919)991-9855 USA experienced marketingandsalesstaff. medical andclinicalexpertiseinneurology, aswellan DIRECTOR DIRECTOR EXHIBITOR INFORMA EXHIBITOR INFORMA

27709-4149 www.allergan.com www.bertek.com www.amershamhealth.com

Y Y Y Y Y Allergan, Inc.headquarteredinIrvine, 117 208 123 214 TION &DIRECTOR TION &DIRECTOR TION &DIRECTOR TION &DIRECTOR TION &DIRECTOR TION TION TION TION TION

Headquartered in

There arepresentlya We areactively AND AND AND AND AND

Bertek has

Since it Y Y Y Y Y 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 43 Products include ISIS IOM and ISIS

These products include FDA cleared and CE These products include

108 232 210

www.inomed.com www.fh-co.com www.gsk.com GlaxoSmithKline continues to strive to provide GlaxoSmithKline continues to strive to Y Y Y Y Y

GlaxoSmithKline is a world leading research-based pharma- GlaxoSmithKline is a world leading research-based the quality of life of ceutical company dedicated to improving patients. for intraoperative inomed GmbH maufactures equipment neurophysiological monitoring, neurological diagnostics and invasive pain therapy. Booth Number: Booth Number: intraoperative products are used for microTargeting® FHC’s recording, micro/macro-stimulation, micro/macro-electrode functional neurosurgery to treat Move- and data analysis in ment Disorders. Booth Number: solutions to many of the problems encountered within the solutions to many of the problems encountered complex field of neurological medicine. inomed Gesselschaft Fuer Interventionelle Medizintechnik MbH 5a Tullastrasse D-79331 Teningen Germany Phone: +49 7641 9414 60 Fax: +49 7641 9414 94 site: Web MER System for intraoperative neurophysiological monitor- ing and Micro Electrode recording. FHC, Inc. 9 Main St. ME 04008 Bowdoinham, USA (207) 666-8190 Phone: +1 Fax: +1 (207) 666-8292 site: Web GlaxoSmithKline New Frontiers Science Park Third Avenue Essex CM19 SAW Harlow, United Kingdom Phone: +44 01279 644360 Fax: +44 01279 646039 site: Web marked microelectrodes, microdrive systems and the marked microelectrodes, mounts on implanted fiducial Platform that microTargeting® the need for a sterotactic frame. markers and eliminates For more

TION & DIRECTOR & TION DIRECTOR & TION TION & DIRECTOR & TION TION & DIRECTOR & TION DIRECTOR & TION The EFNS welcomes

Our products provide benefit in Our products provide

Indicated for a wide range of organic Indicated for a wide

NE28 9NX

235 212 253 113 147

60601

www.dystonia-europe.org www.dystonia-foundation.org www.efns.org www.elsevier.com www.camb-labs.com

38 European national neurological associations are

individual members from all over the world. The aim of the European Federation of Neurological Societies is to advance the development of the neurological sciences in Europe. information visit www.efns.org. Booth Number: Alliance of 19 national dystonia patient support organizations in Europe. Booth Number: The Dystonia Medical Research Foundation is mandated to The Dystonia Medical Research Foundation and ultimately advance research for more effective treatments and to support the a cure; to promote awareness and education; and families. needs and well-being of affected individuals USA Phone: +1 (312) 755-0198 Fax: +1 (312) 803-0138 site: Web Cambridge Laboratories is a highly successful and progres- Cambridge Laboratories sive healthcare company. Alser Strasse 4 10900 Vienna, Austria Phone: +43 1 889 0503 Fax: +43 1 889 050313 site: Web European Federation of Neurological Societies Booth Number: 69 East King Street Helensburgh, G84 7RE United Kingdom Phone: +44 1436 678799 Fax: +44 1436 678799 site: Web European Dystonia Federation Elsevier Molenwerf 1 AG Amsterdam, 1014 Netherlands Phone: +1 3120 485 3104 Fax: +1 3120 485 3809 site: Web Booth Number: One East Wacker Dr. #2430 Dr. One East Wacker Chicago, IL Dystonia Medical Research Foundation Cambridge Laboratories Cambridge Deltic House Way King Fisher Business Park Silverlink & Wear Tyne Wallsend, Booth Number: the disorders, Xenazine 25mg is also hyperkinetic movement Dyskinesia. in the UK for Tardive only licensed treatment registered members of the EFNS. various therapeutic areas, including CNS, one of these various therapeutic 25. products is Xenazine United Kingdom 9307 Phone: +44 191 296 Fax: +44 191 296 9368 site: Web EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR EXHIBITOR INFORMA EXHIBITOR EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR 44 Rome, Italy dates. pursuing internationalhumantrialsfor6NCEdrugcandi- Kyowa Pharmaceutical,Inc.andHakkoU.K.Ltd., are www.wiley.com. services. as wellprofessionalandconsumerbookssubscription books andeducationmaterialsforcollegesuniversities, specializes inscientificandtechnicalbooks,journals,text- fields, linkedtothehistoryofGroup. as wellmedicinescommercialisedforothertherapeutic specialists whoareinvolvedinthetargetedtherapeuticfields, These aredistributedbetweenmedicinescommercialisedfor completed PhaseIIBdevelopmentforParkinson’s disease. Booth Number: Web site:www.kyowa.co.jp/eng/index.htm Fax: +81332841968 UK: +441753566000 Phone: JPN:+81332820007/U.S.:+1(609)919-1100/ Tokyo 100-8185 1-6-1 Ohtemachi,Chiyoda-ku Kyowa HakkoKogyoCo.,Ltd. Web site: Fax: +441243775878 Phone: +441243779777 PO19 8SQ,UK Chichester, West Sussex The Atrium, SouthernGate John Wiley &Sons,Ltd. centres. and endocrinology, whichrepresentitsprioritydevelopment products intargetedtherapeuticfields,particular, oncology Web site: Fax: +441753627611 Phone: +441753627701 England Slough BerkshireSL13XE 190 BathRd. Ipsen THE global publisherofprintandelectronicproducts. Founded in1807,JohnWiley &Sons,Inc.isanindependent, Booth Number: scientists. and London,throughaninternationalnetworkofabout550 ment, carriedoutfromfourcentres:Paris,Boston,Barcelona Ipsen’s turnoverwasreinvestedinResearchandDevelop- 2002, 27.1%outsideofWestern Europe. 3,700, theIpsenGrouphadaturnoverof$718millionin Present inover110 countries,withatotalstaffofnearly Booth Number: foremost biotechnologycompanies. Kyowa HakkoKogyoCo.,Ltd.(KHK)isoneofJapan’s

KW-6002, anadenosine A2a receptorantagonist,has

Currently, Ipsenhasover20productsonthemarket.

MOVEMENT

Wiley’s Internetsitecanbeaccessedat www.wileyeurope.com www.ipsen.com

250 144 138 DISORDERSOCIETY

KHK anditssubsidiaries,

The Groupdevelops

In 2002,18.2%of

Wiley EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR INFORMA promoting researchonST. nity aboutST, advocatingfortherightsofthosewithSTand to STpatients,educatingthepublicandmedicalcommu- organization dedicatedto:providinginformationandsupport The NationalSpasmodicTorticollis Association isanon-profit Booth Number: Web site: Fax: +1(714)378-7830 Phone: +1(714)378-7837 USA Fountain Valley, CA 92708 9920 Halbert Ave. National SpasmodicTorticollis Association side effects. to provideadequatebenefitorconsistentlycausesintolerable pacemaker, torelievesymptomswhenmedicationalonefails uses animplantedneurostimulationsystem,akintoa toms ofParkinson’s disease,EssentialTremor anddystonia. It adjustable treatmentforsomeofthemostdisablingsymp- Medtronic Neurological’s Activa® Therapyisareversibleand Booth Number: Minneapolis, MN 710 MedtronicParkwayNE Medtronic Neurological www.orionpharma.com www.novartis.com For furtherinformation pleasevisitthecompanies’Web sites. Neuroscience Franchiseand OrionPharma. Please feelinvitedtovisitthe combinedexhibitionofNovartis STALEVO®. combination productforParkinson disease(PD),marketedas and alsoasoneofthethree active substancesinanew pharmaceutical ingredientisusedasCOMTESS®/COMTAN® originator andmanufacturerofentacapone.Thisactive Group, istheleadingFinnishhealthcarecompanyand Orion Pharma,thepharmaceuticaldivisionof (STALEVO®,COMTAN®). for disease(EXELON®)andParkinson’sAlzheimer’s disease than 50years,havingpioneeredearlyimportanttreatments Novartis hasbeenaleaderintheNeuroscienceareafor more consumer health,headquarteredinBasel,Switzerland. Novartis AG isaworldleaderinpharmaceuticalsand Booth Number: Fax: +358104293815 Phone: +358104294701 Finland FIN-02200 Espoo Orionintie 1 Orion CorporationPharma Web site: Fax: +41613246652 Phone: +41613241111 Switzerland CH-4002 Basel Lichstr. 35 Novartis Pharma AG Web site: Fax: +1(763)505-1000 Phone: +1(763)505-5000 USA

www.torticollis.org www.medtronic.com www.novartis.com

110 129 200

55432-5604 TION &DIRECTOR TION &DIRECTOR TION &DIRECTOR TION &DIRECTOR TION &DIRECTOR Y Y Y Y Y 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 45 All the

Whatever

229 244 238

We can also order you free sample copies of the We

The theme “Present and Future Perspectives of

We will discuss the possibilities and limitations of We

www.parkinson-berlin.de www.valeant.com www.wisepress.co.uk Y Y Y Y Y

International Congress on Parkinson’s th The 16th International Congress on Parkinson’s Disease and The 16th International Congress on Parkinson’s related Disorders will be held in Berlin from 5th to 9th of June, 2005. Parkinson’s Syndrome” lends a certain futurological perspec- Parkinson’s tive to this Congress, but also includes the retrospective viewpoint. Booth Number: International is a global, publicly Pharmaceuticals Valeant company that discovers, traded specialty pharmaceutical and markets a broad range of develops, manufactures in three therapeutic areas, neurol- pharmaceutical products infectious disease and dermatology. ogy, Booth Number: is pleased to present a display of Online Bookshop Wisepress MDS International publications chosen especially for the leading publishing houses. Congress from the world’s journals on display and take subscription orders. journals on display and take subscription will be happy to help- your book requirements, Wisepress publisher or having whether you are an author seeking a staff will assist difficulty obtaining a title, our professional you. 16 Disease and Related Disorders 44 Paulsbornerstr. Berlin, 14193 Germany Phone: +49 30 300 6690 site: Web the classification, etiopathogenesis and therapy of Parkinson’s disease in the present and in the future. Valeant Pharmaceutical International Pharmaceutical Valeant Ave. 3300 Hyland CA 92626 Costa Mesa, USA (714) 545-0100 Phone: +1 Fax: +1 (714) 556-0131 site: Web Online Bookshop, Ltd. Wisepress The Old Lamp Works 25 High Path London Sw19 2JL Abbey, Merton United Kingdom Phone: +44 208 715 1812 Fax: +44 208 715 1722 site: Web books on display can be ordered directly at the stand or via books on display can be ordered directly site. our Web Booth Number: TION & DIRECTOR & TION DIRECTOR & TION TION & DIRECTOR & TION TION & DIRECTOR & TION DIRECTOR & TION The organization provides

226 220 247 100

55902

www.scisens.de www.schwarzpharma-cns.com www.pfizer.com www.rls.org

The business of Scisens is to develop and manufacture products and procedures in order to make new scientific knowledge gained from medical research and sports training available to people in their everyday life. Booth Number: Booth Number: SCHWARZ PHARMA is a multi-national pharmaceutical is a multi-national PHARMA SCHWARZ company developing and marketing innovative products for PHARMA, with its reputation specialty markets. SCHWARZ is developing innovative products for excellence in cardiology, our neurology, for neurological and urological diseases. Within disease, restless legs therapeutic focus includes Parkinson’s syndrome, epilepsy and neuropathic pain. The Restless Legs Syndrome Foundation is a non-profit The Restless Legs Syndrome Foundation awareness, organization dedicated to increasing universal a definitive cure developing effective treatments, and finding for restless legs syndrome (RLS). USA Phone: +1 (507) 287-6465 Fax: +1 (507) 287-6312 site: Web Booth Number: Pfizer Inc. discovers, develops, manufactures and markets Pfizer Inc. discovers, and medicines for humans and animals, leading prescription brands. Through best known consumer many of the world’s strategic partnerships and an unsur- innovative research, to disease education, Pfizer Neuroscience passed commitment and the leading provider of neurological is dedicated to being in that make a meaningful difference psychiatric medicines and their families around the world. the lives of patients Scisens GmbH 10 Juliusstr. Frankfurt am Main 60487 Germany Phone: +49 69 97 09 76 88 Fax: +49 69 77 24 72 site: Web Schwarz Pharma AG Schwarz Pharma Alfred-Nobel-Strasse 10 Monheim, 40789 Germany Phone: +49 2173 48-0 Fax: +49 2173 48-1608 site: Web 819 Second Street SW MN Rochester, Restless Legs Syndrome Foundation Booth Number: Pfizer St. 235 E. 42nd 10017 NY York, New USA (212) 733-6993 Phone: +1 Fax: +1 (212) 808-8833 site: Web information about RLS, develops local support groups, information about RLS, develops local research for the and funds publishes a quarterly newsletter, study of RLS. EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR EXHIBITOR INFORMA EXHIBITOR EXHIBITOR INFORMA EXHIBITOR INFORMA EXHIBITOR 46 Rome, Italy THE MOVEMENT DISORDERSOCIETY GROUND FLOOR GROUND FLOOR GROUND FLOOR GROUND FLOOR GROUND FLOOR FLOOR PLAN&MEETINGSP FLOOR PLAN&MEETINGSP FLOOR PLAN&MEETINGSP FLOOR PLAN&MEETINGSP FLOOR PLAN&MEETINGSP ACE ACE ACE ACE ACE 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 47 FIRST FLOOR FIRST FLOOR FIRST FIRST FLOOR FIRST FIRST FLOOR FIRST FLOOR FIRST ACE ACE ACE ACE ACE FLOOR PLAN & MEETING SP & MEETING PLAN FLOOR SP & MEETING PLAN FLOOR FLOOR PLAN & MEETING SP & MEETING PLAN FLOOR FLOOR PLAN & MEETING SP & MEETING PLAN FLOOR SP & MEETING PLAN FLOOR

8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 51 MAP OF ROME WITH METRO LINE METRO WITH ROME OF MAP LINE METRO WITH ROME OF MAP MAP OF ROME WITH METRO LINE METRO WITH ROME OF MAP MAP OF ROME WITH METRO LINE METRO WITH ROME OF MAP LINE METRO WITH ROME OF MAP 52 Rome, Italy MONDA MONDA MONDA P20 Clinical features of 49 pathologically proven multiple system atrophy in provenmultiplesystematrophy of49pathologically Clinicalfeatures P20 Clinicalanalysesof50familiesearly-onset autosomalrecessive- P19 masqueradingasFriedreich’s Cerebrotendinousxanthomatosis ataxia P18 SleepdisturbanceinSCA2 P17 type2 Consistent affectionofthethalamusinspinocerebellarataxia P16 scales Reliabilityandvalidityinataxia P15 progressivefreezinggait Kinesiological findingsinprimary P14 type10: Spinocerebellarataxia Descriptionof8familieswithdifferent P13 inaSpanishfamily Anewsacsinmutation P12 in15Indianpedigreesofspinocerebel- Molecularandclinical correlation P11 telangiectasia(AT) ofataxia presentation Late P10 carriersandFragile Xassociated Xpremutation Ocularmotilityinfragile P9 ofthecerebel- resonancespectroscopyandvolumetry Protonmagnetic P8 type2 inspinocerebellarataxia dystonia Cervical P7 ofMachado-Josephdisease, overthreegeneration Neuropathology P6 withsporadiccerebellarataxia allelesinpatients Fragile Xpremutation P5 P4 withclinical Neurophysiologicalmarkersandtheirrelationship P3 Neuroepidemiologicalandclinical characterizationoftheCuban P2 Serumandcerebrospinalfluidlevelsofcooper, ironandzincinpatients P1 Poster numbers1-28 Ataxia Authors PresentEvenNumbers:4:00pmto5:00 Authors PresentOddNumbers:12:00pmto1:00 Poster Viewing: 8:30amto5:00pm THE MONDA MONDA M. Tada, T.O.Onodera,M.Ozawa,Tada, H. Takahashi, M.Nishizawa M. Tada, K. Hara, O. Onodera, H. Date, S. Tsuji, M. Nishizawa S.S.Heier,L. Wu, FruchtS.J. S.M. Boesch, E. Brandauer, B. Frauscher, G.K. Wenning, B. Hoegl, W. Poewe U. Rueb, K. Buerk, L. Schoels, G. Auburger, H. Braak, T. Deller Rosa,De V.A. Falco,G.Coppola,Salvatore,Scarano,E.Fillade A. A. V. Castillo, S. Catalano, Y. Blanc, C. Pot, F. Assal, P. Burkhard H.A. Teive,S.Raskin,B.Roa, W.O. Arruda,L.C. Werneck, T. Ashizawa C. Criscuolo, F. Saccà, O. Combarros, J. Infante, A. Filla, J. Berciano A.K. Srivastava, M. Mukerji, S. Behl, K. Virdi, M. Padma, S.K. Brahmachari T. Jawad, R.L. Stallings, T. Lynch D.A. Hall, V.S. Pelak, R.J. Hagerman, P.J. Hagerman, M.A. Leehey C.M.Schocke,Boesch,Wolf,Felber,S.M. S. W.Poewe,G.K. Wenning K. Zarubova, E. Ruzicka, R. Mazanec, A. Zumrova, M. Bojar K. Hasegawa, S. Yagishita, H. Mitomi Y. Zhao, K. Puong, H. Law, M. Wong, I. Ng, E. Tan S.M. Boesch, E. L.C. Velazquez,G.Sanchez,J.C.Garcia,N. Canales,L. Almaguer,E.Martinez L.G.Sanchez, Velazquez, M. Velazquez,L. Almaguer, Y.Batallan Almira,K. Quevedo J. Garcia, R. Delgado, L. Velazquez, C. Gonzalez, G. Sanchez, A. Gonzalez- the Japanese population the Japanese population intheJapanese spinocerebellar ataxias phenotype 12 lar ataxia syndrome(FXTAS)tremor/ataxia lum inSCA2andMSA-C type2 dopaminergic impairmentinspinocerebellarataxia β molecular parametersintheCubanSpinocerebellar Ataxia Type 2 ataxias hereditary with typeSCA-2 Ataxia fromtheprovinceofHolguininCuba -CIT andIBZMSPECTrevealsaMSA-Clikepatternofnigro-striatal MOVEMENT Y Y Y Y Y , JUNE14 , JUNE14 , JUNE14 , JUNE14 , JUNE14 Donnemiller, K. Seppi, G.K. Wenning, W. Poewe DISORDERSOCIETY P28 Autosomal dominant spinocerebellar ataxias inRussia: Autosomaldominantspinocerebellarataxias The spectrumof P28 Anewcytochemical in testforanalysisofmitochondrialdysfunction P27 Frequency ofSCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA12, SCA17, P26 MJD/SCA3: ofnovelsmallestallele Identification P25 type10: Spinocerebellarataxia A comparisonbetweenBrazilianand P24 in100familieswithspinocerebellar Genotype-phenotypecorrelation P23 type3(Machado-Joseph Anewclassification ofspinocerebellarataxia P22 Motorcortexexcitabilityincerebellarataxia. Clinical-neurophysiological P21 3 Effectsofselectiveproteasomal inhibitorsonventralmidbrain cultures P38 inthedissolutionofneuronalinclusions Involvementofmacroautophagy P37 glutamate Experimentalbasisfortheputative roleofGluR6/kainate P36 Regional vulnerabilityofmesencephalicdopaminergicneuronsin P35 GeneexpressionprofilingofLewybody-bearingneuronsinParkinson’s P34 Neuroleukin, Opsoclonus/ apotentialantigenictargetinpaediatric P33 Dopaminereceptorhypersensitivitycorrelateswithadrug-induced P32 Endogenousdopaminereleasebyrepetitivetranscranialmagnetic P31 Geneexpressionanalysisin1-methyl-4-phenyl-1,2,3,6- P30 of ExploringthepotentialroleofPRK1/PKNinpathophysiology P29 Poster numbers29-90 Basic Science M.V. Ershova, S.N. Illarioshkin, V.S. Sukhorukov, I.A. Ivanova-Smolenskaya N.T. Dragasevic, A.J. Ristic, M. Svetel, B. Culjkovic, S. Romac, V.S. Kostic A.K. Srivastava, Q. Saleem, S. Roy, M. Padma, S. Jain, S.K. Brahmachari H.A. Teive,W.O. Roa,Arruda,S.Raskin,B. T. L.C. Ashizawa, Werneck H.A. Teive, W.O. Arruda,S.I.L.Raskin, L.C.Cendes, Werneck H.A. Teive, W.O.Arruda,L.C. Werneck S. Tamburin,S.Marani,Zanette,G.A. P. Andreoli, Manganotti, A.Fiaschi H.J. Rideout, I.C. Lang-Rollin, M. Savalle, L. Stefanis H.J. Rideout,I.C.Lang-Rollin,L.Stefanis E. Diguet, P.-O. Fernagut, E. Normand, L. Centelles, C. Mulle, F. Tison L. Lu, F. Neff, E.C. Hirsch, W.H. Oertel, A. Hartmann L.F.Lu, Neff, W.H. Schlegel,Oertel,J.Hartmann A. P.M. Candler, R.C. Dale, A.J. Church, G. Giovannoni, J.H. Rees, E.J. Thompson M.A. Delfino, R. Kalisch, C. Larramendy, G.M. Murer, O.S. Gershanik, D.P. Auer T. Ohnishi, T. Hayashi, S. Okabe, H. Matsuda, H. Iida, Y.Ugawa J.-M. Kim, J.-H. Kim, W.-Y. Park, C.-I. Hwang, S.-B. Ko, S.-J. Kwon W. Duan, Y. Zhu T.N. Proskokova S.A. Klyushnikov, S.N. Illarioshkin, E.D. Markova, I.A. Ivanova-Smolenskaya, genetic forms, ofaffectedfamilies DNA-testingandmanagement Friedreich ataxia cerebellar ataxiainSerbia andsporadic withhereditary DRPLA andFRDAmutationinpatients Mexican families ataxias disease) correlations receptor subunitinHuntington’s history diseasenatural study Parkinson’s disease: A humanpostmortemgeneexpressionprofiling disease Myoclonus syndrome(OMS) 7 study at Tesla dyskinesia (DID)rodentmodel: A functionalmagneticresonanceimaging monkeys motorcortexinanesthetizedmacaque stimulation overtheprimary microarray tetrahydropyridine micemodelofParkinson diseaseusingcDNA Parkinson’s disease POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 53 4 nicotinic α –carbolinium derivatives β 4 nAChR in adult mice increases α , D.T. Dexter, R.K. Pearce, M.B. Graeber M.B. Pearce, R.K. Dexter, D.T. , the loss of midbrain dopaminergic neurons production in cellular model Evidence from activated microglial cells in neurodegenerative diseases: vitro induced facilitation monophasic stimulation by inverse in humans on nigral degeneration in MPTP treated primates paralysis with regards to refrigeratordigitorum brevis muscle storage studyA randomized double blind controlled time: A ratmodel of Parkinson’s the six-hydroxydopamine-lesioned rats: disease disease A rat model of Parkinson’s six-hydroxydopamine-lesioned rats: Relationship to transporter-dependent disease: related to Parkinson’s uptake new motor skill in patients with Parkinson disease in patientsnew motor skill with Parkinson rotenone administration for the pathogenesis of the A possible model induced by iron deprivation: restless legs syndrome disease Parkinson’s transporter in axons in mouse heart selective D3 and a D2/D3 antagonist ity model receptors are protected by mecamylamine A. Storch, Y.-I. Hwang, J. Schwarz J. Hwang, Y.-I. Storch, A. Itoyama Y. A. Kikuchi, Hasegawa, T. Kobayashi, M. Takeda, A. Lucius R. Deuschl, G. Sievers, J. Roehl, C. Claasen, J. Wilms, H. A. Fernandes, J.G. Ferreira, E. de Oliveira, S. Ponzoni S. de Oliveira, E. Ferreira, J.G. Fernandes, A. Sommer M. Paulus, W. Tergau, Lang, N. F. Tings, T. Ponzoni S. de Oliveira, E. Fernandes, A. Ferreira, J.G. Schwarz J. Lester, H.A. Labarca, C. Orb, S. Schwarz J. Lester, H.A. Berk, A.J. Labarca, C. Dorigo, O. Schwarz, S.C. Benabid A.-L. Foote, K.D. Brard, P.-Y. Mitrofanis, J. Ashkan, K. Wallace, B.A. Ahn K.Y. Park, M.Y. Yung K.K. Chung, E.K. Yung K.K. Lau, W. D.C. Duke, L.B. Moran, F.E. Turkheimer F.E. Moran, L.B. Duke, D.C. Xavier G.F. Silva, K. Hattori, E.O. Neves, E.T. Souza, C.O. Piemonte, M.E. J.-S. Liu S.-S. Chen, Wang, J.-C. Wu, Lan, H.-S. M.-Y. Chang, Y.-Y. Walters A.S. Neubauer, J.A. Hoang-Le, T. Sun, Y.-M.J. Rajput A.H. Miyashita, H.K. Pasha, M.K. S. Uchihara, H. Orimo, Mizusawa T. Kanazawa, S. Shimazu, T. Amino, T. Trenkwalder C. Virley, D.J. Koch, R. Baier, P.C. P77 Inducible overexpression of tyrosine hydroxylase and dopamine P78 Involvement of benzodiazepine receptors in neuroinflammatory and P68 magnetic repetitive transcranial Reversal of high-frequency stimulation P69 Rotational behaviorintra striatal response to manganese microinjection P70 Dopaminergic neurons of knock-in mice with hypersensitive P71 Enhanced expression of L9’S mutant P72 Neuroprotective effects acid lesioning of the subthalamic nucleus: Kainic P73A on human extensor type of botulinum toxin Comparison of the potency P74 Changes in expression of glutamate in the basal ganglia of transporters P75 Increase in expression of cannabinoid receptor one in the basal ganglia of P76 of cytotoxicity Dopamine transporter-mediated P60 nigra using microarrays of the parkinsonian substantia Expression profiling P61 Correlation to learn a bradykinesia and the ability the severity of between P62 A diffuse neurodegenerative change in mice brain induced by chronic P63 Opioids protect against cell apoptosis substantia nigra dopaminergic P64 Accumulation of alanine in striatum of a rotenone rat model of P65 Immunolocalization norepinephrine of tyrosine hydroxylase and P66 Circadian motor behaviour of the rat after chronic treatment with a P67 L-deprenyl (selegiline) neuroprotective failure in a manganese neurotoxic- -Synuclein α -synuclein induces its aggregation -synuclein α degeneration non-human primate models: A cytochrome oxidase A cytochrome degeneration non-human primate models: histochemistry study ment of performance in a new motor skill after brief training intersubunit interaction and -5 on MPP+-induced apoptosis in human neuroblastoma apoptotic cell death in SH-SY5Y neuroblastoma cells subthalamic nucleus and substantia nigra pars reticulata in rat subthalamic nucleus is remodelled by patterned proprioceptive stimulation and attention parkinsonism Parkinson’s disease Parkinson’s exercise on movement performance accuracy in patientsexercise on movement performance accuracy with Complex Syndrome (type I) Regional Pain model of Parkinson’s disease model of Parkinson’s disease oxidative Parkinson’s stress relevant for in post-streptococcal neuropsychiatric disorders dysfunction dystonia in DYT1 Huntington’s disease Huntington’s M.E. Piemonte, G.P. Faeli, T.T. Capato, C.O. Souza, E.T. Neves, M.S. Haddad M.S. Neves, E.T. Souza, Capato, C.O. T.T. Faeli, G.P. Piemonte, M.E. I. Ghorayeb, E. Cuny, D. Guehl, P. Burbaud, B. Bioulac, F. Tison F. Bioulac, B. Burbaud, P. Guehl, D. Cuny, E. Ghorayeb, I. T. Hasegawa, M.M. Kobayashi, A. Takeda, A. Kikuchi, K. Furukawa, Y. Itoyama Y. A. K. Kikuchi, Furukawa, Takeda, A. Hasegawa, M.M. Kobayashi, T. P.W. Ho, D.Y. Chan, K. Leung, M.H. Kung, D.B. Ramsden, S.-L. Ho S.-L. Ramsden, D.B. Kung, M.H. Leung, K. Chan, D.Y. Ho, P.W. P.T. Pham, W. Woo, V. Nguyen, K.P. Frei, Truong D.D. Frei, Nguyen, K.P. V. Woo, W. Pham, P.T. S. Breit, L. Selten, A. Martin, J.B. Schulz J.B. Martin, A. Selten, L. Breit, S. E.M. Croisier, F. Roncaroli, F.E. Turkheimer, L.B. Moran, M.B. Graeber, R.K. Graeber, M.B. Moran, L.B. Turkheimer, F.E. Roncaroli, F. Croisier, E.M. Pearce Itoyama Y. Takeda, A. A. Kikuchi, Hasegawa, T. Kobayashi, M.M. K. Rosenkranz, J.C. Rothwell K. Ashkan, B.A. Wallace, J. Mitrofanis, P.-Y. Brard, D. Fagret, A.-L. A.-L. Benabid Fagret, Brard, D. Mitrofanis, P.-Y. J. Wallace, Ashkan, B.A. K. D.L. Pountney, M.J. Raftery, P.C. Blumbergs, W. Gai W. Blumbergs, P.C. Raftery, M.J. Pountney, D.L. S. Radovanovic, M. Ljubisavljevic, S. Milanovic, N. Dragasevic, V.S. Kostic, H. Kostic, V.S. Dragasevic, N. Milanovic, S. Ljubisavljevic, M. Radovanovic, S. Johansson G. Pezzoli, A.M. Marczewska, M. Barichella, N. Meucci, G. Sacilotto, B. Cestaro B. Sacilotto, G. Meucci, N. Barichella, M. Marczewska, A.M. Pezzoli, G. R.C. Dale, P.M. Candler, A.J. Church, R. Wait, J.M. Wait, Pocock, G. Giovannoni A.J. R. Church, Candler, Dale, R.C. P.M. Rothwell J.C. Bhatia, K.P. Runis, E. Edwards, M.J. Huang, Y.-Z. G. Gille, G. Xu, B. Doreen, M. Yongjian, R. Wolf-Dieter, R. Heinz R. Wolf-Dieter, R. Yongjian, M. Doreen, B. Xu, G. Gille, G. T. Furuya, H. Mochizuki, K. Yoshimi, H. Hayakawa, M. Miura, Y. Mizuno Y. Miura, M. Hayakawa, H. Yoshimi, K. Mochizuki, H. Furuya, T. P. Gonzalez-Alegre, H.L. Paulson H.L. Gonzalez-Alegre, P. Kim Y.-M. Tanaka, Mouradian, M. E. Junn, M. G.R. Jackson, C. Li, W. Liu, J.M. Abrams, S.L. Zipursky, T.-K. Sang T.-K. Abrams, Zipursky, S.L. Liu, J.M. W. G.R. C. Jackson, Li, N. Stefanova, P.J. Kahle, M. Reindl, F. Tison, W. Poewe, Wenning G.K. Poewe, W. Tison, Reindl, Kahle, M. F. Stefanova, N. P.J. P59 Improve- disease and Huntington disease: Motor learning in Parkinson’s P58 metabolic activity changes in striato-nigral Subthalamic nucleus P56 -4, UCP2, and uncoupling proteins, UCH-L1, Effects of estrogen on Parkin, P57 Oxidized catecholamine metabolites by tyrosinase overexpression induces P55TorsinA Dystonia-associated mutation disrupts (DelGAG) in DYT1 P54 induces hyperactivity of nucleus Lesion of the pedunculopontine P53 Roles of iron in the intracellular aggregation of P52 Glial activity and convergence of pathological pathways in Lewy Body P51 Sensory-motor organisation motor cortex in the hand area of the human P49 diseases of neurodegenerative SUMO-1 in neural inclusions P50 Single photon emission computerised tomography in primate models of P47 Antioxidant properties of levodopa P48 The effects of altered sensory vibration afferent input by muscle and P46 of the human cortex with rTMS Theta burst conditioning P45 Glycolytic enzymes on neuronal membranes are candidate autoantigens P43 of dopaminergic neuron loss in a mouse Caspase-11 is a KEY mediator P44 Pramipexole protects dopaminergic neurons against various forms of P42 Phosphorylation of P41 cellular behavior of mutant torsinA implicates Aberrant envelope nuclear P39 atrophy mouse model of multiple system A novel P40 for Implications Apaf-1 pathogenesis: blocks polyglutamine of Inactivation POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER 54 Rome, Italy P98 Akinesia and hypokinesia are predominent features of gait initiation in ofgait initiation Akinesiaandhypokinesiaare predominentfeatures P98 ProgressiveMRIabnormalitiesandresponsiveness tocorticosteroidsin P97 withSydenham’s Serumfrompatients choreamodifiescalciumlevelsin P96 Treatment ofacuteSydenham’s choreawithmethyl-prednisolonepulse- P95 interneuronsmaydefinethe reductionofstriatal Adisproportionate P94 chainchangesin Huntingtondisease Respiratory P93 Monozygotic twinsdiscordantforHuntington’s diseaseaftersevenyears P92 withHuntington’s inpatients Thepresenceofmotoroverflow disease P91 Poster numbers91-120 Chorea dopaminergicneuronsvia Mitochondrial complexIinhibitiondamages P90 cholinergic receptorsinstriatal Roleofmetabotropicglutamate P89 neuronalvulnerabilitybyinhibitionofmitochondrialcomplexII: Striatal P88 degeneration MPTP +3-nitropropionicacid(3NP)-inducedstriatonigral P87 (SND) degeneration ofMPTP+3-NP-striatonigral Worst motorrecovery P86 Amethodforcombinedmotorperformanceassessmentandneurotrans- P85 Reduction inendogenousparkinlevelsrendersCNScellssensitivetoboth P84 Parkinson’s proteasomal mutantsynphilin-1mediates disease-associated P83 ofneuronalactivityinandaroundtheSubthalamicNucleus Characterization P82 of indopaminergicspecification Intracellularsignalingpathways P81 neuralstemcells: Adult humanbonemarrow-derived A newcellsource P80 ofneuromelaningranulesfromthehumanbrainforsubsequent Isolation P79 THE A. Delval, P. J.-L. Krystkowiak, Blatt, A. Destee, P. Derambure, L. Defebvre C. Moreau, D. Devos, C. Delmaire, C. Gervais, A. Destée, L. Defebvre A.L. Teixeira-Jr., M.M. Guimarães, F. Cardoso, M.A. Romano-Silva A.L. Teixeira-Jr.,F. Cardoso,D.P. Maia,M.C.Cunningham G. Kleiner-Fisman, N.Y. Calingasan, J. Chen, M.F. Beal, A.E. Lang J. Klempir, H. Hansikova, J. Roth, J. Zidovska, J. Zeman M.M. Trieschmann, J.H. Friedman, R.H. Myers, H.H. Fernandez Bradshaw N. Georgiou-Karistianis, A. Churchyard, K. Hoy, M. Farrow, C. Armatas, J. C.M. Testa, T.B.Sherer, Marsteller,C.L. J.T. Greenamyre P. Bonsi, D. Cuomo, P. Calabresi, G. Bernardi, A. Pisani A. Pisani, D. Centonze, G. Bernardi, P. Calabresi E.Diguet, P.-O. Fernagut, L.Centelles, F. Tison E.Diguet,A. P.-O Adam, Fernagut,F. Tison F. Bergquist, D. Andersson, H. Nissbrandt M.M. Muqit, L.P. MacCormac, D.J.Faulkes, N.W. Wood, D.S. Latchman F.P. Marx, D. Berg, S. Dawson, O. Riess, J.B. Schulz, R. Krueger T.Chabardes,B.A.S. Aksyonova,O.Chibirova, Wallace, A. Villa,A.L.Benabid M. Sabolek, M. Heinrich, S. Liebau, J. Schwarz, A. Storch A. Storch, A. Hermann, R. Gastl, S. Liebau, O.M. Popa, M. Maisel F. Tribl,E.Marcus,M.Gerlach,K.Asan,H.E.Meyer, P. Riederer Huntington’s disease(HD) process? recurrenceofSydenham’slate chorea: ofanautoimmune Reactivation PC -12cellsbyacomplement-independentmechanism therapy Chorea(BHC) basisofBenignHereditary pathological stressinorganotypicsubstantianigracultures oxidative transmission: forParkinson’s Implications disease forHuntington’sImplications disease (SND) inmice: A longtermbehavioralstudy byhighdoseoflevodopa mice treated mitter measurementinrats caspase-dependent andcaspase-independentcelldeath proteasomalproteinS6 inhibition andinteractswithregulatory mesencephalic neuralstemcellsinducedbyinterleukin-1 strategies? for neurorestorative proteomic analysis MOVEMENT DISORDERSOCIETY P106 Insulin resistance and decreased insulin secretion capacity simulta- Insulinresistanceanddecreasedinsulinsecretioncapacity P106 JuvenileonsetHuntington’s disease: Likemother, likeson? P105 Paroxysmal ballismindizygotictwins: An unusualformofPNKD P104 forHuntington’s Highdosecreatinetherapy disease: Clinicaland31 P103 Choreainapatientwithceliacdiseaseand TPN-induced manganese P102 FunctionalgeneticsinHuntington’s disease: Phenotypeandgenotype P101 Pallidal aresimilarinHuntington’s neuronsfiringrates andParkinson’s P100 Evidenceforcoexistenceofbothhyperkinesiaandhypokinesiain P99 P118 A case of recurrent hemiballism associated withtheparietallobe Acaseofrecurrent hemiballismassociated P118 analysis ofphenotypesinparkin-positiveandparkin- Comparative P117 intheR6/2transgenicmousemodelof Hypothalamicneuropathology P116 Hemiballism–hemichorearespondingtotopiramate: Clinical and P115 Hemiballism–hemichorea: stimulationstudy A transcranialmagnetic P114 Paroxysmal todiabetes mellitus: related kinesigenicchoreoathetosis P113 ofserotoninsyndrome Choreoathetosis, anunusualpresentation P112 Choreagravidarum: Another conditionassociatedwithSydenham’s P111 Trace with inpatients pathology ofdiffusiontensorrevealscaudate P110 lesionin thesubcortical anisolated hemichoreafollowing Symptomatic P109 chorea CaudatenucleusabnormalitiesonMRIinrheumatic P108 TheUFMGSydenham’s ChoreaRatingScale(USCRS): Reliabilityand P107 N.C. Reynolds, R.W. Prost, S. Neuberger, L.P. Mark, R.D. Jacobson Y.M. Bordelon, L. Leary, S. Frucht Warner S.J.Tabrizi, Manners,Rajagopalan,D.Blamire,B. A.M.Schapira, A.H. T.T. I. Subramanian,J.Bronstein S.Bohlen,R.F.Reilmann, H.Lange,Kirsten, T. D.Merl, Auer J. Tang,E.Moro,Lozano, A.M.Lang, A.E. W.D. Hutchison,J.O.Dostrovsky A. Delval, P. J.-L. Krystkowiak, Blatt, P. Derambure, A. Destee, L. Defebvre T.-B. Ahn,S.-S. Yoon,Chang,D.-I.K.-C.Chung P.A. Slominsky E.D. Markova, T.B. Zagorovskaya, I.A. Ivanova-Smolenskaya, S.N. Illarioshkin, P. Petersén, J. Gil, P. Mohapel, H. Tanila, I. Araujo, P. Brundin C. Civardi, C. Varrasi, R. Vicentini, M. Cecchin, R. Cantello C. Civardi, R. Vicentini, C. Varrasi, M. Cecchin, C. Boccagni, R. Cantello M. ColettiMoja,E.Milano,S.Gasverde,Gianelli,Iudicello,L.Durelli D.A. Hodnett, D.I. Renganathan, D.P.Fitzgerald, D.A. Galvin A.J. Church,F. Cardoso, R.C. Dale, E.J. Thompson, A.J. Lees, G. Giovannoni Mair,K.J. Seppi,M.F.K. Schocke,W. Jaschke, W. Poewe,G.K. Wenning T.Baumer, C. Weiller, Munchau A. C.S. Sankhla,B.S.Singhal A.L. Teixeira,D.P. F.Maia, Cardoso V.S. Kostic, N.M. Lalic, M. Svetel, A. Jotic, J. Maric neously presentinnormoglycemicpatientswithHuntington’s disease resonancespectroscopy( phosphorous magnetic deposition inthebasalganglia ological measures lengthandobjectiveneurophysi- correlation asassessedbyCAGrepeat disease patients Huntington’s disease(HD): ofgait A biomechanicalstudy dysfunction withjuvenileparkinsonism patients negative Huntington diseasecausesnarcolepsy-Relevancetohuman neurophysiological findings Follow-up oftwocases chorea andanti-basalgangliaantibodies Huntington’s disease(HD) white matter consistency two yearstudy POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 31P MRS) findingsina 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 55 differences between in vivo stimulation in patients with Huntington’s disease and levodopa-induced stimulation in patients with Huntington’s dyskinesias dyskinesias disease – preliminaryin Parkinson results tions? morphometry and bilateral motor performance disease palsy and Parkinson’s progressive supranuclear disease activity of subthalamic neurons in patients with Parkinson’s syndrome Tourette patients with Gilles de la cal study nisms disease thalamic electrodes in patients with dystonia of artificial neural networks stimulation of 206 patients contralateral hand without changing the amplitude of the contingent disease negative variation in Parkinson’s A. Traba, A. Esteban, J. Prieto, C. Martin, J. Fernandez J. Martin, C. Prieto, J. Esteban, A. Traba, A. and Dysport™) A (BOTOX® two types of botulinum toxin type Barnard P.W. van Coller, R. Boulle, de K. Smuts, J.A. A. Berardelli A. C. Lorenzano, G. Inghilleri, Fabbrini, Curra, M. L. Dinapoli, I. Holler, H.R. Siebner, R. Cunnington, W. Gerschlager W. Cunnington, R. Siebner, H.R. Holler, I. Bhatia K.P. Rothwell, J.C. Heywood, P. Filipovic, S.R. Devos, D. Maurage, C. Destée, A. L. S. Defebvre Defoort-Delhemme, Tir, M. U. Dillmann, G. Fuss, C. Krick, J. Spiegel Wolters A. A. Grossmann, Krieghoff, L. R. E. Wittstock, Benecke, Kunesch, M. Doi Y. Osaki, Y. Morita, Y. Hallett M. Matteson, S. Mari, Z. Sadikot A.F. Vanderwerf, Y. Paus, T. Strafella, A.P. Kuo, C.-C. C.-C. Lee Yang, Y.-W. Chang, M.-K. Tsai, F.-C. Lu, C.-H. Rothwell J.C. Robertson, M.M. Amann, B. Orth, M. S.Y. Kang, Y.H. Sohn Y.H. Kang, S.Y. Rothwell J. Siebner, H. Quinn, N. Gillio, F. Matsunaga, K. Mir, P. A.S. Thor, A.B. K.A. Furgala, Kruczek, P.J. Ossowski, Krygowska-Wajs, P.A. A.T. Szczudlik Krauss J.K. Hennerici, M.G. Grips, E. Weigel, R. Blahak, C. Wohrle, J.C. Accornero N. Scappini, G. Bombelli, F. Gregori, B. A. Berardelli, Inghilleri M. Lorenzano, C. Frasca, V. Conte, A. Gilio, F. Savrun F.K. Uzun, N. Ciftci, R.S. Kiziltan, M. P158 An electrophysiological study to demonstrate P159 studied with repetitive transcranial magnetic Motor cortex excitability P148 Repetitive transcranial magnetic stimulation (rTMS) for levodopa induced P149 Does retinopathy contribute to hallucina- in dementia with Lewy bodies P150 Effects of pergolide on gait initiation patients in parkinsonian P151 MRI TMS, Callosal function in cerebral microangiopathy tested by P152 Usefulness of transcranial magnetic in differentiation stimulation between P153 Event-related desynchronization prior to psychogenic jerks P154 magnetic stimulation of the motor cortex influences the Transcranial P155 Movement-related cortical potentials in essential tremor P156 and afferent sensory in inhibition Nicotine corrects impaired motor-motor P157 Electrophysiologi- encephalomyelitis with muscular rigidity. Paraneoplasic P140 different intracortical inhibitory interaction between Reciprocal mecha- P141 disease the premotor cortex in Parkinson’s 5 Hz rTMS over Subthreshold P142 in idiopathic Dysfunction of gastric myoelectrical activities Parkinson’s P143 Median nerve somatosensory evoked potentials from pallidal and P144 MMG for diagnosis Surface EMG and of motor system disease by means P145A study magnetic with 5 Hz-repetitive transcranial Synaptic potentiation: P146 Demographic Hemifacial spasm: and electrophysiological data summary P147 improves bradykinesia Prolonged 5-Hz rTMS of the motor cortex the in movements in Parkinson’s disease (PD): A transcranial magnetic disease (PD): movements in Parkinson’s stimulation (TMS) study hyperactivity disorder (ADHD) Parkinson’s disease Parkinson’s evoked potentials and delayed in essential tremor delivered during the reaction time on sequential rapid arm movements in normal subjects electrode implantationdeep brain stimulation of movement disorders for potential in patients with Parkinson’s disease potential in patients with Parkinson’s dysfunction? Evidence from a gating study in a SEP paradigm parkinsonian syndromes? dyskinesias in patients with Huntington’s disease dyskinesias with Huntington’s in patients A. Wolters, F. Haessler, R. Benecke, E. Kunesch, J. Buchmann J. Kunesch, E. Benecke, R. Haessler, F. Wolters, A. M. Cincotta, A. Borgheresi, F. Balestrieri, A. Ragazzoni, P. Vanni, F. Benvenuti F. Vanni, Ragazzoni, A. P. Balestrieri, F. Borgheresi, A. Cincotta, M. R. Jech, D. Urgosik, E. Ruzicka, M. Volfova, T. Serranova, O. Novakova O. Serranova, T. Volfova, M. Ruzicka, E. Urgosik, D. Jech, R. T. Bäumer, U. Hidding, A. Münchau A. Hidding, U. Bäumer, T. Bazzucchi I. Sbriccoli, P. Traballesi, M. Accornero, N. Felici, F. Filligoi, G. S.W. Hung, G.F. Molnar, P. Ashby, R. Chen, V. Voon, A.E. Lang A.E. Voon, V. R. Chen, Ashby, P. Molnar, G.F. Hung, S.W. G. Tamas, A. Magyar, L. Palvolgyi, A. Takats, I. Szirmai, A. Kamondi A. Szirmai, I. Takats, A. L. Palvolgyi, A. Magyar, Tamas, G. Chen R. Lang, A.E. Gunraj, C. Espay, A.J. Li, J.-Y. L. Dolenc Groselj, I. Ghorayeb, J. Kobal, T. Pollmacher, F. Tison F. Pollmacher, T. Kobal, J. Ghorayeb, I. Dolenc Groselj, L. N. Biary, M. Kabiraj, B. Yaqub, S. Al Deeb S. Yaqub, M. B. Kabiraj, Biary, N. Chen R. Lozano, A.M. Hanajima, R. S.R. Vaidya, S.G. Patil, S.V. Khadilkar, R.D. Gursahani, N.A. M.H. Mehta, Bhatt N.A. R.D. Gursahani, Khadilkar, S.V. S.G. Patil, Vaidya, S.R. B. Gregori, A. Curra, L. Dinapoli, N. Accornero, A. Berardelli A. Accornero, Curra, A. Dinapoli, L. N. B. Gregori, X. Liu, P. Bain, T. Aziz, J. Stein J. Aziz, T. Bain, Liu, X. P. S. Rossi, S. Bartalini, M. Uivelli, A. Mantovani, P. Castrogiovanni, S. Passero S. Castrogiovanni, P. Mantovani, A. Uivelli, M. Bartalini, S. Rossi, S. Rektorova I. Sochurkova, D. Kanovsky, P. Brazdil, M. Bares, M. Rektor, I. H.A. Shill, A. Green A. Shill, H.A. C. Trompetto, M. Bove, R. Marchese, L. Marinelli, L. Avanzino, G. Abbruzzese G. Avanzino, L. Marinelli, L. Marchese, R. Bove, M. Trompetto, C. M. Kofler M. P. Mazzoni, R. Ravindran, J.W. Krakauer, C.B. Moskowitz, K. Marder K. Moskowitz, C.B. Krakauer, J.W. Ravindran, R. Mazzoni, P. M. Kapisyzi, J. Kruja J. Kapisyzi, M. P139 excitability in children with attention Changes of cortical deficiency P138 Mechanisms underlying motor overflow with intended unimanual P137 DBS/STN-related changes of the EEG and visual evoked potentials in P136 invasive electromyography tremor by non Observing Parkinson’s P134 Does it always help? Electrophysiologic testing in psychogenic tremor: P135 Pseudoathetosis – a phenomenon with different pathophysiology P133 disease of mirror movements in Parkinson’s Pathogenesis P131 patients findings in neuroacanthocytosis Polysomnographic P132 disease beta synchronization is reduced in Parkinson’s Post-movement P130 components of somatosensory Origin of the thalamic high frequency P128 An unusual case of hemimasticatory spasm P129 Silent period in sensory dystonia or pseudoathetosis P127 Effects of single and repetitive transcranial magnetic stimulation P126 Intraoperative during monitoring the motor symptoms using surface EMG P125 Cognitive and movement related potentials in the basal ganglia P124 Is Obsessive Compulsive Disorder (OCD) a sensorimotor integration P123 Dopamine agonists prolong the latency p300 event-related of the Poster number 121-163 P121suppresses long-loop reflexes at Levetiracetam the cortical level P122A useful tool in the differential diagnosis of inhibition: Transcallosal Clinical Electrophysiology P119amantadine for treatment and tolerability of efficacy The of choreic P120 disease in Huntington’s motor skill learning Impaired POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER 56 Rome, Italy P178 Unusual prolonged duration of improvement following treatment with treatment ofimprovementfollowing Unusualprolongedduration P178 bydeepbrain Electricfieldandpotential distributiongenerated P177 Poster number177-312 Dystonia duetoclozapine with Pisasyndrome(truncaldystonia) inapatient P176 Drug-inducedparkinsonismintheelderly: in A community-basedsurvey P175 Clonazepamresponsivetardivevocaltics-Reportofthreecases P174 Autosomaldominant, neuroleptic-inducedreversible, and dystonia P173 characterizationofapossibleexperimentalrodentmodel Preliminary P172 ofseveretardivedyskinesia: Pyridoxineinthemanagement A double P171 Parkinsonian MDMA(Ecstasy)addiction syndromefollowing P170 Tetrabenazine: fortardivedyskinesia Effectivetreatment P169 withresistanttardivedyskinesia Aripiprazoleonapatient P168 andpersistent Fluoxetine-inducedoral-buccal-lingualdyskinesia P167 inadvancedParkinson’s Effectoflevodopadoseondyskinesia disease P166 with tardivedyskinesia Severemotorworseningandaccelerated P165 antipsychotics withtypicalversusatypical Incidenceoftardivedyskinesia P164 Poster number164-176 Drug-induced MovementDisorders Involvementoftherightdorsalpremotorcortex(PMC)inneuralcontrol P163 ofsteppingrhythms Corticalrepresentation P162 processingin auditory Tourette andpreattentive Impairedattentive P161 conductionasatesttoevaluateresponse accessoriusnerve Nervus P160 THE S. Badarny, S. Zvi, S. Honigman S. Hemm, N. Vayssiere, L. Cif, A. Gannau, G. Mennessier, P. Coubes J. Miravite, M. Tagliati e Costa M.T. Barbosa,F. Cardoso, P. Caramelli, D.P. Maia, M.C. Cunningham, M.F. Lima I. Schlesinger N.L. Khan, M. Bhatt, N. Khan, D.J. Brooks, P. Piccini, K.P. Bhatia M.R. Gluck, L.A. Santana, M.D. Yahr P. Venegas, M.E. Millan, M. Miranda, M. Sinning G. Fabrizi, S. Monaco, A. DallaLibera J. Jankovic, C.B. Hunter, N. Mejia, K. Vuong G. Fabiani, A. Astete, F. Follador J.J. Chen,D.M.Swope N. Keijsers, M. Horstink, S. Gielen, L. Verhagen S.E. Hirsch, L.S. Boylan Z.S. Adwan A. Borgheresi, M. Cincotta, F. Balestrieri, S. Rossi, A. Ragazzoni, G. Zaccara H. Stolze, J. Raethjen, F. Kopper, S. Pohle, R.B. Govindan, D. Guenther W. Nager, R. Dengler, K.R. Müller-Vahl, C. Schröder, T.F. Münte, S. Johannes J.A. Smuts, P.W. Barnard botulinum toxin A forhemifacial spasmandblepharospasm oftheglobuspallidusinternus stimulation Parkinson’s disease Brazil parkinsonism movements levodopa-induced abnormalinvoluntary blind, placebocontrolledandcrossoverstudy withbotulinimtoxintype-A treated mandibular dystonia with on-offfluctuations Dementia aripiprazole inLewyBody highriskpatients in very (TMS) stimulation magnetic unimanual movements: usingtranscranial An interferenceapproach syndrome. potentials(ERPs) Evidencefromevent-related botulinum toxintherapy MOVEMENT DISORDERSOCIETY 17Thedisorderofcorticalexcitabilityandinhibitioninfocaldystonia P187 fordystonia: Deepbrainstimulation long-term follow-up(3 Outcome at P186 withpontomesencephaliclesions Segmentaldystoniaassociated P185 tolesionsin Abnormalsensorimotorinteractionsindystoniasecondary P184 Thesyndromeoffixeddystonia- of105patients An evaluation P183 DystoniaandchoreoathetosisafterglutaricaciduriatypeI P182 Pallidal andparkinsonism activityinamonkeymodelofdystonia P181 ofeyelid afterchildhoodencephalitiswithapraxia Segmentaldystonia P180 progressingto orshoulder-elevation Posttraumatic dystonia cervical P179 P202 Observations ontheuseofbotulinum toxintypeB(BoNT-B), Observations inpatients P202 inmyoclonus-dystonia syndrome(MDS) Deepbrainstimulation P201 Multifocaldystonias: A criticalappraisal P200 theeffectofDYT1 mutationontorsinAfunction Investigating dystonia P199 Botulinumtoxininjectionsforanunusualcaseofwriter’s dystonia P198 Familial dystonicsyndromewithseabluehistiocytes P197 Decreasesinadenosine A1 receptorbindinginananimal modelof P196 Writingandmotorsequencelearningin Writers’ Cramp P195 Cognitivefunctionsindystonia P194 greynuclei lesionsinDYT1 StereotacticalMRIdemonstrates dystonic P193 optionforwriter’s Ismotortrainingatherapeutic cramp? P192 indentatorubral-pallidoluysianatrophy dystonia Cervical P191 PhenotypicunpredictabilityofDYT carriersinSerbia 1mutation P190 inreflexsympathetic Itrathecalbaclofen forgeneralizeddystonia P189 withacetazolamide improvementofparoxysmalchoreathetosis Dramatic P188 T.J. Loher, A. Kaelin-Lang, S. Weber, J.-M. Burgunder, J.K. Krauss T.J. Loher, J.K. Krauss S. Tamburin,P.Fiaschi, A. Zanette Manganotti,G. A.E. Schrag, M.R. Trimble, N.P. Quinn, K. Bhatia E. Bidabadi J.W. Mink, S. Moerlein, J.S. Perlmutter E.C. Lim, M.-H. Tan K.A. Josephs, S.M. Torgrimson, J.Y. Matsumoto, E.J. Ahlskog D.G. Rogers L.E.Cif, Valente, N. P.Hemm,S. Vayssiere,S.Serrat, Coubes C.P. Das, R.P. Asimi, S. Prabhakar, P.S. Kharbanda, D. Khurana, V. Lal R.E. Goodchild, J. Roseman, J. Arias, W.T. Dauer J.-H. Tan,H.-L. Teoh,E.C.Lim M.H. Bhatt, S.R. Vaidya, A. Hegde A. Richter, K. Barlow, R. Raymond, M. Hamann, J.N. Nobrega M. Balas, N. Giladi, L. Gruendlinger, A. Karni M. Balas,R.B.Scott,N.Giladi N. Vayssiere, P. Delort, L. Cif, N. Patau, B. Viaud, P. Coubes K.E. Zeuner, H.A. Shill, Y.H. Sohn,F.M. Molloy, B.C. Thornton, M. Hallett Y. Okuma, T. Hatano, M. Iijima, K. Fujishima, K. Goto, Y. Mizuno M.V. Svetel, N. Ivanovic, N.T. Dragasevic, J. Jovic, V.S. Kostic F.Mastrandea Bono,Lupo,C.M.M.R. A.Lavano,Giliberto, Aloisi,C. V. Michel, A. Lagueny, D. Guehl, B. Bioulac, P. Burbaud P. Kanovsky, M. Bares, H. Streitova, H. Klajblova, P. Daniel, I. Rektor magnetic stimulation recordings stimulation magnetic evokedpotentialsandtranscranial evidence fromsomatosensory successfulbotulinumtoxintreatment: is normalisedfollowing An years orlonger) system the somatosensory opening: review Video reportandliterature generalized dystonia previously treated withtype previously treated A (BoNT-A) paroxysmal dyskinesia patients dystrophy: A casereport POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 57 C. elegans Schiavo, J.M. Cooper, T.T. Cooper, J.M. Schiavo, h, R. Saunders-Pullman, S.B. Bressman, L. Bressman, S.B. Saunders-Pullman, R. h, brain stimulation placebo-controlled trial do the benefits outweigh the disadvantages? Report of 4 cases A: Toxin Botulinum DYT1 gene carriers dystonia surgery management of cervicalclinical dystonia or blepharospasm (The REAL DOSE Study)—a comparison of dose ratio distribution based on drug start trauma dystonia and spasmodic torticollis cramp parkinsonism and normal Macaque disease Parkinson’s dystonia of DYT1 human neuronal cell model case report A treament term botulinum toxin R.G. Bittar, T.Z. Aziz, J. Yianni, J. Stein, S. Wang, X. Liu X. Wang, S. Stein, J. Yianni, J. Aziz, T.Z. Bittar, R.G. Wohrle J.C. Krauss, J.K. Hennerici, M.G. Blahak, C. Capelle, H.-H. Grips, E. Speelman J.D. Visser, Ongerboer de B.W. Koelman, J.H. Kruisdijk, J.J. Lees A. Misra, P. Cordivari, C. Catania, S. I. Skogseid, E. Kerty Bhatia K.P. Rothwell, J.C. Mir, P. Huang, Y.-Z. Edwards, M.J. Lee W. S. Lee, Jeong, E. Yoon, W. Lync T. Raymond, D. O’Riordan, S. Daly A.M. Lozano Lang, A.E. Poon, C. Y.-YW. Hamani, E. Moro, Toda, H. Naumann Reiners, M. K. Wolters, A. Stefan, K. Schramm, A. Weise, D. Pirtosek Z. Larsen, J. Ahmed, F. Magar, R. Marchetti, A. Findley, L. Aziz T. Stein, J. Bain, Gregory, R. P. Bradley, K. Yianni, J. S.A. Hannan S. Bohlen, I. Decius, C. Konrad, J. Vollmer-Haase, R. Reilmann R. Vollmer-Haase, J. Konrad, C. Decius, I. Bohlen, S. Berardelli A. A. Nemeth, Valente, E. Vacca, Brancati, L. F. G. Fabbrini, Turner R.S. Simmons, D. Lindsey, N. Rau, G. Marks, W.J. Starr, P.A. Evatt M.L. Sawabini, K.A. Caldwell K.A. Gelwix, C.C. Songsong, C. Caldwell, G.A. G. Gschmeissner, S. Misbahuddin, A. Placzek, M.R. Warner Hallett M. Leon-Sarmiento, F. Bohlhalter, S. Beuter A. Legros, A. P241 of recurrence of dystonia Pattern after discontinuation of chronic deep P242 randomized, Double-blind, cramp: Botulinum toxin treatment for writer’s P243 B for patients with oromandibular dystonia resistant to Toxin Botulinum P232 and non manifesting Differential motor system plasticity in manifesting P233 Blepharospasm and apraxia of eyelid opening in parkinsonism P234 Age at onset as a factor in determining the phenotype of primary torsion P235 Roperation 40 years after successful thalamic for generalized dystonia: P236 Disturbance of associative in focal hand dystonia motor cortical plasticity P237 in the Retrospective evaluation of the dose of Dysport® and BOTOX® P238 Effect of GPi DBS on functional imagingof the brain in dystonia P239 Sucessful treatment of eversion foot dystonia secondary to peripheral P240 Rate of improvement following deep brain stimulation for generalized P223in patients motor output control Impaired dystonia with focal of writers P224 genetic study clinical and A dystonia-Italian family with early onset of an P225 with Comparison of dystonia: Spontaneous pallidal discharge in 15 cases P226 Alternative therapy use in patients with cervical dystonia P227 neuroprotection against 6-OHDA toxicity in Torsin-mediated P228 in a stably transfected study An ultrastructural of torsinA inclusions P229A Abnormality in motor cortex excitability in peripherally induced dystonia: P230 Movement disorder quantification of dystonic syndromes P231 satisfaction Patient and course of disease in cervical dystonia with long- literature dystonia and age-matched controls problem The Cervical Dystonia Impact Profile (CDIP-58) measure: injections for cervical dystonia – a patients’ perspective spasmodic torticollis in patients with muscles by functional MRI variations on classic themes? variations on classic by mutation in intron 3 of GTP cyclohydrolase 1 gene by mutation in intron 3 of GTP cyclohydrolase cervical dystonia noise? sclerosis in three patients sclerosis proteins in treatment of blepharospasm by EMG of multiple muscle pairs preceding and subsequent to botulinum by EMG of multiple muscle Does the patterntoxin therapy: change? Cerebral Palsy M.E. Jenkins, J.W. Mink J.W. Jenkins, M.E. E. Roze, E. Paschke, T. Eck, N. Lopez, A. Maurel Ollivier, D. Doummar D. Maurel Ollivier, A. Lopez, N. Eck, T. Paschke, E. Roze, E. S.J. Cano, J.C. Hobart, A.J. Thompson, K. Bhatia, R. Fitzpatrick, T.T. Warner T.T. Fitzpatrick, Bhatia, K. R. Thompson, A.J. Hobart, J.C. Cano, S.J. W. Kim, O. Kim, H. Kim, M. Lee M. Kim, H. Kim, O. Kim, W. Hidalarachchi P. Pathirana, K.D. S.R. Filipovic, M. Jahanshahi, R. Viswanathan, P. Heywood, D. Rogers, K.P. Rogers, D. Heywood, Viswanathan, P. R. Jahanshahi, M. Filipovic, S.R. Bhatia E.W. Gieteling, M.A. van Rijn, H.M. Hoogduin, B.M. de Jong, J.J. van Hilten, K.L. van Hilten, J.J. de Jong, B.M. Hoogduin, H.M. van Rijn, M.A. Gieteling, E.W. Leenders P. Shashidharan, R.H. Walker, K.S. McNaught, M.F. Brin, C.W. Olanow C.W. Brin, M.F. McNaught, K.S. Walker, R.H. Shashidharan, P. Harris J.C. Schretlen, D.J. Puig, J.G. Torres, R.J. Visser, J.E. Jinnah, H.A. M.H. Pourfar, R. Guerrini, S.J. Frucht S.J. Guerrini, R. Pourfar, M.H. Bajaj N. Sawle, G. Cifelli, A. T.D. Sanger T.D. M. Bove, G. Brichetto, R. Marchese, G. Abbruzzese, M. Schieppati M. Abbruzzese, G. Marchese, R. Brichetto, G. Bove, M. S. Chung, J.-H. Im, S. Ahn, C.-S. Ki, J.-W. Kim, M. Lee M. Kim, J.-W. Ki, C.-S. Ahn, S. Im, J.-H. Chung, S. P. Roggenkämper P. E. Riva-Amarante, J.C. Martinez-Castrillo, J. Masjuan, J.C. Alvarez-Cermeño J.C. Masjuan, J. Martinez-Castrillo, J.C. Riva-Amarante, E. D.D. Duane, G.E. Heimburger N. Biary, W. Khoja, M. Sofi, B. Yaqub B. Sofi, M. Khoja, W. Biary, N. Al Moutaery K. Sofi, M. Bakhsh, E. Biary, N. L. Cif, H. EL Fertit, N. Vayssiere, S. Hemm, S. Serrat, P. Coubes P. Serrat, S. Hemm, S. Vayssiere, N. EL Fertit, H. Cif, L. P222 of a reach-grasp-drink task in children with primary Kinematic analysis P221 GM1 type 3 gangliosidosis: Report of four cases and review of the P220 Development and validation of a new dystonia patient-based outcome P219A discomfort rather than a cosmetic Hemi-facial spasms in Sri Lanka - P218 Botulinum toxin restores reciprocal inhibition of H reflex in forearm P217 Presence of head tremor reduces the effectiveness of the botulinum toxin P216 Cortical activation in reflex sympathetic dystrophy (RSD) dystonia studied P214 dystonia mouse model of childhood onset Transgenic P215 variant Lesch-Nyhan disease The motor disorder of P213 presenting as dystonic tremor Neuroacanthocytosis P212A new subtype or Classification in paroxysmal dyskinesias: conundrums P211 Consistent errors or random Reaching movements in childhood dystonia: P209 variable dopa-reponsive dystonia caused with clinically family A Korean P210 vibration during quiet upright stance in patients with Neck muscle P208A free of complexing type and safety of a new botulinum toxin Efficacy P207 manifestation hemidystonia as the presenting of multiple Paroxysmal P206 overactivity in cervical dystoniaas determined muscle of nuchal Patterns P205 Hemidystonia - Hemiatrophy syndrome P203brain stimulation Deep post anoxic disorders due to in movement P204 rubral tremor secondary Dystonic to midbrain hemorrhage POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER 58 Rome, Italy P265 Presynaptic dopamine transporter in patients with idiopathic focal withidiopathic dopaminetransporter inpatients Presynaptic P265 indystonia: Longtermoutcomeofchronic GPIstimulation 15cases P264 Praying-inducedoromandibular dystonia P263 andnon-dystonic Shortenedcorticalsilentperiodinbothdystonic P262 ofblepharospasm inthediagnosis Blinkrate P261 ofDYT1 torsion Clinicalfeatures andnon-DYT1 earlyonsetprimary P260 insporadicandfamilial torsiondystonia Onsetandprogressionofprimary P259 pallidaldeepbrainstimulationfor BlinkreflexR2inhibitionfollowing P258 over stimulation Lackofinterferencerepetitivetranscranialmagnetic P257 Paroxysmal inacutetransversemyelitis dystonia P256 dystonia Headacheincranialandcervical P255 inseveral causestransientdystonia MPTP-induceddopaminedenervation P254 inducedillusionofmovementin Theinheritanceofabnormalvibration P253 Long-termefficacy ofbotulinumtoxin A inthetreatmentofble- P252 dystonia cervical inprimary Diffusiontensorimaging P251 model dystonia Geneexpressionstudiesinanovelrat P250 withwriter’s Shortlatencyafferentinhibitioninpatients cramp P249 blepharospasm Clinicalgeneticsofprimary P248 eye: blepharospasmanddry Primary An age-dependentassociation P247 adult-onsetdystonia Fatigue inprimary P246 oftheepsilon-sarcoglyan(SGCE)promoterregionin Evaluation P245 ExtractingsuperimposedrhythmicandtonicEMGactivityinpatientswith P244 THE N. Tambasco, F. Fabiani, F. Corea, A. Faricelli, A.Rossi, A.Bocola K. Boetzel,B.Bereznai,J.H.Mehrkens,U. Steude T.V. Ilic, M. Pötter, I. Holler, G. Deuschl, J. Volkmann B. Donmez, R. Cakmur, F. Uzunel P.A.Bentivoglio,A. Tonali, A. Albanese,Fasano A. N.Nardocci,A.E.Elia, A.Bentivoglio, Fasano, A. A. Albanese A.E.Elia,G.Filippini,A.Bentivoglio, A. Fasano, T.Ialongo, A. Albanese S. Tisch, P. Limousin, J. Rothwell, P. Asselmann, K. Bhatia, M. Hariz A. Schramm,M.Naumann,K.Reiners,J.Classen S.J. Kim, B.G. Yoo, E.K. Kim P. Barbanti, G. Fabbrini, C.Pauletti, G. Defazio, G. Cruccu, A. Berardelli S.D. Tabbal, J.W. Mink, J.S. Perlmutter N. Frima,R.A. Grünewald Barbosa L. Silveira-Moriyama, L.R. Gonçalves, A. Maria-Santos, H.F. Chien, E.R. C. Colosimo, V. Calistri, P. Pantano, G. Fabbrini, A. Berardelli D. Alvarez-Fischer, M. Grundmann, L. Lu, C. Moller, W.H. Oertel, O. Bandmann K.R. Kessler, D. Ruge, T.V. Ilic, U. Ziemann Masi,E.M.M.S.G.D.Martino, Valente, Aniello, Defazio G. Berardelli, A. Martino,G.P.D.Defazio,G. Abbruzzese, M.Girlanda, Tinazzi, Berardelli A. G. Masi, G. Defazio, S. Lamberti, V. Lucchese, P. Lamberti, P. Livrea Schuele,S.R.Montcel, Tezenas O. Bandmann,Brice,de A. T. Gasser, F. Asmus S. Wang,X.Liu,J.Yianni, T. Aziz,J.F. Stein dystonia comparedtoParkinson’sdystonia disease: A [(123)I]-FP-CIT-SPECT study study stimulation magnetic dystonia: withcervical muscles ofpatients cervical A transcranial (PTD)inItaly dystonia Italian cases dystonia patients trickmaneuverintorticollis the posteriorparietalcortexwithsensory species primate dystonia pharospasm overa10-yearperiod (M-D) myoclonus-dystonia shrinkage wavelet usingadaptive dystonia MOVEMENT DISORDERSOCIETY P274 New formulation ofBOTOX: Newformulation failurein therapy Completeantibody-induced P274 botulinumtoxintypeBwitha Detectingneutralisingantibodiesagainst P273 dystonia:Frequency ofcervical BotulinumtoxintypeBdenovotherapy of P272 motorcortex primary Abnormalregionalcorticalactivationincontralateral P271 Pretarsalblepharospasm:Clinicalandelectrophysiologicalcharacteristics P270 generalizeddystonia: inprimary GPistimulation A H P269 Botulinumtoxin-Aandmuscle afferentblockinX-linkedDystonia- P268 in mirrorwritingmovements(mirror dystonia) fMRIcorrelatesofbilateral P267 stimulation repetitivetranscranialmagnetic Subthresholdlow-frequency P266 P286 The cognitive profile of primary dystonia: findingsofa Thecognitive profileofprimary Preliminary P286 Paroxysmal spreadingandrostro-caudal withcontralateral hemidystonia P285 Homocysteine indystonia andserummarkers ofimmuneactivation P284 ofthehandin Differencesinthedisorderedsensorimotororganisation P283 Painful repetitive spasmscanbereducedbylow-frequency TMS ofthe P282 impairmentinwriter’s Motorimagery cramppatients P281 withblepharospasm Long-termpotentiationoftheblinkreflexinpatients P280 Afferenteffectsofbotulinumtoxintype A: Evidencefromthetonic P279 Mirror-movements inwriter’s cramp- A multi-channelEMGstudy P278 disorder: asensory Childrenwitharm dystonia Ischildhoodsecondary P277 of Validation oftheBethIsraeldystoniascreen(BIDS)fordiagnosis P276 oromandibular trickmanoeuvresinidiopathic Characteristicsofsensory P275 D. Dressler, M. Lange, H. Bigalke D. Dressler, H. Bigalke D. Ruge, K.R. Kessler, U. Ziemann F.Lopez-Manzanares,Grandas,L. A. Traba,Esteban A. O. Detante, L. Vercueil, S. Thobois, E. Broussolle, N. Costes, F. Lavenne R.L. Rosales, M.S. Delgado, M.V. Malicdan M.Merello, S. Carpintiero, E. Fridman, F.Meli, A.Cammarota, R.Leiguarda N. Murase, R. Kaji, T. Mima, N. Murayama, H. Shibasaki, J.C. Rothwell J.Mueller, Bartha,L. W. Eisner, G.K. Wenning,T. Benke, W. Poewe F. Fattapposta, M. Bartolo, A. Perrotta, M. Serrao, F. Pauri, L. Parisi U.J. Mueller, B.Frick, D. Fuchs, G.K. Wenning, W. Poewe, J. Mueller K.Rosenkranz, A.Butler,K. Williamon, Cordivari,Rothwell C.J.C.A.Lees, P. Nguyen J.-P. Lefaucheur, G. Fénelon, I. Ménard-Lefaucheur, S. Wendling, P. Cesaro, J.- V. Rizzo, A. Quartarone, S. Bagnato, D. Crupi, A. Berardelli, P. Girlanda A. Quartarone, A. Sant’Angelo, F. Morgante, E. Aiello, H.R. Siebner, P. Girlanda C. Trompetto, A.Currà, A.Buccolieri, A.Suppa,G. Abbruzzese, A.Berardelli R. Borgohain, V. Ramaraju, S.N. Pandit, M.A. Kanikannan, S. Mohandas S. Kukke, T.D. Sanger Bressman, J.Shriberg R.Saunders-Pullman, J. Soto-Valencia, D.Raymond, K.Haberman, S. A. Schramm,J.Classen,K.Reiners,M.Naumann D. Dressler hemifacial spasm assay mouse diaphragm therapyfailure antibody-induced in patientswithwriterscrampexclusively duringawriting-task Parkinsonism ofPanay a writer’s cramppatient over thepremotorcortexmodulatesupperlimbdystonia prospective study withDevic’sprogression inapatient disease ogy? musician’s andwriter’s dystonia cramp: Cluefordifferentpathophysiol- premotor cortexingeneralisedsecondarydystonia reflexinupperlimbdystonia vibration discrimination adeficitoftactilesensory dystonia andcerebralpalsyhave dystonia openingdystonia yaw POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 2 15 O study 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 59 -synucleins promotes neuronal differentiation of promotes neuronal -synucleins α in vitro Dutch family sleep stages and association with sleep disorders progenitor cells and derived neurons lesioned rats oxygen TH and GTPCH1 in a rat model of gene transfer of vector-mediated disease Parkinson’s parkinsonian rats with intrastriatal dopaminergic transplants legs syndrome (RLS) and different from Periodic Limb Movements during Sleep (PLMS) or tremor with epilepsy’ ‘familial cortical myoclonus pathology approach for writer’s cramp dystonia approach for writer’s disease neural stem cells in rat of Parkinson’s model a presymptomaticexperimental model reproducing phase of Parkinson’s disease stem cells murine neural stem cells (NSC) A.-F. van Rootselaar, E. Aronica, E.N. Jansen Steur, J.M. Rozemuller-Kwakkel, J.M. Jansen Steur, E.N. Aronica, E. van Rootselaar, A.-F. Tijssen M.A. Vos, de R.A. Tijssen M.A. C. Tijssen, E.M. K. Gerritz, Klein, M. Foncke, Hedrich, C.C. Poewe W. Hoegl, B. Kunz, A.B. F. Wegner, S.C. Schwarz, E. Frick, J.W. Wieacker, A. A. Storch, Schwarz J. Wieacker, S.C. J.W. E. Schwarz, Frick, Wegner, F. Johannes S. Alexander, S. Susanne, Dirk, E. W. Jan, W. Schwarz, S.C. Schwarz J. Storch, A. Schwarz, S.C. Poppe, M. Milosevic, J. Kirik D. Bjorklund, A. Dengler, R. Muzyczka, N. Carlsson, T. Winkler, C. Kirik D. Bjorklund, A. Dengler, R. Carlsson, T. Georgievska, B. Winkler, C. Montagna Lugaresi, P. E. Provini, F. Plazzi, G. Vetrugno, R. M.A. Brown, P. Leenders, K.L. Koelman, J.H. Maurits, N.M. van Rootselaar, A.-F. Tijssen J.P. O’Dwyer, M. Hutchinson M. O’Dwyer, J.P. G. Fiaschi, L. Moretto, A. Bertolasi, Zarattini, S. Farina, Smania N. Tinazzi, S. M. Li B. Lu, G. Liu, W. Chen, S. Savasta M. Mallet, J. Brizard, M. Carcenac, C. Zigova T. Chen, N. Walczak, R. Heller, J. Sanchez-Ramos, Kamath, S. P. Isacson O. Ferree, A. Perrier, A. Ferrari, D. Studer, L. Sanchez Pernaute, R. Schwarz J. Storch, A. Jungnitsch, M. P326 tremor as part of the myoclonus-dystonia phenotype in a large Trunk P327 distribution in Frequency, Analysis of fragmentary myoclonus in sleep: P318 characterization Electrophysiological of human fetal mesencephalic P319 cells reverse functional deficits in 6-OHDA Human neural precursor P320 Effect of Proliferation and differentiation of murine neural stem cells: P321AAV and motor impairments by dyskinesia Reversal of L-DOPA-induced P322 Functional effects of GDNF gene therapy on motor performance in Myoclonus Poster numbers 323-333 P323A motor phenomenon found in restless (PSM): Propriospinal myoclonus P324 EEG-EMG and EMG-EMG frequency analysis in Dutch patients with P325 or tremor with epilepsy’ and cerebellar cortical myoclonus ‘Familial P311 of associative Disturbance dystoniacortical plasticity in focal hand motor P312A new therapeutic electrical nerve stimulation (TENS): Transcutaneous and Cell-Based Therapies Gene Therapies 313-322 Poster numbers P313 and regeneration Dopaminergic protection by neurturin-expressing c17.2 P314 Restoring reinnervation system indced by GDNF in an of the dopaminergic P315 Switching cell fate with human Neuro-D1 P316from primate embryonic of dopamine neurons derived Transplantation P317 Ectopic expression of cervical dystonia sarcoglycan mutation positive myoclonus-dystonia disease): A case report disease): of adult patients bilateral cerebellar infarction neuromotor rehabilitation proteins in treatment of cervical dystonia primary dystonia study of a new family D. Weise, A. Schramm, K. Stefan, A. Wolters, K. Reiners, K. Wolters, Naumann M. A. A. Stefan, K. Schramm, Weise, D. A.B. Deutschländer, T. Stephan, M. Naumann, T. Gasser, T. Brandt, F. Asmus F. Brandt, T. Gasser, T. Naumann, M. Stephan, T. Deutschländer, A.B. Likitjaroen Y. Phanthumchinda, K. A. Alkhani, S. Bohlega S. Alkhani, A. J.P. O’Dwyer, M. Hutchinson M. O’Dwyer, J.P. Nardocci N. Barzaghi, C. Ciano, C. Zorzi, G. Ghezzi, D. Garavaglia, B. H.A. Teive, E.R. Pereira, S. Raskin, T. Werneck J.A. Hamada, McGrath, L.C. T. S. Raskin, E.R. Pereira, Teive, H.A. E.R. Antoniuk, Werneck Barbosa, S.A. M.M. Scaff, Souza, M. L.C. Teive, H.A. K. O’Rourke, M. Hutchinson G.D. O’ Connor, P. Hodnett, D. Schmidt, B. Sweeney B. Schmidt, D. Hodnett, P. O’ Connor, G.D. H. Shang, N. Clerc, D. Lang, J.-M. Burgunder, A. Kaelin-Lang A. Burgunder, J.-M. Lang, D. Clerc, N. Shang, H. C. Maragoto, G. Rodríguez, G. Lopez, R. Melo, L. Alvarez L. Melo, R. Lopez, G. Rodríguez, G. Maragoto, C. Bhatia K. Quinn, Schrag, N. A. Tarsy, D. K.P. Frei, M. Pathak, D.D. Truong D.D. Pathak, M. Frei, K.P. Chang Y.-Y. Wu, H.-S. Su, C.-S. Chang, C.-C. Lan, M.-Y. Liu, J.-S. C.W. Olanow, K.S. McNaught K.S. Olanow, C.W. C. Tassorelli, F. Mancini, G. Sandrini, R. Zangaglia, G. Nappi, C. Pacchetti C. Nappi, G. Zangaglia, R. Sandrini, G. Mancini, F. Tassorelli, C. T.M. Entner, J. Mueller, G.K. Wenning, W. Poewe W. Wenning, G.K. Mueller, J. Entner, T.M. Jankovic J. Vuong, K.D. Thomas, M. R. Benecke K. Kabakci, K. Isbruch, K. Hedrich, P.L. Kramer, M. Schwarz, C. Klein C. Schwarz, M. Kramer, P.L. Hedrich, K. Isbruch, K. Kabakci, K. M.J. Edwards, E. Trikouli, D. Martino, A.J. Church, G. Giovannoni, K.P. Bhatia A.J. Church, G. Martino, D. Giovannoni, K.P. Trikouli, M.J. Edwards, E. D. Gaudin, L. CIF, P. Coubes, G. Bouvier G. Coubes, P. CIF, L. Gaudin, D. Hallett M. Wong, M. Shill, H. Kanchana, S. P310 Sensory thresholds using grating orientation tasks at the fingertip in P309 Hallervorden-SpatzThailand Syndrome in P307 Unilateral pallidotomy for primary hemidystonia P308 Brain activation patterns during motor tasks in patients with epsilon- P305 The age of onset in cervical dystonia is independent of level of education P306 syndrome Clinical and genetic variability in myoclonus-dystonia P304 Report of four cases Status dystonicus: P303 Generalized dystonia associated with Lipoid Proteinosis (Urbach-Wiethe P301 Dystonia as a presentation of anti-Hu paraneoplastic syndrome P302 Acquired paroxysmal torticollis and bilateral belpharospasm following P300 Clinical presentation of familial and sporadic primary dystonia in a cohort P298A Cuban experience Bilateralfor generalized dystonia: pallidotomy P299 Psychogenic facial spasm (The Smirk) P297 Cervical dystonia associated with droopy shoulder syndrome P295 Neuropathology dystonia in DYT1/torsina-linked P296 Segmental dystonia responsive to amiodarone P294 Integrated approach to cervical dystonia with botulinum toxin and P293 Clinical characteristics and long term progression Psychogenic dystonia: P291A free of complexing type and safety of a new botulinum toxin Efficacy P292 follow-upA resistant of botulinum toxin B treatment in type Two-year P290 Genetic heterogeneity in rapid-onset Description dystonia-parkinsonism: P289A prospective antibodies in atypical dystonia Antibasal ganglia and tics: P287brain stimulation Deep on the cervico-axial results long-term dystonia, P288 Survey sensory of and motor tricks POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER POSTER SESSION 1 SESSION POSTER 1 SESSION POSTER 60 Rome, Italy P343 Cocontractions related to obstetrical brachial plexus palsy treated with toobstetricalbrachialplexuspalsytreated Cocontractionsrelated P343 Adouble-blind, randomised, efficacy placebo-controlled studytoevaluate P342 pain: ThesyntheticcannabinoidNabilone®reducesspasticity-associated P341 Treatment ofspasticitywithbotulinumtoxin: study A ten-yearsfollow-up P340 botulinumtoxintype following Ocularmyasthenia A injectionforlimb P339 baclofenimprovesfunctionalmotorcontroland Intrathecal pumptherapy P338 Perception inParkinson’s ofemotionalprosody disease P337 Awaytoimprovetheeffectivenessofbotulinumtoxininspinalcordinjury P336 enhancestheeffectivenessofbotulinum Short-termelectricalstimulation P335 Two yearrandomised, doubleblind, parallelgroup, placebo controlled, P334 Poster number334-343 Spasticity Actionmyoclonus -Renalfailuresyndrome;afurthercasereport P333 Myoclonus withlong-standingpoliomyelitisisduetocentral associated P332 myoclonus withbotulinumtoxin successfullytreated Diaphragmatic P331 ‘Familial corticalmyoclonus ortremorwithepilepsy’: A reviewonthe P330 Myoclonus incortico-basaldegeneration: Isitofcorticalorigin? P329 AcaseofGuillain-Barresyndromewithperipheralmyoclonus and P328 THE L.R. Gonçalves, L. Silveira-Moriyama, C.O. Heise, J.L. Gherpelli, E.R. Barbosa F.Mancini,C.PacchettiMoglia,M. A.Nappi,G. G.Sandrini, Allena, J. Wissel, T.Entner, J.Mueller, Brenneis,C. T. Berger, W. Poewe M. Bottanelli, S. Vicentini, G. Rossato, E. Fincati, N. Rizzuto, L. Bertolasi M. Umaiorubahan, V.C. Uthamarayan R. Izor, S. Fisher, R. Simpson, K. Johnson, T. Tran, M. Schiess C. Schroeder, S. Martin, F. Szymanowski, W. Nager, T.F. Muente, R. Dengler W.A. Raza, N. Green, H. Francis E. Frasson, B. Ruzzante, G. Didonè, M. Bottanelli, A. Priori, L. Bertolasi Mohamed A.P.Moore,R.A. Ade-Hall,C. Tudor-Smith, J.Rosenbloom,L.R. Walsh,K. L. Vadlamudi,F.L. Ierino, S.F. Berkovic, A.J. Hughes Cordivari,N.J.C. Toms, Catania,S. V.P. Misra,P.Lees, A.J. Brown P. Simal, J.C. Martinez-Castrillo, F. Vivancos Maagdenberg, J.H. Koelman, M.A. Tijssen A.-F. vanRootselaar, I.N. vanSchaik, P.M. Callenbach, A.M. vanden Z. Mari, M. Matsuhashi, H. Shibasaki, M. Hallett M. Bozi, K. Filippopolitis, I. Hatzigeorgiou, M. Tzortzi, A. Georgali botulinum toxin ofspasticparaparesis toxin type forthetreatment A (dysport) and safetyofbotulinumtoxintypeb(myobloc/neurobloc) A double-blindplacebo-controlledcross-overtrial spasticity quality oflifeinspastichemiplegiaafterstroke patients toxin inspasticity spasticity incerebralpalsy multi-injection cycle withbotulinumtoxin trialoftreatment A forleg reorganization clinical, geneticandelectrophysiologicalaspects syndrome ofpainfullegsandmovingtoes MOVEMENT DISORDERSOCIETY POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1 POSTER SESSION1

8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 63 -CIT SPECT imaging in the differential diagnosis of β I] 123 patients with PD revealed by functional MRI double blind placebo controlled study disease, gait in Parkinson’s utility of factorial discriminant analysis disease Parkinson’s dichotomy disease in Parkinson’s disease disease disease patients on strict diagnostic based criteria disease impairment in patients with Parkinson’s disease complicationsinhibitors for levodopa-induced in Parkinson’s North East of England with morbus Parkinson parkinsonian syndromes R. Faber R. Rezai A.R. Lowe, M.J. Phillips, M.D. Kopell, B. Cooper, S. Baker, K.B. Berendse H.W. Wolters, E.C. Winogrodzka, A. Booij, J. Bosscher, L. Stoffers, D. Giladi N. Weizmann, N. Moore, O. Peretz, C. Gurevich, T. G.J. Bernatzky, P.P. Bernatzky, H.P. Hesse, E. Mueller, M. Grobovschek, G. Grobovschek, M. Mueller, E. Hesse, H.P. Bernatzky, P.P. Bernatzky, G.J. Ladurner Destée A. Steinling, M. Duhamel, A. Lecouffe, P. Defebvre, L. Kreisler, A. Chiba Y. Hashimoto, T. Maruyama, T. A. Nebe, E. Georg Hausdorff J.M. Herman, T. Balash, Y. Giladi, N. Baltadjieva, R. J.M. Herman, T. Baltadjieva, R. Gruendlinger, L. Giladi, N. Toledo-Frankel, S. Hausdorff N. Hausdorff, J.M. Herman, T. Baltadjieva, R. Gruedlinger, L. Lowenthal, J. Giladi Hausdorff J.M. Gruendlinger, L. Simon, E.S. Giladi, N. Yogev, G. Sakuta M. Nishiyama, K. Ooishi, C. Okano, H. J.H. Yeung, on Behalf of the Hong Kong Parkinson’s Disease Registry Disease Study Parkinson’s of the Hong Kong on Behalf Yeung, J.H. Group K. Kashihara, M. Ohno Chun S.M. Kim, W.J. Kim, J.W. Spieker C.E. Clarke, K.H. Deane, S. Goyal, Singh S. V. Srivastava, T. Lazarus, Handa, K.K. M. Behari, J.P. Srivastava T. Singh, S. Goyal, V. Handa, K.K. Lazarus, J.P. Behari, M. Shing M. R. Renner, Werner, G. Storch, A. U. Polzer, Odin, P. Walker R. Macfarlane, R. Porter, R.W. P380 disease Electroconvulsive therapy in Parkinson’s P381 Activation in deep brain structures during therapeutic DBS of the STN in P382 of early [ Value P383 on freezing of to the calf muscles The effect of botulinum toxin injections P372The Degenerative parkinsonian syndromes assessed by HmPaO-SPECT: P373 in treatment Effectiveness of milnacipran of depression associated with P374 disease Double vision in Parkinson’s P375A force / rhythm disease patients: Parkinson’s Gait changes in de novo P376an external cue to improve gait rhythm and stability walking as Treadmill P377 Effects of rhythmic auditory stimulation on gait dynamics in Parkinson’s P378 mental loading and gait variability in Parkinson’s Executive function, P379 Clinical and electrophysiological study of hand deformity in Parkinson’s P363 disease features differences in clinical Gender of Chinese Parkinson’s P364 MIBG uptake is correlated Reduction of myocardial with cognitive P365 disease in Parkinson’s Non-motor off symptoms P366 Cochrane systematic review of catechol-O-methyl transferase (COMT) P367 and videolaryngoscopic study A clinical in PD patients P368 disease patients in Indian Parkinson’s profile and acoustic signs Voice P369 agonist High dose dopamine treatment P370 in the Tyneside in an area of North disease The prevalence of Parkinson’s P371 Stimulating music increases fine motor coordination in patients afflicted , JUNE 15 , JUNE 15 , JUNE , JUNE 15 , JUNE , JUNE 15 , JUNE 15 , JUNE Y Y Y Y Y levodopa treatment in Parkinson’s disease levodopa treatment in Parkinson’s side presents first? Parkinson’s disease Parkinson’s following instrastriatal MPP+ injection Parkinson’s disease Parkinson’s disease Evaluation of Ib inhibition into soleus motor neurons A cross sectional community-based study disease (PD) clinical and treatment profiles of ethnic Chinese patients and treatment profiles of ethnic using strict clinical diagnostic criteria with Parkinson’s disease on L-dopa monotherapy disease with Parkinson’s J.H. Yeung, on Behalf of the Hong Kong Parkinson’s Disease Registry Study Parkinson’s on Behalf of the Hong Kong Yeung, J.H. Group M. Lee, H. Kim, C. Lyoo, J. Kim J. Lyoo, C. Kim, H. Lee, M. D. Lee, K. Park, S. Koh, J. Han J. Koh, S. Park, K. Lee, D. A.N. Lieberman, J. Levine, R. Myerburg, L. Vela L. Myerburg, R. Levine, J. Lieberman, A.N. Martinelli P. Barbiroli, B. Iotti, S. Lodi, R. Scaglione, C.L. Tonon, C. A.N. Lieberman, A.R. Rezai A.R. Lieberman, A.N. H. Miwa, Y. Kubo, S. Morita, I. Nakanishi, T. Kondo T. Nakanishi, I. Morita, S. Kubo, Y. Miwa, H. Neophytides A.N. Singer, C. Lieberman, A.N. W. Le, Q. Jiang, W. Xie, S. Hintermann, J. Jankovic J. Hintermann, S. Xie, W. Jiang, Q. Le, W. K.A. Grosset, F. Needleman, G. Macphee, D.G. Grosset D.G. Macphee, G. Needleman, F. Grosset, K.A. L.M. Allcock, S. Tordoff, T. Hildreth, K. Wesnes, R. Kenny, D.J. Burn D.J. R. Kenny, Wesnes, K. Hildreth, T. Tordoff, Allcock, S. L.M. Braak E. Steur, E. Vos, de R. Rueb, U. Tredici, Del K. Braak, H. C.L. Scaglione, G. Rizzo, G. Lopane, M. Marchi, D. Resi, P. Martinelli P. Resi, D. Marchi, M. Lopane, G. Rizzo, G. Scaglione, C.L. H.J. Woodford, R.W. Walker R.W. Woodford, H.J. M.F. Lew, R. Pahwa, J. Bertoni J. Pahwa, R. Lew, M.F. C.F. Orr, D.B. Rowe, G.M. Halliday G.M. Rowe, D.B. Orr, C.F. J.H. Yeung, on Behalf of the Hong Kong Parkinson’s Disease Registry Study Parkinson’s on Behalf of the Hong Kong Yeung, J.H. Group W.C. Koller, M.B. Stern, L. Stone, J. Blazer J. Stone, L. Stern, M.B. Koller, W.C. L. Mazzella, N. Huang, A. Di Rocco, M.D. Yahr M.D. Di Rocco, A. Huang, N. Mazzella, L. POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER TUESDA TUESDA P362 Does it matter which disease as an asymmetrical disorder: Parkinson’s P360 disease studies in Parkinson’s Polysomnographic P361 Abnormal temporal discrimination threshold and its responsiveness to P359 In vivo proton MR spectroscopy study of brain metabolism in Early-Onset P357 disease (PD) gambling and Parkinson Sex, P358 Is there a relationship? disease (PD): and Parkinson Co Q 10, Statins, P356 Are panic attacks and freezing episodes related? P354 disease therapy Nurr1 gene targeting for Parkinson P355 Extensive oxidative stress and microglial activation in substantia nigra P353 in dopamine agonist Ergot side-effect issues treatment of Parkinson’s P352 staging of brain destruction related Pathoarchitectonic to idiopathic P351 disease: Orthostatic hypotension and cognitive impairment in Parkinson’s P349 disease hospital admissions in idiopathic Parkinson’s Emergency P350 disease: s Spinal cord inhibitory mechanisms in early onset Parkinson’ P348 disease and safety of Zydis® selegiline in Parkinson’s Long-term efficacy P347 Immune-inflammatorynigra in Parkinson’s changes in the substantia P345 of life disease on quality of the impact of Parkinson’s An assessment P346A multi-centre study of Registry: Disease Parkinson’s The Hong Kong Poster numbers 344-694 Poster numbers P344 fluctuations Dyskinesias predict the onset of motor response in patients Parkinson’s disease 1 disease Parkinson’s TUESDA pm 8:30 am to 5:00 Poster Viewing: am to 12:30 11:30 Present Odd Numbers: Authors pm pm Even Numbers: 4:00 pm to 5:00 Authors Present POSTER SESSION 2 SESSION POSTER TUESDA TUESDA POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER 64 Rome, Italy 44Prevalence studiesinParkinson’s disease: A systematic reviewof P404 withtremor inpatients Responseoftremor tosubcutaneousapomorphine P403 Effectofzonisamideonparkinsonian tremor: in A pilotcross-overstudy P402 EffectsofropiniroleonposturalstabilityinParkinson’s disease: A P401 ofdrug-inducedpsychosisinPDtheGPandspecialists’office Therapy P400 inParkinson: Gaitfestination Insightsintopathophysiological mechanisms P399 insuredpatients andexpendituresamongprivately Healthcareutilization P398 posturometry: anddynamic Effectofdeepbrainstimulationthe Static P397 EffectofrotigotineonlocomotoractivityanddisabilityscoresinMPTP- P396 MPP lisurideattenuates Thedopaminereceptoragonist P395 Pergolide valvulopathy: associated A Belgianexperience P394 specifically andcharacterizationofanovelbiomarkerthat Identification P393 movementsinParkinson’s Nocturnalbody disease: LargerangesinHoehn P392 Falls inParkinson’s disease: analysis Clinico-statistical P391 with GeneticanalysisofDJ-1inethnicChineseandMalaypatients P390 TheSCOPA-Motor ScaleforassessmentofParkinson’s disease: P389 impactscalefordailyuse(D-FIS)in Metricpropertiesofafatigue P388 PrevalenceofParkinson’s diseaseintheEolian Archipelago P387 Parkinsonism withexcessivedaytimesleepiness: A narcolepsy-like P386 withParkinson’s Exercisehabitsofpatients disease: basedstudy A survey P385 andneuropsychiatric betweenthelevelofeducation Theassociation P384 THE M. Hellmann, T. Sabach, E. Melamed, R. Djaldetti I. Nakanishi, J. Kohmoto, H. Miwa, T. Kondo G.-H. Lee,J.-I.Kim D. Brandstaedter, A. Schneider, J. Lotze, S. Spieker, G. Ulm, W.H. Oertel R. Iansek, J.L. McGinley,F.E. Huxham L.S. Orsini, J. Castelli-Haley, S. Kennedy, D.M. Huse D. Guehl, P. Dehail, M. deSèze, E. Cuny, M. Barat, P. Burbaud D.K. Scheller, L. Smith, A. Breidenbach, M. Jackson, S. Rose, P. Jenner Braungart,K.Gerlach,E.M. Tovar, M.Hoener, Engfer, A. P. Riederer F.L.Evrard, A.Flamez,G. Camp, Van T.Muller, M.J.Dupuis,C.Dilman G.M. Pasinetti N. Kuehnl,M.H. Strothjohann, D.J. Emmans, G.A. Fuchs Y. Balash, C. Peretz, G. Leibovich, T. Herman, J.M. Hausdorff, N. Giladi V.R.C.Chandran, Tan, Z. Yi, K. Yew,E.K.Hui,S. Tan Martinez-Castrillo P. Martinez-Martin, J. Benito-Leon, J.A. Burguera, A. Castro, G. Linazasoro, J.C. Zamarbide, E.Cubo P. Martinez-Martin, M.J. Catalan, A. Ortega-Moreno, J. Benito-Leon, I. L. Morgante, M. Zappia, U. Bonuccelli, R. Marconi, Q. Aldo, S. Giovanni Bassetti C. Baumann, L. Ferini-Strambi, D. Waldvogel, E. Werth,M. Bischof, C.L. A. DaleyRyan, A. Kaszmarek, T. Simuni Cohen,D.O.S. Tanne,Hassin-Baer E.S.J.Chapman,Z.Nitsan, Vakil, prospective data sets prospective data Parkinson’spredominant idiopathic disease comparison withtrihexyphenidyl study posturography computerized dynamic in Germany with Parkinson’s diseaseintheUnitedStates subthalamic nucleus onposturalstabilityinParkinson disease commonmarmosetsfollowingsubcutaneousadministration treated predicts Parkinson’s disease and Yahr IItoIV! stages Parkinson’s disease Consistency andvalidity Parkinson’s disease disorder? inParkinson’smanifestations disease dopaminergic neurodegeneration inC.dopaminergic neurodegeneration elegans MOVEMENT DISORDERSOCIETY + -induced 42ModulationofserotoninreceptorsinMPTP-lesionedmonkeys P412 LoadforceduringmanualtransportinParkinson’s disease P411 Atypicalclinical inpatientswith parkingenemutations presentations P410 subthalamicnucleus Effectsoncardiovascularregulationofbilateral P409 MitochondrialcomplexIactivityinfamilialandsporadicParkinson’s P408 CorticalandthalamiccholinergicactivityinLewybodydisease relation P407 with emergenceinpatients Isdrugprofileariskfactortohallucinations P406 Effectoflocuscoeruleusnoradrenalinedepletiononlevodopa-induced P405 45Theeffectofpramipexolon themaintenanceofwakefulnessin P425 Parkinson’s diseaseintheNavajopeople: of 100patients Evalutation P424 isfoundinPDpatients Abnormalstancestrategy P423 motorperformancedecline Timed innormal testsdetectage-related P422 EchogenicityofthesubstantianigrainParkinson’s disease–anopenand P421 MalignantsyndromeinParkinson’ disease: ofthree cases Presentation P420 withaparkinsonian Assessmentofautonomicfunctioninpatients P419 Lipopolysaccharide(LPS)inducespermanentreductions in Prenatal P418 anddysfluency onspeechrate Theeffectsoflevodopatreatment P417 forimprovingspeechabilitiesandcommunication Groupintervention P416 ofexecutiononpredictablesequencessaccadesin Effectofrate P415 Parkinson’s diseasesleepscaleinKorea P414 (Glu)metabolisminParkinsons Cerebralglutamate disease(PD)model P413 C. Chassain, A. Eschalier, F. Durif X. Guo, N. Hosseini, T. Zackrisson, B. Eriksson, B. Johnels, G. Steg E.F.Munoz,J.Campdelacreu, M.J. Valldeoriola,Marti,E. Tolosa P. Cortelli, G. Barletta,P. Guaraldi, L. Romito, G. Pierangeli, A. Albanese H.A. Hanagasi, D. Ayribas, K. Baysal, M. Emre I. Ziabreva, C. Ballard, D. Aarsland, J.-P. Larsen, E. Perry N.Shabtai,D.Merims,H. Weizman,Peretz,C. Korczyn, A. N.Giladi C.E.Marin, Aguilar, B.M.Bonastre, Verhoeff R. Almeida-Freire,J.J.Ferreira, J. Costa,Sampaio C. H. Kumru, J.Santamaria, F. Valldeoriola, F.Marti, E. Tolosa J. Marjama-Lyons, L. Clark, A. Singleton, J. Barr, K. Parko E.S.Hocherman Weissblueth,M.Schwartz, P.J. GarciaRuiz, V. SanchezBernardos P. Ressner, D. Skoloudik, P. Kanovsky C. Gaig, M. Gomez-Choco, S. Amaro, M. Marti, E. Tolosa D.I. Tiple,Odobescu,S.S. V.I. Moldovanu Vovc,I.I. P.M. Carvey, Q.A. Chang,Z. Ling Y. Manor, G. Ovadia, H. Zadok, H. Shabtai, R. Ezrati-Vinacour,N. Giladi Y. Manor, J. Posen, O. Amir, N. Dori, N. Giladi B. Spieth, M.R. MacAskill, T.J. Anderson J. Baik, J. Kim, J. Park, Y. Kim C. Chassain, G. Bielicki, J.-P. Donnat, J.-P. Renou, A. Eschalier, F. Durif stimulation inParkinson patients disease to dementiaandparkinsonism advanced Parkinson’s disease? inhemiparkinsonianrats motor fluctuations Parkinson’s disease controls controlled pilotstudy occurring duringthe2003heatwave syndrome homeostasis asananimalmodelforParkinson’s disease dopamine neurons: inCNSinflammatory Effectofepigeneticalterations characteristics inpatientswithParkinson’s disease withParkinson’sskills inpatients disease Parkinson’s disease rat: An in vivo vivo in dynamic dynamic 13 C nuclear magnetic spectroscopy(NMS)study C nuclear magnetic POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 65 antagonist is not associated CSC 2A , receptors mediate actions of anti-parkinsonian , 3 Groth, M.S. Dougherty, S.E. Pålhagen S.E. Dougherty, M.S. Groth, , but not D , 2 receptor agonists, S32504 and ropinirole, in the MPTP-lesioned and ropinirole, S32504 receptor agonists, 3 /D 2 with a normalization of the indirect striatopallidal pathway activity Parkinson’s disease Parkinson’s disease dopa in Japanese patients with Parkinson’s disease (PD) with Parkinson’s Parkinson’s disease Parkinson’s induced by glutathione in neuron/glia mesencephalic cultures depletion to peak-dose dyskinesias diagnosis of parkinsonism in the real life disease Parkinson’s ment of the off duration and severity and correlation with quality of life and performances in activities of daily living neurodegeneration by the adenosine A neurodegeneration by the adenosine disorders in North-East Scotland disease and other parkinsonian evaluation disease and cognitive impairment patients with Parkinson’s disease and control subjects simulator marmoset model of Parkinson’s disease marmoset model of Parkinson’s M.P. Hill, M. Silverdale, A.R. Crossman, J.M. Brotchie, C. Rochat, M.J. Millan M.J. Rochat, C. Brotchie, J.M. Crossman, A.R. Silverdale, M. Hill, M.P. Gielen S. Cools, L. Admiraal, M. Bloem, B. Keijsers, N. Yamamoto M. Kondo, T. K. Abe, Hasegawa, Kuno, S. T. Mizuno, Y. Thickbroom, Burns M. Mastaglia, G. Anderson, G. F. Hammond, Thomson, M. K. S. Compere, A. Blanchard, L. Defebvre, A. Thevenon A. A. Blanchard, Defebvre, L. S. Compere, Jahanshahi M. Quinn, N. Morley, D. Schrag, A. Jahanshahi M. Quinn, N. Morley, D. Hovris, A. Schrag, A. Menendez, M. Mena S. de Bernardo, S. Canals, M. Casarejos, R. Solano, J. Paulus W. Trenkwalder, C. Knauth, M. Meller, J. Sommer, M. Happe, S. Pauletti C. Grassini, P. Valente, M. Vacca, L. Massa, R. Stocchi, F. Livrea P. Iliceto, G. Fraddosio, A. de Mari, M. Zoccolella, S. Lamberti, P. T. D. Nyholm, Westin, J. Tassinari C.A. Calbucci, F. Nassetti, S.A. Sturiale, C. Valzania, F. Tropeani, A. J. Bové, J. Serrats, G. Mengod, R. Cortés, E. Tolosa, C. Marin C. Tolosa, E. Cortés, R. Mengod, G. Serrats, J. Bové, J. Pierelli F. Modugno, N. Chiacchiari, L. Soldati, G. Curra, A. Agostino, R. Harris C.E. Gordon, J.C. Counsell, C.E. Taylor, K.S. Tanne D. Sela, B.-A. Nitsan, Z. Vakil, E. Cohen, O. Hassin-Baer, S. Tanner C.M. Langston, J. Smith, A.R. Quinlan, P.J. Goldman, S.M. Tan V. Yew, S. K. Cheah, Tan, E. Dubaniewicz M. Wieczorek, D. Lass, P. Slawek, J. Derejko, M. Desloovere K. Rochester, L. Wegen, Van E. Dom, R. Sofuwa, O. Nieuwboer, A.M. the D P466 The accuracy of pointing movements to remembered visual targets in P467 effective on motor function as adjunct therapy Ropinirole is highly to L- P468 The preparation and execution of sequential movements in individuals P457 disease on patients’ children adolescent and adult Impact of Parkinson’s P458 and carer quality of life in contributing to caregiver burden Factors P459 signal-regulated Role of extracellular protein kinase in neuronal cell death P460 Psychogenic parkinsonism with intravenous apomorphine abuse leading P461 spect in the A study to assess the validity and utility of DATSCAN P462 Effects of antiparkinsonian drugs on plasma Homocysteine P463 to enteral infusion of levodopa in patients Analysis of response with P464 Improve- disease: 12 months of subthalamic stimulation in Parkinsons P465 Dopamine D P448 against Neuroprotection 6-OHDA-induced dopaminergic striatal P449 disease Prolonged practice scarcely improves bradykinesia in Parkinson’s P450 A pilot study outcome of Parkinson’s of the incidence and long-term P451 disease characteristics in Parkinson’s Plasma homocysteine and clinical P452 disease in twins Manganese exposure and risk of Parkinson’s P453A pharmacogenetic disease: in Parkinson’s The use of pyridoxine P454 Regional cerebral blood flow and MRI white matterin hyperintensities P455kinetics and kinematics Comparing the of gait in patients with Parkinson’s P456 Evaluation on driving disease patients: of Parkinson’s Ability to drive mutations in Serbian early-onset mutation frequency depends on ethnic origin mutation frequency DJ-1 Parkin and Parkin of patients advanced Parkinson’s disease advanced Parkinson’s using continuous and discrete drawing tasks Parkinson’s disease Parkinson’s B inhibitor: Results from single- and multiple-dose phase I studies Implications trials for clinical nurse practitioners, residents and movement disorders experts nurse practitioners, residents and movement disorders disease and incidental Lewy bodies Parkinson’s disease movement initiation and execution in advanced Parkinson’s between freezers and non-freezers with Parkinson’s disease between freezers and non-freezers with Parkinson’s disease: A pilot study disease: people with PD disease clinic? disease Parkinson’s Parkinson’s disease: disease: Parkinson’s A. Djarmati, K. Hedrich, O. Riess, S. Romac, C. Klein, V. Kostic V. Klein, C. Romac, S. Riess, O. Hedrich, K. Djarmati, A. M. Guttman, M. Torti, J.J. Warsh, S. Houle, J. St-Cyr, S.J. Kish S.J. St-Cyr, J. Houle, S. Warsh, J.J. Torti, M. Guttman, M. J. Xie-Brustolin, M. Desmurget, S. Thobois, V. Gaveau, H. E. Mollion, Broussolle V. Thobois, J. Xie-Brustolin, M. Desmurget, S. X. Liu, C. Carroll, S.-Y. Wang, J. Zajicek, P. Bain P. Zajicek, J. Wang, S.-Y. Carroll, C. Liu, X. C.B. Carroll, P.G. Bain, L. Teare, X. Liu, C. Joint, C. Wroath C. Joint, C. Liu, X. Teare, L. Bain, P.G. Carroll, C.B. Schnitzler A. Timmermann, L. Dirks, M. Gross, J. Pollok, B. R. Levy, J.J. Thébault, M. Guillaume M. Thébault, J.J. Levy, R. T. Chung, K. Ko, M. Kwan, W. Cheng, S. Lau, Y. Liu Y. Lau, S. Cheng, W. Kwan, M. Ko, K. Chung, T. R.M. Stewart, G.V. Kondraske, M.K. Sanghera M.K. Kondraske, G.V. Stewart, R.M. M. Lee, S. Oh, C. Lyoo, H. Kim, J. Kim, Y. Kim Y. Kim, J. Kim, H. Lyoo, C. Oh, S. Lee, M. E. Zikouli, Kazazi A. Fragia, T. Kafantari, A. Katsarou, Z. Bostantjopoulou, S. H. Petrovitch, G.W. Ross, R.D. Abbott, J. Nelson, L.R. White L.R. Nelson, J. Abbott, R.D. Ross, G.W. Petrovitch, H. B. Post, M.P. Merkus, R.M. de Bie, A.W. Lemstra, R.J. de Haan, J.D. Speelman J.D. de Haan, R.J. Lemstra, A.W. de Bie, R.M. Merkus, M.P. Post, B. A.M. Nieuwboer, F. Chavret, A.-M. Willems, G. Kwakkel, D. Jones, R. R. Dom Jones, D. Kwakkel, G. Willems, A.-M. Chavret, F. Nieuwboer, A.M. A. Destee, Defebvre L. Tyvaert, Auzou, Dujardin, K. L. C. Ozsancak, P. I. Rektorova C. Janvin, D. Aarsland, J. Larsen, K. Hugdahl K. Larsen, J. Aarsland, D. Janvin, C. S. Ozekmekci, S. Ertan, G. Kiziltan, T. Ertan, E. Erginoz E. Ertan, T. Kiziltan, G. Ertan, S. Ozekmekci, S. Karayalcin C. Almak, G. Demirkiran, M. A. Bowron, R. Porter, B. Chandler, R. Walker R. Chandler, B. Porter, R. Bowron, A. D. Guehl, E. Cuny, A. Benazzouz, A. Rougier, F. Tison, P. Burbaud P. Tison, F. Rougier, A. Benazzouz, A. Cuny, E. Guehl, D. J.C. Sharma, L. Macnamara J.C. Sharma, P447 Detection of P446 Brain serotonin transporter levels are decreased in patients with clinically P444 Clinical relevance of quantifying drug-induced dyskinesias arms in the P445 disease On-line motor control in patients with Parkinson’s P443 The cerebral oscillatory network of voluntary tremor P441 selective and irreversible MAO- A potent, The pharmacology of rasagiline: P442 disease? A role in Parkinson’s Cannabis – P440 and disease specific risk factors of depression in Local prevalence P439 theory Performance and formation of composite outcome measures: P438 disease and cognitive function in Parkinson’s Mild hyperhomocysteinemia P437 stimulationand levodopa treatment on Effects of subthalamic nucleus P435 and intra-rater the UPDRS motor examination reliability of for Inter-rater P436 clinical Substantia nigra neruon denstity in the presence and absence of P434 disease Handicap Index (VHI) in patients Voice with Parkinson’s P433 Differences Synchronising walking to various auditory cueing frequencies: P431 disease cognitive impairment in Parkinson’s The course of mild P432Alzheimer’s disease and Effect of donepezil on dementia in Parkinson’s P430 disease A decade and more with Parkinson’s P429 Relationship between age symptoms in Parkinson’s and type of psychotic P428 Preliminary of a sexual dysfunction results study in Lets talk about sex. P426 disease in patients gender differences Are there attending a Parkinson’s P427 stimulation in and late Early subthalamic nucleus effectiveness of POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER 66 Rome, Italy P490 The effect of a 12-week vestibular rehabilitation therapyprogramon Theeffectofa12-weekvestibular rehabilitation P490 subthalamicdeep Isdepressionapredictorof outcomeafterbilateral P489 Cardiovascularchangesandperceivedexertionduring isometric exercise P488 Thetwotowers, Parkinson’s disease andcognition P487 Parkinson’s disease, acasereport blepharospasmandapomorphine; P486 inParkinson’s evolutionofdysarthria Natural disease P485 Polymorphism with oftheprionproteingeneinGermanpatients P484 analysisoflevodopa-induced Pharmacokineticandpharmacodynamic P483 boundariesisalteredinParkinson’s ofbody Subjectiveestimation disease P482 altersposturalstabilityamongParkinson’s Changeinvisualinformation P481 TheburdenofParkinson’s diseaseinSpain P480 ofParkinson’s Invivoneuropathology disease(PD): Lossof18F-dopa P479 MechanismofactionlevodopatoxicityinratE14ventralmesencepha- P478 inautopsyverifiedLewybody COMTallelesandmotorfluctuations P477 Thepushandreleasetest: An improvedclinical postural stabilitytestfor P476 TheeffectofstoopedpostureinParkinson’s diseaseonmultidirectional P475 Thecaregivers’burden, depression, andanxietyinParkinson’s disease P474 ThecontrolofvolitionaleyemovementsinParkinson’s disease: Self- P473 LPS-inducedsubstantianigral Caspase-11andmicrogliamediate P472 Pain-pressure witnParkinson’s thresholdinpatients diseasewithand P471 CognitivepredictorsofdementiainParkinson’s disease P470 withParkinson’s Cognitiveprofileofpatients diseaseanddementia P469 THE C. Adams, V.Lange,P.Lun,B. Wiley, S.Oksana M.K. York, Y.S.Silay,N. Chaytor,Jankovic Simpson,J.R.K. J.-A.C. Lazarus, S.R. Brueggemann, A. Chourasia, A. Garg, B.A. Ward A. McKinlay, J.C. Dalrymple-Alford, T.J. Anderson, J.N. Fink, P. Barrett H.L. Tyne, G. Medley, J. Parsons, R. Bulloch, M.J. Steiger C.Ozsancak,L. Tyvaert,P. Auzou, A.Destee,L.Defebvre B. Herting,S.Moeckel,G.Gossrau,H.Reichmann,J.B.Lampe Simon,N.A.Boulamery-Velly, S. F. Arguillere, Bruguerolle B.O.Blin, Viallet, D.Ulla,D.Nico,M. Auclair, S.Broussolle,E. Thobois,Sirigu A. J. Doan, S. Cooper, S. Pellis, I. Whishaw, O. Suchowersky, L. Brown Genova E. Cubo, A. Elena, C. Morant, J. dePedro Cuesta,P. MartinezMartinuten, R. R.Y. Moore, A.L. Whone, D.J. Brooks M.W. Khan, R.A. Bakay A.H. Rajput, R. Camicioli, C. Reece, M.L. Rajput, A.H. Rajput F.B. Horak, J.V. Jacobs, V.K. Tran, J.G. Nutt J.V. Jacobs, D.M. Dimitrova, J.G. Nutt, F.B. Horak J.-H. Im,S.R.Kim,S.J.Chung,M.C.Lee C.Millist,O.B.N.Georgiou-Karistianis,L. White Winograd-Gurvich, H.Miura,Mochizuki,M.H.Y. Arai, Mizuno L. Vela,K.E.Lyons,Singer,C. Lieberman A.N. C. Janvin, D. Aarsland, J. Larsen, K. Hugdahl C. Janvin, D. Aarsland, J. Larsen, K. Hugdahl computerized dynamic posturography inParkinson’s posturography computerized dynamic diseasepatients withParkinson’s inpatients brain stimulation disease? in womenwithParkinson’s disease: A pilotstudy Parkinson’s disease inadvancedParkinson’sdyskinesias disease disease patients uptake inmotorcortex cultures lon primary Parkinson’s disease withParkinson’spatients disease postural responses pacing andreprogrammingsaccades dopaminergic neurotoxicityinmice without dyskinesias MOVEMENT DISORDERSOCIETY 47RNAinterferenceand P497 Intraduodenalinfusionofagelsuspensionlevodopa/carbidopa, P496 EffectofSTNstimulationonmood, motivationandpersonalityinPD P495 IIIparkinsonianpatients: instage Cognitivedeficitsinmotorimagery P494 ofthesubthalamicnucleus Effectofunilateralelectrostimulation (STN)on P493 A2yearrandomized,placebocontrolledtrialoftheneuroimmunophilin P492 ofdruginduceddyskinesias Effectsoflevetiracetaminthemanagement P491 P510 Levodopa-dyskinesia incidence by age ofParkinson’s Levodopa-dyskinesiaincidencebyage diseaseonset P510 toasymmetric rhythmicmotorperformancein Isfreezingofgaitrelated P509 duringself-pacedmovements Modulationofsubthalamicbeta oscillations P508 MotorperformancecharacteristicsinwomenwithParkinson’s disease P507 withearlystage AdoseescalationtrialofrotigotineCDSinpatients P506 Geneticpolymorphismofcatechol- P505 Vividdream/nightmaresaccompany, butdonotpredictfuturehallucina- P504 Detectionofpreclinical Parkinson’s approach disease;theolfactory P503 parkinsonismleadto early Doesacutelevdopaexposureinuntreated P502 frequency Low subthalamicnucleus in stimulationworsensbradykinesia P501 Enterallevodopainfusionasmonotherapyissuperiortoconventionaloral P500 a-Synuclein expressionisincreasedintheperipheralbloodleukocytes of P499 RecruitmentproblemsintrialsofphysicaltherapyforParkinson’s disease P498 A.D. Hope, J. Lewis, D. Bumcrot, S. Elbashir, T. Zimmerman, M.J. Farrer Aquilonius D. Nyholm, T. Lewander, A. Johansson, P.A. LeWitt, C. Lundqvist, S.-M. C.Ardouin, Batir, A. P. Krack,Funkiewiez, A.P. A.-L.Benabid, Pollak E. Pourcher, H. Cohen, V. Frak E.Q.Bakay, Wang,R.Metman,L. VerhagenJ. Arzbaecher, Bernard B. GPI 1485 Trial Group B. Tousi, T.Subramanian N.Kumar, Bower,J.H.Gerpen,J.A. J.E. Van Ahlskog M. Plotnik,J.M.Hausdorff,N.Giladi L. Doyle, M. Hariz, A. Kuhn, A. Kupsch, M. Koning-Tijsen, P. Brown K. Mottus, P. Taba, M. Paasuke, H. Gapeyeva, J. Ereline W.M. Güldenpfennig, B. Boroojerdi, K.H. Poole, K.W. Sommerville M. Contin, P. Martinelli, M. Mochi, R. Riva, A. Fiorenzo, B. Agostino C.G. Goetz, L. Curgian, J. Wuu, S.E. Leurgans M.M. Ponsen, D. Stoffers, J. Booij, E.C. Wolters, H.W. Berendse A. Forbes, F.Stegie, V. Dhawan, H. Whitehead,K. Chaudhuri P.K.Gunraj,C.A.Lang,E.Moro,Chen Pal, A.E.R.Lozano, A.M. Askmark D. Nyholm, N. Dizdar, I. NilssonRemahl, B. Holmberg, S.-M. Aquilonius, H. B.S.Jeon,T.-B. Kim,S. Ahn, Y.-H. Suh S. Keus,B.R.Bloem,B.J.vanHilten,M.Munneke disease withParkinson’s inpatients pattern pharmacokinetic-phamacodynamic and dosage Duodopa®, inadvancedParkinson’s disease: Safety, tolerability, efficacy patients task ofamotorimaging Exploration speech inParkinson’s disease(PD) disease progression: baselinecharacteristics Designandpatient ligand, GPI1485ondopaminetransporterdensityandParkinson’s in patientswithParkinson’s disease patients withParkinson’spatients disease? by levodopainpatientswithParkinson’s disease Parkinson’sidiopathic disease tions inParkinson’s disease challenge testingin34peoplewithparkinsonism oflevodopa followupstudy dyskinesia ontreatment? An observational Parkinson’s disease treatment ofadvancedParkinson’s disease the patientswithParkinson disease α -synuclein POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 O -methyltransferase andlevodopa 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 67 F]fluorodopa uptake and frontal cognitive functions in early F]fluorodopa uptake and frontal cognitive functions 18 study disease surgical evaluation of Parkinson’s electromyographic assessment of visual cueing and L-DOPA effects electromyographic of visual cueing and L-DOPA assessment disease Parkinson’s disease Parkinson’s The outcome of the 15 year follow-up from the Sydney disease: Multicentre Study analysis disease influenced by provocation strategy? intravenous olfactometry fibers in peripheral tissues in patientshydroxylase (TH) -positive with disease Parkinson’s in the Navajo disease Parkinson’s ratdopaminergic neurons of vector substantia nigra by rAAV placebo and entacapone double blind, disease; a prospective randomized, controlled study nationwide population of brain donors of the 6-OHDA dopamine depleted rat Parkinson’s disease Parkinson’s W.K. Scott, L. Zhang, J.M. Stajich, B.L. Scott, M.A. Stacy, J.M. Vance J.M. Stacy, M.A. Scott, B.L. Stajich, J.M. Zhang, L. Scott, W.K. Putzke J.D. Wszolek, Z.K. A.J. Strongosky, Tsuboi, Y. Baba, Y. R.J. Uitti, Kubu C.S. Rezai, A. Stott, H.D. Shaw, R. Busch, R.M. A. Sharott, P.J. Magill, W. Meissner, D. Harnack, A. Kupsch, P. Brown P. Kupsch, A. Harnack, D. Meissner, W. Magill, P.J. Sharott, A. Rocca W.A. Ahlskog, J.E. Peterson, B.J. Maraganore, D.M. Bower, J.H. Ordonselli, Provinciali, L. CeravoloM.G. T. Bombace, V.G. M. Capecci, Kordower J. Chu, Y. Kompoliti, K. Dawson J.D. Rodnitzky, R.L. Anderson, S.W. Shi, Q. Rizzo, M. Uc, E.Y. Rinne J.O. Bergman, J. Nurmi, E. Aalto, S. Bruck, A. Traficante R. Adena, M.A. Morris, J.G. Hely, M.A. Halliday, G.M. Reid, W.G. Wood A.J. Quinn, Lees, N. K. Bhatia, Abou-Sleiman, N.W. P.M. D.G. Healy, Ghadiali, E. M.J. Steiger G. Medley, Tyne, H.L. Chavret Willems, K. L. Desloovere, A.-M. Janssens, F. R. Dom, A.M. Nieuwboer, K. Isonishi, F. Moriwaka, K. Itoh, S. Kaneko, T. Kashiwaba T. Kaneko, S. Itoh, K. Moriwaka, F. Isonishi, K. Mikami T. Tsushima, K.-I. Sasaki, H. Nara, H. Uehara, O. Nunomura, J.-I. Orimo S. Takahashi, A. Amino, T. Uchihara, T. Kojo, T. Marjama-Lyons J. Barr, J. Clark, L. Parko, K. Singleton, A. Mizuno Y. Wada, H. Mochizuki, K. Yamada, M. Yasuda, T. Wada, K. LARGO Study Group** on Behalf of the European Giladi, N. Mash D.C. Lieberman, A. Gonzalez, J. Papapetropoulos, S. P550A family-based case-control disease: use and risk of Parkinson Pesticide P551The influence of handedness disease: Asymmetry of Parkinson’s P552 The utility of the frontal systems behavior in the pre- scale (FrSBe) P541 studyA case-control disease: Inflammation and Parkinson’s P542 Leg muscle activation Surface- patterns gait: during parkinsonian P543 neurons in Nurr1 expression in the remaining nigral dopaminergic P544 Driver landmark idenfication and safety errors in mild-moderate P545 Cortical [ P546 A neuropsychological study of prevalence of dementia in Parkinson’s P547 disease; a case-control study and meta- gene and Parkinson’s Tau P548 disease Gambling in Parkinson’s P549 Is the EMG-pattern in the lower limbs before freezing in Parkinson’s P533 disease by MRS Activation study in Parkinson’s P534 disease patients - Study using Olfactory function among Parkinson’s P535 Immunohistochemical study significant reduction of tyrosine revealed no P536of Barriers in the ascertainment and treatment The cultural divide: P537 Hydoralse-L1 (UCH-L1) in Overexpression of Ubiquitin Carboxyterminal P538 Rasagiline treatment can improve freezing of gait in advanced Parkinson’s P539 correlates in a Prevalence and clinical disease. Dementia in Parkinson P540 and cerebral cortex Coherent beta oscillations in the subthalamic nucleus development of dyskinesia in the MPTP-lesioned macaque model of disease Parkinson’s brain stimulation DATScan data in patients with Parkinson’s disease data in patients with Parkinson’s DATScan randomised controlled trials subjects with Parkinson’s disease subjects with Parkinson’s disease: Impact on depression, cognition, and motor function transcranial doppler study adverse effects in patients with Parkinson’s disease adverse effects in patients with Parkinson’s dyskinesia in rats by entacapone Chinese) disease disease patients Parkinson’s P.J. Hallett, A.W. Dunah, A.R. Crossman, J.M. Brotchie, D.G. Standaert D.G. Brotchie, J.M. Crossman, A.R. Dunah, A.W. Hallett, P.J. Chen R. Lozano, A.M. Lang, A.E. Moro, E. Paradiso, G. Cunic, D. M. Canesi, R. Benti, R. De Notaris, A. Antonini, G. Pezzoli G. Antonini, A. De Notaris, R. Benti, R. Canesi, M. Wheatley K. Gray, R. Clarke, C.E. Counsell, C. Ives, N.J. Stowe, R.L. J.E. Olsson D. Weintraub, D. Taraborelli, J.E. Duda, P.J. Moberg, I.R. Katz, M.B. Stern M.B. Katz, Moberg, I.R. J.E. Duda, P.J. Taraborelli, D. Weintraub, D. L. Rocchi, L. Chiari, F.B. Horak F.B. Chiari, L. Rocchi, L. H. Groetzsch, N. Vokatch, P.R. Burkhard, R. Sztajzel R. Burkhard, P.R. Vokatch, N. Groetzsch, H. Vanderheyden J.-E.G. L.M. de Lau, M. Bornebroek, J.C. Witteman, A. Hofman, P.J. Koudstaal, M.M. Koudstaal, P.J. Hofman, A. Witteman, J.C. Bornebroek, M. de Lau, L.M. Breteler B.A. Racette, S.D. Tabbal, D. Jennings, L.M. Good, J.S. Perlmutter, B.A. Evanoff B.A. Perlmutter, J.S. Good, L.M. Jennings, D. Tabbal, S.D. Racette, B.A. K. Yoshimi, Y. Yim, M. Yamada, M. Onodera, H. Mochizuki, Y. Mizuno Y. H. Mochizuki, Onodera, M. Yamada, M. Yim, Y. Yoshimi, K. Evanoff B.A. Perlmutter, J.S. Good, L.M. Jennings, D. Tabbal, S.D. Racette, B.A. M. Watanabe, N. Ohkoshi, K. Yoshizawa, T. Yoshizawa, A. hayashi, A. shoji S. Yoshizawa, T. Yoshizawa, Watanabe, Ohkoshi, N. K. M. D. Offen, O. Sadan, M. Stroomza, Y. Gilgun- Sherki, D. Atlas, E. Melamed E. Atlas, D. Sherki, Gilgun- Y. Stroomza, M. Sadan, O. Offen, D. Haas C.T. Turbanski, S. Schmidtbleicher, D. D. Offen, Y. Levy, S. Bulvik, Y. Barhum, A. Burshtien, A. E. Burshtien, Melamed Barhum, Y. S. Bulvik, Levy, Y. Offen, D. R. Wu, R. Bounds, S. Lincoln, M. Hulihan, C. Lin, W. Hwu W. Lin, C. Hulihan, M. Lincoln, S. Bounds, R. Wu, R. Rochon P.A. Shulman, K.I. Sykora, K. Lang, A.E. Kopp, A. Marras, C. J. Benetin, P. Valkovic, P. Blazicek, L. Valkovicova, K. Gmitterova, P. Kukumberg P. Gmitterova, K. Valkovicova, L. Blazicek, P. Valkovic, P. Benetin, J. J.L. Ostrem, G.A. Kang, M. Guarnieri, J. Hubble, A. Rabinowicz, J.M. Bronstein J.M. Rabinowicz, A. Hubble, J. Guarnieri, M. Kang, G.A. Ostrem, J.L. A. Cristian, R.H. Walker R.H. Cristian, A. P532 deep Source generators of evoked potentials from subthalamic nucleus P531 Alterations in striatal NMDA receptor subunits associated with the P530A systematic review of disease: MAOBI therapy in early Parkinson’s P529 Severe striatal damage after long-term exposure to hydrocarbon-solvents: P527 Escitalopram for the treatment of major depression in Parkinson’s P528 after 7 years An interim analysis - Study” Kohort “The Swedish Parkinson P526 Effect of levodopa and DBS on anticipatory postural adjustments in P525 disease? An antique witness of Parkinson’s The Old Fisherman: P524A disease: Cerebral autoregulation in patients with Parkinson’s P522 for mass screening for parkinsonism A rapid method P523 disease Dietary fatty acids and the risk of Parkinson’s P520 Regenerativemouse substantia nigra cells in P521 in a large cohort of welders Prevalance of parkinsonism P519 Association study with pergolide-induced of CYP2D6 gene polymorphism P518 disease vibration Effects of whole-body on postural control in Parkinson’s P516 bone marrow Stem cells from human like neurons to dopaminergic- P517attenuates haloperidol- induced a novel brain- target antioxidant, AD4, P515 Canada Antipsychotic use in patients therapy on dopaminergic in Ontario, P514 (ethnic Taiwanese parkinsonism in mutations and early-onset Parkin P513 in levodopa-treated patients Hyperhomocysteinemia Parkinson prevented P511Parkinson’s protocol in the treatment of of an acupuncture The role P512 Exploratory effect of entacapone analysis of the levels in on homocysteine POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER 68 Rome, Italy P571 Reduced sural sensory nerve actionpotential (SNAP)amplitudeasa nerve Reduced suralsensory P571 tractsymptoms inpatientswithParkinson’s urinary Lower disease: P570 with inpatients Thetolerabilityofintermittentsubcutaneousapomorphine P569 Theincidenceandclinical hypotensionin significanceoforthostatic P568 ropinirole toreverseL- oftheabilitydopamineagonist Investigation P567 Useoftrimethobenzamideforthecontrolnauseainadvanced P566 ofthenoveldopaminestabiliser Apilotstudy ACR16 inadvanced P565 hypokinesia Blockadeofnociceptin/orphaninFQtransmissionattenuates P564 versusplacebo or ofrasagiline randomisedstudy Acomparative P563 Parkinson’s DJ-1immunoreactivityincontrolandidiopathic disease P562 Dementia ComparisonoftheMMPbriefcognitivetestandMattis P561 Effectofhighfrequency ofthesubthalamicnucleus stimulation on P560 “Chinonchest” phenomenoninParkinson’ sdisease P559 inbrainironmetabolismParkinson’s Geneticvariations disease P558 tomind-readingabilityinParkinson’s Deficitsofdecision-makingrelating P557 Pallidal proceduresforParkinson’s disease. resultswith14 Preliminary P556 Randomized, ofzonisamidewithplaceboinadvanced double-blindstudy P555 Doclinicalandbaseline trialinfrastructuresimpactenrollmentrates P554 EffectsofpesticidesonproteasomalactivityandcellviabilityinHEK P553 THE Y. Sunada, Y. Ohsawa, K. Kurokawa, M. Sonoo, S. Henmi, K. Iwatsuki Sallem C.M. Gomes, R.I. Lopes, Z.M. Sammour, E.R. Barbosa, M.S. Haddad, F.S. D. Koller, D. Pahwa, the APO-303 Investigators D. Pahwa,the Investigators APO-303 P. Jenner, S. Rose, L. Smith, M. Jackson, G. Al-Barghouthy D.B. Dewey, Jr., the APO-401 Investigators J. Tedroff,N.C.Sonesson,S.Waters, Waters,A.Carlsson M. Marti, F. Mela, C. Trapella, C. Bianchi, M. Morari O. Rascol, Group** onBehalfoftheLARGOStudy Lees R. Bandopadhyay, A.E. Kingsbury, I.M. Evans, D.W. Miller, M.R. Cookson, A.J. G.Fénelon,Leroy, A. P. F.Cunin, Mahieux,P. A.-C.Bachoud-Levi, Cesaro M.W.Schüpbach,I.C.Straus,Arnulf, T. Similowski, Y. Agid,J.-P. Derenne C. Oishi, H. Okano, A. Chiba, M. Sakuta D. Berg, H. Hochstrasser, B. Felletschin, J. Deplazes, N. Akbas, U. Walter M. Kawamura, R. Oeda A.T. Kouyialis, E.J. Boviatsis, D.E. Sakas, T. George, P. Stathis, K. Stephanos M. Murata, K. Hasegawa, I. Group Kanazawa, ZonisamideStudy theJapan C.M. Tanner,F.G. P. Wooten, Yuko, E.Jordan C. Kamp, A. Shinaman, K. Kieburtz, B. Ravina, B. Tilley, A. Brocht, K. Shannon, X.-F.Bronstein J.M.Li,X.-X.S. Wang, sonism (PARK2) of autosomalrecessivejuvenileparkin- indicator possible diagnostic symptom scales basedondifferent withseverityofneurologicdysfunction Correlation advanced Parkinson’s disease apomorphine advanced Parkinson’s treatedwithsubcutaneous diseasepatients inMPTP-treatedmarmosets dopa-induced dyskinesias Parkinson’s withsubcutaneousapomorphine treated diseasepatients Parkinson’s disease in hemiparkinsonianrats (theLARGOStudy) with motorfluctuations asadjuncttolevodopainParkinson’sentacapone disease(PD)patients brain: withDJ-1mRNAexpression Correlation withParkinson’s Scalein120patients Rating disease withParkinson’s controlinpatients respiratory disease disease patients Parkinson’s disease inearlyParkinson’sdemographics disease(PD)studies? SH-SY5Y cells MOVEMENT DISORDERSOCIETY 58Parkinson’s disease: A clinical offactorswithimpactonquality study P578 ofthetolerabilityandsafetyStalevo™ Aprospectiveevaluation P577 in Predictingincidentnon-motorcomplicationsofdopaminergictherapy P576 Efficacy, inthetreatmentofmajor tolerabilityandsafetyofmirtazapine P575 Pharmacokineticsofapomorphinenasalpowder: An ascendingdose P574 AmygdalarandhippocampalMRIvolumetricreductionsinParkinson’s P573 asa Modulationofproteinexpressioninvitrobyelectricalstimulation P572 P589 Rapid improvement in balance of patients withParkinson’s Rapid improvementinbalanceofpatients disease P589 and dopaminergicdegeneration Relationshipbetweennigrostriatal P588 with inpatients apomorphine Growthhormoneresponsetolow-dose P587 inearlyParkinson’s therapy Dopamineagonist disease: A systematic P586 EffectofrasagilineonseverityOFFinParkinson’s disease P585 ThePDQ-39isasensitivemeasureofchangeinqualitylifeearly P584 SaccadiceyemovementsinParkinson’s diseasewithandwithout P583 ofthemotorresponsetolevodopainParkinson’s Alongitudinalstudy P582 strongly Fibroblast factor20polymorphismsandhaplotypes growth P581 Frequency intolerance hypotensionasacauseoforthostatic oforthostatic P580 Subthalamicnucleus improvesbalancereactionsin stimulation P579 W. Koller, D. Silver, M. Guarnieri, J. Hubble, A. Rabinowicz Group K.M. Biglan, R.G. Holloway, M.P. McDermott, I.H. Richard, Parkinson Study R. Weiser, J. Hernadez-Rojas, J. Flores, M. Gallardo, M. Garcia, M. Grau P. Lambert, S. Freear Junque B. Ramirez-Ruiz, M. Marti, E. Tolosa, C. Summerfield, B. Gomez-Anson, C. R.F.Xia, Berger,M.Bayle, Bouamrani,B. A.Piallat, Benabid A.L. M.E. Piemonte, E.S. Takata, M.C. Moura, T.T. Capato, M.C.Fornari, E.R. Barbosa K. Winge, L. Friberg, L. Werdelin, K.K. Nielsen, H. Stimpel K.Helmschmied,S.Happe, T. Tings, W. Wuttke, W.Paulus,C. Trenkwalder N.J. Ives, R.L. Stowe, C.E. Clarke, R. Gray, K. Wheatley, L. Shah F. Stocchi, onBehalfoftheLARGOStudyGroup** Collaborative Group N.J. Ives, C. Jenkinson, R. Fitzpatrick, K. Wheatley, C.E. Clarke, PDMED U.P. Mosimann, R.M. Mueri, D.J. Burn, J.T. O’Brien, I.G. McKeith B.B. Clissold, C.D. McColl, K.A. Reardon, M. Shiff, P.A. Kempster Vance, E.R. Martin J.M. vander Walt, M.A. Noureddine, W.K. Scott, M.A. Pericak-Vance, J.M. K.F. Nahm, S. Nouri, M.D. Yahr, H.C. Kaufmann J.E. Visser,J.H.M.G.Carpenter, Allum, M.Bakker, Bloem B.R.Esselink,R.A. M.E. Toma, A. DiRocco, M.D. Yahr life. Predictorsfornursinghomeplacement experiencing wearing-off (carbidopa, inParkinson’s levodopaandentacapone) diseasepatients CALM-PD trial withearlyParkinson’spatients disease: analysisofthe A secondary depressive disorderduetoParkinson disease study disease withdementia function offrequency through trainingbasedonmovements guidedbyrhythmiccues symptomsinParkinson’surinary disease restless legssyndromeandParkinson’s disease review ofrandomisedcontrolledtrials Parkinson’s disease dementia disease influence riskofParkinson disease in Parkinson disease Parkinson’s disease POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 69 -synuclein-associated α P.R. Burkhard, J.-G. Villemure, F.J. Villemure, J.-G. Burkhard, P.R. clinical monitoring during deep brain clinical : A possible environmental cause of Parkinson’s : disease? stimulation surgery in Parkinson’s disease stimulation surgery in Parkinson’s case-control study on 483 consecutive patients parallels severity of extremity symptoms in Parkinson’s disease patients parallels severity of extremity symptoms in Parkinson’s symptoms different? Are the diagnosed disease (PD). with Parkinson Predictive value of intra-operative (IO) disease (IPD): Parkinson’s improvement of motor function to long-term outcome disease arise? Parkinson’s improving PD care? inclusions in mice disease levodopa-treated patients with advanced Parkinson’s apomorphine for 6 months in patients with advanced Parkinson’s disease apomorphine advanced Parkinson’s 6 months in patients with for disease control in Parkinson’s disease familial Parkinson’s surveyadditional results of a questionnaire diagnosis for the early of PD study A retrospective disease (STN-DBS): stimulation in Parkinson’s disease with deep brain stimulation surgical treatment of Parkinson’s disease advanced Parkinson’s P.A. LeWitt, B.L. Beaman, D.M. Camp, D.A. Loeffler D.A. Camp, D.M. Beaman, B.L. LeWitt, P.A. Girotti F. Piccolo, I. Soliveri, P. Musicco, M. Scigliano, G. Tsujihata M. Seto, M. Tomita, I. Iwanaga, K. Satoh, A. Nakao, Y.K. Kang S.Y. Sohn, Y.H. Shin, H.-W. Y. Baba, J.D. Putzke, A.J. Strongosky, M.F. Turk, Z.K. Wszolek, Wszolek, R.J. Uitti Z.K. Turk, M.F. A.J. Baba, Putzke, Strongosky, J.D. Y. Rampini P. Ardolino, Caputo, E. G. Tamma, F. Chiesa, V. A. Pesenti, Konrad P.E. Albea, J.R. Fang, J.Y. Davis, T.L. Charles, D.P. Kao, C.C. Mash D.C. Lieberman, A. Gonzalez, J. Papapetropoulos, S. Heit G. Koop, M. Urbano, M. Fujikami, G. Rajan Das, R. Bronte-Stewart, H. Spokes E.G. Mindham, R.H. Hughes, T.A. Read, N.L. Dunn, E.M. Wright L. Greenwood, G. Hunter, A.-M. Short, C. Dyer, P. Nasar, A. Mizuno Y. Kaneko, H. Imamichi, Y. Kawamura, Y.C. Hattori, N. Hatano, T. US-005/US-006 Clinical Investigator Group LeWitt, P.A. Nocardia asteroides D.M. Trosch, the APO-303 Investigators Trosch, D.M. Topka Limousin, J.C. H.R. Rothwell, Hariz, P. D.A. M. Nowak, Tisch, S. Chase B.A. Avery, L. McComb, R.D. Dickson, D.W. Markopoulou, K. Oertel W.H. Ries, V. A. Metz, E. I. Baum, Rissling, Hoeglinger, G. Ghika, J.A. Viollier, S. Gronchi-Perrin, A. Vingerhoets D.M. Swope Trenkwalder C. Klinke, H. Rausch-Hertel, M. Sixel-Doering, F. P626A disease: Risk factors for vascular disorders are reduced in Parkinson’s P627 disease Plasma brain natriuretic peptide (BNP) levels in Parkinson’s P628 disease Sensory dysfunction in idiopathic Parkinson’s P617 Intraoperative tapping test for P618 Asymmetrysubthalamic nucleus of overactivity between left and right P619 Alzheimer disease (AD) pathology and pathologically in patients clinically P620 nucleus deep brain stimulation (STN DBS) in idiopathic Subthalamic P621 How long after the onset of motor symptoms does dementia in P622 at disease (PD) club Can we measure the effectiveness of a Parkinson’s P623 Proteasomal inhibition leads to nigral degeneration with ubiquitin positive P624 in time reduction from adjunctive use of istradefylline (KW-6002) “Off” P625 P609following in UPDRS motor scores Decrease subcutaneous intermittent P610 improves manipulative nucleus stimulation Subthalamic finger force P611 phenotype of is a potential modifier of the Parkin P612 and dementia at the primary care level – depression, Incidence of PD, P613 deep brain and behavior Personality subthalamic nucleus changes after P614 Apomorphine subcutaneous injection in a patient who has undergone P615 agonists Combining dopamine of different dopamine receptor profiles in P616 disease phenotype Gender and the Parkinson’s treatment of “off” episodes in patients with advanced Parkinson’s disease episodes in patients with advanced Parkinson’s “off” treatment of studyA longitudinal among 425 initially treated with dopamine agonist? patients neuron associated genes: DAT, VMAT-2, and Nurr1 VMAT-2, DAT, neuron associated genes: A positive safety profile with supporting efficacy disease: Parkinson’s induced dyskinesias in MPTP-lesioned primates parkinsonian patients: A 6-month planned intermediate ANALYSIS of the ANALYSIS A 6-month planned intermediate parkinsonian patients: study2-year Parkinson-regain cognitive impairment disease Parkinson’s disease novo Parkinson’s ziprasidone disease in Parkinson’s Parkinson’s disease Parkinson’s stimulation on Parkinson disease symptoms stimulation on Parkinson sleepiness on motor performance, independence in daily life activities and sleepiness on motor performance, disease with Parkinson’s quality of life for patients patients for with supervised weekly program of home-exercises, 24-month in early and advanced stages disease of evolution: Parkinson’s interim report training based on movements guided by rhythmic cues on movements guided training based L. Ouchchane, S. Perrette, N. Saïkali, B. Aublet-Cuvelier, F. Durif F. Aublet-Cuvelier, B. Saïkali, N. Perrette, S. Ouchchane, L. K.L. Hull, Jr., L. Gutman, the APO-302 Investigators the Gutman, L. Jr., Hull, K.L. F. Bibbiani, A. Kielaite, T.N. Chase T.N. A. Kielaite, Bibbiani, F. M.A. Stacy, the US-005 and US-006 Investigator Group Stacy, M.A. T. Pan, W. Xie, J. Jankovic, W. Le W. J. Xie, Jankovic, W. Pan, T. O. Rascol, O. Gershanik, O. Blin, J. Ferreira, N. Bodjarian, A. Lees A. Bodjarian, N. Ferreira, J. Blin, O. Gershanik, O. Rascol, O. E.E. Labyt, F.F. Cassim, D.D. Devos, J.-L.J. Bourriez, L.L. Defebvre, P.P. Defebvre, L.L. Bourriez, J.-L.J. Devos, D.D. Cassim, F.F. Labyt, E.E. Derambure M. Relja, S. Telarovic S. Relja, M. I. Alafuzoff, T. Kauppinen, T. Pirttilä, J. Autere, L. Autere, L. Parkkinen Pirttilä, J. T. Kauppinen, T. Alafuzoff, I. M. Oechsner, A. Korchounov A. Oechsner, M. Sullivan K.L. Wallach, P. Hoffman, M. Hauser, R.A. Giunta, B. Zesiewicz, T.A. C. Moreau, C. Ozsancak, J.L. Blatt, P. Derambure, A. Destee, L. Defebvre L. Destee, A. Derambure, P. Blatt, J.L. Ozsancak, C. Moreau, C. C.S. Kubu, R.M. Busch, R. Shaw, H.D. Stott, A. Ahmed, A. A. Rezai Ahmed, A. Kubu, R.M. C.S. Stott, H.D. R. Busch, Shaw, M. Ushe, M. Hong, J.W. Mink, F. Revilla, J.L. Dowling, J.S. Perlmutter J.S. Dowling, J.L. Revilla, F. Mink, J.W. Hong, M. Ushe, M. Damier P. Brachet, P. Lescaudron, L. Paillé, V. M.E. Piemonte, D.M. Almeida, K. Burgi, M.C. Melo, M.M. Morimoto, E.R. Morimoto, M.M. Melo, M.C. Burgi, K. Almeida, D.M. Piemonte, M.E. Barbosa R. Iancu, P. Mohapel, P. Brundin, G. Paul G. Brundin, P. Mohapel, P. Iancu, R. F.M. Semeraro, T.T. Capato, E.O. Hattori, E.R. Barbosa, M.E. Piemonte M.E. Barbosa, E.R. Hattori, Capato, E.O. T.T. Semeraro, F.M. T.T. Capato, E.S. Takata, M.C. Moura, M.C. Fornari, E.R. Barbosa, M.E. Barbosa, E.R. Fornari, M.C. Moura, M.C. Takata, Capato, E.S. T.T. Piemonte P608 Is levodopa-induced dyskinesias risk decreased in parkinsonian patients P607 Onset of action of intermittent subcutaneous apomorphine in the P605 as adjunctive therapy in patients Istradefylline (KW-6002) with advanced P606 antagonists further reduces levodopa- AMPA Combined use of NMDA and P604 The pharmacological and biological effects of pramipexole on dopamine P603 in monotherapy (150 to 300 mg/day) in de novo Piribedil efficacy P601 Prospective study on the use of ropinirole in patients with advanced P602 Abnormal cortical oscillatory relaxation activity in voluntary in de muscle P600 pathology Alpha -synuclein does not predict extrapyramidal signs or P599 and cardiovascular dysfunction Levodopa-induced hyperhomocysteinemia P598 disease with treatment of acute psychosis in Parkinson’s Parenteral P596 A prospective study of reduced impulse control in patients with idiopathic P597 disease Oral festination in Parkinson’s P595 disease A new bilateral rat model of Parkinson’s P594 Effects of bilateral deep brain and unilateral subthalamic nucleus P592 disease A unilateral Parkinsons toxin-induced mouse model for P593 a based on of a physiotherapeutic scheme, Long term effectiveness P591apathy and daytime fatigue, Assessment into the impact of depression, P590 through disease Rapid in patients gait improvement with Parkinson’s POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER 70 Rome, Italy P649 Glucocerebrosidase gene mutations in Glucocerebrosidase genemutations Ashkenazi Jewishpatientswith P649 ofautonomicfunctioninParkinson Electrophysiologicalevaluation P648 Preclinical PDpatients prediction ofthebestcontactinSTNstimulated P647 of mightoccurintheearlystage denervation nerve Cardiacsympathetic P646 ofgaitinParkinson’s Analysisofdynamics disease P645 withParkinson’s DepressioninagroupofPuertoRicanpatients disease P644 Efficacy andsafetyof P643 Systemicexposuretoproteasomeinhibitorscausesprogressive P642 RNAiscreeningforeffectorsof Systematic P641 Fas andBcl-2 expressionin T leucocytesofpatients withParkinson’s P640 Consumptionofmilkandcalciuminmid-lifethefuturerisk P639 Neuroprotectionofdopaminergicneuronsbyelectroconvulsiveshockin P638 inceruloplasmin (CP)in Biochemicalanalysisofmissensemutations P637 with inpatients kinematicsandspeechdysfunction Articulatory P636 Geneticsof P635 forParkinson’s Neurosurgery anearlystage: diseaseat Impactonquality P634 ofD1butnotD2dopaminereceptorsafterl-dopa Internalization P633 Neuroprotectiveroleofnicotine,cigarettesmokeandextracts P632 in treatment Safinamideadd-ontolevodopaanddopamineagonist P631 Thesideeffectprofileofcabergoline, aclinical anergotagonist; followup P630 Patient homediary: A reproducibleandreliabletooltoassessmotor P629 THE J.Gershoni-Baruch Rosenbaum,R. Aharon-Peretz,H. M. Umaiorubahan, V.C. Uthamarayan A.L.Benabid,B.A. Wallace,S.Chabardes, A.Batir, V.Fraix, P. Pollak Takahashi Orimo,S. T. Amino, T.Kojo, A. Takahashi,T. K.Uchihara,H. Wakabayashi, J.S. Yoon,S.B.Koh, K.W.Lee,S.H. Park,Lee D.H. Serrano,Pita,C.I.L. V. Wojna R. Peng, D. Zhou, X.H. Lai, G.G. Yuan K.S. McNaught, C.W. Olanow K.A. Caldwell,S.B.Fulghum,S.Cao,G.A.Caldwell S. Bostantjopoulou, Z. Katsarou, O. Hatzizisi, G. Kyriazis G.W. Ross, M. Park, H. Petrovitch, L.R. White, C.M. Tanner, R.D. Abbott G.A. deErausquin, A. Anastasia, R. Reynoso, H. LópezMorra, D.H. Mascó H. Hochstrasser, U. Walter, J. Spiegel, S. Behnke, I. Csoti, P. Bauer S.A.Venkatesan, V.V.Ranganathan,L.R. Venkatachalam, Y.S. Subramanian M. Farrer, P. Pals, S. Lincoln, D. Dickson, A. Hope, C. Van Broeckhoven D. Maltête, J.-L. Houeto, M. Schüpbach, M.-L. Welter, P. Cornu, Y. Agid M.-P. Muriel, G. Orieux, E.C. Hirsch A. Hild, V. Marchand, B. Dumery, E.C. Hirsch F. Stocchi, L. Vacca, P. Grassini, G. Battaglia, M. Altibrandi, S.A. Ruggieri F.P.Stegie, Metcalf, V. Dhawan, A. Williams,Forbes,K.R.Chaudhuri A. M. Faighel,J.-M. NGuyen, P. Damier degradation in degradation Parkinson disease disease Parkinson’s disease advanced Parkinson’s disease: An open-labelstudy parkinsonism inrats disease Parkinson’s disease an animalmodelofParkinson’s disease Parkinson’s disease(PD) Parkinson’s disease resultsat12-months) of lifeandsocialadjustment(preliminary afterropiniroletreatment andabsenceofinternalisation treatment MPTP-inducedneutoxicity against Parkinson disease. dosestudy An openescalating inParkinson’sstudy diseaseandrestlesslegssyndrome inParkinson’scomplications disease MOVEMENT α -synucleinopathies C. elegans C. α -dihydroergocryptine in the treatment ofearlyand inthetreatment -dihydroergocryptine DISORDERSOCIETY α -synuclein foldingand 67Levodopaassociatedhomocysteine increaseandsuralaxonal P657 withParkinson’s Neuropsychologicalstudyinpatients diseaseandlong- P656 EmotionanddecisionmakinginParkinson’s disease: Effectsoflevodopa P655 GaitdisorderandcognitiveimpairmentinpatientswithParkinson’s P654 PrevalenceofParkinson’s diseaseinCentralRussiabasedonpopulation P653 EffectsofSTNdeepbrainstimulationongaitstabilityinadanced P652 imageanalysis(SPM/eZIS)basedonbrain Usefulnessofstatistical P651 inParkinson’s Analysisofgaitpattern disease: toclinical Relationship P650 P667 Plasma concentrations of fluoxetine and motor signs in patients with Plasmaconcentrations offluoxetineandmotorsignsinpatients P667 Historyofobsessive compulsivebehavior, ofsymptoms youngerage P666 Homocysteine with levelsandMTHFRC67Tgenotypeinpatients P665 associativeprojectioncortices activates Highfrequency STNstimulation P664 DyskinesiasinducedbysubthalamotomyunresponsivetoNMDAinhibitor P663 Thezonaincertamaybeabettertargetthanthesubthalamicnucleus for P662 Statisticalissuesinanalysisofalargesimpleneuroprotectiontrial(LST) P661 facialmovements inParkinson’s Dissociationofemotionalandvoluntary P660 Predictorsoflong-termefficacy with pramipexoletherapyinpatients P659 Family caregiversofParkinson’s professionals deserve diseasepatients P658 D. DeGaspari, M. Canesi, C. Siri, G. Pezzoli I. Benatru, N. Camille, S. Thobois, P. Mertens, A. Sirigu, E. Broussolle N.A. Unizshenko, O.S. Levin, D.Y. Olyunin O.S. Levin, M.A. Lobov, L.V. Dokadina, V.N. Shtok J.M. Hausdorff, D. Tarsy, L. Scollins, S. O’Herron, J. Solomont, L. Gruendlinger N. Sasaki, H. Watanabe, F. Maki, H. Sugihara,M. Kawakami, Y. Takahashi S.B. Koh, J.S. Yoon, S.H.Lee, K.W. Park, D.H.Lee E. Dzoljic, I. Kovacevic, M. Pokrajac, M. Mijajlovic, M. Milosevic, V. Kostic N. Giladi, N. Weitzman, C. Peretz, H. Shabtai, S. Schreiber Z.Novakovic,D.Mirkovic,E.Dzoljic,I. Todorovic, M.Prostran, V.Kostic E. Kalbe, R. Hilker, L. Burghaus, K. Herholz, J. Kessler, V. Sturm M. Merello P. Plaha, Y.B. Shlomo, N.K. Patel, D.O. Brien, K.O. Sullivan, S.S. Gill Elm, P. Guimaraes, K. Shannon, F. Wooten, C. Tanner B.C. Tilley, Y.P.Palesch, C.Kamp,J. Goetz,C.G.B.Ravina,K.Kieburtz, Huang, H. Topka,D.C.Droll, Wildgruber, Dichgans J. I.G. Smolentseva, O.S. Levin, B. Tserensodnom, N.V. Fedorova, L.V. Dokadina O. Moore,N.Giladi T. Muller, K. Renger, W. Kuhn neurodegeneration term exposuretohydrocarbon-solvents and subthalamicnucleus (STN)stimulation disease survey Parkinson’s disease: DisparitybetweenUPDRSscoresandgaitstability excessive daytimesleepiness– perfusion SPECTinpatientswithParkinson’s with disease–relation features Parkinson’s disease disease in patientswithParkinson’sdevelopment ofaddiction-likebehavior withdopamineagonists areriskfactorsforthe onset andtreatment Parkinson’s diseasewithandwithoutlevodopatherapy advanced Parkinson’s disease with of thebasalgangliaandimprovesmemoryfunctioninpatients amantadine deep brainstimulationforParkinson’s disease in Parkinson’s disease(PD) disease Parkinson’s disease caregivers’ clinic andsupport:attention A reportfromoneyearofexperiencewith POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 POSTER SESSION2 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 71 severe leg edema secondary to amantadine: Case reports severe leg edema secondary to amantadine: death both in rat PC12 cells and PhosphoryltedLewy is a novel component of as its target protein IkBa bodies administration survey in Brazil dementia and dementia with Lewy bodies Alzheimer disease (AD) pathology and non- disease (PD) and Parkinson Alzheimer demented patients disease and also with confirmed Parkinson disease S. Papapetropoulos, J. Gonzalez, A. Lieberman, D.C. Mash D.C. Lieberman, A. Gonzalez, J. Papapetropoulos, S. Roberts E. Lieberman, A. Gonzalez, M.A. Papapetropoulos, S. Singer, C. T.-B. Ahn, B.S. B.S. Jeon Ahn, T.-B. Mizuno Y. Hattori, N. Jensen, P.H. Gai, W.P. Kitami, T. K. Noda, Mizuno Y. Yamaguchi, M. Mochizuki, H. Ohizumi, H. Lima M.F. Cunningham, M.C. Maia, D.P. Caramelli, P. Cardoso, F. Barbosa, M.T. e Costa Mizuno Y. Yamada, M. Mochizuki, H. Mizuno Y. Itaya, M. Takanashi, M. Guo, L. Mori, H. P694 patients Rimantadine as an alternative with to amantadine in Parkinson P687 cell role of heat Protective during lactacystin-induced shock protein70 P688 inclusions: the formation NEMO binding domain inhibits of cytoplasmic P689 cells in the striatum Analysis of progenitor and midbrain by MPTP P690A community-based in the elderly: disease and Parkinson’s Parkinsonism P691 disease by rAAV-parkin Gene therapy for Parkinson’s P692 disease with study Pathologic on the relationship between Parkinson P693 A comparison of demented patients confirmed with pathologically treatment for speech dysfunction in Parkinson’s disease patients? treatment for speech dysfunction in Parkinson’s shifting impairments in Parkinson’s disease shifting impairments in Parkinson’s studyA safety disease patients - function in Parkinson’s rating scale motor scores and are improved by both medication and bilateral subthalamic deep brain stimulation functional reach in subjects with and without Parkinson’s disease functional reach in subjects with and without Parkinson’s disease patients disease patients in Parkinson’s patients and a physiotherapist-supervised exercise program on gait parameters in disease population a Parkinson’s sectional clinical surveysectional clinical PD patients in and age-matched controls training of screeners of participants and medical Effects of literacy India: and implications efforts in developing countries for screening disease studyacoustic and aerodynamic basal ganglion output in Parkinson’s disease output in Parkinson’s basal ganglion A.E. Dias, F. Fregni, S.P. Rigonatti, A. Pascual-Leone, M.A. Marcolin, E.R. Marcolin, M.A. Pascual-Leone, A. Rigonatti, S.P. Fregni, F. Dias, A.E. Barbosa A. Taylor Tavares, G.S. Jefferis, G. Fujikami, T. Courtney, B. H. Hill, Bronte- Courtney, T. G.S. G. Jefferis, Fujikami, Tavares, Taylor A. Stewart F. Fregni, P.S. Boggio, M.T. Silva, M.A. Marcolin, A. Pascual-Leone, E.R. Barbosa E.R. Pascual-Leone, A. Marcolin, M.A. Silva, M.T. Boggio, P.S. Fregni, F. A.E. Slabosz, S.J. Lewis, A.M. Owen A.M. Lewis, S.J. Slabosz, A.E. O. Ozturk, F. Ozer, L. Hanoglu, H. Meral H. Hanoglu, L. Ozer, F. Ozturk, O. C. Marras, M.J. Korell, F. Kamel, J.A. Hoppin, D.M. Umbach, C.M. Tanner C.M. Umbach, D.M. Hoppin, J.A. Kamel, F. Korell, M.J. Marras, C. F. Fregni, C.M. Santos, M.A. Marcolin, A. Pascual-Leone, L. Silveira-Moriyama, L. Pascual-Leone, A. Marcolin, M.A. Santos, C.M. Fregni, F. E.R. Barbosa S. Haegele, I. Zerr, T. Vogt T. S. I. Haegele, Zerr, M. Kiljako, P. Taba, U. Krikmann, E. Olt E. Krikmann, U. Taba, P. Kiljako, M. Horstink M.W. Haaxma, C.A. V. Lun, N. Pullan, C. Adams, B. Ramage, J. Ronsky, O. Suchowersky O. Ronsky, J. Ramage, B. Adams, C. Pullan, N. Lun, V. G.N. Rizzo Barbosa E.R. Pascual-Leone, A. Bermpohl, F. Boggio, P.S. Maia, F. Fregni, F. R. Rattihalli, N. Sarangmath, G. Gopalkrishna, S.K. Doddaballapur, E.D. Louis, E.D. Doddaballapur, S.K. Gopalkrishna, G. Sarangmath, N. Rattihalli, R. U.B. Muthane J.J. Ferreira, J.M. Silva, R. Freire, J. Pignatelli, L.C. Guedes, A. Feijó A. Guedes, L.C. Pignatelli, J. Freire, R. Silva, J.M. Ferreira, J.J. R. Marconi, S. Carapelli, L. Morgante, A. Epifanio, N. Vanacore, G. Meco Vanacore, R. Marconi, Epifanio, A. Carapelli, S. N. Morgante, L. Teston B. Purson, A. Jankowski, L. Viallet, F. A.B. Guekht, E.S. Chikina, K.S. Glushkov, A.A. Shpak, E.I. Gusev E.I. Shpak, A.A. Glushkov, K.S. Chikina, E.S. Guekht, A.B. M. Merello, J. Balej, C. Aveleyra, R. Leiguarda R. Aveleyra, C. Balej, J. Merello, M. P686 May it be a potential Repetitive transcranial magnetic stimulation: P685 Quantitative digitography scores correlate disease with unified Parkinsons P683The cognitive basis of attentional set- Learned irrelevance revisited: P684 Rapid-rate repetitive transcranial magnetic stimulation and cognitive P682 anxiety and cognitive disorders in patients with Parkinson’s Depression, P681 Pull test and The relationship between two measures of postural stability: P680 is as effective as fluoxetine in the treatmentTMS of depression Repetitive P679 proteins in cerebrospinal fluid of Parkinson Tau Amyloid peptides and P677 disease Bladder dysfunction in patients with Parkinson’s P678 disease Gender differences in Parkinson’s P675acute effect? Is this an disease patients: The placebo effect in Parkinson’s P676the effects of a self-supervised Comparison of home exercise program P674 disease Somnolence and sleep attacks in a small sample of Parkinson’s P673 disease screening questionnaire in of a modified Parkinson’s Validity P672A cross- disease: skin lesions in Parkinson’s Neoplastic and preneoplastic P671An disease: on laryngeal effects dysfunction in Parkinson’s L-DOPA P670 A simple method to assess oxidative in subjects with Parkinson’s stress P668 evaluation Kinematical total interruption of after partial and of movement P669 disease (PD) with Parkinson’s of life (QoL) in patients Quality POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER POSTER SESSION 2 SESSION POSTER 2 SESSION POSTER

8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 73 F- 18 –synuclein in human CSF: A biomarker for Parkinson in human CSF: –synuclein α disease? disease fluctuations and dyskinesias in advanced Parkinson’s with Parkinson’s disease with Parkinson’s disease (PD) who had initially received patients with early Parkinson’s ropinirole or L-dopa disease (PD) Parkinson’s quality of life and cognitive, A two-year clinical, disease: Parkinson’s disease onset Parkinson’s ‘wearing- living and quality of life in parkinsonian patients experiencing off’ type complications dominant Parkinson’s disease family dominant Parkinson’s of tolerance to pulsatilethe developing dopaminergic stimulation in patients disease (PD) Parkinson’s demented patients disease enon in Parkinson’s neuropsychological follow-up at 12 months in patients with complicated PD H. Reichmann, on Behalf of the ComQol Study Group Reichmann, H. El-Agnaf O. Sudarsky, L.R. Kahn, I. Schlossmacher, M.G. D. Pålhagen, S. Maehle-Schmidt, M. Wedlund, J.-E. Sydow, O. Lewander, T. Nyholm M. Wang, K. Shiba, Y. Chikaoka, N. Hattori, Y. Mizuno Y. Hattori, N. Chikaoka, Y. Shiba, K. Wang, M. B. Bayulkem Yildiz, Y. Asantugrul, G. E. Bayulkem, K. B. Bayulkem, Gurpinar, on Behalf of the Lang, A.E. Korczyn, A.D. Watts, R.L. De Deyn, P.P. Rascol, O. 170 Study Group Fattapposta F. Locuratolo, N. Valletta, L. Bartolo, M. Perrotta, A. Parisi, L. Pandey R. Srivastava, A.K. Behari, M. Barone Bonavita, P. V. Amboni, Pellecchia, M. R. Vitale, Marconi, M.T. C. Aristu, J.A. Obeso A. Alonso, Rodriguez-Oroz, M.C. I. F. Zamarbide, Gill S.S. Brooks, D.J. Bunnage, M. Plaha, P. Hotton, G.R. Patel, N.K. Salvatore M. Salvatore, E. Pellecchia, M. Amboni, M. Pappatà, S. Varrone, A. S. Jain, A.B. Singleton, W.P. Gilks, N.L. Khan, D.J. Nicholl, N.W. Wood Gilks, N.L. Khan, D.J. Nicholl, N.W. W.P. A.B. Singleton, S. Jain, Alegre, M.C. Rodriguez J.A. Artieda, Alonso, M. Obeso J. Oroz, I. F. Zamarbide, Miwa H. Nakanishi, I. Kondo, T. Barone Grossi, N. D. Fragassi, P. Trojano, Ravallese, L. V. M. Pellecchia, Krack, G. Deuschl P. Wenzelburger, A. Morsnowski, R. Raethjen, S. J. Pohle, Kondo T. Oobu, S. Miwa, H. Kihira, T. Kohmoto, J. Mizuno Y. H. Mochizuki, Yamada, Furuya, M. T. Yoshimi, M. K. Fukuda, Pezzoli G. Mariani, C. Morgante, L. Landi, A. De Gaspari, D. Antonini, A. dopa outcome study P730 Characterization of P731 motor A computerized method for blinded assessment of Videoscoring - P720 aggregation 4-hydroxynonenal (HNE) enhances alpha-synuclein P721 folate and vitamin B12 levels in patients treated Plasma homocystein, P722 Reduced dyskinesias with ropinirole in a naturalistic 8.5-year follow-up of P723 disease reflexes in Parkinson’s Trigemino-cervical-spinal P724 disease in Indian patients Quality of life with Parkinson’s P725 disease Response to apomorphine in early Parkinson’s P726 Efficacy in patients with advanced Continuous apomorphine infusion: P727 Intraputamenal infusion of glial cell line-derived neurotrophic factor in P728 Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early- P729 levodopa with entacapone Efficacy of combining on activities of daily P712 in a autosomal disease locus Confirmation and fine mapping of PARK8 P713 in oscillatory Changes antedates (STN) subthalamic nucleus activity in the P714 of levodopa potency doses of cabergoline enhance the Subclinical P715 neuropsychological studyA in non- disease: Hallucinations in Parkinson’s P716 disease precision grip in Parkinson’s Action tremor during P717 and pergolide intervention Quality of life (QOL) for wearing-off phenom- P718 diseased models Analysis of microglia activation in Pakinson P719 Clinical and STN-DBS: Subcutaneous apomorphine infusion vs. , JUNE 16 , JUNE 16 , JUNE , JUNE 16 , JUNE , JUNE 16 , JUNE 16 , JUNE Y Y Y Y Y pharmacological study spared in cardiac sympsthetic function in MIBG scintigraphy neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine disease mouse model of Parkinson disease patients (PD) Parkinson’s brain stimulation of the subthalamic nuclei: Our experience and meta- brain stimulation of the subthalamic nuclei: analysis of the literature haloperidol-induced catalepsy in rats parkinsonian rats with and without levodopa therapy disease, Parkinson’s a new wireless measurement system (PD) disease dementia Parkinson’s be predicted? for good prognosis disease and a possible predictor and without cognitive impairment M. Yamamoto, H. Ujike, N. Hattori N. Ujike, H. Yamamoto, M. R. Katzenschlager, A. Evans, A. Manson, P. Patsalos, N. Ratnaraj, A.J. Lees A.J. Ratnaraj, N. Patsalos, P. Manson, A. Evans, A. Katzenschlager, R. F. Alonso, M. Alegre, I. Zamarbide, M.C. Rodriguez-Oroz, J. Artieda, J.A. Obeso J.A. Artieda, J. Rodriguez-Oroz, M.C. Zamarbide, I. Alegre, M. Alonso, F. K. Obi, T. Furuya, H. Mochizuki, H. Akiyama, Y. Mizuno Y. Akiyama, Furuya, H. H. Mochizuki, T. K. Obi, S. Hunot, M. Vila, E. Hirsch, S. Przedborski, P. Rakic, R. Flavell R. Rakic, P. Przedborski, S. Hirsch, E. Vila, M. Hunot, S. Y. Balash, D. Merims, N. Giladi N. Merims, D. Balash, Y. T. Sato Armellino Luciano, A. K. Thomas, Iacono, D. A. Onofrj, M. M. Marti, F. Mela, F. Martina, G. Remo, B. Clementina, M. Michele M. Clementina, B. Remo, G. Martina, F. Mela, F. Marti, M. H. Russmann, A. Salarian, K. Aminian, J. Villemure, P.R. Burkhard, F.J. P.R. Villemure, Aminian, J. A. Salarian, K. Russmann, H. Vingerhoets E. Dzoljic, I. Novakovic, D. Mirkovic, Z. Todorovic, M. Prostran, V. Kostic V. Prostran, M. Todorovic, Z. Mirkovic, D. Novakovic, I. Dzoljic, E. C. Capper-Loup, J.-M. Burgunder, A. Kaelin-Lang A. Burgunder, J.-M. Capper-Loup, C. B. Mollenhauer, C. Trenkwalder, F. Sixel-Doering, M. Bibl, M. Canelo, J. Canelo, M. Bibl, M. Sixel-Doering, F. Trenkwalder, C. Mollenhauer, B. Schindehuette M. Iijima, T. Kitami, S. Hori, A. Kakizuka, N. Hattori, Y. Mizuno Y. A. Hattori, N. Kakizuka, Kitami, S. Hori, T. Iijima, M. S.Y. Kang, J.-S. Kim, Y.H. Sohn Y.H. Kim, J.-S. Kang, S.Y. J.K. Dobson, R.L. Rodnitzky, E.Y. Uc E.Y. Rodnitzky, R.L. Dobson, J.K. S. Papapetropoulos, J. Ellul, P. Polychronopoulos, E. Chroni, T. Papapetropoulos T. Chroni, E. Polychronopoulos, P. Ellul, J. Papapetropoulos, S. WEDNESDA WEDNESDA P711 disease who are Analyses of the parkin gene in patients with Parkinson’s P710 and A double-blind clinical disease: Mucuna pruriens in Parkinson’s P708 disease Caspase11 and microglial activation in Parkinson’s P709 Oscillatory (STN) in dyskinetic activity in the subthalamic nucleus P707 is a transcriptional target gene of JNK and induces COX-2 P705 revisited A concealed syndrome disease: Akinesia in Parkinson’s Acute P706 disease treated by deep Suicidal thoughts in patients with Parkinson’s P704 disease? What are factors associated with dementia in Parkinson’s P703 FQ transmission attenuates Intranigral blockade of nociceptin/orphanin P702 of Validation disease: Longtem ambulatory gait monitoring in Parkinson’s P700 Modulation interneuronal activity in the motor cortex of of GABAergic P701 serum levels and MTHFR C67T genotype in patients with Homocystein P698 disease Examination of valosin containing protein (VCP) in Parkinson’s P699 fluid in dementia with Lewy Bodies and Analysis of cerebrospinal P697 Unilateral orthostatic tremor as an initial manifestation of Parkinson’s P696 Can it disease: in Parkinson’s trial participants clinical Compliance among Poster numbers 695-814 Poster numbers P695 disease with control investigation case A registry-based, of Parkinson’s Parkinson’s disease 2 disease Parkinson’s WEDNESDA pm 8:30 am to 5:00 Poster Viewing: am to 12:30 11:30 Present Odd Numbers: Authors pm pm Even Numbers: 4:00 pm to 5:00 Authors Present POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER WEDNESDA WEDNESDA POSTER SESSION 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER 74 Rome, Italy P750 Unilateral deep brain stimulation improvescontrolofbimanualforcesin deepbrainstimulation Unilateral P750 Ameta-analysisofsixprospective studiesoffallsinParkinson’s disease P749 InvitrocomparisonofBN82451andRiluzole.vivointeractiononthe P748 ofdepressiontopsychomotorsymptomsinthe Therelationship P747 2’-AcetylacteosideblocksMPP+-induceddopaminergicneuronaldeath P746 Parkinson’s Theprevalenceofidiopathic diseaseandneuroleptic-induced P745 dependsonelectrode ImprovementinparkinsonismbySTNstimulation P744 ElectrophysiologicalpropertiesofpallidalcellsinParkinson’s disease P743 learningandmotorplanninginPDmaysharecommon Abnormalspatial P742 syndromeonnocturnalsleep aretherepercussionsofsleepapnea What P741 subthalamotomiesinParkinson’s Simultaneousbilateral disease: P740 withParkinson’s Dopaminetransporterin150patients diseaseand P739 subthalamotomyfor afterbilateral Theevolutionofdyskinesias P738 Efficacy, safety, in andtolerabilityoftherotigotinetransdermalpatch P737 Stalevo(levodopa/carbidopa/entacapone) P736 andinducedstepsinParkinson’s Voluntary disease, startingfrom P735 (CBT)for ArandomizedcontrolledtrialofCognitiveBehavioral Therapy P734 Entacapone, aCOMTinhibitor, theseverityoflevodopa- attenuates P733 ofseizuresinParkinson’s Aretrospectivestudy with treated patients P732 THE J.L.Elder,C. Alberts, J.L. Vitek R.M. Pickering, G. Mazibrada, B.H. Wood, P. Gray, G.K. Kerr, B.R. Bloem P.E. Chabrier, S. Cornet, V. Roubert, C. Soulard, C. Touvay, J. Schulz E. DiRosa, F. Tatì, G. Martino, A. Epifanio, L. Morgante, A.E. DiRosa Z. Ma, M. Farlow, Y. Du G.K. Wenning, K. Seppi, J. Mueller, S. Kiechl, J. Willeit, W. Poewe A. Batir, F. Torny, V. Fraix, P. Krack, A.-L. Benabid, P. Pollak J.Hamani,C. Tang, Dostrovsky,J.O. Lozano A.M. M. Ghilardi,G.Silvestri,D.Eidelberg,C.Ghez N.J. Diederich, M. Leischen, M. Vaillant, G. Mancuso, S. Golinval, R. Nati L. Alvarez, E. Casabona, M. Leon, S. Salazar, R. Macias, I. Litvan A. Antonini, R. DeNotaris, R. Benti, S. Tesei, M. Canesi, G. Pezzoli Macias,R.E.L. Alvarez,Guridi M.C.Rodriguez-oroz,J.Pavon, Alvarez,N. R.L. Watts,J. Wendt,P.L. Nausieda,B.Boroojerdi,Poole,K.H. K.W. Sommerville W. Oertel, onBehalfofthe Group TC-INIT Study L. Rocchi, L. Chiari, A. Gross, F.B. Horak R.G. Brown, D.L. Secker C. Marin, E. Aguilar, J. Obeso E.B. George Parkinson’s diseasepatients loss ofdopamineinducedbyMPTPinmice Parkinson’s disease Bruneck study parkinsonism inthegeneralcommunityofSouth Tyrol: Datafromthe placement: Effectsofreimplantation motorscores pre-operative withhighandlow patients bases patients in Parkinson’s in49 disease? case-controlstudy A polysomnographic andneuropsychologicalaspects Neuropsychiatric <5years:disease duration study A DaTSCAN/SPECTimaging Parkinson’s disease multinational, randomized, double-blind, placebo-controlledtrial withearly-stage, Parkinson’spatients idiopathic disease. A multicenter, withentacapone levodopa/DDCI givenincombination Parkinson’scontrol influctuating comparableto diseasepatients different stanceconditions withParkinson’scarers ofpatients disease inhemiparkinsonianrats induced dyskinesias quetiapine MOVEMENT DISORDERSOCIETY provides improvedsymptom P758 REM behavior disorder and hallucinations inParkinson’s REMbehaviordisorderandhallucinations disease P758 Young-onset Parkinson’s versuslate-onset disease: and Clinicalfeatures P757 neurons ofdifferentiated Longtermresultsofautologoustransplantation P756 Non-motorsymptomspreceedingonsetofmotorparkinsonism P755 Worsening ofParkinson’s diseasebyacolinesteraseinhibitor: Casereport P754 ofsertralinevs. Arandomizedsingle-blindstudy amitriptilineforthe P753 Hyperhomocystinemia: A riskfactorfordementiainParkinson disease? P752 Significantassociationbetweensingle-nucleotide polymorphismsinthe P751 71UPDRSactivity ofdailylivingscoreas markerofParkinson’s disease P771 Parkinson’s diseaseandthyroiddysfunction P770 Differentclinical characteristicsbetween Parkinson’s diseasepatients P769 ResponsetodobutamineinpatientswithParkinsons diseaseand P768 ‘Fast Tapping’ isnotasuitable parameterforcontrolofdopaminergic P767 Cabergolineversuspergolideinlevodopa-treatedParkinson’s disease P766 ofParkinson’s Intermitentapomorphineinthetreatment disease. Our P765 ofParkinson’s Oxidativestressinthepathogenesis disease P764 ofParkinson’s treatment Dopamineagonist diseaseintheelderly P763 at Egenepolymorphismandage Correlationbetweenapolipoprotein P762 ATK-0091, andrelatedalpha-substitutedanaloguesofMDMA(“Ecstasy”), P761 inParkinson’s Mentaldysfunctions disease: Prevalenceinanoutpatients P760 RiskfactorsinParkinson’ withonsetbefore50 sdiseasepatients P759 C. Pacchetti, R. Manni, R. Zangag G.A. Silver, K. Vuong, J. Jankovic M.F. Levesque, T. Neuman Papadopoulos P. Vrentas, V.Panayiotopoulou, V.C. S.Kiriakakis,O.Sameli,Georgiadou, D.E. Riley, C.M. Whitney A. Antonini,Zecchinelli,S. A. Tesei,PezzoliMeucci,G.G.Sacilotto,N. E. Pourcher, L. Bond, M.-C. Fortin, A. Beausoleil Li M.A. Noureddine, X.-J. Qin, M.A. Hauser, M.A. Pericak-Vance, J.M. Vance, Y.-J. R.C. Frysinger, M.B. Harrison, D. Huss, G.F. Wooten, L.J. Currie R.P.Munhoz,H.A. Teive, A.R. Troiano,P.R. Leiva,Hauck,M.H.L.C. Werneck P. Stathis, C. Grigoris, K. Andreas C.W. Silveira R.P. Munhoz, R. Hollanda, O.J. Hernandez-Fustes, L. Benthien, A.L. deLemos, P.H.P.Kraus, Klotz,J.Hoffmann,Przuntek A.H. Andrich, C. Trenkwalder, M. Canelo, A.Forbes, M. Leroux, K.R. Chaudhuri M.A. Gamero,J.R.Chacon,J.M.Garcia-Moreno Smolenskaya, S.N. Illarioshkin G.K.Bagieva, T.N. Fedorova,Stvolinsky,S.L. Boldyrev, A.A.Ivanova- I.A. S.H. Isaacson,D.L.Kreitzman B. Jasinska-Myga, G. Opala, S. Ochudlo, G.Klodowska-Duda, J. Tustanowski M.J.Piggott,K. Wagg, T.Johns C. Pacchetti, R. Zangaglia, M. Ossola, S. Cristina, M. Allena, G. Nappi G. Duda, G. Opala, B. Jasinska-Myga, A. Gorzkowska, M. Swiat disease progression from adulthumanneuralstemcellsforParkinson’s disease and literaturereview withParkinson’streatment ofdepressioninpatients disease neuron-specific RNA-bindingproteinELAVL4 andParkinson’s disease progression with andwithoutlacunarinfarctsofbasal gangliaterritory diminished myocardialuptakeof123I-MIBG therapy efficacy,trial toevaluate tolerability, andqualityoflife withnocturnaldisabilities:patients A randomised, double-blindcrossover experience in22patients onset ofParkinson’s disease ofParkinson’s potentialinthetreatment may have disease population POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 ton, J. Lee, J. Gomez-Ramirez, J.M. Brotchie lia, M. Ossola, E. Martignoni, G. Nappi 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 75 follow up of a randomized controlled study disease with early Parkinson’s Preliminary results disease: late stage SOF Parkinson’s Parkinson’s disease Parkinson’s disease of constipation in Parkinson’s resonance spectroscopy disease pergolide dose in the treatment of Parkinson’s disease in Parkinson’s in everyday life in patients with Parkinson’s disease in everyday in patients life with Parkinson’s disease people with Parkinson’s disease disease Z1 and smoking in Parkinson’s T1 and P1, GSTM1, disease cephalic movements in Parkinson’s electrodes a macrolide through drug interaction with clarithromycin, N.O. Subutay, M.F. Oztekin M.F. Subutay, N.O. Korucu D. Oztekin, M.F. Subutay, N.O. Dagdelen F. Oztekin, M.F. Subutay, N.O. M. Nomoto, M. Nagai, A. Nakatsuka, H. Yabe, T. A. Moritoyo, Moritoyo T. Yabe, A. M. Nagai, Nakatsuka, Nomoto, M. H. Munhoz, L.C. R.P. Troiano, A.R. M.D. Schafranski, E.S. Paiva, Teive, H.A. Werneck Orhan S. Boylu, E. Unal, Z. Anca M.H. T.A. Dunne, P.B. Maldonado, J.L. Hauser, R.A. Staffetti, J.F. Sullivan, K.L. Zesiewicz B. Ritz, K. Gail, B. Jeff, M. Donna Hanstock C. Wieler, M. Martin, W. Lew M.F. Hui, J.S. Oztekin M.F. Subutay, N.O. Oztekin M.F. Subutay, N.O. N. Karapathiou, A. Sarafianos, E. Karageorgiou, C.E. Karageorgiou C.E. Karageorgiou, E. Sarafianos, A. Karapathiou, N. Humhal K. Svatova, J. Guieu J.-D. Derambure, P. Destee, A. Blatt, J.-L. Cassim, F. Bleuse, S. Barker R.A. Spillantini, M.G. Carpenter, R.H. Fritz, D. Luheshi, L. Michell, A.W. Mellick G.D. Boyle, R. Silburn, P.A. Dunne, M.P. Newman, B. Deng, Y. Pierre P. Alain, Paul, K. V. Pelisson, D. Tilikete, Sauleau, C. P. Benabid A.L. Vighetto, A. D. Tilikete, Pelisson, C. Krack, Sauleau, P. P. Damier P. Lajat, Y. Verin, M. Faighel, M. Leduc, D. Raoul, S. P811 Results of a 3 year monotherapy in the treatment of early PD: Pergolide P812 and piribedil on parkinsonian tremor in patients The effect of pergolide P813 a non-ergoline dopamine agonist in the treatment of early and Ropirinol, P802 disease Prevalence of fibromyalgia syndrome in patients with Parkinson’s P803 as adjunctive therapy Ropinirole versus pergolide to levodopa in P804 disease A preventive rehabilitation program in Parkinson’s Gyrokinetics: P805 (Zelnorm) for the treatment Tegaserod randomized trial of A double-blind, P806 A population-based features disease study in early Parkinsons of clinical P807 disease studied with magnetic Brain energy metabolism in Parkinson’s P808 disease Dopamine-related behavioral disorders in Parkinson’s P809 Early combination of domperidone with pergolide allows quick titration of P810 The effectiveness of pergolide and cabergoline as an adjunct to levodopa P793pragmatic difficulties and of the impact of speech Comparison difficulties P794 vigilance test modification in and driving ability of Bourdon’s Possibilities P795 Anticipatoryadjustments during shoulder flexion in Parkinson’s postural P796 disease biomarkers of Parkinson’s Peripheral P797 Case-only study between genetic polymorphisms of of interactions P798 stimulation Effects of deep brain nucleus on oculo- of the subthalamic P799 in gaze orientation? What is the role of the subthalamic nucleus P800 results of staged DBS lesions through and clinical Experimental studies P801 Bioavailability cabergoline increases dopamine receptor agonist, of a dopamine agonists can be highly effective antiparkinson drugs without dopamine agonists can be highly effective antiparkinson 1 disease patients, while D1 stimulation may restore it. Difference between while D1 stimulation may restore it. disease patients, acute and chronic stimulation a retrospective review possible anti-Parkinson’s activity possible anti-Parkinson’s motor fluctuations and quality of life in patients with Parkinson’s sleep, disease patients with advanced Parkinson’s disease patients with advanced Parkinson’s disease Parkinson’s undergoing surgical procedures disease impaired in Parkinson’s complications and discharge destinations disease (PD) Parkinson’s disease Parkinson’s Parkinson’s disease Parkinson’s A. Pisani, L. Brusa, S. Galati, P. Stanzione, F. Petta, E. Finazzi Agrò Finazzi E. Petta, F. Stanzione, P. Galati, S. Brusa, L. Pisani, A. Anik I. Karabas, G. Tokay, T. Efendi, H. Bayulkem, K. Iseri, P. S.M. Farris, M.L. Giroux, J.L. Vitek J.L. Giroux, M.L. Farris, S.M. Ozkaynak S. Kizilay, F. S. Happe, M. Kungel, P. Rink, M. Ebrecht, S. Modell, C. Trenkwalder C. Modell, S. Ebrecht, M. Rink, P. Kungel, M. Happe, S. M.R. Gluck, L.A. Santana, H. Granson, M.D. Yahr M.D. Granson, H. Santana, L.A. Gluck, M.R. N. Pankratz, L. Byder, C. Halter, A. Rudolph, C.W. Shults, P.M. Conneally P.M. Shults, C.W. Rudolph, A. Halter, C. Byder, L. Pankratz, N. D. Gutmann, the APO-302 Investigators the Gutmann, D. J. van Vugt, M. Stijl, J. van Dijk J. Stijl, M. Vugt, van J. Klose J. Motz, C. Krauss, S. Goldberg, M.S. Sagi, D. Palacino, J.J. G.J. Salazar, R.J. Wix, J. Monells, J. Valls, E. Tolosa E. Valls, J. Monells, J. Wix, R.J. Salazar, G.J. K.A. Smalky, R. Tintner R. Smalky, K.A. K.A. Smalky, R. Tintner R. Smalky, K.A. R.B. Mailman, K. Neitzel, D.E. Nichols, S. Southerland J.M. Gorell, S. Coon, E.L. Peterson, A. Gloi, J.G. Pounds, D.R. Chettle D.R. Pounds, J.G. Gloi, A. Peterson, E.L. Coon, S. Gorell, J.M. Belger A. Troster, A. Ford, S. Vaughn, B. Chen, Huang, X. P. J. Elm, B.C. Tilley, P. Huang, K. Kieburtz, B. Ravina, C. Goetz, Y. Palesch, C. Palesch, Y. Goetz, C. Ravina, B. Kieburtz, K. Huang, P. Tilley, B.C. Elm, J. Tanner C. Wooten, Shannon, K. Guimaraes, F. Kamp, P. J.-M. Gracies, W. Tse, D. Crisan, L. Guo, R. Kahoud, W. Koller W. Kahoud, R. Guo, L. Crisan, D. Tse, W. Gracies, J.-M. W. Bara-Jimenez, T. Dimitrova, A. Sherzai, T. Chase T. Sherzai, A. Dimitrova, T. Bara-Jimenez, W. Riley D.E. Maddux, B.N. Tarler, M. Giuffrida, J.P. Moro-de-Casillas, M.L. R.P. Munhoz, M.R. Piovesan, H.A. Teive, M. Mader, L.C. Werneck L.C. Mader, M. Teive, H.A. Piovesan, M.R. Munhoz, R.P. inducing tolerance P792 disease L-Dopa dependence in a young-adult patient with Parkinson’s P791 in untreated Parkinson’s D2 stimulation worsen bladder over-activity may P790 disease High dosage of pergolide in Parkinson’s P789 disease with dementia, of rivastigmine in Parkinson’s Safety and efficacy P788 Effects of controlled-release L-Dopa (NACOM® Retard/SinemetTM CR) on P787 response of an anti-convulsant agent Novel dopamine releasing with P785 Safety following a single subcutaneous injection of apomorphine in P786APOE4 allele results in significantly earlier onset of Presence of an P784 Mitochondrial dysfunction and oxidative damage in parkin-deficient mice P783 Antagonist prior to and during voluntary inhibition agonist contractions is P781 disease (PD) delirium in patients with Parkinson’s Postoperative P782 disease and MSA-p in Parkinson’s Occulo-Jaw synkinesia P780 disease - Postoperative Orthopedic surgery in patients with Parkinson’s P779 D P777 disease body lead burden and the risk of Parkinson’s Total P778 disease Functional studies of monozygotic twin discordant for Parkinson’s P776 Statistical studies in Parkinson’s issues in design of Phase II futility P775 marker for as a clinical Contribution of step length to walking speed P774 monitor of a lightweight wireless movement disorder Clinical assessment P772 disease evaluation An of cognitive dysfunction in idiopathic Parkinson’s P773 glutamate of nonselective inhibition of Effects advanced release in POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER 76 Rome, Italy P831 Spinal cord stimulation in patients with primary orthostatic tremor with primaryorthostatic inpatients Spinalcord stimulation P831 Improvedmotorresponding, butcentralslowing, subtha- afterbilateral P830 Subthalamicnucleus deepbrainstimulationeffectinelderlypatients P829 onposturalinstabilityandgaitin Effectsofstereotacticneurosurgery P828 ofGPineuronsin Effectofpropofolanesthesiaonthefiringpattern P827 betweenthepatient’s Correlation abilitytoperformmotortasks, their P826 Subthalamicnucleus forParkinson’s deepbrainstimulation diseaseusing P825 fordistressfulbelching Deepbrainstimulation P824 movementdisorders: paradigmindystonic Newtreatment Multifocal P823 PredictivevalueoftheFloridaSurgicalQuestionnaireforParkinson’s P822 Effectofhighfrequency ofthesubthalamicnucleus stimulation on P821 Methodologicalconceptsinsubthalamicnucleus targeting: Controversies P820 subthalamicnucleus contralateralto Unilateral deepbrainstimulation P819 after onimmunosuppressivetherapy inapatient Deepbrainstimulation P818 PC-baseddeepbrainrecordingsystemforstereotacticandfunctional P817 onbrainstemexcitabilityinparkinsonian TheimpactofSTNstimulation P816 Subthalamicnucleus inParkinson’s stimulation diseasepatients P815 Poster numbers815-948 Surgical Therapy following Continuedeffectofintermittentsubcutaneousapomorphine P814 THE J.K. Krauss, H.H. Capelle, C. Blahak,H. Bäzner, R. Weigel, J.C. Wöhrle Y. Temel,W.E. Weber,Blokland,L. A.Ackermans,P. Boon, V. Visser-Vandewalle Rascol F. Ory, C. Brefel-Courbon,P. Chaynes,M. Simonetta-Moreau, Y. Lazorthes,O. B.R. Bloem M. Bakker, R.A. Esselink, M. Munneke, P. Limousin-Dowsey, H.D. Speelman, F.S. Steigerwald, F. Kopper, J. Herzog, J. Volkmann, H.M. Mehdorn, G. Deuschl C.A.Joint, T.Z. D.Shamley, Aziz,C.Fletcher, R.B.Scott, D.Foxcroft S. Chen, Y. Chou, S. Lin, Y. Hsin, S. Lin, C. Lee E.Cuny, Rougier, A. P.I.Gorayeb,I.Sitbon,Benazzouz, A. Burbaud J.K. Krauss, H.H. Capelle, C. Blahak,H. Bäzner, R. Weigel, J.C. Wöhrle K.D. Foote,H.H. Fernandez,P. Seignourel, M.S. Okun C.Carcenac,Lacombe,Bertrand,Boulet,E. A.S. Poupard, Savasta M. A. S.G. Echebarria A. Samii,J.C.Slimp,R.Goodkin A. Samii,J.C.Slimp,R.Goodkin J. Tejeiro,Morales L.M.G.J.M.Lopez,R.J.Macias, Alvarez,C.Maragoto, Pötter,M. F. Kopper, R. Wenzelburger, Deuschl,J.G. Volkmann K.E. Lyons,S.B. Wilkinson, R.Pahwa D.F. Pfeiffer, the APO-302 Investigators lamic nucleus withParkinson’s inpatients stimulation disease with Parkinson’s disease Parkinson’s review disease;asystematic generalized dystonia inParkinson’sthese withlevodopaanddeepbrainstimulation disease perception ofthisability, theirmoodandaffect, of andtherelationship studyofoutcome trode recording–acomparative withandwithoutmicroelec- forlocalization resonanceimages magnetic deep brainstimulation disease (FLASQ-PD) freely movinghemiparkinsonianrats of andGABAinsubstantianigraparsreticulata extracellular glutamate (DBS)/neuraltransplantation referring todeepbrainstimulation inParkinson’sthalamic stimulation disease renal transplant neurosurgery patients intolerant tolevodopatherapy withadvancedParkinson’slong-term useinpatients disease MOVEMENT DISORDERSOCIETY P839 Deep brain stimulation oftheGPitreatsrestlesslegssyndrome Deepbrainstimulation P839 PseudobulbarcryingspellduringmicroelectroderecordingoftheGPiina P838 STNvs. effectsofunilateral GPiDBSonmovementtime, Comparative P837 inPDleadstoadecreasementalspeed BilateralSTNstimulation P836 dementiainapatientwithParkinson’s Lewybody diseasedeveloping P835 subthalamic continuoussubcutaneousinfusionandbilateral Apomorphine P834 Treatment ofParkinson’s diseasebydeepbrainstimulation: Evaluationof P833 resonanceimaging Qualitycontrolprocedureforstereotacticmagnetic P832 P850 Bilateral stimulation ofthesubthalamicnucleus(STN)inParkinson’s Bilateralstimulation P850 andsubthalamicnucleus Reversiblecatatonia/catalepsy deepbrain P849 Pallidal neuronalactivityingeneralized dystonia P848 Ondemanddeepbrainstimulationforessentialtremor: An approachto P847 Fear recognitionisimpairedbysubthalamicnucleus stimulationin P846 ondepressionand AcuteeffectsofL-dopaandsubthalamicstimulation P845 Chronicbilateralsubthalamicnucleusstimulationinadvanced P844 Onlyphysicalaspectsofqualitylifearesignificantlyimprovedby P843 DifferentimprovementofsignsParkinson’s diseaseafter1yearof P842 Anauditoftheincidenceandtypesepilepsyoccurringafterdeepbrain P841 ofsubthalamicdeep oftremorafterdiscontinuation Rapidreappearence P840 D.P. Wint, K.D.Foote, M.S. Okun K. Nakamura, C.W. Christine, P.A. Starr, W.J. Marks, Jr. H.M. Smeding,B.Schmand,J.D.Speelman M. Alegret,F. Valldeoriola,E. Tolosa, Rey,M. Pilleri J.Rumià,M. M. Pilleri, M. Martí, F. Valldeoriola, E. Tolosa, O. Morsi, M. Alegret N. Vayssiere, G. Guarrigues, L. Cif, S. Hemm, P. Coubes N. Vayssiere, H. ELFertit, L. Cif, S. Hemm, P. Coubes C. vanderLinden,H. Colle S.A. Ellias,J.Nazzaro L. Hinz, F. Steigerwald, U. Fietzek, H. Mehdorn, G. Deuschl, J. Volkmann M.Kronenbuerger, C. Fromm, F.Block, V.A. Coenen, I.Rohde, V.Rohde I. Biseul, S. Drapier, P. Sauleau, I. Rivier, F. Lallement, M. Verin C. Daniels, K. Witt, J. Reiff, J. Herzog, D. Lorenz, J. Volkmann H. Baezner, E. Grips, C. Blahak, R. Weigel, J.K. Krauss, J.C. Woehrle S. Drapier, P. Sauleau, D. Drapier, S. Raoul, E. Leray, M. Verin F.S.A.Nassetti, Valzania,Sturiale,C. A. Tropeani, A.Andreoli,C.A. Tassinari T.Johnson,J.M.Saifee, Yanni, T.Z.Pearce,P.G. Aziz,R.K. Bain C. Blahak, H.H. Capelle, H. Baezner, M.G. Hennerici, J.K. Krauss, J.C. Woehrle M.S. Okun, H.H. Fernandez, K.D. Foote associated withdystonia: Reportofacase withParkinson’spatient disease dexterity, andreactiontime logic study cognitive changeswhileundersubthalamicstimulation: A clinicopatho- comparative study ofadvancedParkinson’sstimulation inthetreatment disease: A pilot undergeneralanesthesia an MRI-basedsurgery ofmovementdisorders during neurosurgery clinical in117patients complications disease (PD): upofnon-surgical,A long-termfollow non-reversible stimulation (STNDBS)inParkinson’s disease(PD) tolerance? avoid Parkinson’s disease hedonic toneinParkinson’s disease year postoperatively Parkinson’s disease: 3monthsandat1 Computerizedgaitanalysisat subthalamicstimulationinParkinson’sbilateral disease subthalamic stimulation stimulation fordystonia transmission interference inParkinson’sbrain stimulation disease–evidenceforadirectneuro- POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 77 of the subthalamic nucleus benefit of frequency on the clinical but does not improve early morning painful dystoniadyskinesia, in patients Parkinson’s deep brain stimulation thirteen cases disease motor scores in Parkinson’s stimulation electrodes with scanning and transmission electron microscopy Case studies subthalmic nucleus: Implication of changes in energysubthalamic stimulation: expenditure main components of ataxia patients multiple sclerosis in Parkinson’s disease when procedure is done under general anesthesia? A anesthesia? is done under general disease when procedure Parkinson’s prospective study of 75 patients disease patients with advanced Parkinson’s ologic results symptoms study dysarthria in patients Preliminarydystonia: with generalized results trode recordings prior to the implantation of deep brain stimulation disease electrodes for people with Parkinson’s L. Verhagen Metman, C.C. Goetz, B.C. Myre, J.M. Arzbaecher, N.A. Verweij, R.A. Verweij, N.A. Arzbaecher, J.M. Myre, B.C. Goetz, C.C. Metman, Verhagen L. Bakay Hung S. Mahant, N. Tokcaer, A. Poon, Y.-Y.W. Lang, A.E. Moro, E. Arle J. Shils, J. Barlow, P. Lamont, S. Apetauerova, D. J.E. Castner, H.J. Chenery, D.A. Copland, P.A. Silburn P.A. Copland, D.A. Chenery, H.J. Castner, J.E. F.J. Villemure, J.-G. Bogousslavsky, J. Ghika, J.A. Pollo, C. Carruzzo, A. Vingerhoets A. Sturm, V. Joergens, S. Suedmeyer, M. Timmermann, L. Wojtecki, L. Schnitzler Vaz R. Fonseca, R. Basto, M. Linhares, P. Mendes, A. Rosas, M. N.A. Fletcher M.J. Varma, Steiger, T.R. A. Sinnott, S.H. Fox, Tyne, H.L. Bain P.G. M.B. Graeber, Aziz, T.Z. Ryder, T.A. J. Moss, Linderoth B. Meyerson, B.A. Winter, J. Lind, C. Lind, G. Durif F. Morio, B. Boirie, Y. Derost, P. Bannier, S. Montorier, C. J. Spiegel, G. Fuss, J.R. Moringlane, U. Dillmann T. Witjas, J. Régis, F. Viallet, M. Sethian, J. Péragut, J. Azulay J. Péragut, J. Sethian, M. Viallet, F. Régis, J. Witjas, T. Siderowf A.D. Leng, L. Loveland-Jones, C. Jaggi, J.L. Chou, K.L. Liang, G.S. Alterman R.L. A. Koss, Tagliati, J.L. Shils, M. Alterman R.L. Tagliati, M. Shils, J.L. Alterman R.L. Tagliati, M. Koss, A. Shils, J.L. Csavoy A. Rosenow, J.M. Gaede, S.E. Holloway, K.L. Henderson, J.M. Rothwell J. Hariz, M. Limousin-Dowsey, P. Tisch, S. Pinto, S. Tripoliti, E. P886 Randomized double-blind evaluation of unilateral deep brain stimulation P887 Importance disease: Bilateral globus pallidus stimulation for Huntington’s P888 Subthalamic nucleus deep brain stimulation is effective for disabling P878 Oculomotor sub-region within the STN: Evidences from DBS in PD P879 settings in subthalamic Modulation functions by frequency of executive P880after Assessement disease: Deep brain stimulation for Parkinson’s P881 stimulation and medication on The additive effect of subthalamic nucleus P882 explanted deep brain The ultrastructural analysis of the surface of P883 Long-term result of treament for essential tremor with stimulation of the P884 Mechanisms of body weight gain in parkinsonian patients after P885 (VIM) improves Stimulation of the thalamic ventralis intermedius nucleus P870 Is bilateral effective in less stimulation nucleus of the subthalamic P871 in of bilateral Long-term outcomes stimulation of the subthalamic nucleus P872 Clinical and neurophysi- Effects of STN DBS in post pallidotomy patients: P873 lead/extension failure testing Non-Invasive experimental and clinical DBS P874contact and stimulation DBS electrode effect on parkinsonian frequency P875An accuracy placment of deep brain stimulation electrodes: Frameless P876 Effects of GPi stimulation features on perceptual and acoustical of P877 in language Microelec- nucleus The role of the subthalamic processing: dysarthria in patients with Parkinson’s disease: Preliminary results disease: dysarthria in patients with Parkinson’s disease patients with advanced Parkinson’s following globus pallidus internus deep brain stimulation Safety and long-term efficacy nucleus: (STN) and posterior hypothalamic gray matter deep brain stimulation (DBS) subthalamic nucleus in treated Parkinson’s disease treated in Parkinson’s subthalamic nucleus Parkinson’s disease Parkinson’s age disease Parkinson’s Parkinson disease Parkinson stimulation in Parkinson’s pallidotomy and bilateral subthalamic nucleus disease fixation after thalamic stroke (DBS) parameters in PD patients patinets with Parkinson’s disease treated with deep brain stimulation in patinets with Parkinson’s the subthalamic nucleii disorders? procedures for movement in Parkinson’s disease (PD): Correlation electrode results with of clinical disease (PD): in Parkinson’s position R. Hilker, J. Voges, L. Burghaus, M. Maarouf, A. Koulousakis, K. Koulousakis, A. Herholz L. Maarouf, Burghaus, M. Voges, J. R. Hilker, S. Pinto, E. Tripoliti, P. Silberstein, P. Limousin-Dowsey, M. Hariz, J. Rothwell J. Hariz, M. Limousin-Dowsey, P. Silberstein, P. Tripoliti, E. Pinto, S. P. Guaraldi, G. Barletta, D. Grimaldi, G. Pierangeli, P. Cortelli P. Pierangeli, G. Grimaldi, D. Barletta, G. Guaraldi, P. N. Allert, J. Volkmann, C. Dohle, S. Kelm, J. Voges, R. Lehrke R. Voges, J. Kelm, S. Dohle, C. Volkmann, J. Allert, N. T. Trottenberg, J. Volkmann, G. Deuschl, B. Schrader, G.H. Schneider, A. A. Kupsch Schneider, G.H. G. Volkmann, B. Deuschl, Schrader, J. Trottenberg, T. N. Fogelson, A.A. Kuhn, P. Silberstein, P. Dowsey Limousin, M. Hariz, T. Hariz, DowseyM. Limousin, P. Silberstein, P. Kuhn, A.A. Fogelson, N. Trottenberg C. Wider, J. Ghika, J.-G. Villemure, P. Burkhard, J. Bogousslavsky, F. Burkhard, Bogousslavsky, J. P. Villemure, J. Ghika, J.-G. Wider, C. Vingerhoets P. Derost, D. Morand, B. Debilly, J.-J. Lemaire, J. Coste, F. Durif F. Coste, J. Lemaire, J.-J. Debilly, B. Morand, D. Derost, P. A. Sailer, D.I. Cunic, M. Elena, A.E. Lang, A.M. Lozano, R. Chen R. Lozano, A.M. Lang, A.E. Elena, M. Cunic, D.I. Sailer, A. R.A. Esselink, R.M. de Bie, R.J. de Haan, R.P. Schuurman, A.D. Bosch, J.D. Bosch, A.D. Schuurman, R.P. de Haan, R.J. de Bie, R.M. Esselink, R.A. Speelman M. Ito, T. Nimura, T. Oikawa, R. Fukatsu, T. Ando, S.-I. Ando, Niwa T. Oikawa, R. Fukatsu, T. Nimura, T. Ito, M. S.E. Krahl, R.V. Patwardhan, A. Pedroso, E.J. Behnke, A.A. DeSalles A.A. Behnke, E.J. Pedroso, A. Patwardhan, R.V. Krahl, S.E. A. Beric, D. Sterio, C. Drafta, P. Taverna, M. Xu, P.J. Kelly P.J. Xu, M. Taverna, P. Drafta, C. Sterio, D. Beric, A. A. Kupsch G.-H. Schneider, Trottenberg, T. Hälbig, Kopp, U.A. T.D. Gruber, D. D. Apetauerova, P. Barlow, K. Hreib, J. Shils, J. Arle J. Shils, J. Hreib, K. Barlow, P. Apetauerova, D. C.A. Joint, R. Stross, G. Mallon, K. O’Sullivan C.A. Joint, R. Stross, G. Mallon, P. Blomstedt, M.I. Hariz M.I. Blomstedt, P. A.-L. Törnqvist, L. Schalén, S. Rehncron S. Schalén, L. Törnqvist, A.-L. M. Mata, J.J. Lopez Lozano, G. Rey, R. Martinez, G. Bravo, J. Burzaco J. Bravo, G. Martinez, R. Rey, G. Lozano, Lopez J.J. Mata, M. P868 Effect of STN stimulation on perceptual and acoustical assessements of P869 Deep brain stimulation of the STN activates the electrode target area in P866 Non-microelectrode guided deep brain stimulation of the subthalamic P867 The acute cardiovascular and respiratory nucleus effects of subthalamic P865 progress of severe tardive dystonia Post-operative and dyskinesia P864 of stimulation of the Differential effects of different frequencies P862 Effect of the disease: Deep brain subthalamic stimulation in Parkinson’s P863 High incidence of osteo-articular complications after STN DBS in P861 deep brain stimulation restores afferent inhibition in Subthalamic nucleus P859 stimulation in patients Impact on mood of subthalamic nucleus with P860 One year follow-up of a randomized multicenter trial comparing unilateral P858 Intraoperative MR-imagingto to confirm DBS lead placement prior P857 Neuropsychological outcome of bilateral pallidal stimulation in dystonia P856stimulation (STN) deep brain of subthalamic nucleus Long-term changes P854 nurse specialist The role of the surgical movement disorder P855 involuntary Gpi DBS has only moderate benefit for mixed movements P853 Are complications stimulation less common in deep brain ablative than in P852 in parameter settings on the intelligibility of speech Effects of different P851 Unilateral (STN-DBS) deep-brain stimulation of the subthalamic nucleus POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER 78 Rome, Italy P908 Relief of hemiballism with ventral subthalamic stimulation following Reliefofhemiballism withventralsubthalamicstimulation P908 ofthe Neuropsychological outcomeofthedeepbrainstimulation P907 ofParkinson’s Surgicalmanagement disease. of Deepbrainstimulation P906 withdeepbrainstimulation ofhemidystonia Management P905 chronichighfrequency Bilateral inParkinson’s subthalamicstimulation P904 parametersaffectmoodandmental Dochangesindeepbrainstimulation P903 nonmotorfluctuations: Life-threatening An emergency forsub- indication P902 Cognitive,motorandqualityoflifeoutcomesaftersubthalamic P901 reportofthe tardivedyskinesia: Preliminary Pallidal totreat stimulation P900 Retrospectivecomparisonoftheefficacy andcostsofSTN-DBS P899 istheimpedanceofelectrodesusedformicroelectroderecording How P898 Ageisnotanindependentfactorinfluencingtheshort-termoutcomein P897 effect indeepbrain tostimulation parameters’relationship Stimulation P896 inParkinson’s Apracticalguidetodeepbrainstimulation diseaseand P895 Neuronalactivityof P894 Subthalamicnucleus forParkinson’s stimulation disease: Anatomical P893 Two subthalamicnucleus ofbilateral in yearfollow-up stimulation P892 vs. Conscioussedation localanaesthesiaindeepbrainstimulation P891 subthalamicnucleusstimulation following Unusualobservations P890 Subthalamicnucleus withorwithoutmicroelec- deepbrainstimulation P889 THE V.L. Wheelock,C.T. Pappas,J.Scanlon,K.A. Sigvardt Fukatsu,R.T. Nimura, T. Ando, T.Saito,H.Oikawa, T. Fujii G.J. Arango, W.Fernandez, M.Rueda,E.Jairo M.Espinosa,Rueda,J. W. Fernandez,G.J.Ruiz Arango, E. M.F.Romito,L.M. C.Marras,Contarino,Franzini, A.M.Scerrati, A. Albanese C. Siri, J. Green, J.L. Vitek, M. Haber, M.R. Delong T. Witjas, J. Régis, E. Fakra, J. Péragut, J. Azulay V.L. Wheelock, C.I. Higginson, C.T. Pappas, D.S. King, D. Levine, J. Scanlon P.Damier, S. Thobois, T.P.D.Guel,S.Raoul, Wijas, Derkinderen T. vanLaar, L. Werdelin K. Ashkan, A.Batir, B.A. Wallace,P. Pollak,Benabid A.-L. S. Lin, S. Chen, S. Lin, Y. Chou, C. Lee S.E.Cooper, A.M.Kuncel,J. Henderson, Rezai,A.E.B.Montgomery, W.M.Grill R. Stross,G.Mallon,K.O’Sullivan,C.A.Joint M. Merello, E. Tenca, D. Cerquetti B.A. Wallace,K.J.LeBas,P.S.Chabardes, Ashkan, Pollak, A.L.Benabid N.A. Chhaya, P.K. Doshi, S.R. Vaidya, M.H. Bhatt A. Mariscal,J.C.Martinez-Castrillo P.K. Doshi, N.A. Chhaya, M.H. Bhatt Y.C. Chou, S.Y. Chen, S.H. Lin, S.Z. Lin subthalamic nucleus deepbrain stimulatorimplantation subthalamic nucleus inpatients withParkinson’s disease the prelemniscalradiations disease: Long-termneurologicalfollow-up withParkinson’sfunction inpatients disease? thalamic nucleus (DBS) (STN)deepbrainstimulation forParkinson’sstimulation disease French STARDYS multicentricstudy advanced Parkinson’s disease with inpatients continuous subcutaneousinfusionofapomorphine disease? surgeryforParkinson’s totheoutcomeofdeepbrainstimulation related subthalamic nucleus ofthe treatedwithdeepbrainstimulation parkinsonian patients ofthethalamus stimulation other movementdisorders oftheexacttarget localization Parkinson’s disease forParkinson’ssurgery disease analysisintwogroups trode recording-Complications MOVEMENT zona incerta zona DISORDERSOCIETY inParkinson’s diseasepatients P916 Brain perfusion SPECT before and 6 months after surgery duringSTN- BrainperfusionSPECTbeforeand6monthsaftersurgery P916 Tremor inParkinson’s STNstimulation inductionbyunilateral disease P915 Theefficacy ofSTN-DBSinadvancedParkinson’s diseasebasedon P914 monitoringgivingabetter Istheneurophysiologicalintraoperatory P913 Sideeffectsofsubthalamicnuclei deepbrainstimulation inParkinson’s P912 tardivecervical inmedicallyrefractory Bilateralpallidalstimulation P911 Mosteffectrivestimulationsiteforsevereintentiontremor P910 Pathological cryinginducedbydeepbrainstimulation: A casereport P909 98Theanatomicspecificity ofresttremorsuppression P928 Theeffectsofpallidotomy onmotorfunctioninMPTP-treated, L-DOPA P927 Aprospective, randomized trialofglobuspallidusvs. subthalamicnucleus P926 onmotorsymptomsin Detrimentaleffectsof10HzSTNstimulation P925 Effectofstimulationsubthalamicnucleus onparkinsonianvoice: A P924 dystonia(Meige’s Pallidal forcraniocervical surgery syndrome) P923 withParkinson’s Backpaininpatients disease: A mini-invasiveapproach P922 withaminimallyinvasive riskofmajorsurgicalcomplications Low P921 subthalamicnucleus ofbilateral deep Double-blindmulticentrestudy P920 Deathbysuicideafterdeepbrainstimulation P919 alimitingfactortoselectParkinson’s Isadvancedage for diseasepatients P918 (DBS)maybeeffectivefordystonia. Deepbrainstimulation Sixmonth P917 A. Antonini, R. Benti, R. Cilia, A. Landi, C. Mariani, G. Marotta E. Wolf,G. Wenning, W.Eisner, Müller,J. W.Poewe A.T. Portman, T. vanLaar, M.J. Staal, W. Rutgers, H.L. Journee, K.L. Leenders L.Bartolomei, T. F.Nordera,Piacentino,G.Mesiano,M. Colombo, V. Toso A. Artiges, F. Supiot, M.U. Manto, M. Levivier, N. Massager, D. ZegersDeBeyl M.Rinnerthaler, J.Mueller, F.K.Kalteis, Alesch, W.Poewe J.Herzog,W. Hamel,R. Wenzelburger, Mehdorn,J.H.M. Deuschl Volkmann,G. L. Wojtecki, J. Nickel, L. Timmermann, R. Seitz, V. Sturm, A. Schnitzler T.L. Davis,P.D. Charles, C.Kao, J.Y. Fang,G.M. Fenichel,P.E. Konrad S.S. Costa, M.M. Iravani, M.J. Jackson, P. Jenner W.J. Marks, Jr., C.W. Christine, J.L. Ostrem, P.A. Starr L.Timmermann, L.J.Gross,J. Wojtecki,Voges, V.Sturm,Schnitzler A. F.Mancini, D. Servello, G. Bertino, L. Geremia, G. Nappi, C.Pacchetti M. Rezak, S.M. Vergenz, J.W. Cozzens, L.P. Bernstein, E.K. Nenonene, K. Novak M. Porta, G.R. Maggioni, M. Camerlingo, A. Ortolina, S. Radice Dowling F.J. Revilla, J.W. Mink, P. SchneiderGibson, J.S. Perlmutter, K.M. Rich, J.L. Study Group V. Fraix, Y. Agid, A. Destée, P. Burbaud, P. Pollak, onBehalfoftheFrench Spark Ghika P.R.Burkhard,F.J. Vingerhoets,Berney, A. Bogousslavsky,J. J.-G.Villemure,J. F. Tamma,G.Caputo,M.E.Egidi, Ardolino, Priori,P. A. Rampini N. Galvez-Jimenez, M. Hargreave, S. Nair DBS inadvancedParkinson’s disease diariesandmotorscores:patient data 1-yearfollow-up patients outcome inDBStherapyforParkinson’s disease?: Ourexperiencein31 2003 disease: between1998and treated of25patients A retrospectivestudy dystonia: A casereport primed commonmarmosets deep brainstimulationforParkinson’s disease Parkinson disease study spectroscopic andvideolaryngostroboscopic stimulation forPD STN inbilateral withintraoperativeelectrophysiologicmapping approach Study Group inParkinson’sbrain stimulation disease: ResultsoftheFrench SPARK DBS treatment? follow up POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 79 H.C. Watt, A.J. A.J. Lees Watt, H.C. I) striatal uptake in patients with PSP without 123 -synuclein pathology-synuclein in aging human brain α effects of botulinum toxin treatment diagnosis of vascular parkinsonism cerebrovascular disease and clinical deceased older men without Parkinson’s disease deceased older men without Parkinson’s VIM thalamotomy nigral lesion resolved after entity? of the neck in generalized dystonicof the neck in treated syndromes with botulinum toxin followed by deep brain stimulation disease Parkinson’s of falling longitudinal population-basedA prospective study dementia: syndrome and Richardson’s palsy: cally proven progressive supranuclear PSP-Parkinsonism C.M. Peralta, M. Stampfer, E. Karner, T. Benke, W. Poewe, G.K. Wenning G.K. Poewe, W. Benke, T. Karner, E. Stampfer, M. Peralta, C.M. Harper C.M. Maraganore, D.M. Ahlskog, J.E. Klos, K.J. the NNIPPS-Study-Group Herting, B. Suessmuth, S.D. Schrader, C.H. Lorberboym M. Melamed, E. Lampl, Y. Djaldetti, R. D.R. Williams, D.C. Paviour, Paviour, D.C. Williams, D.R. Vaidya, M.H. S.R. Bhatt Vaidya, J. S. Singh, S.R. Shah, M.H. Bhatt White L.R. Tanner, J. Abbott, C.M. Nelson, R.D. Ross, Petrovitch, H. G.W. Ali-Chérif, J. Pouget A. Attarian, Witjas, S. T. Azulay, J.-P. Lomeña M. F. Martí, Tolosa, Pilleri, M. E. Valldeoriola, O. F. Morsi, Wilder-Smith B.-C. Goh, E. Tambyah, P.A. Tan, J.-H. Mecir P. Vymazal, J. Jech, R. Roth, J. Urgosik, D. Ruzicka, E. Cardozo A. Fuentes, M. Mullol, J. Marin, C. Pujols, L. Saldaña, M. Defebvre L. Destée, A. Doutriaux Mercier, C. Jan, M. Auzou, P. Ozsancak, C. Agid Y. Dormont, D. Hahn-Barma, V. Etchepare, F. Houeto, J.-L. Bloch, F. S. Jain, T. Subramanian T. Jain, S. Dal Sasso F.F. Dalla Libera, A.A. K. Hahn, G. Ebersbach Caroyer J.-M. Dethy, S. Hausdorff J.M. Giladi, N. Hadar-Frumer, M. K.A. Jellinger Mayeux R. Tang, M.X. Louis, E.D. evident signs of parkinsonism P966 Orthostatic hypotension and attention in Lewy body disorders P967 Distinctive features secondary Parkinsonism to mitochondrial cytopathy: P968 nature and palsy - Frequency, Retrocollis in progressive supranuclear P969 [123I]-FP-CIT SPECT imagingpatients with of dopamine transporters in P956 Reversible parkinsonism following hyponatremia P957 Reversible parkinsonism following acute liver failure P958 Association in of parkinsonian signs with substantia nigra neuron density P959 syndrome associated Parkinsonian with gluten sensitivity P960 of Ioflupane( Reduction P961 parkinsonism mimicking progressive supranuclear palsy Paraneoplastic P962 Hemiparkinsonism and levodopa induced dyskinesias following focal P963 expression Dementia with Lewy bodies and cyclooxygenase-2 P964A perceptual analysis degeneration Dysarthria in corticobasal (CBD): P965A new clinical Camptocormia (Bent spine) and parkinsonian syndrome: P948 and disability in patients subjective improvement Assessing with dystonia Other Parkinsonism - 949-1016 Poster numbers P949 Diffuse Lewy Body disease with late onset of parkinsonian syndrome P950 Sonographic assessment of urinary in MSA and idiopathic retention P951 associated Reversible parkinsonism with hemochromatosis P952 fear Effects of reducing gait disorder of the elderly: “cautious” Idiopathic P953 Lewy body-related P954of incident signs in older people in the community and risk Parkinsonian P955 phenotypes observed in pathologi- Characteristics of two distinct clinical attachment to microcarriers for parkinsonism stimulation disease patients in Parkinson’s subthalamic nucleus thalamic ischemia: A report of two cases thalamic ischemia: implications stimulation somatic symptoms and distress in patients with Parkinson’s disease somatic in patients symptoms and distress with Parkinson’s questionnaire results intraoperative monitoring study subthalamic deep brain stimulation experience Venezuelan year follow up: subthalamic nucleus deep brain stimulation for Parkinson’s disease brain stimulation deep for Parkinson’s subthalamic nucleus dystonia disease patients treated deep brain stimulation subthalamic nucleus with and kinematics in stride length, gait velocity, deep brain stimulation on disease patients with Parkinson’s neurectomy, blepharoplasty and elevation of eyebrows for treatment of neurectomy, facial dyskinesias stimulation on quality of life in patients with Parkinson’s disease quality of life in patientsstimulation on with Parkinson’s interfere? R.A. Bakay, S. Triche, J. Wuu, J.L. Woodard, M.R. Delong, J.L. Vitek Delong, J.L. M.R. Woodard, J.L. Wuu, J. Triche, S. Bakay, R.A. A. Koss, M. Tagliati, Alterman J.L. Shils, R.L. Tagliati, M. A. Koss, T. Subramanian, K. Venkiteswaran, P. Redman, E. Gilbert E. Redman, P. Venkiteswaran, K. Subramanian, T. J.E. Arle, Arle, L. Mei J.E. J.P. Sutton J.P. V. Voon, J.A. Saint-Cyr, A.M. Lozano, E. Moro, K. Dujardin, A.E. A.M. Lang Lozano, A.E. Moro, E. K. Dujardin, J.A. Voon, Saint-Cyr, V. M. Remacle, J.-M. Gonce, M. Delvaux, V. Maertens de Noordhout, A. Mouchamps M. Sensi, R. Eleopra, M. Cavallo, R. Schivalocchi, F. Dalpozzo, R. Quatrale R. Dalpozzo, F. Schivalocchi, R. Cavallo, M. Eleopra, R. Sensi, M. R. Eleopra, L. Lopiano, A. Priori, Italian DBS Group Italian Priori, A. Lopiano, L. Eleopra, R. K. Kalteis, H. Standhardt, I. Kryspin-Exner, F. Alesch F. Kryspin-Exner, I. Standhardt, H. Kalteis, K. G.J. Salazar, R.J. Wix, J.C. Jimenez, R.J. Weiser, S. Tolosa Starosta, S. E. Weiser, J.C. Wix, Jimenez, R.J. R.J. Salazar, G.J. M. Tagliati, J. Miravite, J.L. Shils, A. Koss, R.L. Alterman R.L. Koss, A. Miravite, Shils, J.L. J. Tagliati, M. M. Tagliati, J. Miravite, J.L. Shils, S.B. Bressman, R. Saunders-Pullman, R. Saunders-Pullman, R. Bressman, S.B. Shils, J.L. Miravite, J. Tagliati, M. Alterman J.C. Rothlind, R.W. Cockshott, J.A. Walker, J.L. Ostrem, P.A. Starr, W.J. Marks, W.J. Starr, P.A. Ostrem, J.L. Walker, J.A. Cockshott, R.W. Rothlind, J.C. Jr. M.S. Piper, M.E. Melnick, P.A. Starr, C.W. Christine, W.J. Marks, Jr. Marks, W.J. Christine, C.W. Starr, P.A. Melnick, M.E. Piper, M.S. S.L. Heath, J.L. Ostrem, P.A. Starr, W.J. Marks, Jr. Marks, W.J. Starr, P.A. Ostrem, J.L. Heath, S.L. M.J. Teixeira, A. Maria-Santos, E.T. Fonoff, L. Silveira-Moriyama, Fonoff, Barbosa, E.R. A. Maria-Santos, E.T. Teixeira, M.J. Marchese A.T. B.-P.W. Bejjani, M.G. Jabr, G. Nohra, K.G. Habib K.G. Nohra, G. Jabr, M.G. Bejjani, B.-P.W. A. Siderowf, C. Loveland-Jones, L. Leng, G. Liang, M. Stern, G. Kleiner-Fisman G. Stern, M. Liang, G. Leng, L. Loveland-Jones, C. Siderowf, A. P946 Ipsilateral hyperhidrosis as a side effect of subthalamic deep brain P947 Predicting success after deep brain stimulation placement in the P945 Ex-vivo gene therapy with modified retinal pigment epithelial cells without P944 Calculated solutions and DBS electrode electric field potentials: P943 (STN) and Deep brain stimulation (DBS) of the subthalamic nucleus P942 disease Side effects of subthalamic deep brain stimulation for Parkinson’s P941 disease undergoing subthalamic Suicide risk in patients with Parkinson’s P939The stimulation”: “deep brain of the Italian group on “census” The 2003 P940A neurophysiological Deep brain stimulation (DBS) treatmentfor dystonia: P938 subthalamic deep brain stimulation The influence of on psychological and P937 one disease surgery outcomes and complications, clinical Parkinson’s P936 Improvement of post-ischemic hemidystonia with low-frequency P935 of pallidal DBS for treatment Long-term efficacy of medically refractory P934 Neuropsychological functioning after staged bilateral pallidal or P933 and globus pallidus of bilateral Long-term effects nucleus subthalamic P932 of dyskinesia Anatomic locus for induction and suppression in Parkinson’s P931 selective facial facial nerve radiofrequency neurectomy, Percutaneous P929 brain effects of deep of short-term and long-term A comparison P930 Can we still disease: subthalamic stimulation in Parkinson’s Failed POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER 80 Rome, Italy 98Thehealthcare deliveredtoveterans withparkinsonisminthePacific P988 observation: Xexpanded Increased frequency offragile Apreliminary P987 Clinical, andgeneticstudiesoffrontotemporaldementia and pathologic P986 syndrome(FXTAS) tremor/ataxia Xassociated offragile Misdiagnosis P985 Reducedintracorticalandinterhemisphericinhibitionsincorticobasal P984 Parkinsonism withprominentcognitivedecline changes andbehavioural P983 whitematter withage-related Gaitandmotordisturbancesarecorrelated P982 ofdementiawithLewybodies Galantamineforthetreatment P981 filteringindementiawithLewybodiesand Disturbanceofattention P980 ofprogressivesupranuclear Theaccuracy ofclinicaldiagnosis palsy: P979 Theaccuracy ofclinical ofmultiplesystematrophy: diagnosis Applica- P978 ofGuadeloupeanparkinsonism Experimentalevidenceforatoxicetiology P977 effectsofclonidine intwocontrastingmodelsof Haemodynamic P976 and involvementofthestriatonigral Thespectrumofpathological P975 presentationofprogressivesupranuclearpalsy: Cerebellarataxic Report P974 intheParkinson pathways onstriatopallidal Progressivedegeneration P973 and Levodopa-inducedhypotensioninmultiplesystematrophy P972 Sheddinglightonwalkinginthedark: A contrastoftheeffectongait P971 Clinicalheterogeneityinvascularparkinsonism P970 THE K. Swarztrauber, R. Bourdage Leehey,M.A. Zhang,L. V. F. Wheelock, Tassone, P.Hagerman,R. Hagerman B.Ghetti, J.R.Murrell, F.Epperson, M.R. Farlow,M. Goedert, M. Spillantini Hagerman M.A. Leehey, E. Berry-Kravis, S. Jacquemont, L. Zhang, R. Hagerman,P.J. P.K. Pal, C.A. Gunraj, A.E. Lang, R. Chen A. Cardozo, J. Díaz, E. Tolosa, M. Rey, M. Revilla, I. Ferrer Group LADIS Study H. Baezner, C. Blahak, M.G. Hennerici, L. Pantoni, D. Inzitari, onBehalfofthe K. Edwards, L. Hershey, M. Farlow, D. Lichter, S. Johnson M.P. Perriol, K. Dujardin, P. Derambure, J.L. Bourriez, L. Defebvre, A. Destee Y.Osaki, Y. G.K.Colosimo,C.Ben-Shlomo, Wenning, N.P. Lees, A.J. Quinn Y.Osaki, Y. G.K.Ben-Shlomo,N.P. Wenning,Lees, C.J.Mathias, A.J. Quinn G.U. Hoglinger, P.P. Michel, W.H. Oertel, E. Hirsch, M. Ruberg, A. Lannuzel T.M. Young,Mathias C.J. T. Ozawa, T. Revesz, J.L. Holton, N. Quinn, A.J. Lees, K.A. Josephs B.E. Murray, T. Lynch K. Seppi, M.F. Schocke, K.J. Mair, W. Jascke, W. Poewe, G.K. Wenning N. Sarangmath, S.K. Doddaballapur, C.J. Mathias, U.B. Muthane G. Leibovich, A. Kessler, T. Herman, N. Giladi, J.M. Hausdorff R.K. Mahapatra, M. Bozi, P. Mir, C. Chuang, M.J. Edwards, K.P. Bhatia Northwest criteriaforMSA meetdiagnostic that alleles inpatients inthe exon 10+3mutation withthe parkinsonism linkedtochromosome17(FTDP-17)associated degeneration by cerebrovascularchanges diseaseaccompanied as theclinical expressionofbrainstemLewybody DISability) project changes -Cross-sectionalresultsoftheLADIS(Leukoaraiosis And Parkinson’s diseasedementia with Applications “grey”cases andtruenegativecases tions with “grey”cases andtruenegativecases autonomic failure: andpureautonomicfailure Multiplesystematrophy logical correlations olivopontocerebellar systemsinmultiplesystematrophy: Clinicopatho- of twocases study variant ofmultiplesystematrophy: A longitudinaldiffusionweightedMRI occurrence Parkinson’s disease: Characteristicsandfactorsthatpredictits of olderadultswithahigher-level gaitdisorderandcontrols MOVEMENT Tau DISORDERSOCIETY gene P996 Urogenital dysfunction at thefirstvisit: Urogenitaldysfunctionat Differences betweenParkinson’s P996 qualityoflifeinMSAmeasuredbytheshortform 36 health Health-related P995 disorders IncreasedOGG1inparkinsonismrelatedneurodegenerative P994 MSA-P: Symptomatic A casereportofanunusualphenotypeassociated P993 Non-invasivenasalcontinuouspositiveairwaypressure(CPAP) inmultiple P992 infarcts Parkinsonism striatocapsular following P991 Differentialdiagnosisofparkinsoniansyndromeswithtranscranial P990 Vascular features parkinsonism–clinical andneuroimagistic P989 10 Psychogenicparkinsonism: Clinicalfeaturesofalargecaseseries P1008 ofnon–Alzheimer’s Earlypresentationof gaitdisorderisindicative P1007 ApatientwithPSP-likebrainandspinal cordNFT-tau pathology P1006 ischemic toacontralateral Dopa-responsivehemiparkinsonismsecondary P1005 ComparisonofDWIand[123-I]-IBZM-SPECT forthedifferentiationof P1004 stimulation(rTMS)on Theeffectsofrepetitivetranscranialmagnetic P1003 Dopa-responsivehemiparkinsonismduetomidbrain Virchow-Robin P1002 Putaminalatrophyinmultiplesystem P1001 withSCA8mutation presentation Corticobasaldegeneration-like P1000 withadorsorostralmidbrainlesionsparing PSPlookalikeinapatient P999 andcognitiveimpairmentinprogressivesupranuclear Limbapraxia palsy P998 DifferencesinfirstsymptomsbetweenParkinson’s diseaseandmultiple P997 EMSA-SG M. Sawires, F. Geser, K. Seppi, G. Kemmler, W. Poewe, G. Wenning onbehalfof J.Fukae,M.Takanashi, Y.N.Hattori,Nakabeppu, Y. Mizuno Wenning M. Stampfer-Kountchev, R. Granata, K. Seppi, E. Trinka, W.H. Poewe, G.K. I. Ghorayeb, F. Yekhlef, B.Bioulac, F. Tison C.M. Peralta, P. Werner, B. Holl, S. Kiechl, W. Poewe T. Kawakami, K.-I. Fujimoto C. Falup-Pecurariu, I. Varga, C. Francu, D. Minea J.C. Morgan, P. Mir, R.K. Mahapatra, K.P. Bhatia, K.D. Sethi L.M. Allan,D.J.C.G.Burn,Ballard,R.Kenny T. Scaravilli, S. Papapetropoulos, H. Morris, N.P. Quinn, F. Scaravilli, K.P. Bhatia G. Fénelon, C. Guidoux, E. Itti, P. Remy, P. Cesaro A. Diem, K. Seppi, M.F. Schocke, E. Donnemiller, G.K. Wenning, W. Poewe M. Tamaki, Y.Sawada, Y. K.Ichikawa,K.Sudo Arasaki, M. Krause,S.Hähnel,H.-M.Meinck H.Y.Shin, Y.H. J.H.Sohn, Yang,Kim Lee,J.-S. M.S.Kim, H.S. Y. Baba, Z.K. Wszolek, M. Farrer, R.J. Uitti J. Lewerenz, B. Zurowski, A. Munchau P. Soliveri, S. Piacentini, F. Girotti S.P. V,M. Doddaballapur,S.K.Adhyam, C.J.U.B.Muthane Mathias, S.P. V,M. Doddaballapur,S.K.Adhyam, C.J.U.B.Muthane Mathias, disease andmultiplesystematrophy Study baseline analysisoftheEMSA-SG-NaturalHistory questionnaire(SF-36)inEuropeanMSApatients: survey A cross-sectional with anextensivedural AV-fistula (MSA)patients:system atrophy Safety, acceptabilityanddeterminants stimulation(TMS) magnetic dementia presenting asyoungonsetspasticparaplegia dopaminergicpathway lesion ofthenigrostriatal withtheParkinsonpatients fromPD variantofmultiplesystematrophy frozen gaitinthepatientswithparkinsonism spaces dopamine deficiency? dopaminergic nigrostriatalprojection-Isaxialrigidityindependentof system atrophy POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 POSTER SESSION3 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 81 Viltart, M.-L. Caillet-Boudin, M.-L. Viltart, disorders (APD) multiple system atrophy – an analysis of baseline data (MSA) interim analysis of the EMSA-SG (European MSA-Study Group) Registry nary patients cross-sectional analysis of 79 European MSA-P Effects of prenatal to to post-natal exposure stress on the sensitivity the ratpesticides in L. Donker Kaat, A. Boon, P. Heutink, J.v. Swieten J.v. Heutink, P. Boon, A. Donker Kaat, L. G. Meco, N. Vanacore, V. Bonifati, Bonuccelli, U. De G. Michele, De M. V. Mari Vanacore, Meco, G. N. F. Geser, M. Stampfer-Kountchev, K. Seppi, J.-P. Ndayisaba, G. Wenning, W. Wenning, G. Ndayisaba, J.-P. Seppi, K. Stampfer-Kountchev, M. Geser, F. on behalf of the European MSA-Study Group (EMSA-SG) Poewe, Bex V. Daenen, F. de Noordhout, Maertens A. F. Geser, M. Stampfer-Kountchev, K. Seppi, J.-P. Ndayisaba, W. Poewe, G.K. Poewe, W. Ndayisaba, J.-P. Seppi, K. Stampfer-Kountchev, M. Geser, F. on behalf of the European MSA-Study Group (EMSA-SG) Wenning, A. Pierce, D. Vieau D. Pierce, A. W. Wenning, G. Ndayisaba, J.-P. Seppi, K. Stampfer-Kountchev, M. Geser, F. of the European MSA-Study on behalf Group (EMSA-SG) Poewe, I. Cantuti-Castelvetri, M. Ingelsson, J. Klucken, K. Ramasamy, B.T. Hyman, D.G. Hyman, B.T. Ramasamy, K. Klucken, J. Ingelsson, M. Cantuti-Castelvetri, I. Standaert C.C. Vanbesien-Mailliot, M.-C. Chartier-Harlin, O. M.-C. Chartier-Harlin, Vanbesien-Mailliot, C.C. P1016 in the Netherlands Palsy Progressive Supranuclear P1015 Profile and severity of parkinsonian features in atypical parkinsonian P1014 Dopa-responsive parkinsonism after acute subdural hematoma P1013An presentation of multiple system atrophy The clinical (MSA) in Europe: P1012 MSA-Study The European Group (EMSA-SG) natural history of study P1011A prelimi- signs (‘red flags’)in multiple system atrophy Warning (MSA): P1010 Dysregulation of chaperone proteins in Dementia with Lewy Bodies P1009 origins of neurodegenerative New insights in the environmental disorders: POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER POSTER SESSION 3 SESSION POSTER 3 SESSION POSTER

8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 83 Parkin- (YOPD) patients dramatically improves following smoking tions in Parkinson’s disease tions in Parkinson’s disease syndromes in Serbian population disease by using the pooled DNA method gene causes myoclonus-dystonia syndrome with prominent psychiatric features syndrome disease patients type 17(SCA17) direct mutation(SPG4) using detection risk factor for obsessive-compulsive behaviour A shared genetic (BDNF) - syndrome? Tourette and Gilles de la palsy progressive supranuclear anticipation and cortical blindness M. Merello, J. Balej, C. Aveleyra, R. Leiguarda R. Aveleyra, C. Balej, J. Merello, M. Moller C. Oertel, W.H. Burmester, R. Hoft, C. Bandmann, O. Rissling, I. G. Lopez Gwinn-Hardy, K. Werner, J. A. Crawley, O. Dogu, J.G. Goldman, C.G. Goetz, E. Berry-Kravis, S.E. Leurgans, C. DeSai, L. Zhou L. DeSai, C. Leurgans, S.E. Berry-Kravis, E. Goetz, C.G. Goldman, J.G. A. Auburger, Caputo, M.M. Muqit, G. V. Abou-Sleiman, P.M. Valente, E. Bentivoglio Markova E.D. Kostic, V. Illarioshkin, S.N. Svetel, M. Slominsky, P.A. Djuric, G. Murata M. Hattori, N. Yamamoto, M. Mizuta, I. Satake, W. Toda, T. Warner T.T. Lennox, G. Placzek, M.R. Misbahuddin, A. the Italian Bonifati, V. Heutink, P. Meco, G. Oostra, B.A. Bertoli-Avella, A.M. Genetics Network Parkinson Meitinger T. Strom, T.M. Pastore, A. Auer, D.P. Lichtner, Winkelmann, P. J. Muller- B. Strom, T.M. Meitinger, T. Trenkwalder, C. Lichtner, Winkelmann, P. J. Myhsok J.E. Nielsen, T. Petersen, A. Noerremoelle, A. Gjedde, L. Ehlers, L. Hasholt L. Ehlers, L. Gjedde, A. Noerremoelle, A. Petersen, T. Nielsen, J.E. L. Noerremoelle, A. Neerup-Jensen, L. Kjaergaard, S. Koefoed, P. Nielsen, J.E. Hasholt Bandmann O. Hebebrand, J. Ziegler, A. Koenig, I. Klaffke, S. (PD) disease associated Parkinson’s Klein C. Pramstaller, P.P. Kramer, P.L. Pichler, I. Kabakci, K. Maniak, S. the European Gasser, T. A. Mueller-Myhsok, B. Zimprich, J. Prestel, Sharma, M. PD (GSPD) Consortium of Genetics in A.J. Lees J. Hardy, Wood, R. de A.J. Myers, N.W. Pittman, A.M. Silva, Heutink P. Hawkins, C. Nightingale, S. Nicholl, D.J. P1050 DJ1 and NR4A2 gene mutations in young onset PD Prevalence of UCHL1, P1051 A subject with a homozygous exon 4 parkin deletion whose parkinsonism P1041 transporter gene and hallucina- Genetic polymorphisms of the dopamine P1042 mitochondrial protein causing Parkinson’s a novel Identification of PARK6, P1043 Clinical and molecular genetic analysis of hereditary dopa-responsive P1044 Genome-wide microsatellite association studies for sporadic Parkinson’s P1045 A novel mutation causing exon skipping within the epsilon-sarcoglycan P1046 Clinical and genetic study of parkin disease in a large sample set P1047 Mutational analysis of divalent metal transporter 1 in restless legs P1048further genetic locus heterogeneity in restless legs syndrome Evidence for P1049 Effect of l-dopa and subthalamic surgery on proprioception in Parkinson’s P1034 features and neuropsychological PET ataxia in a case of spinocerebellar P1035 Prenatal diagnosis dominant hereditary of autosomal spastic paraplegia P1036 neurotrophic factor polymorphism of the brain derived Val66Met The P1037 LA) with family (Family Restless legs syndrome (RLS) in a large P1038 disease in European families is not linked with Parkinson’s PARK11 P1039 Definition of the tau gene haplotype block that is associated with P1040 An English family with a dominantly inherited PSP-like illness, genetic in a Brazilian and Turkish in a Brazilian and Parkin , JUNE 17 , JUNE 17 , JUNE , JUNE 17 , JUNE , JUNE 17 , JUNE 17 , JUNE Y Y Y Y Y repeat expansions in the FMR1 gene disease polymorphisms on the risk for Parkinson’s observational study (PHAROS) Lewy body dementia Parkinson disease Parkinson disease Parkinson’s Parkinson’s disease Parkinson’s the essential tremor is responsible of the most common familial form of desease disease in Koreans M.-C. Chartier-Harlin, J. Kachergus, C. Roumier, P. Amouyel, M. Farrer, A. Farrer, M. Amouyel, P. Roumier, C. Kachergus, J. Chartier-Harlin, M.-C. Destee A. Håkansson, L. Westberg, H. Niazi Shahabi, S. Nilsson, E. Eriksson, H. Eriksson, E. Nilsson, S. Niazi Shahabi, H. Westberg, L. Håkansson, A. Nissbrandt C. Kamm, K. Buerk, T. Illig, E. Wichmann, European Multiple System Atrophy European Multiple System Wichmann, E. Illig, T. Buerk, K. Kamm, C. Gasser T. (EMSA) Study Group, A.E. Ashley-Koch, L. Zhang, J.M. Stajich, S. West, M.A. Pericak-Vance, J.R. M.A. Pericak-Vance, West, Zhang, L. Stajich, Ashley-Koch, J.M. S. A.E. Gilbert E.P. Kayson, Huntington Study Group/PHAROS Investigators Kayson, E.P. J. Campdelacreu, M. Ezquerra, E. Muñoz, M.J. Marti, F. Valldeoriola, E. Tolosa E. Valldeoriola, F. Marti, M.J. Muñoz, E. Ezquerra, M. Campdelacreu, J. J. Alegre, J.J. Zarranz, J. Hoenicka, J.C. Gomez Esteban, J. G de Yebenes, E. Yebenes, G de J. Gomez Esteban, J.C. Hoenicka, J. Zarranz, J.J. Alegre, J. Lezcano E. Tan, K. Tang, C. Tan, Y. Zhao, Chong, S. Lee C. Y. Tan, C. Tang, K. Tan, E. Garcia-de- J. Benavides, J. Sanchez, M. Mena, M. Gallego, E. Serrano, A. Yebenes J. Clarimon, A. Singleton, J. Johnson, N.W. Wood, O. Dugu, A.J. A.J. Lees Dugu, Wood, O. Singleton, A. J. J. N.W. Johnson, Clarimon, L.E. Hjermind, L.G. Johannsen, R.A. Wevers, N. Blau, L. Friberg, L. Regeur L. Friberg, L. Blau, N. Wevers, R.A. Johannsen, L.G. Hjermind, L.E. M. Ezquerra, J. Campdelacreu, E. Munnoz, M. Marti, F. Valldoriola, E. Tolosa E. Valldoriola, F. Marti, M. Munnoz, E. Campdelacreu, J. Ezquerra, M. Bracco F. Tagliavini, Albanese, F. A. Scaravilli, T. Gasparoli, E. G. Rossi, G. Lucotte, B. Funalot, P. Sokoloff P. Funalot, B. Lucotte, G. A. Kishore, R. H.M., A. Anand A. H.M., R. Kishore, A. J.-J. Lin, K.-C. Yueh K.-C. Lin, J.-J. J.-S. Kim, C. Song, I. Yoon, Y.-I. Kim, S.-B. Ko, K.-S. Lee K.-S. Ko, S.-B. Kim, Y.-I. Yoon, I. Song, C. Kim, J.-S. families due to independent events THURSDA THURSDA P1033 disease locus duplication causes familial Parkinson’s alpha-synuclein P1032 receptor beta gene Combined effect of interleukin-6 and estrogen P1031 Screening of a large cohort of patients with atypical parkinsonism for P1029 the Prospective Huntington at The welfare of research participants in risk P1030 for a novel essential tremor locus A genomic screen P1028 palsy progressive supranuclear Analysis of CRHR1 and NSF genes in P1027 insomnia and causes Parkinson, -synuclein of E46K, The new mutation, P1026 Motor behaviour of parkin knock out mice P1025 disease MDR1 haplotype analysis in Parkinson’s P1023 disease A patient with dopa-responsive dystonia and juvenile Parkinson’s P1024 deletion of the exon 4 in the Homozygous P1022 A new mutation in the tau gene in a family with PSP-like syndrome and P1021 Association gene polymorphism with of a dopamine D2 receptor P1020 gene Allele 2 of the Ser9Gly polymorphism in the dopamine D3 receptor P1018 to receptor polymorphism and genetic susceptibility A CD14 monocyte P1019 among South Indians disease in early-onset Parkinson’s mutations Parkin P1017 Association vitamin D receptor gene polymorphism and Parkinson’s of Genetics 1017-1072 Poster numbers THURSDA pm 8:30 am to 4:30 Poster Viewing: to 1:00 pm 12:00 pm Present Odd Numbers: Authors to 2:00 pm 1:00 pm Present Even Numbers: Authors POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER THURSDA THURSDA POSTER SESSION 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER 84 Rome, Italy 17 Asinglecycle therapycanstopprogressionof of ironchelation P1071 Thecontribution ofPARK2 toParkinson’s disease, genetic a population P1070 genotypetoinfluencethecourseofParkinson’s acetylation Slow disease? P1069 EgeneandParkinson’s Apolipoprotein diseaseinRussianpopulation P1068 genesforParkinson ofcandidate Identification disease(PD)usinggenetic P1067 Theroleoftheepsilon-sarcoglycangene(SGCE)in Gilles dela Tourette P1066 confirmelevatedfrequencyofrestlesslegs Blindeddiagnoses in relatives P1065 Aconsanguineous Turkish familywithearly-onsetParkinson’s disease P1064 ageneforParkinson’s Mapping diseaseinNorway P1063 inthe Analysisofpolyglutamine-codingrepeats TATA-binding proteinin P1062 ofalargeBrazilianfamilywithearly-onset Clinicalandgenealogicalstudy P1061 Analysisofpolymorphismsin APOE, ACE, alpha-synuclein and Tau genes P1060 Fronto-temporal dementiasyndromewithparkinsonismina Colombian P1059 ofPark2 affected byearly-onset Molecularstudy genein266patients P1058 Familial clustering isolatein ofrestlesslegssyndromeinapopulation P1057 toidentifygene(s)associatedwithage- map Chromosome1association P1056 PARK6-linked autosomalrecessive early-onsetparkinsonisminEuropean P1055 inessentialtremorandspinocerebellar TheroleforFragile Xpremutation P1054 dystonia Adultonsethereditary P1053 Parkin inautosomalrecessiveearly-onsetparkinsonism(AR- mutations P1052 THE M. Pandolfo, I. Haemers, S. Goldman P.M. Abou-sleiman, D.G. Healy, K.K. Ahmadi, D.B. Goldstein, N.W. Wood G. Duda, G. Opala, T. Wilczok, B. Jasinska-Myga, J. Samelska, M. Bialecka T.B. Zagorovskaya, M.A. Hauser, M. Noureddine, C.M. Hulette, L. Yi-Ju, S. Clemens, J.M. Vance Gasser F. Asmus, S. Schoenian,P. Lichtner, B. Mueller-Myhsok, O. Bandmann, T. W.A.Hening, W. Mystinna, A.P. Earley E.J.Suzanne,L.Richard, O. Dogu, J. Johnson, D.G. Hernandez, M. Hanson, J. Hardy, H. Apaydin M. Toft,L.Skipper, M.Hulihan,J. Aasly, M.Farrer Y.-R.Fung Lee-Chen,H.-C.G.-J.Chen,C.-M. Wu, H. Chien, M. Costa, V. Bonifati, E. Barbosa Benitez,D.B.Forero,C. Alvarez,G. Arango, W.Fernandez,H. Arboleda Pena,M.Lozano,Duarte,J.N. W. Fernandez,G. Arboleda, H. Arboleda D. Ghezzi, F. Invernizzi, E. Marelli, M. Zeviani, B. Garavaglia I. Pichler, S. Maniak, F.D. Vogl, G. Casari, K. Christine, P.P. Pramstaller Oliveira,L.S.A.P.-V.A. Yi-Ju,Q.Xuejun, Margaret, V.M. Jeffery Y.Hatano, T. K.Sato,Shimazaki, V. N.Hattori,Bonifati, Y. Mizuno E. DiMaria, M. Grasso, G. Abbruzzese, P. Mandich, S. Ratto, R. Sciolla K.P. Frei, M. Pathak, P. Pham, D.D. Truong H.Hattori,N. Yoshino, Y.Imamichi, Y.Miuzno aceruloplasminemia forasustainedperiod oftime based study andgeneexpressioninthesubstantianigra linkage patients ofRLS syndrome (RLS)probandsinacase-controlfamilystudy and anexon4 diseases different neurodegenerative Parkinson’s disease Colombia intheParkinand screeningofmutations geneinParkinson’s diseasein family withE280Apresenilin-1mutation Parkinson disease South Tyrol (NorthernItaly) andriskforParkinsonat-onset disease populations and Asian ataxia: Findings fromtwocohortsofItalianpatients EP) MOVEMENT Parkin I.A. Ivanova-Smolenskaya, S.N. Illarioshkin, E.D. Markova deletion DISORDERSOCIETY 17 Voxel basedanalysisof[ P1077 dopamineD2receptorfunctionmeasuredbyinvivo[ Striatal P1076 Asymmetriclossofdopaminetransportersintremor-predominant hemi- P1075 Perfsuion-weighted with imaging Tc-SPECT orperfusion-weightedMRIin P1074 afterdopaminergic ReversibiltyofD2dopaminereceptordownregulation P1073 Poster numbers1073-1130 Neuroimaging in GlutathioneS-transferaseP1andZ1allelesinfluenceonsetage P1072 18 Brainstem P1087 Choreaassociatedwithnon-ketosichyperglycaemia andhiperintensityin P1086 in ontheroleofsigma-receptorsindopa-induced dyskinesia APETstudy P1085 Changesincorticalmotoractivityinducedbylevodopaadministration P1084 Dopaminetransporterimaging(b-CIT-SPECT) indisulfiram-induced P1083 ComparisonofFP-CITSPECTscanswithF-DopaPETinasimilar P1082 CerebralglucosemetabolismanddopaminetransporterPETinSCA P1081 SuperiorCerebellarPeduncle (SCP)volumemeasurementonMRI P1080 withbrainstemlesions limbmovementsinpatients Repetitiveinvoluntary P1079 ofmotortiminginParkinson’s Neuralcorrelates diseaseandtheeffectof P1078 Parkinson’s diseasefrommultiplesystematrophy S.W. Scholz, E. Y.-M. Shon, J.-S. Kim, Y.-A. Chung, K.-S. Lee F. Hertel, C. Walter, M. Schmitt, M. Moersdorf, M. Bettag, W. Jammers S. Thobois, P. Pollak, F. Vingerhoets, P. Mertens, A.-L. Benabid, E. Broussolle Papapetropoulos, L.I. Golbe, G. DiIorio, K.M. Markopoulou, A. Athanassiadou, S. L. Hanoglu, H. Meral, F. Ozer, A. Dincer V. Puente, C. Oliveras, I. Volmer, J. Jimenez, N. Segura T.Nimura, T. K. Ando, Yamaguchi,Itoh,M.Shirane,R. T. Tominaga C. Brefel-Courbon, P. Payoux, J. Azulay, F. Durif, F. Tison, O. Rascol F. Tison, F. Macia, E. Bertandeau, M. Guyot, E. Bussy, M. Allard S.A. Eshuis, P. Jager, R.P. K.L. Maguire, Leenders U. Wüllner, M. Reimold, K. Bürk, M. Abele, M. Minnerop, H.-J. Machulla D.C. Paviour, S.L. Price, J. Stevens, A.J. Lees, N.C. Fox P. Lee, J. Lee, D. Shin, K. Huh M. Jahanshahi, C. Jones, J. Zijlmans, R. Katzenschalger, C. Frith, N. Quinn C. Scherfler, K. Seppi, E. Donnemiller, W. Poewe, G.K. Wenning behavioural disorders behavioural Parkinson’s disease with gaitdisorderscausedbynormalpressurehydrocephalus ofpatients withaspinaltaptestishelpfulinthediagnosis combination [ disease: A andsubthalamicnucleus inParkinson’streatment withdrawal stimulation Parkinson’s diseasecausedbythe symptoms andimages basal gangliaon T1-weighted MRI. Presentationofacasewithbilateral withadvancedParkinsonpatients disease cerebellar multiplesystematrophy: study A positronemission tomography striatal damage disease ofParkinson’sgroup ofpatientswithdenovoandadvancedstages (MSA),atrophy Parkinson’s disease(PD)andcontrols differentiates progressivesupranuclear palsy(PSP)frommultiplesystem human involving pontinetegmentum: regionin Evidenceforpontineinhibitory studiedwithPET apomorphine sized spiny neurons sized spiny medium- ofstriatal pinhole SPECTcorrelateswithex-vivoquantification [1] 11 H-MRSinParkinson with andwithoutREMsleep patients C]-Raclopride PETstudy Donnemiller, R. Moncayo, W. P R.L. Watts 123 POSTER SESSION4 POSTER SESSION4 I] bð-CITSPECTdistinguishesidiopathic POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 α -synuclein A53T mutation -synuclein A53T oewe, G.K. Wenning, C. Scherfler 123 I]-IBZM 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 85 I In 123 F-DOPA 18 C-MP and regulatory changes in 11 Co striatal phantom to reduce the variance of quantitative 57 study of MRI-related heating at and implications 1.5 tesla for vitro dopamine transporter imaging in Parkinson’s disease in Parkinson’s Nyhan disease and its variants longitudinal PET study syndromes by voxel-based magnetization transfer imaging Evidence for aging effects in subjects before 45 years of age system VBM A atrophy: study MRI T2* weighted coronal section of disease patientsVim DBS treated with during motor and vocal tics in patients with Tourette syndrome: An event- syndrome: Tourette in patientsduring motor and vocal tics with related functional MRI study manifestation?An early predictor of disease parkin mutation carriers - A preliminary report Lewy bodies (DLB): (MSA) A PD: imaging during surgery in Parkinson’s disease imaging surgery during in Parkinson’s E. Kraft, W. Loichinger, M. Diepers, W. Becker, J. Schwarz, A. Storch A. J. Schwarz, Becker, W. Diepers, M. Loichinger, W. E. Kraft, Wong D.F. Puig, J.G. Torres, R.J. Schretlen, D.J. Harris, J.C. Jinnah, H.A. J.P. Seibyl, I.G. Zubal, P. Barone, W. Oertel, W. Poewe, Tolosa E. Poewe, W. Oertel, W. Barone, Seibyl, P. I.G. Zubal, J.P. Lang A.E. A. Dagher, Poon, Y.-Y.W. A.M. Strafella, Lozano, Moro, E. A.P. Stoessl A.J. D.B. Calne, Ruth, T.J. Sossi, V. Schulzer, Au, M. W. Eckert T. Heinze, H.-J. Dengler, R. Schrader, C. Kaufmann, J. Peschel, T. A.J. Stoessl Ruth, D.B. Calne, T.J. Sossi, V. M. Schulzer, Troiano, A.R. A.O. Ceballos-Baumann Alesch, Boecker, H. K. F. Kalteis, B. Haslinger, Yen T.-C. Lu, C.-S. Weng, Y.-H. Poewe W. Wenning, G.K. Schocke, M. Seppi, K. Egger, K. Brenneis, C. Itoyama Y. Iwasaki, Y. Mochizuki, H. Fukatsu, R. Hisanaga, K. Oikawa, T. Eidelberg D. Fodstad, H. Okulski, J. Dhawan, V. Simon, E.S. Trošt, M. R. Bhidayasiri, J.M. Bronstein, S.S. Sinha, S. Ahn, E.J. Benhke, M.S. Cohen M.S. Benhke, E.J. Ahn, S. Sinha, S.S. Bronstein, J.M. Bhidayasiri, R. Leenders K. den Boer, J. Kortekaas, R. Maguire, R. Keitz, M. Hallett M. Kansaku, K. Garraux, G. Matteson, S. Goldfine, A. Bohlhalter, S. Toni I. Bloem, B.R. De Lange, F.P. Helmich, R.C. Dressler D. Pramstaller, P.P. Benecke, R. Hilker, R. Klein, C. Walter, U. Hershey Wack, L.A. D. K. Wray, Marton, Bednarczyk, E.M. L. D.G. Lichter, Karsten S. Minnerop, M. Klockgether, T. P1124 anatomy on the functional of bimanual movements The effect of L-DOPA P1125 PET imagingdopamine transporters in Lesch- reveals profound loss of P1115A PET study pallidus stimulation: disease and globus Huntington’s P1116A four year disease: Aging effect on the rate of progression in Parkinson’s P1117 of neuropathological In vivo detection changes in different parkinsonian P1118 disease: PET tracers for dopamine terminals in Parkinson’s Comparison of P1119 cortex disease modulates motor Subthalamic stimulation in Parkinson’s P1120 The aging process of dopamine tansporter is faster in younger healthy P1121 Supra- and infratentorial atrophy in the cerebellar variant of multiple P1122 Discrimination disease using of multiple system atrophy from Parkinson P1123 Clinical and metabolic brain changes in tremor predominant Parkinson’s P1107 Bilateral neurostimulation brain stimulation: systems used for deep P1108 processing – an fMRI study recognition and motor response Reward, P1109 activated insula and parietal operculum commonly Anterior cingulate, P1110 disease Body and motor imagery posture in Parkinson’s P1111nigra hyperechogenicity in asymptomatic Substantia and symptomatic P1112to galantamine in dementia with Brain metabolic and clinical response P1113Application to multiple system atrophy relaxometry Voxel-based (VBR): P1114 a multi-center imaging network for AMADEUS consortium, Developing the I] FP-CIT study 123 C]dihydrotetrabenazine and positron 11 emission tomography PSP, PD and MSA using MRI PSP, disease Wilson’s neurological symptoms in FDG PET disease Parkinson’ in Parkinson’s disease in Parkinson’s Parkinson’s disease: A follow-up FDOPA-PET studyA follow-up FDOPA-PET disease: Parkinson’s system atrophy activity in frontotemporal dementia and parkinsonism linked to chromo- activity in frontotemporal dementia and parkinsonism some 17 syndrome Tourette’s patients with Parkinson’s disease Parkinson’s Lewy bodies detected with [ type 2 and type 3 but not idiopathic Palsy stem structures in Progressive Supranuclear disease Parkinson’s medulla compression and hypertension in Hemifacial Spasm medulla compression and powerful to differentiate idiopathic Parkinson’s disease (IPD), multiple disease (IPD), powerful to differentiate idiopathic Parkinson’s system atrophy palsy (PSP) (MSA) and progressive supranuclear U. Walter, K. Krolikowski, B. Tarnacka, R. Benecke, A. A. Czlonkowska, R. Dressler D. Benecke, Tarnacka, Krolikowski, K. B. Walter, U. S.L. Price, D.C. Paviour, R.I. Scahill, J.M. Stevens, A.J. Lees, N.C. Fox N.C. Lees, A.J. Stevens, J.M. Scahill, R.I. Paviour, D.C. Price, S.L. Y. Osaki, Y. Morita, M. Fukumoto, N. Akagi, S. Yoshida, Y. Doi Y. Yoshida, Akagi, S. Fukumoto, Morita, M. N. Y. Osaki, Y. T. Eckert, A. Barnes, S. Frucht, V. Dhawan, A. Feigin, D. Eidelberg D. Feigin, A. Dhawan, V. A. Frucht, S. Barnes, Eckert, T. R. Cunnington, L. Carabott, G. Egan, R. Iansek Remy P. Hantraye, P. Bachoud-Lévi, A.-C. Maroy, R. Ribeiro, M.-J. Douaud, G. E. Lee, H. Cho, S. Kim, W. Lee W. Kim, S. Cho, H. Lee, E. A.T. Portman, T. van Laar, R.P. Maguire, M.J. Staal, J. Pruim, K.L. Leenders K.L. Pruim, J. Staal, M.J. Maguire, R.P. van Laar, T. Portman, A.T. Leenders K.L. Koning, M. Pruim, J. Maguire, R.P. Portman, A.T. van Beilen, M. A. Lerner, E. Boudreau, A. Bagic, T. Hanakawa, D. Murphy, M. Hallett M. Murphy, D. Hanakawa, T. Bagic, A. Boudreau, E. Lerner, A. S. Hirano, H. Shinotoh, T. Kobayashi, Y. Tsuboi, Z.K. Wszolek, A. Aotsuka A. Wszolek, Z.K. Tsuboi, Y. Kobayashi, T. S. H. Hirano, Shinotoh, S. Gilman, K.A. Frey, R.A. Koeppe, R.L. Albin, L. Junck, M. Heumann M. Junck, L. Albin, R.L. Koeppe, R.A. Frey, K.A. Gilman, S. F. Yoshii, N. Namai, K. Hatakeyama, T. Shimizu, H. Takahashi, Y. Shinohara Y. Takahashi, Shimizu, H. Hatakeyama, T. K. Namai, N. Yoshii, F. C.R. Blain, G.J. Barker, J.M. Jarosz, S.C. Williams, P.N. Leigh P.N. Williams, S.C. Jarosz, J.M. Barker, G.J. Blain, C.R. J.-Y. Li, C.-S. Liu, P.-H. Lai, P.-C. Chen P.-C. Lai, P.-H. Liu, C.-S. Li, J.-Y. L. Chan, E. Tan, W. Lim W. Tan, L. Chan, E. M. Wieler, C. Hanstock, W. Martin W. Hanstock, C. Wieler, M. V.L. Marshall, W.H. Oertel, D.M. Hadley, O. Pogarell, A. Gerstner, D.G. Grosset D.G. Gerstner, A. Pogarell, O. Hadley, D.M. Oertel, W.H. Marshall, V.L. Y. Rolland, B. Bruneau, M. Verin, C. Payan, G. Bensimon, the NNIPPS Study the NNIPPS Bensimon, G. Payan, C. Verin, M. Bruneau, B. Rolland, Y. Group P1105 VBM as a tool to identify regions which may aid differential diagnosis of P1106 correlates lentiformis hyperechogenicity Nucleus with severity of P1104 Three dimensional streotactic surface projection SPECT analysis in P1103The diagnostic value of Differential diagnosis of parkinsonian disorders - P1102 disease patients Quantifying striatal atrophy in Huntington’s P1101 increases activation Attention to action of the supplementary motor area P1099 advanced PD PET and cognition in Striatal uptake measured with FDOPA P1100 Comparison of magneticimaging resonance in subtypes of multiple P1098 Assessment of the nigrostriatal pathway after STN-DBS in advanced P1097 Neuroimaging of neuronal circuits involved in generation of tics in P1096 emission tomographic measurement of acetylcholinesterase Positron P1095 disease and dementia with Differences between idiopathic Parkinson’s P1094 Regional cerebral blood flowactive music therapy during in patients with P1093 Imaging demonstrates brain differential involvement of Tensor Diffusion P1092 Magnetic resonance spectroscopy in patients ataxia with spinocerebellar P1090 disease Brain energy metabolism in Huntington’s P1091 evaluationTOF MRA of rostral ventro-lateral 3-Dimensional MR CISS and P1089 an [ disease, early Parkinson’s Progression of P1088 Brainstem atrophy by magnetic quantification imaging resonance (MRI) is POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER 86 Rome, Italy P1143 The diagnosis and management ofpergolide-inducedfibrosis and management Thediagnosis P1143 Thedopamine stabiliser in ACR16 preventsL-dopa-inducedsensitisation P1142 5(mGlu5)receptorantagonist-induced Metabotropicglutamate P1141 Cabergoline, adopamineagonist, prevent levodopa-induced abnormal P1140 DesipramineincreasesL-DOPA-derived extracellulardopamineinthe P1139 dosesofbotulinumtoxinin100 Shortandlongtermeffectoflow Tunisian P1138 LevodoparaisespainthresholdinParkinson’s disease: A clinical and P1137 PlasmahomocysteineParkinson’s levelsinpergolidetreated disease P1136 L- increasesandextendsstriataldopaminereleasefollowing Entacapone P1135 Deleteriouseffectsofminocycline inanimalmodelsofParkinson’s P1134 onL-dopaabsorption LongtermeffectsofHelicobacterpylorieradication P1133 Dopamineandadenosinereceptorinteractionasbasisforthetreatment P1132 Effectsofriluzoleas “rescue therapy” inaMPTP+3-NPmousemodelof P1131 Poster numbers1131-1166 Neuropharmacology MRIanddeepbrainstimulation: considerations Safety-related P1130 [123-I] P1129 thediagnosticaccuracy Evaluating of[123-I] P1128 withParkinson’s Changesofglucosemetabolisminpatients diseasewith P1127 abnormalitiesinbasalgangliafronotemporaldementia? Areany A P1126 THE parkinsonian syndrome potentiated byan potentiated A P.Fahn,S.J. Agarwal,S.Frucht H.Ponten, Carlsson,N.J.Kullingsjo,C. A.Sonesson,J. Waters, Tedroff A. Kachroo, D.K. Grandy, J.-F. Chen, L. Orlando, M.A. Schwarzschild K.-I. Tanaka,Ogawa N. A. Arai, K. Kannari, H. Shen, M. Baba, M. Matsunaga N. Gouider-Khouja, G. ElEuch, I. Turki, S. Chebel, F. Hentati Rascol C. Brefel-Courbon, P. Payoux, C. Thalamas, M. Galitzky, J. Montastruc, O. S. Ozkan, O. Colak, C. Kutlu, M. Ertan, O. Alatas M. Gerlach, M. vandenBuuse, C. Blaha, D. Bremen, P. Riederer E.Diguet, P.-O. Fernagut,X. Wei, Y. Du, E. Bezard, F. Tison L. Brusa, A. Pietroiusti, M. Pierantozzi, S. Galati, E. Fedele, P. Stanzione Morelli,M. A.R.Carta,P. Annalisa, T.Nicola Elisabetta,S. E.Diguet, P.-O. Fernagut, C.Scherfler, G. Wenning, F. Tison K.B.Baker, Nyenhuis,J.A.J. Tkach, A.Sharan,F.G. Shellock, A.R.Rezai D.L. Jennings, J.P. Seibyl, R. Tabamo, K. Marek D.L. Jennings, J.P. Seibyl, R. Tabamo, K. Marek T. Eckert, A. Barnes, S. Frucht, V. Dhawan, M.F. Gordon, D. Eidelberg Karageorgiou Sifakis,P.N.J.Papatriantafyllou, Zikos, V.Kontoyanni, T. C. Visviki, the 6-OHDA-lesionedrat locomotion requiresadenosine A content andinhibitionofcaspaseactivitiesin6-OHDA-lesionedmice mainlyduetoincreaseofglutathione increase oflipidperoxidation of6-hydroxydopamine-lesionedrats striatum overan8-yearperiod patients study positron emissiontomography patients DOPA/benserazide intherat treatment disease andHuntington’s disease in Parkinson’s diseasepatients of Parkinson’s disease system atrophy degeneration: Experimentalrationaleforitsuseinmultiple striatonigral disease duration (SPECT) withioflupane(I123-FP-CIT) throughsinglephotonemissioncomputedtomography study preliminary MOVEMENT β -CIT and SPECT as a diagnostic tool in lower bodyparkinsonism toolinlower -CIT andSPECTasadiagnostic 2A antagonist DISORDERSOCIETY 2A anddopamineD β -CIT andSPECTin 2 receptorsandis 15 Open-label, doseescalation, ofBotulinum safetystudy Toxin Type B P1150 Effectsof P1149 Asimple P1148 Effectofzolpidemonparkinsoniansymptomsinpatientswithadvanced P1147 ModulationofhistamineH3receptor-mediated transmissionintheMPTP- P1146 Treatment ina ofrestlesslegssyndromewithsubcutaneousapomorphine P1145 androdent junctionblockadeintheMPTP-lesionedprimate Effectsofgap P1144 16 Aripiprazolein the treatmentofmovementdisorders P1162 Changesin neuroendocrineresponsetoL-DOPA duringlongterm P1161 effectatthe endofa12week Doubleblindevaluationofsymptomatic P1160 Effectof(–)-BPAP ontheexpressionofneurotrophinsandtheirreceptors P1159 synthesisandsecretionofneurotrophicfactors by Cabergolinestimulates P1158 Continousstimulation: of levodopa/carbidopawith Supplementation P1157 Ahighthroughputscreeningassayforidentifying potential P1156 Threecasesofperipheraledemacausedbyprolongeduseropinirole P1155 Tetrabenazine inhyperkineticmovementdisorders treatment P1154 modeloftardive TheeffectsofNMDAreceptorantagonisminarat P1153 proteins, Subcellularre-distributionofthesynapse-associated PSD95and P1152 Levodopaforchronicneckpain: A cross-overdoubleblind, placebo P1151 R.M. Trosch,C.H. Adler T. Johnston, J.M. Brotchie T. Johnston, J. Lee, J. Gomez-Ramirez, S.H.Fox, J.M. Brotchie G.A. Tagaris,V. P.Sakkou, Zikos,P. A.Sarafianos, Karageorgiou C.E. Vrentas, J. Gomez-Ramirez, J. Lee, T. Johnston, S.H.Fox, J.M. Brotchie T.Tings,Stiens, G. W. Paulus,C. Trenkwalder, Happe S. J. Lee, J. Gomez-Ramirez, T. Johnston, P. Carlen, A.E. Lang, J.M. Brotchie M.S. Eisa,B.Jabbari D. Garcia-Borreguero, R. Egatz, O. Larrosa, C. Serrano M.Onofrj, A. P. Thomas, Fabbrini,G.FarielloNordera,R.Sala,G. K.S.Shimazu, Takahata, F.Hayashi,Hirami,K.C. Yoneda, A. Akaike S.A.Kuno,K.Ohta, A.Fujinami, Sakakimoto, A. Y. M.Ohta Kitaura, T. Muller, J. Welnic, N. Meisel, S. Muhlack, D. Woitalla, D. Bremen J.E. Nash, S.Y. Lee, S. Kalia, A.M. Lozano D.P.J.Srinivasan, Apetauerova, Gross D. Paleacu, N. Giladi, O. Moore, M. Stein, S. Honigman, S. Badarny C. Tsironis,D.Kiortsis, A.Evangelou,S.Konitsiotis J.E. Nash, J. Gomez-Ramirez, G.L. Collingridge, C.C. Garner, J.M. Brotchie M. Marziniak, V. Guralnik, U. Dillmann, G. Becker (MYOBLOC™) inpatientswithHemifacialSpasm Parkinson’s disease dyskinesia lesioned non-humanprimateandrodentmodelsofL-DOPA-induced withshortbowlsyndrome patient models ofL-DOPA-induced dyskinesia treatment inrestlesslegssyndromeaugmentation treatment withsafinamide, anewneuroprotectant in mesencephalicslicecultures primary culturedneuronsorastrocytes entacapone reducesmovementfluctuations neuroprotective agentsinParkinson’s disease dyskinesia dyskinesia SAP97 inanimalmodelsofParkinson’s diseaseandL-DOPA-induced controlled study for L-DOPA-induced dyskinesia complications antagonist, idazoxan, onthedevelopmentofL-DOPA-induced motor in vivo in de novo de assayintherodentforidentifyingnoveldrugtherapies treatment withthealpha-2adrenergicreceptor treatment POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 87 subthalamic stimulation disorder in Sydenham Chorea sign clinical preliminary study disease Parkinson’s disease bladder function in Parkinson’s disease? aggravate apathy in Parkinson’s degeneration impact on activities of daily living impulsivity in Tourette syndrome Tourette impulsivity in disease ranging from early to advanced disease symptoms in Parkinson’s MSA; long-term follow-up data and safety on the efficacy disease Parkinson’s results M.-A. Bedard, F. Paquet, S. Chouinard, P. Blanchet, V. Soland, J. Filion J. Soland, V. Blanchet, P. Chouinard, S. Paquet, F. Bedard, M.-A. Burn D.J. McKeith, I.G. O’Brien, J.T. Molloy, S.A. Lang A.E. Moro, E. Lozano, A.M. J.A. Saint-Cyr, Voon, V. R.G. Beato, F.E. Cardoso F.E. Beato, R.G. Teixeira A.L. M.C. Cardoso, Cunningham, F.E. Maia, D.P. Levin O.S. Makedonsky, P.V. Leiguarda R. Merello, M. Manes, F. Russo, G. Aveleyra, C. Mansur L.L. Barbosa, E.R. Radanovic, M. Haddad, M.S. Azambuja, M.J. Kostic V. Maksimovic, A. Dragasevic, N. Ziropadja, L. Potrebic, A. E. Stefanova, Stimpel H. Nielsen, K.K. Werdelin, L. Friberg, L. Winge, K. Arnold G. Jordan, J. Lipp, A. Agid Y. Mesnages, V. Welter, Czernecki, B. M.-L. Houeto, J.-L. Pillon, V. Toso V. Sgaramella, L. Bartolomei, T. C. Monaca, C. Laloux, R. Bordet, L. Defebvre, A. Destee, P. Derambure P. Destee, A. Defebvre, L. Bordet, R. Laloux, C. Monaca, C. Chouinard S. Rouleau, G. Marti, S. Thibeault, M. Richer, F. Dowling, J.L. Schneider-Gibson, J.S. P. Wernle, A. Revilla, F.J. Hershey, T. Perlmutter K.E. Lyons Tanner, R. C.M. Pahwa, Tröster, A.I. Kupsch A. Ebersbach, G. Kopp, U.A. Wodarz, F. Hälbig, T.D. Chaudhuri K.R. Chris, C. Linda, K. Frauke, S. Alison, F. Gulati, A. Leenders K.L. Heesters, M.A. van Laar, T. Stochhi F. Meoli, I. Iannella, C. De Simone, G. Stefanelli, F. De Pandis, M. P1201 ascertain the effect of levodopa on mood in parkinsonism To P1202 disease patients presenting for Neuropsychiatric symptoms in Parkinson’s P1191 Obsessive-compulsive behavior and hyperactivity and attention deficit P1192 in patients Affective disturbances and quality of life with essential tremor P1193A useful early Defective imitation of limb gestures in Lewy body dementia: P1194A disease: in Huntington’s letter and action fluency Comparing semantic, P1195 Depression predicts the pattern of cognitive impairment in early P1196 The result of dopaminergic degeneration on and the effects of medication P1197 Osmolarity depended effect of water on blood pressure P1198 Does bilateral stimulation high-frequency of the subthalamic nucleus P1199 Cognitive initial symptoms and disease progression in cortico-basal P1200 Its prevalence and direct disease: The frontal syndrome in Parkinson’s P1182 mice the MPTP states Vigilance model, in a parkinsonian P1183 Anticipatory in rapid responses motor as a measure of stimulus streams P1184cognitive control during deep brain stimulation Decreased STN of the P1185 Questionnaire (QUEST) Tremor Validation of the Quality of Life in Essential P1186 disease Emotional memory in Parkinson’s P1187clinical observational A study of the pattern of non-motor and occurrence P1188 disease and Radiotherapy as treatment of hypersalivation in Parkinson’s P1189 Modification of respiratory parameters in patients function with severe P1190 Preliminary chorea: in adult patients Cognitive function Sydenham’s with opioid receptors in the anti- opioid receptors 2 and delta 1 Trieschmann, J.H. Friedman J.H. Trieschmann, parkinsonian actions of the delta opioid receptor agonist actions of the delta opioid parkinsonian in the SNC80 reserpine-treated rat in Parkinson’s disease in Parkinson’s practice disease-specific instrument for use in research and clinical Parkinson’s disease Parkinson’s supranuclear palsy supranuclear dementia C) manifestations of the disease? Preliminary experience history of drug-induced psychosis accompanied by dystonia in MPTP-lesioned non-human primates previously treated with L-DOPA botulinum toxin, type A (Botox) and botulinum toxin, type B (Myobloc) on toxin, A (Botox) and botulinum type botulinum toxin, symptoms and physiologysystemic and ocular autonomic in patients with cervical dystonia dyskinesia macaque in the MPTP-lesioned K. Haugarvoll, D. AArsland, J.P. Larsen J.P. AArsland, D. Haugarvoll, K. Wessley S.C. Findley, L. Dittner, A. Brown, R.G. A. Gulati, A. Forbes, F. Stegie, C. Clough, R.K. Chaudhuri R.K. Clough, C. Stegie, F. Forbes, A. Gulati, A. A. Funkiewiez, C. Ardouin, P. Krack, B. Dubois, A.-L. Benabid, P. Pollak P. Benabid, A.-L. Dubois, B. Krack, P. Ardouin, C. Funkiewiez, A. Marks W.J. C.M. Heinks, L.O. Fox, Ramig, T. S. Houde, Nagarajan, J.F. J.B. Leverenz, D.W. Tsuang, E.B. Larson, T. Montine, M. Kraybill, D. D. Nochlin Kraybill, Montine, M. T. Larson, E.B. Tsuang, D.W. Leverenz, J.B. J. Fielding, N. Georgiou_Karistianis, L. Millist, A. Churchyard, E. Chiu, O. White O. Chiu, E. Churchyard, A. Millist, L. Georgiou_Karistianis, N. Fielding, J. N.J. Cordato, C. Pantelis, D. Caine, D. Velakoulis, S.J. Wood, J.G. Morris J.G. Wood, S.J. Velakoulis, D. Caine, D. Pantelis, C. Cordato, N.J. C.C. Juri, P.C. Chana, T.J. Parrao, J.N. Tapia, C.R. Kunstmann, D.S. Kunstmann, C.R. Tapia, J.N. Parrao, T.J. Chana, P.C. Juri, C.C. Alburquenque K. Bürk, C. Globas, I. Daum J. Roth, M. Preiss, J. Klempir, H. Brozova, O. Ulomanova, E. Ruzicka E. Ulomanova, O. Brozova, H. Klempir, J. Preiss, M. Roth, J. P. Blumen, S.C. Carasso, R.L. Schechtman, E. Paleacu, D. Inzelberg, R. Nisipeanu A. Chatterjee, E.C. Jurewicz, L.M. Applegate, E.D. Louis E.D. Applegate, L.M. Jurewicz, E.C. Chatterjee, A. H.H. Fernandez, M.E. Trieschmann, M.S. Okun M.S. Trieschmann, M.E. Fernandez, H.H. H.H. Fernandez, M.E. M.E. Fernandez, H.H. T. Johnston, S.H. Fox, J. Gomez-Ramirez, J. Lee, J.M. Brotchie J.M. Lee, J. Gomez-Ramirez, J. Fox, S.H. Johnston, T. R. Tintner, R.L. Gross, U.F. Winzer, K.A. Smalky, J. Jankovic J. Smalky, K.A. Winzer, U.F. Gross, R.L. Tintner, R. P. Hallett, J.M. Brotchie J.M. Hallett, P. M. Van Der Stelt, S.H. Fox, V. Di Marzo, J.M. Brotchie J.M. Di Marzo, V. Fox, S.H. Der Stelt, Van M. P1181a new The development of Scale (PFS-16): Fatigue The Parkinson P1179 An observational study of pattern and occurence of non-motor symptoms P1180 risk factors for dementia in PD The role of cerebrovascular P1178voice therapy The effect of on feedback control in parkinsonian speech P1177 Effects of levodopa and STN stimulation on decision making in P1175 disease Visuospatial attention in Huntington’s P1176 disease dementia in a community-based autopsy sample of Parkinson’s P1174 memory deficits correlate Working with frontal atrophyprogressive in P1173 disease Quetiapine for sleep disorders in Parkinson’s P1172 in multiple system atrophy of the cerebellar type (MSA- Cognitive function P1170 disease flexibility and verbal memory in Huntington’s Psychomotor speed, P1171 disease risk factors for hallucinations in Parkinson’s Familial P1169 non-motor Additional evidence of in essential tremor: Personality P1168 patients with a Discontinuation in stable Parkinson of antipsychotic drugs Poster numbers 1167-1209 P1167 disease: in Parkinson’s Aripiprazole for drug-induced psychosis Non-motor Aspects of Movement Disorders Non-motor P1166 receptor stimulation Anti-parkinsonian effects of delta opioid are P1165 group design comparison of A double-blind, randomized, parallel P1163 and L-DOPA-induced are altered in parkinsonism levels Endocannabinoid P1164 of both delta Involvement POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER 88 Rome, Italy P1223 Does actigraphy provide good PLM counts? A validation study with providegoodPLMcounts? study Doesactigraphy A validation P1223 totherapy: with Succesfulltreatment Restlesslegssyndrome refractory P1222 Psychogenicornon-psychogenicdysarthrophonia? P1221 Daytimesomnolencein withthedopamine ADHD patientstreated P1220 fiberlayerthinninginParkinson’s Retinalnerve disease P1219 RestlesslegssyndromewithLthyroxine:Clinical,biochemical and P1218 elderlyfallers: Deficitsinexecutivefunctionidiopathic with Association P1217 Screeningforfalls,strokeordementiariskfactorsinaself- referral, P1216 Attention: ofstride-to-stridevariabilitygaitmayrequires Regulation P1215 cognitivedecline Gaitvariabilityinolderadultswithage-associated P1214 Cognitivefunctiontestingin ADHD children: Potential utilityofanovel, P1213 nucleus oftheventralcaudate iseffectivein Deepbrainstimulation P1212 with communitypopulation Cognitiveassessmentofarepresentative P1211 OsteoporosisinParkinson’s disease P1210 Poster numbers1210-1277 Other Clinical Long-termeffectofcontinuouspositiveairpressure(CPAP) inthe P1209 Severe “off anxiety” ofthe improveswithdeepbrainstimulation P1208 PsychosisinthecourseofParkinson’s diseaseandthetreatment P1207 Parkinson’s diseaseandpesticideexposure: Doesaselectivecognitive P1206 inducedbyantidepressantsinPDpatients Hallucinations P1205 inbasalgangliadisease Impairmentoflinguisticruleapplication P1204 THE B. Hogl, V. Gschliesser, B. Frauscher, E. Brandauer, H. Ulmer, W. Poewe J. Haan, A. Koulousakis, D. Lenartz, V. Sturm D. Haubenberger,M. Vigl, I.Busslinger, D.-M.Denk, E. Fertl, E. Auff Gerlach,M.Peter,S.Claus, A. W.Christoph, A.Warnke Inzelberg,R.P. A.Ramirez, Carasso,R.L.Nisipeanu,Ophir A. P. E. Ratnagopal, Tan, S. Ho, L. Koh S. Springer, N. Giladi, E.S. Simon, J.M. Hausdorff Gruendlinger N. Giladi, M. Mordechovitch, J.M. Hausdorff, H. Shabtai, Y. Balash, L. Y. Leitner, R. Barak, N. Giladi, L. Gruendlinger, J.M. Hausdorff J.M. Hausdorff,M.Mordechovitch,N.Giladi R. Barak, Y. Leitner, E.S. Simon, N. Giladi, J.M. Hausdorff B.Cuny,E. Aouizerate,H.Martin-Guehl,D.Guehl, P.C. Amieva, Burbaud R.J. Athey,R.W. Porter, R. Walker B. Wood,J.Hunter, R. Walker E.Iranzo,J.Santamaria,A.Tolosa, I.F. Vilaseca, Marti Valldeoriola,M. D.E. Hardesty, S.L.Ryan, C. Henchcliffe, P. Piboolnurak, L. Winfield, B. Ford T. Sobow, M. Gorczowski, I. Kloszewska M. Gasparini, G. Caldora, E. Fabrizio, S. DiRezze, N. Vanacore, G. Meco E. Fabrizio, C. Pauletti, C. Aurilia, M. Colasanti, G. Fabbrini, G. Meco M.M. Teichmann,Dupoux,E.E. Bachoud-Lévi A.-C.A. polysomnography morphineapplication continuous intrathecal ropinirole receptor agonist correlation polysomnographic fall risk population:middle age Isitworththeeffort? attention web-based battery obsessive-compulsive disorderandmajordepression (CAMCOG-R) Parkinson’s diseaseusingtheCambridgeCognitive Assessment-Revised (MSA) ofnocturnalstridorinmultiplesystematrophy treatment subthalamic nucleus antipsychotics response toatypical profile exist? MOVEMENT DISORDERSOCIETY P1232 The long-term management ofRLSwithropinirole: Thelong-termmanagement Maintainedefficacy P1232 Treatment facialnerve following offacial synkinesisandhyperlacrimation P1231 Prevalenceandseverityofrestlesslegssyndrome inFrance - The P1230 toimprovethereliabilityandvalidityofRLSdiagnoses: Anewapproach P1229 Opticataxiaduetoimpairedvisuomotortransformation P1228 restlesslegs levetiracetamintreating Efficacy ofgraduated-dose P1227 Staticdisturbancesindifferentvariantsofcerebrovascular pathology P1226 Parkinsonism andexposure to neurolepticdrugsinresidentsofanItalian P1225 ofBelgrade Incidenceofvascularhemiballisminthepopulation P1224 P1245 A family with atypical parkinsonism and diffuse leukoencephalopathy with Afamilywithatypicalparkinsonism anddiffuseleukoencephalopathy P1245 Alternating hemiplegiaofchildhood: A family withpossiblerecessive P1244 TheevidencebaseforropiniroleinRLS: Resultsfromanextensiveclinical P1243 ofRLS Theadverse-eventprofileofropiniroleinthetreatment P1242 AntidepressantsandPeriodic LegMovementDisorder P1241 Painful armandmovingfingers: ofsixcases Clinical features P1240 Periodic limbmovementsduringsleeporrestlesslegssyndromein P1239 Safetyandefficacy oftetrabenazineinchildhoodhyperkineticmovement P1238 Aninbred-strainofmiceasananimalmodel restlesslegssyndrome P1237 andsubstantialimprovementofidiopathic Pramipexoleinducesarapid P1236 after disease(LBD)inyoungpatient SymptomsmimingofLewybody P1235 with Post-infectious disorderassociated autoimmuneneuropsychiatric P1234 Restlessarmssyndrome P1233 T.Abe,C. Tanaka,K.M.Sako,Mizobuchi,Nihira, A. T. Matsushita F. Tison,Lainey,E. D.Leger, Hasnaoui Bouee,S. A.Crochard,El A. H. Benes T. Haid, M. Kofler, E. Pucks-Faes, A. Mayr, E. Quirbach, S. Felber D.M. Lacey L.L. Kononova,N.J. Anan’eva,O.A. Balunov G. Riboldazzi, D. Calandrella, A. Citterio, C. Mascetti, G. Bono, E. Martignoni V.S. Kostic, T. Pekmezovic, M.V. Svetel, A. Ristic, R. Raicevic, N. Ivanovic Y. Baba, R.J. Uitti, D.W. Dickson, Z.K. Wszolek, T. Bird, B. Ghetti A. deFalco, V. Scarano, M. Buongiorno, E. Marano, G. DeMichele, A. Filla L. Ferini-Strambi, J.Montplaisir, T. Dreykluft P. Montagna, P. Tidswell, B. Yee G.N. Rizzo S.Lee, W. Yoon,Jeong,E. W. Lee Y. Oka, S. Koike, Y. Inoue, K. Yamamoto, H. Kadotani, A. Ikeda K. Vuong,Hunter,C.B.Jankovic Mejia,J. N. B.C. Jones, E.J. Chesler, Partinen,M.K.Hirvonen, A.J. L.Jama, Alakuijala, Terttunen D. Kountouris, K. Koutsoubelis G. Fabiani, H. Teive L. Queiroz,F.C. Freitas J. Haan, D. Volc, J. Montplaisir over 36weeks palsy withbotulinumtoxin “INSTANT Study” index(RLS-DI) The restlesslegssyndromediagnostic syndrome andassociatedhypersomnia: A pilotstudy nursing home spheroids inheritance trial programme onhemodialysis patients disorders (RLS) placebo-controlled dose-findingstudy restless legssyndrome:Resultsofalargerandomizeddouble-blind heroin intoxication streptococcus (PANDAS), isitaself-limiteddisease? A six-yearfollow-up R.W.Beard J.L. Williams, POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 , R.P. Allen, C.J. Earley 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 89 computerized cognitive tests identify MCI and mild patients with Gilles de la Tourette syndrome Tourette patients with Gilles de la syndrome patients Tourette’s syndrome 1-Tc99m Trodat NeuroSPECT of an external trigger syndrome Tourette salivary core body subjective vigilance and temperature, melatonin, disorder observations in childhood-recognition of the movement amantadine hydrochloride disorder A comparison study in human: dementia even in the presence of depression C. Moller, B. Tackenberg, K. Muller-Vahl, M. Heinzel-Gutenbrunner, W.H. Oertel, W.H. M. Heinzel-Gutenbrunner, K. Muller-Vahl, Tackenberg, B. C. Moller, O. Bandmann Robertson M.M. Rothwell, J.C. Snijders, A.H. Richardson, M.P. Kirby, R. Orth, M. Maggioni G.R. Porta, M. E.S. Simon, D.M. Zucker, H. Chertkow, T. Dwolatzky, H. Crystal, G.M. Doniger G.M. Crystal, H. Dwolatzky, T. Chertkow, H. Zucker, D.M. Simon, E.S. Olanow W.C. Modugno, N. Grassini, P. Vacca, L. Battaglia, G. Stocchi, F. S.G. Michon, Minarik A.M. Awaad, Y.M. Munchau A. Robertson, M.M. Trimble, M.R. Orth, M. Bloem, B.R. Snijders, A.H. Segro, L.C. Seeberger V. Agarwal, Kumar, R. P. Jankovic J. Mejia, N. Vuong, K. Hunter, C.B. Fruns M. Hernandez, M. Miranda, M. Mena, I. Brescia G. Morra, De Michele V. Mancini, P. Tucci, T. Volpe, Scarano, G. V. Chouinard S. Blanchet, P.J. Soland, V.L. Richer, F. Filion, J. Giovannoni G. Robertson, M.M. Orth, M. Dale, R.C. Church, A.J. Martino, D. M. Michaud, M. Dumont, B. Selmaoui, J. Paquet, M.L. Fantini, J. Montplaisir J. Fantini, M.L. Paquet, J. Selmaoui, B. Dumont, M. Michaud, M. Earley C. Allen, R. Lesage, S. Davis T.L. Fang, J.Y. Montplaisir J. Strambi, Ferini L. Rompré, S. Gagnon, J.-F. Fantini, M. Montplaisir J. Strambi, Ferini L. Gagnon, J.-F. Michaud, M. Fantini, M. Rosenbaum K. Greene, C. Lavenstein, B.L. Young R. Khan, F.I. Rossetto O. Quatrale, R. Tugnoli, V. Vito, De A. Scanelli, G. Eleopra, R. Mindstreams P1287 Repetitive transcranial magnetic stimulation has no effect on tics in P1288 Use of tramadol in the treatment of motor and vocal tics in severe P1277 of continuous dopaminergic stimulation Clinical models Tics Poster numbers 1278-1289 P1278 syndrome Tourette Levetiracetam in treatment of tics in P1279 syndrome Tourette Video assessment of rTMS for P1280 Aripiprazole is beneficial in refractory tics P1281Tourette effective in the treatment of monoamine depleter, Tetrabenazine, P1282 Evaluation by syndrome: Tourette Dopamine transporter imaging in P1283 syndrome in a semi-isolated population Tourette’s Bilinear transmission of P1284 Geriatric tics are often linked to an exacerbation of early life symptoms by P1285 syndrome Tourette’s Soluble adhesion molecules in P1286 and natural killer cell subsets in T-, analysis of B-, Immunocytological P1268 Relationships with legs syndrome symptoms: rhythm of restless Circadian P1269 sleep-related movement A new dyskinesia: quiescegenic Nocturnal P1270 welding Manganese, movement disorders, and P1271 features Polysomnographic of REM sleep behavior disorder P1272 Further leg movements in REM sleep behavior disorder: Periodic P1273 Dystonia secondary to tetrahydrobiopterin deficiency treated with P1274 Diagnostic for primary pallidotomy CNS lymphoma (case report) P1275 Different botulinum neurotoxin serotypes injection on the parotid glands P1276 claustrum-caudate complex claustrum-caudate antiphospholipid syndrome Sträussler-Scheinker disease (F198S-V129) Sträussler-Scheinker behavior disorder preceding parkinsonism syndrome (RLS) symptoms legs syndrome patients: Example from the cabergoline dose-finding trial legs syndrome patients: syndrome extrapyramidal features manifestation of trigeminal cranial neuropathy legs syndrome patients Creutzfeldt-Jacob disease An autopsy corticobasal degeneration: motor neuron disease mimicking case neurodegeneration with brain iron accumulation (NBIA) 5- A placebo-controlled, in restless legs syndrome: sleep disturbances polysomnographic study multicenter, randomized, double-blind, week, N.-K. Chew, D. Martino, P. Mir, N. Bajaj, M. Edwards, K.P. Bhatia K.P. Edwards, M. Bajaj, N. Mir, P. Martino, D. Chew, N.-K. G. Sechi, P. Galistu, V. Agnetti, Agnetti, I. Pirastru, B. K.S. Murgia, Paulus V. Galistu, Sechi, G. P. K. Yamaguchi, B. Ghetti, P. Piccardo, F. Epperson, L. Miravalle, M.R. Farlow M.R. Miravalle, L. Epperson, F. Piccardo, P. Ghetti, B. Yamaguchi, K. M. Thomas, P. Banuelos, K.D. Vuong, J. Jankovic J. Vuong, K.D. Banuelos, P. Thomas, M. Lella F. Maggioni, G.R. Porta, M. T. Dreykluft, J. Karrasch, J. Smuts, D. Volc, R. Grunstein, J. Montplaisir J. Grunstein, R. Volc, D. Smuts, J. Karrasch, J. Dreykluft, T. C. Colosimo, M. Chianese, G. Fabbrini, G. Defazio, M. Prencipe, A. Berardelli A. Prencipe, M. Defazio, G. Fabbrini, G. Chianese, M. Colosimo, C. M. Kelly Mistry, Allen, P.C. R.P. H.-I. Ma, Y.-J. Kim, M.-K. Chu, K.-H. Yu, B.-C. Lee Kim, Yu, M.-K. Chu, K.-H. Y.-J. H.-I. Ma, R.P. Allen, Allen, S. Lesage, C.J. Earley R.P. Meinck H.M. Goebel, H.H. Schabitz, W.R. B. Ho, D. Apetauerova, J. Arle, J. Russell J. Arle, J. Apetauerova, D. Ho, B. M. Fantini, A. Desautels, M. Michaud, D. Petit, J. Montplaisir J. Petit, D. Michaud, M. Desautels, A. Fantini, M. R. Kohnen, H. Benes, M. Leroux, K. Stiasny-Kolster, W.H. Oertel W.H. Stiasny-Kolster, K. Leroux, M. Benes, H. Kohnen, R. N. Galvez-Jimenez, A. Podichetty, M. Hargreave M. Podichetty, A. Galvez-Jimenez, N. H. Benes, M. Leroux, R. Kohnen R. Leroux, M. Benes, H. Tsiftsis Vrentas, N. Kapsalakis, P. Y. Kiriakakis, V. S.-J. Kwon, J.-M. Kim, K. Cho, B. Jeon S.-J. Kwon, J.-M. Kim, K. Cho, K. Iwanaga, I. Tomita, A. Satoh, M. Tsujihata, Y. Takahashi Piao, H. Y. Tsujihata, A. Satoh, M. Tomita, K. Iwanaga, I. B. Donmez, I. Oztura, R. Cakmur W.H. Oertel, H. Benes, S. Happe, R. Kohnen, M. Leroux, K. Stiasny-Kolster K. Leroux, M. Kohnen, R. Happe, S. Benes, H. Oertel, W.H. L. Bartolomei, G. Billo, V. Toso V. G. L. Bartolomei, Billo, P1267 of movement disorders associated Clinical heterogeneity with P1266 A case of restless legs syndrome secondary to ischemic stroke in the P1264 with botulinum toxin Treatment Obesity in severe neurological diseases: P1265 and molecular genetic studies on Gerstmann- neuropathologic, Clinical, P1262 The long-term safety and tolerability of ropinirole in RLS P1263 Long term prognosis of psychogenic movement disorders P1261 Ropinirole reduces periodic leg movements in sleep in patients with RLS P1259 REM ehavioral manifestations in the female patients with REM sleep P1260 study and epidemiological A clinical Hemifacial spasm: P1258A syndrome deserving look a closer Camptocormia or bent spine? P1257 effects on restless legs Anti-histamine and daytime benzodiazepine P1256 myelinolysis presenting with Reversible extra-pontine and central pontine P1254 relevance of treatment outcome in studies with restless Defining clinical P1255 Long-term effects of pramipexole in the treatment of restless legs P1253A rare unilateral spasm of the jaw Paroxysmal with facial atrophy. P1252A case-series study of 97 patients syndrome: Restless legs P1250 moving toes syndrome A case with painless P1251 Lessons learned from the long-term cabergoline safety trial in restless P1248 epilepsia partialis continua as initial signs in probable Chorea and P1249 tauopathy degeneration and with astrocyte-predominant Frontotemporal P1246 L-Dopa therapy on a late working only in a case of phase of disease P1247the treatment of cabergoline for Efficacy symptoms and of sensori-motor POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER 90 Rome, Italy P1308 Evaluation ofessential tremor: Evaluation Comparisonofclinical scales, visual, and P1308 Theeffect of ondigitalmotorperformanceinessential Vim surgery P1307 testingdifferentiatesbenignessentialtremorfromtremulous Olfactory P1306 tremor Neurophysiologicfindingsinorthostatic P1305 tremor analysisandtree- Psychogenictremoridentifiedusingquantitative P1304 ofessential tremorand Complextremoranalysisinthediagnosis P1303 Cognitivefunctioninessentialtremor: nestedcase A population-based P1302 allelesinpatientswithessential ScreeningforFragile Xpremutation P1301 withessentialtremor Assessmentofmovementtimeinpatients P1300 QuantifyinghandwritingcontrolinEssentialtremor and Parkinson’s P1299 ofascreeninginstrumentforessentialtremor Evaluation P1298 Task-specific liptremorinafluteplayerresponsivetobotulinumtoxin P1297 Contrastingeffectsofucb34714anddrugsforessential tremoron P1296 withessentialtremor Alcoholimprovesgaitinpatients P1295 Dodifferencesbetweenimperceptible(subclinical) parkinsoniantremor P1294 EssentialtremorinMersin, Turkey: door-to-doorA population-based study P1293 with Interactionsbetweenabnormaleyeandhandmovementsinpatients P1292 fortremor Neurosurgicalstereotacticbrainoperations P1291 Effectofzonisamideonessentialtremor: in A pilotcross-overstudy P1290 Poster numbers1290-1338 Tremor inGillesdela Efficientinternalpallidalstimulation Tourette Syndrom. A P1289 THE O. Ulmanova, E. Ruzicka, R. Jech, R. Ulman, V. Capek Berryhill V.C. Anderson,J.-S.Lou,R.W. R.L.Eaton, Anderson,S.P.C.Seetharaman, C.H. Hawkes, M. Shah, N. Muhammed, L.J. Findley P. Piboolnurak, Q. Yu, S.L. Pullman P. Piboolnurak, N. Rothey, D. Xu, B. Ford, Q. Yu, S.L. Pullman Z.Farkas,Palvolgyi,Csillik,L. A. A. Takats,I.Szirmai, A.Kamondi J. Benito-Leon, F. Bermejo-Pareja, E.D. Louis K. Puong, Y. Zhao, H. Law, M. Wong, I. Ng, E. Tan S. Ozekmekci,M. Vural, G. Kiziltan, S. Ertan, H. Apaydin, E. Erginoz C. Toro D. Lorenz, H. Frederiksen, R.Govindan, F. Kopper,K. Christensen, G.Deuschl W. Lee, S. Lee, B. Kim M. DeRyck, A. B. Matagne, Kenda, P. Michel, H. Klitgaard S.Klebe, K. Grensing, H. Stolze, J. Volkmann, F. Kopper, G. Deuschl A. Beuter, E. Barbo, R. Rigal, P.J. Blanchet O. Dogu, S. Sevim, E.D. Louis, H. Kaleagasi, M. Aral P.Feys, W.Helsen,X.Liu, B.Nuttin, S. A.Swinnen Lavrysen, Koulousakis,A. V.Sturm,J. Voges S. Morita, H. Miwa, I. Nakanishi, T. Kondo N.J. Diederich, A. Bumb, E. Mertens, K. Kalteis, M. Stamenkovic, F. Alesch digitized analysisofhanddrawing tremor Parkinson’s disease algorithms based statistical Parkinson’s disease control study tremor disease withatemplated Archimedes spiral injection rats in harmaline-induced elicitedversusspontaneoustremorandsedation and physiologicaltremorexist? intention tremorduetomultiplesclerosis comparison witharotinolol case report MOVEMENT DISORDERSOCIETY 11 Influenceofperipheralinputonorthostatictremor P1316 Transient betweenpallidal synchronizationandphaserelationships P1315 Amulticenter, double-blind, in placebo-controlledtrialoftopiramate P1314 Electrophysiologictransitionfromphysiologictremor toessentialtremor P1313 Postural tremorin Wilson’s disease(WD): A magnetoencephalographic P1312 ABelgian “Tremor” withParkinson’s onpatients survey disease P1311 contractionsin Changesincorticalinhibitionduringtask-specificdystonic P1310 orthostatictremor: Primary A casereport P1309 13 Prevalenceoftandem gaitandintentiontremorinfamilialessential P1330 computerizedtremoranalysismethod with Validation ofquantitative P1329 Cerebellartremorwithglutamicaciddecarboxylaseautoantibodies P1328 toaparietallesion tremorsrelated Symptomatic P1327 onthemotorsystem encephalopathy Influenceofhepatic P1326 midbrainlesion DaTSCANimaginginHolmestremorfollowing P1325 tremor: Computerizedtremoranalysisofvalproate-induced A prospective P1324 EnvelopeofaccelerometrictremorsignalinpatientswithPDandET P1323 tremors Cortical-muscularcoherenceinpathological P1322 Acaseofcorticaltremormasqueradingasparkinsonism: When jerk P1321 doesnotinhibittremorgeneratordirectly VIMstimulation P1320 Frequency tremor driftinorthostatic P1319 Clinicalanalysisinfamilialmyoclonic corticaltremorallowsdifferential P1318 Reducedbodymassindexinessentialtremor: study A population-based P1317 J. Spiegel,G.Fuss,C.Krick,U.Dillmann K.A. Sigvardt, J.M. Hurtado, L.L. Rubchinsky, V.L. Wheelock, C.T. Pappas Hulihan, L. Schwarzman, S.-C. Wu J. Jankovic, W.G. Ondo, M.A. Stacy, R.J. Elble, R. Pahwa, G.S. Connor, J.F. R.J. Elble,C.Higgins,S.Elble M. Suedmeyer, B. Pollok, H. Hefter, J. Gross, L. Timmermann, A. Schnitzler J.-E.G. Vanderheyden,P. Gonce M.Bourgeois, M.R.Ljubisavljevic,Kacar, A. M.Svetel,S.Milanovic, V.S. Kostic C. Civardi, R. Vicentini, M. Cecchin, C. Varrasi, F. Pisano, R. Cantello J.M. Stajich, S. Knauer,S.J.M.Stajich, J.M. Scott, Vance,B. A.E.Gilbert J.R. Ashley-Koch, M.Rudzinska,Izworski, A. T.M.Banach,S.Bukowczan,Szczudlik Lech, A. K.S. Paulus, F.M. Sulas, G. Sau, P. Galistu, V. Agnetti, G. Sechi F. Torny, A.Batir, P. Krack, V.Fraix, L. Vercueil,P. Pollak L. Timmermann, J. Gross, G. Kircheis, M. Butz, D. Haussinger, A. Schnitzler P. Remy, E. Itti, Z. Malek, G. Fénelon, E. Evangelista,P. Cesaro M.Rinnerthaler, J.Mueller, K.Seppi,G. Luef, E. Trinka,J. Wissel G. Sahin,M.Demirci,B.Elibol T. Mima, K. Toma, T. Oga, H.Fukuyama, H. Shibasaki,M. Hallett Z. Mari,M.Hallett T. Vogt,H.Stefan S.E. Cooper F.Bourdain,E. Apartis,J.-M. Trocello,J.-S. Vidal,M. Vidailhet E.D. Louis, O. Dogu, S. Sevim, H. Kaleagasi, M. Aral organization activity andlimbtremorinParkinson’s disease: Implicationsfornetwork essential tremor study stimulation study withPrimary patients Writing Tremor –atranscranialmagnetic tremor graphic digitizingtablet successfully treatedwithcarbamazepineplustopiramate tions ofvalproate ofcontinuous-releaseversusconventionalprepara- comparative study analysis provesvaluable diagnosis withessentialtremor in MersinProvince, Turkey POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 POSTER SESSION4 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 91 evidence of hyperactivationof the inferior olive in two patients J. Raethjen, F. Kopper, R.B. Govindan, J. Volkmann, G. Deuschl G. Volkmann, J. Govindan, R.B. Kopper, F. Raethjen, J. Palacio S.B. Zeppa, G.E. S. Fiaschi, A. Moretto, G. Orrico, D. Simonetti, S. Alessandrini, F. Morini, A. Tinazzi M. Farina, P1336tremor in psychogenic pathogenetic mechanisms different Two P1337 presentation of primary Familial orthostatic tremor P1338 Sensory Functional neuroimaging tricks in essential palatal tremor: in essential tremor J.P. Rodrigues, D. Edwards, M. Byrnes, S.E. Walters, R. Stell, F.L. Mastaglia F.L. Stell, R. Walters, S.E. Byrnes, M. Edwards, D. Rodrigues, J.P. Deuschl G. Govindan, R.B. Kopper, F. Raethjen, J. A. Schnitzler, C. Munks, M. Butz, L. Timmermann, J. Gross J. Timmermann, L. Butz, M. Munks, C. Schnitzler, A. Ashley-Koch A.E. Vance, J.M. Scott, B. Knauer, S. Stajich, J.M. Gilbert, J.R. M. Ushe, S. Tabbal, M. Hong, J.W. Mink, K.M. Rich, J.S. Perlmutter J.S. Rich, K.M. Mink, J.W. Hong, M. Tabbal, S. Ushe, M. P1334 of gabapentinAn open-label study Tremor: Primary Orthostatic P1335 involvement in generation of essential tremor Motor cortex P1333 familial essential tremor Prevalence and severity of tremor in P1331thalamic stimulation tremor suppression with dependence of Frequency P1332 oscillatory The essential tremor network of cortico-subcortical POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER POSTER SESSION 4 SESSION POSTER 4 SESSION POSTER